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On a global scale there are few greater threats to human health than the rapid rise of antibiotic 
resistance. It is therefore of crucial importance to discover and develop new antibiotics for clinical use. 
This thesis describes investigations into synthetic strategies to antibiotic natural products and novel 
derivatives. 
Chapter one describes the first total 
synthesis of kalimantacin A 1, a 
bacterial natural product isolated from 
Pseudomonas fluorescens possessing 
potent antibiotic properties. Semi-
synthetic studies of 1 revealed that the 
hydroxyl and the carboxylic acid could 
be reversibly masked as the TBS ether 
and methyl ester respectively to give 9 
as the new synthetic target. The 
enantioselective route includes three 
key couplings: an organolithium 
addition to an aldehyde, a Sonogashira 
reaction to form an enyne, and an 
amide coupling. Additionally, the 
synthesis was designed to be 
convergent in order to facilitate the future preparation of analogues and putative biosynthetic 
intermediates. Using this approach, the natural product was prepared in 2.3% overall yield with a 
longest linear sequence of 24 steps. 
Chapter two describes investigations into the antibiotic pleuromutilin 125. In 
this work, 20 derivatives of the biosynthetic intermediate mutilin 129 were 
prepared through semi-synthesis, with modifications focussed on the 
cyclopentanone ring. Six of these analogues were incubated with an A. oryzae 
transformant containing genes encoding for acetyltransferase (ATF) and P450 
enzymes isolated from the pleuromutilin biosynthetic pathway. Conversion to 
the corresponding 14-O-acetylated analogues was observed in all cases, with two derivatives also 
showing further hydroxylation to the full glycolic acid side-chain. These results demonstrate that the 
final two enzymes of the pathway can tolerate structural variations to the five-membered ring. 
Preliminary antibiotic testing has also been undertaken, with an enone derivative displaying enhanced 





Firstly, I would like to thank and dedicate this thesis to my parents. Without their continuous support, 
love, and encouragement I would not be where I am today, and I will always be grateful for that.  
I would like to thank Chris for her endless enthusiasm and guidance over many (many) years. During 
my time in the group I have had the freedom and encouragement to peruse my own ideas which has 
allowed me to become more rounded, passionate, and confident as scientist. Thanks also for the 
opportunity to work on some truly fascinating projects and for allowing me to present my work at 
some incredible conferences around the world. 
I feel extremely lucky to have worked with some brilliant people over the course of my PhD, and I can 
genuinely say I have looked forward to coming in (almost) every single day. Firstly, I would like to say 
a huge thank you to Nick who has taught me so much over the years with his near encyclopedic 
knowledge of chemistry. It was a pleasure learning the correct operating procedures for liquid 
nitrogen, agreeing over which door of the balance is best, and discovering the wonders of bouncing a 
frisbee into a bin. Thanks to David for being my exercise partner all these years. Be it running across 
the Downs, climbing up walls, skiing down mountains, or sitting very still in a pub, your company has 
been much appreciated. Thanks to Paul for kindly introducing me to the Monday-run-day routine, 
recruiting me into team Kalimantacin, patiently explaining to me the basics of biochemistry, and 
convincing me that inanimate objects can indeed be ‘guys’. Thanks to (grandpa) Joe for taking time 
out his busy outreach schedule to audaciously take credit for growing the plants, push the rotary 
evaporator into my fume hood, ponder the pointless, and most notably, be the butt of all jokes. You 
may be a bad lab manager but you do make a fantastic sled! Thanks to Abi for inviting me on holidays. 
I had some wonderful times from the lows of the dead sea to the highs of the Rockefeller Center. 
Thanks to Sbu, whose cheery personality and people skills have been a wonderful contrast to my own. 
Also, for hosting some classy wine and cheese evenings, showing that hair can also function as a 
Christmas tree, and for making me feel better about the relative structural integrity of my knee. 
Thanks to Angus, a fellow connoisseur of Woky Ko, port, chilis, and Bugles. I’m sure I could write 
another thesis on our hijinks alone, but alas, the publishers weren’t interested. Thanks to Rachel for 
the delicious lunch trips, the Hot Fuzz quotes, and most importantly, for reminding Angus that he isn’t 
funny. Thanks to Beth, resident cheese enthusiast and the best speed bowler the third floor has ever 
seen. Thanks to Dr Wang for his HPLC assistance and scathing put downs, all of which while ruling over 
his own democratic republic. Thanks to Jenny, my master’s student, for making my job particularly 
easy, conducting some of the most interesting pleuromutilin research, and checking that the eye wash 
was still working. Thanks to Jimmy, who in his short time in our group has taught me to love pigeons 
 
iii 
and hate music. Thanks to (baby) Joe for setting records for the world’s strongest coffee and most 
crossword-based yellow cards. Last, but surely not least, thanks to Drew for his entertaining opinions 
of turkey and his incorrect opinions of Star Wars. Also, for making me feel better about the structural 
integrity of my knee. Thanks also to Alex, Hanim (Minty), Kun, Lisa, Claudio, Song, Catherine (Spence), 
Dao, Dan (Doffles), Jawaher, Edith (Edo), Marija, and Dr Knowles for making my time in the group as 
enjoyable as it was. 
A special thanks must go to my flatmates, Beks and Zoë, who never fail to make me smile (which is 
not always easily done). I feel extremely lucky to have you as two of my closest friends. 
Thank you to Prof. Jun-ichi Yoshida for kindly hosting me during my time in Japan. I was deeply 
saddened to hear of your passing. 
Thank you to Andy Bailey for his encouraging words and help with all things fungal. 
Thank you to the CDT, EPSRC, and the University of Bristol for funding my research. Thanks also to my 
friends James, Dabs, Louise (and Izzy), Lydia, and Phillipa for all the happy memories. 
Finally, thank you to all the analytical and technical staff that make that the School of Chemistry a 
genuinely world-class research environment. In particular: Craig Butts (NMR), Paul Lawrence (NMR), 





The work described in this thesis was carried out in the School of Chemistry, University of Bristol under 
the supervision of Professor C. L. Willis between May 2016 and December 2019. The work is original, 
except where indicated by reference in the text, and has not been submitted for any other degrees. 






[α]D   Specific optical rotation 
A   Adenylation domain 
Ac   Acetyl 
ACP   Acyl carrier protein 
ADMET   Absorption, distribution, metabolism, excretion, and toxicity 
AIBN   Azobisisobutyronitrile 
AIDS   Acquired immune deficiency syndrome 
AT   Acyltransferase 
ATF   Acetyltransferase 
BHT   Butylated hydroxytoluene 
BLAST   Basic local alignment search tool 
Boc   tert-Butyloxycarbonyl 
brsm   Based on recovered starting material 
c   Concentration 
C   Condensation domain 
CABP   Community-acquired bacterial pneumonia 
CE   Common Era 
CMP   Czapek-dox broth premix, maltose, peptone medium 
CoA   Coenzyme A 
COMU® (1-Cyano-2-ethoxy-2-oxoethylidenaminooxy)dimethylamino-
morpholino-carbenium hexafluorophosphate 
COSY   ¹H-¹H Correlation spectroscopy 
Cp   Cyclopentadiene 
Cyc   Cyclase 
CYP   Cytochrome P450 
d.r.   Diastereomeric ratio 
DABCO   1,4-Diazabicyclo[2.2.2]octane 
DBB   Di-tert-butylbiphenyl 
DBE   Dibromoethane 
DBU   1,8-Diazabicyclo[5.4.0]undec-7-ene 
DCE   1,2-Dichloroethane 
DCM   Dichloromethane 
DDQ   2,3-Dichloro-5,6-dicyano-1,4-benzoquinone 
DEAD   Diethyl azodicarboxylate 
DH  Dehydratase 
 
vi 
DIAD   Diisopropyl azodicarboxylate 
DIBAL   Diisobutylaluminium hydride 
DMAP   4-(Dimethylamino)pyridine 
DMAPP   Dimethylallyl pyrophosphate 
DMF   N,N-Dimethylformamide 
DMP   Dess-Martin periodinane 
DMSO   Dimethyl sulfoxide 
DNA   Deoxyribonucleic acid 
ECH   Enoyl-CoA hydratase 
EDCI   N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide 
ER   Enoylreductase 
FAS   Fatty acid synthase 
FASII   Type two fatty acid synthase 
FDA   U.S. Food and Drug Administration 
fMet   N-Formylmethionine 
FPP   Farnesyl pyrophosphate 
GGPP   Geranylgeranyl pyrophosphate 
GGS   Geranylgeranyl pyrophosphate synthetase 
ggs   Geranylgeranyl pyrophosphate synthetase gene 
GPP   Geranyl pyrophosphate  
H2BC   Heteronuclear 2 bond correlation 
HCS cassette  3-Hydroxy-3-methylglutaryl CoA-synthase cassette 
HEDSO   Hexaethyldisiloxane 
HG2   Second generation Hoveyda-Grubbs catalyst 
HIV   Human immunodeficiency virus 
HMBC   Heteronuclear multiple bond correlation 
HMGS   3-Hydroxy-3-methylglutaryl synthase 
HPLC   High-performance liquid chromatography 
HSQC   Heteronuclear single quantum coherence spectroscopy 
INADEQUATE  Incredible natural abundance double quantum transfer experiment 
IPP   Isopentenyl pyrophosphate 
IR   Infrared 
KR   Ketoreductase 
KS   Ketosynthase 
KS0   Ketosynthase (lacking cysteine required for condensation) 
LAEDA   Lithium acetylide ethylenediamine complex 
LDA   Lithium diisopropylamide 
 
vii 
LG   Leaving group 
LiHMDS  Lithium bis(trimethylsilyl)amide 
LLS   Longest linear sequence 
m   meta 
M   Molar  
m.p.   Melting point 
m/z   Mass-to-charge ratio 
mCPBA   meta-Chloroperoxybenzoic acid 
MDR   Multidrug-resistant 
MEP   Methyl erythritol 4-phosphate 
MIC   Minimum inhibitory concentration 
Min   Minutes 
mRNA   Messenger ribonucleic acid 
MRSA   Methicillin-resistant Staphylococcus aureus 
MS   Mass spectrometry 
Ms   Methanesulfonyl 
MT   Methyltransferase 
MVA   Mevalonic acid 
NADH   Nicotinamide adenine dinucleotide (reduced form) 
NFSI   N-Fluorobenzenesulfonimide 
NIS   N-Iodosuccinimide 
NMO   N-Methylmorpholine N-oxide 
NMR   Nuclear magnetic resonance 
nOe   Nuclear Overhauser effect 
NOESY   Nuclear Overhauser effect spectroscopy 
NRPS   Nonribosomal peptide synthase 
OPP   Pyrophosphate 
ORF   Open reading frame 
p   para 
PCP   Peptidyl carrier protein 
PDR   Pandrug-resistant 
PEG   Polyethylene glycol 
PFA   Paraformaldehyde 
PKS   Polyketide synthase 
PMB   para-Methoxybenzyl 
PMP   para-Methoxyphenyl 
ppm   Parts per million 
 
viii 
PTC   Peptidyl transferase centre 
PTSA   para-Toluenesulfonic acid 
Quant.   Quantitative 
rpm   Revolutions per minute 
rRNA   Ribosomal ribonucleic acid 
rt   Room temperature 
SAM   S-Adenosyl methionine 
SAR   Structure-activity relationship 
SCX-2  ISOLUTE® Si-propylsulfonic acid column 
SDR   Short-chain dehydrogenase/reductase 
Selectfluor™ 1-Chloromethyl-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane 
bis(tetrafluoroborate) 
SET   Single electron transfer 
spp.   Species 
t   tert 
TB   Tuberculosis 
TBAF   Tetrabutylammonium fluoride 
TBS   tert-Butyldimethylsilyl 
TCA   Trichloroacetimidate 
TE   Thioesterase 
TES   Triethylsilyl 
Tf   Trifluoromethanesulfonyl  
TFA   Trifluoroacetic acid 
TFAA   Trifluoroacetic anhydride 
THF   Tetrahydrofuran 
TLC   Thin-layer chromatography 
TMS   Trimethylsilyl 
tRNA   Transfer ribonucleic acid 
Ts   para-Toluenesulfonyl 
TSA   Tryptic soy agar 
TSB   Tryptic soy broth 
TTC   2,3,5-Triphenyl-2H-tetrazolium chloride 
uSSSI   Uncomplicated skin and skin structure infections 
VRSA   Vancomycin-resistant Staphylococcus aureus 
WHO   World Health Organisation 
XDR   Extensively drug-resistant  
 
ix 
Table of Contents   
Abstract i 
Acknowledgements ii 
Author’s Declaration iv 
Abbreviations v 
Table of Contents ix 
1. The Enantioselective Total Synthesis of Kalimantacin A 1 
1.1. Introduction 2 
1.1.1. Antibiotics 2 
1.1.2. Antibiotic Resistance 5 
1.1.3. Secondary Metabolite Natural Products 7 
1.1.4. Polyketide Biosynthesis 9 
1.1.5. β-Branching in Polyketides 11 
1.1.6. Kalimantacin Antibiotics 13 
1.1.7. Mode of Action of Kalimantacin Antibiotics 14 
1.1.8. Kalimantacin Biosynthesis 15 
1.1.9. Elucidation of the Relative and Absolute Stereochemistry of Kalimantacin A 19 
1.2. Project Aims 20 
1.3. Results and Discussion 21 
1.3.1. Isolation and Semi-Synthetic Studies of Kalimantacin A 21 
1.3.2. Retrosynthetic Analysis of Kalimantacin A 24 
1.3.3. Synthesis of Fragments A and B 25 
1.3.4. Towards the Synthesis of Fragment C 28 
1.3.5. Synthesis of Fragment D 32 
1.3.6. Revised Retrosynthetic Analysis of Kalimantacin A 35 
1.3.7. Revised Synthesis of Fragments A and C 36 
1.3.8. Synthesis of Fragment E 39 
1.3.9. Synthesis of Fragment F and Final Steps 44 
1.4. Conclusions and Future Work 49 
2. New Strategies to Bioactive Targets Inspired by the Antibiotic Pleuromutilin 51 
2.1. Introduction 52 
2.1.1. Terpene Biosynthesis 52 
2.1.2. Pleuromutilin Antibiotics 53 
2.1.3. Metabolism of Pleuromutilin Antibiotics 57 
2.1.4. Mode of Action of Pleuromutilin Antibiotics 57 
 
x 
2.1.5. Pleuromutilin Biosynthesis 59 
2.2. Project Aims 63 
2.3. Results and Discussion 64 
2.3.1. Synthesis of Mutilin and Dihydromutilin 64 
2.3.2. Protection of the 11- and 14-Hydroxyls 64 
2.3.3. Derivatisation at C-3 69 
2.3.4. Derivatisation at C-2 74 
2.3.5. Cyclopentenone Synthesis and Derivatisation 78 
2.3.6. Studies Towards the Synthesis of 14-Epi-Mutilin 83 
2.3.7. Synthesis of Pleuromutilin and 14-O-Acetyl Mutilin 89 
2.3.8. Biotransformations 91 
2.3.9. Antibiotic Testing 94 
2.4. Conclusions and Future Work 96 
3. Experimental 99 
3.1. General Experimental Details 100 
3.2. Experimental for Kalimantacin A Research 102 
3.2.1. Synthesis of Compounds 102 
3.3. Experimental for Pleuromutilin Research 162 
3.3.1. Purification via Preparative HPLC 162 
3.3.2. Synthesis of Compounds 162 
3.3.3. Biotransformation Studies 204 
3.3.4. Antimicrobial Bioassays 209 
4. References 211 
5. Spectra 220 
5.1. Spectra for Kalimantacin A Research 221 
















In the history of modern medicine there are few moments of greater importance than the discovery 
of antibiotics in the early-to-mid twentieth century. These discoveries marked the beginning of the 
‘antibiotic era’, a time in which countless lives have been saved through the mass production and 
marketing of antibacterial drugs. The impact of these findings is marked by three separate Nobel 
prizes, awarded for the discovery of the antibiotics Prontosil, penicillin, and streptomycin in 1939, 
1945, and 1952 respectively.1 
The commercialisation of antibiotics means that once life-threatening diseases such as streptococcal 
pharyngitis (strep throat), syphilis, and bacterial pneumonia can now, in most cases, be cured with 
relative ease. In the case of Haemophilus influenzae meningitis, mortality rates have dropped around 
95% since the 1920s due to the introduction of treatments such as chloramphenicol, ampicillin, and 
cephalosporin.2 Antibiotics have also allowed for significant advancements to be made in other fields 
of medicine such as cancer chemotherapy treatments, invasive surgical procedures, organ transplants, 
and neonatal medicine.3 
Although the discovery and identification of antibiotics occurred in the twentieth century, substances 
possessing antibacterial properties have been beneficial to humans for thousands of years. One of the 
earliest proven examples comes from the Nubian people of ancient Sudan.4 Bone samples dating back 
to 350-550 CE have shown traces of tetracycline, a broad-spectrum antibiotic that is easily traced 
through its strong binding to phosphorus and calcium in bones. It is hypothesised that this exposure 
occurred through the ingestion of beer contaminated with Streptomyces bacteria, which naturally 
produce tetracycline.5 This may explain the low rates of infectious disease recorded in the ancient 
Nubian population.4 Similarly, traces of tetracycline have also been observed in skeletons recovered 
from the Dakhleh Oasis in Egypt.6 These remains date back to the late Roman period (400-500 CE), 
and again, the presence of tetracycline in the diet may have contributed to the low rates of infection 
reported in this population.6 
Other evidence for the use of antibacterial substances in the pre-antibiotic era is mostly anecdotal 
and based on medicinal folklore. However, some possible examples include the use of honey and 
mercury salts by the ancient Egyptians,7 the use of Hypericum perforatum (St John’s Wort) by the 
ancient Greeks,8 and many examples in traditional Chinese medicine.9 All of these substances have 
since been shown to possess antibiotic activity.9,10 
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The first synthetic antibiotics were developed in Germany in the laboratory of Paul Ehrlich. The 
inspiration for Ehrlich’s work came from his observations that certain synthetic dyes were capable of 
staining specific microorganisms, whilst others were not. This led him to develop his now famous 
concept of a ‘magic bullet’, that is, a drug that is able to selectively target a pathogen without harming 
the host organism.11 Using this idea, Ehrlich went on to screen hundreds of arsanilic acid derivatives 
for antisyphilitic properties. He eventually succeeded, with the 606th compound in the series showing 
the desired activity.12 This drug went on to be marketed as Salvarsan (also known as arsphenamine) 
in 1910, making it the first man-made antibiotic and first successful chemotherapeutic drug 
(Figure 1).12 Due to the severe side-effects of Salvarsan, it was replaced by the less toxic and more 
water-soluble neosalvarsan in 1912 (Figure 1).13 
 
Figure 1. The structure of arsphenamine which is proposed to consist of a mixture of a trimer and a pentamer,14 and the 
structure of neosalvarsan. 
The next significant advancement came with the development of Prontosil in 1932 (Figure 2). This 
synthetic drug was discovered by Gerhard Domagk at the Bayer laboratories of I. G. Farben.15 Domagk 
was working as part of a research team investigating the antibacterial properties of azo dyes. 
Unfortunately for Bayer, Prontosil was revealed to be a prodrug, with the antisyphilitic activity 
resulting from para-aminobenzenesulfonamide (sulfanilamide) formed in vivo (Figure 2).16 
Sulfanilamide had been patented in 1909 for use as a dye intermediate, and by the time its antibiotic 
properties were discovered in 1932 the patent had expired.17 Because sulfanilamide was off-patent, 
cheap to synthesise, and easy to modify, several pharmaceutical companies began trying to produce 
and optimise sulfanilamide derivatives. This led to the rapid growth of the sulfonamides as a new and 
important class of antibiotics which include sulfapyridine, sulfadimidine, sulfadiazine, and 
sulfamethoxazole.18  
 
Figure 2. The structures of Prontosil, sulfanilamide, and benzylpenicillin. 
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Perhaps the most revolutionary breakthrough in antibiotics came with the discovery of penicillin by 
Alexander Fleming in 1928.19 This occurred serendipitously after Fleming returned from a holiday to 
find that he had left a culture of Staphylococcus bacteria uncovered. He observed that the plate had 
become contaminated with the fungus Penicillium notatum, and that the bacterial colonies closest in 
proximity to the fungus had been destroyed. This led him to conclude that the fungus was secreting a 
compound that possessed antibacterial properties, which he later named penicillin. Despite the 
significance of his findings Fleming struggled to generate much interest in penicillin and was unable 
to isolate the active compound due to its instability.17 Fortunately, the work was revitalised in 1939 
by a team of researchers at Oxford University. This team included Sir Howard Florey, Sir Ernst Chain, 
and Norman Heatley who successfully devised a protocol for the purification and scalable production 
of penicillin G (benzylpenicillin) (Figure 2), turning it into a viable drug.20 This work allowed penicillin 
to become the first mass-produced antibiotic, with over-the-counter availability commencing in 
1945.17 
The introduction of sulfonamides and penicillin marked the beginning of a golden age for antibiotics, 
with over 20 new classes identified in the following 30 years.21 Many of these classes derive from 
natural products, such as the aminoglycosides, which began with the isolation of streptomycin in 
1943.22 This important drug was extracted from a soil sample by a student of Selman Waksman, and 
was the first antibiotic found to be active against tuberculosis.23 Another class are the 
semi-synthetically produced cephalosporins, which derive from compounds produced by the fungus 
Cephalosporium acremonium. These compounds were first isolated in 1948 from a culture taken from 
a sewage pipe off the coast of Sardinia.24 A range of synthetic antibiotics were also developed during 
this time, including the nitrofurans, the hexamines, and isoniazid (Figure 3). 
 
Figure 3. The structures of nitrofurantoin, methenamine hippurate, and isoniazid. 
With a plethora of novel antibiotics discovered between 1940 and 1970, it appeared for a while that 
the pharmaceutical industry had the upper hand in the fight against bacterial infections. 
Unfortunately, this was not to last and between 1970 and 2000 mupirocin was the only drug to be 
approved for clinical use that belonged to a novel antibiotic class (Figure 4).21 The vast majority of 
other antibiotics released since 1970 are chemically modified derivatives of pre-existing drugs.25 
Alarmingly, this has now reached the point where every class of antibiotic in use today was initially 
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discovered prior to the mid-1980s,26 although this could soon change with the breakthrough of 
teixobactin (Figure 4).27,28 
 
Figure 4. The structures of pseudomonic acid A (the main component of mupirocin) and teixobactin. 
1.1.2. Antibiotic Resistance 
The dangers posed by antibiotic resistance were identified even before penicillin had entered clinical 
use. Alexander Fleming was one of the first to recognise this threat, and warned of the dangers of 
misusing antibiotics in his Nobel Prize acceptance speech.29 In fact, the first penicillinase (β-lactamase) 
was isolated and identified by Edward Abraham and Ernst Chain as early as 1940.30 In the following 80 
years antibiotic resistance has seen a meteoric rise to prominence, and we are now faced with the 
potential of entering a post-antibiotic era.31 
Antibiotic resistance is not a modern phenomenon, it is a naturally occurring evolutionary process and 
predates the discovery of antibiotics by hundreds of thousands of years.32 Resistance is acquired in 
one of two ways, either through genetic mutations or through horizontal gene transfer, that is, the 
exchange of genetic material with a bacterium that possesses the resistance trait.33 Although this is a 
natural process, the overuse of antibiotics by humans has created a selective pressure that has greatly 
exacerbated the issue.  
There are several ways in which antibiotics are misused, but one of the biggest factors is 
overprescription by doctors. In the U.S. alone it was recently calculated that 30% of oral antibiotic 
prescriptions were inappropriate or unnecessary,34 and this number is potentially as high as 60% in 
intensive care units.35 This misapplication is often compounded by patients failing to take the full 
course of the antibiotic prescribed. This is perhaps reflective of a general lack of understanding of 
bacteria and antibiotics by the public. This is demonstrated by a 2013 EU survey in which 49% of 
people wrongly answered that “antibiotics kill viruses”.36 Antibiotics have also seen extensive use in 
the agricultural industry. This includes widespread prophylactic usage in livestock,37 horticulture,38 and 
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aquaculture;39 as well as extensive employment as a subtherapeutic growth promoter in food 
animals.37 
A recent report by the World Health Organisation (WHO) highlighted that antibiotic resistance is now 
a global problem and can affect anyone, of any age, anywhere on the planet.40 An alarming 
consequence of increased antibiotic use is the emergence of multidrug-resistant (MDR) bacteria, or 
‘superbugs’. Multidrug resistance was initially observed as far back as the late 1950s in strains of 
Escherichia coli, Shigella, and Salmonella.41 Since then, many more MDR bacteria have developed, the 
most prominent example being methicillin-resistant Staphylococcus aureus (MRSA). Methicillin was 
introduced as a treatment to combat penicillin-resistant strains of S. aureus, as methicillin is resistant 
to penicillinases (Figure 5).42 Unfortunately, S. aureus shows a remarkable ability to acquire resistance 
to essentially any antibiotic.43 This means that as well as resistance to penicillins and methicillin, MRSA 
usually shows resistance against aminoglycosides, macrolides, tetracycline, chloramphenicol, and 
lincosamides, leaving vancomycin as the drug of last resort.44 Although still rare, vancomycin-resistant 
strains (VRSA) have also now been observed. In the U.S. alone MRSA now kills ~19,000 people a year 
which is more than emphysema, HIV/AIDS, Parkinson’s disease, and homicide combined,45 as well as 
generating $3-4 billion per annum in additional healthcare costs.46 
 
Figure 5. The structures of methicillin and ciprofloxacin (a widely used fluoroquinolone). 
Another prominent disease prone to multidrug-resistance is tuberculosis (TB), caused by 
Mycobacterium tuberculosis, which accounts for ~1.5 million deaths each year.47 Multidrug-resistant 
tuberculosis (MDR-TB) is a major global concern with 484,000 new cases diagnosed in 2018 across 
every WHO member state (194).47 Some MDR-TB strains now show resistance to both first-line (e.g. 
rifampicin and isoniazid) and second-line treatments (e.g. fluoroquinolones and aminoglycosides) 
(Figure 5). These strains are classified as extensively drug-resistant (XDR-TB) and can require up to two 
years of treatment, amounting to an average cost of €170,744 per case of XDR-TB across 18 EU 
states.48 More concerning still is that strains of Klebsiella pneumoniae, Pseudomonas aeruginosa, and 
Acinetobacter baumannii can now be considered pandrug-resistant (PDR),49,50 that is, they display 
resistance to every currently available antibiotic.51 It is important now more than ever that we discover 
and develop new antibiotics in order to counter this growing threat. 
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1.1.3. Secondary Metabolite Natural Products 
A natural product can be broadly defined as any compound produced by a living organism i.e. found 
in nature. Due to their staggering structural diversity and broad range of properties, natural products 
have played a central role in human history as medicines, perfumes, dyes, flavourings, and 
cosmetics.52-56 As per the classification system proposed by German Nobel Prize winner Albrecht 
Kossel in 1891, natural products can either be considered primary or secondary metabolites.57 By this 
definition, primary metabolites are compounds directly involved in the development, growth, and 
survival of an organism, whereas secondary metabolites are less ubiquitous and are not required to 
keep an organism alive, but can provide beneficial ecological properties. For this reason, a significant 
percentage of secondary metabolites are bioactive, and have attracted considerable interest from the 
pharmaceutical and agricultural industries for their potential commercial applications.  
Secondary metabolites can be further classified based on their biosynthetic origin. Some of the major 
classes and an overview of their biosyntheses are shown in Scheme 1. 
 
Scheme 1. A simplified overview of the biosynthesis of some of the major classes of secondary metabolites.  
Amino acids represent some of the most important building blocks of biological materials. They are 
formed through several processes, but two of the most significant are the shikimate pathway, 
responsible for the production of the aromatic amino acids, and the Krebs cycle (or citric acid cycle) 
which accounts for 10 of the 17 aliphatics. From these, several classes of secondary metabolites are 
derived. This includes the alkaloids, usually distinguished by the presence of one or more basic 
nitrogen atoms (Figure 6). Examples include coniine, the poisonous component of hemlock rumoured 
to have to killed Socrates;58 nicotine, the addictive constituent of cigarettes;59 and epibatidine, a 
potent toxin secreted by an Ecuadorian poison dart frog (Epipedobates tricolor).60 Two of the aromatic 
amino acids, phenylalanine and tyrosine, also form the basis of the phenylpropanoids which include 
curcumin, the bright yellow component of turmeric,61 and naringenin, the predominant flavour in 
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grapefruit.62 Lastly, amino acids can be assembled into complex structures through amide bond 
formations to produce nonribosomal peptides. One prominent example is vancomycin, the famed 
antibiotic of last resort. 
 
Figure 6. Representative examples of some of the major classes of secondary metabolites. 
Acetyl-CoA is an important biological intermediate in which an acetyl group is activated for transfer 
through a thioester linkage to a coenzyme A moiety (Figure 7). As well as being the starting point for 
the Krebs cycle, acetyl-CoA is also the point of divergence for several secondary metabolic pathways. 
This includes the malonic acid pathway leading to fatty acids and polyketides, and the mevalonic acid 
(MVA) pathway leading to terpenes. Interesting secondary metabolites derived from fatty acids 
include (Z)-9-tricosene, an insect pheromone released by bees during the waggle dance,63 and the 
prostaglandins, a family of signalling molecules which produce hormone-like effects in animals.64 
Polyketides and terpenes will be discussed in more detail in Sections 1.1.4. and 2.1.1. respectively. 
 
Figure 7. Structure of coenzyme A (CoA). 
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1.1.4. Polyketide Biosynthesis 
The polyketides are a large and important class of secondary metabolite natural products. As well as 
encompassing a staggering range of complexity and structural diversity, they also display an 
astounding array of useful biological activities including anticancer, antifungal, antibiotic, 
immunosuppressive, and cholesterol lowering properties (Figure 8).65 In fact, approximately 1% of all 
known polyketides display some form of drug activity66 (five times the average for natural products) 
and comprise 20% of the top-selling pharmaceuticals worldwide.67 
 
Figure 8. Representative examples of bioactive polyketide natural products. 
The biosynthesis of polyketides is undertaken by multifunctional enzymes, or multienzyme complexes 
known as polyketide synthases (PKSs).68 Whilst these large systems ultimately produce advanced 
intricate structures, synthesis initially begins from basic building blocks, often acetyl-CoA and 
malonyl-CoA (see Scheme 1, Section 1.1.3.). The biosynthetic pathways of polyketides are very closely 
related to that of fatty acids, and it is therefore helpful to discuss both concurrently.69 In both PKSs 
and fatty acid synthases (FASs) the construction process is undertaken by a series of enzymes, with 
each domain responsible for a single biochemical transformation. These domains can also be grouped 
into modules, which oversee the introduction of one building block onto the growing polyketide chain, 
as well as performing the required reductive processing. 
In both PKSs and FASs the construction process is initiated by a loading module, which involves the 
transfer of an acetyl-CoA unit onto the thiol of an acyl carrier protein (ACP) catalysed by an 
acyltransferase (AT) domain (Scheme 2). The chain extension cycle then begins upon loading of this 
starter acyl unit onto a ketosynthase (KS) domain. At this point, a decarboxylative Claisen-like 
condensation occurs between an ACP-bound extender unit (malonyl-CoA in this example) and the 
KS-bound acyl group resulting in a new C-C bond and a β-keto moiety. From here, the β-ketone can be 
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sequentially processed by a ketoreductase (KR) to an alcohol, a dehydratase (DH) to an 
α,β-unsaturated thioester, and an enoylreductase (ER) to the fully saturated alkyl chain. In FASs this 
full reductive process always occurs, and from here the chain can either be reloaded onto a KS domain 
for further iterative chain extensions or can instead be cleaved by a thioesterase (TE) domain to give 
the fatty acid product. Contrastingly, in PKSs each of these reductive steps are optional and at any 
stage the substrate can be reloaded onto a KS domain for further chain extensions. Similarly, a TE 
domain can act at any point to cleave the chain through hydrolysis, cyclisation, or lactonisation to give 
the required polyketide product.70 
 
Scheme 2. An overview of polyketide and fatty acid biosynthesis. For fatty acids, each chain extension cycle results in the 
complete reduction of the β-ketone (black arrows). For polyketides, the reductive processing can be interrupted at any 
stage. Intermediates can either undergo further chain extensions (red arrows) or hydrolysis by a TE domain (blue arrows). 
Additional complexity can also be installed through alkylation of the growing chain of the polyketide 
at the α-position by a methyltransferase (MT) domain, which utilises S-adenosyl methionine (SAM) to 
introduce a methyl group.71 Alternatively, an α-methyl group may be incorporated into the extender 
unit, for example, as propionyl-CoA. Alkylation at the β-position is also possible but far less common 
and will be discussed in Section 1.1.5. 
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After release of the polyketide product by the TE domain further complexity and diversity may be 
introduced by post-PKS tailoring enzymes. Example transformations include oxidation, O-methylation, 
cyclisation, halogenation, and glycosylation.72 
PKSs can be further classified as type I, II, or III based upon the structural organisation of their domains, 
and the mechanisms by which they act (Figure 9).73 In type I systems enzymes are covalently bound to 
form large multifunctional proteins comprised of numerous domains.69 Conversely, in type II systems 
enzymes are usually monofunctional and instead aggregate to give transient protein complexes.74 
Lastly, type III PKSs exist as relatively small self-contained homodimers with just a single active site on 
each monomer.68 Type III systems are also easily distinguished by their lack of ACP domains, with 
coenzyme A instead used to aid polyketide transfer. 
Type I PKSs can also be described as iterative or modular.75 In iterative systems polyketide chain 
growth is facilitated by a limited set of domains which are reused multiples times, whereas in modular 
(non-iterative) systems each domain acts only once, with the polyketide passed sequentially between 
modules in a process analogous to that of an assembly line.76 Furthermore, modular type I PKSs can 
be subdivided depending on the location and promiscuity of the AT domains. These domains can 
either be embedded within the PKS system and act only once (cis-AT) or can be free-standing enzymes 
(trans-AT) that intercept the growing chain to deliver an extender unit when required, often acting 
throughout the entire pathway.77 
 
Figure 9. Classification system of polyketide synthases. 
1.1.5. β-Branching in Polyketides 
As discussed previously (Section 1.1.4.), functionalisation at the α-position is a common process by 
which complexity and diversity is introduced to polyketides. Similarly, it is also possible, although far 
less common, for polyketides to be derivatised at the β-position in a process known as β-branching.78 
This is primarily observed in trans-AT PKSs (although notable examples do exist in cis-AT systems78) 
and proceeds with a reversal of polarity compared with α-branching, with a nucleophile now required 
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to attack the polyketide at the electrophilic β-position. At the time of writing 11 different types of 
β-branches have been identified within polyketide natural products, with selected examples 
presented in Figure 10. 
 
Figure 10. Examples of polyketide natural products containing β-branches (blue circles). 
Using gene cluster analysis, it was revealed that the introduction of these alkyl branches is undertaken 
by a set of enzymes known as a 3-hydroxy-3-methylglutaryl CoA-synthase (HCS) cassette (Scheme 3).79 
These cassettes are comprised of five standard enzymes: a free-standing ACP, a KS domain lacking the 
cysteine residue required for condensation (thus termed KS0), a 3-hydroxy-3-methylglutaryl synthase 
(HMGS), and two enoyl-CoA hydratases (ECH). Depending on the exact nature of β-branch being 
installed additional tailoring enzymes may also be present. 
The mechanism of β-branching begins with an ACP-bound malonyl unit which is decarboxylated by 
the KS0 domain to give the corresponding thioacetate (Scheme 3).80 This is subsequentially transferred 
onto a cysteine residue in the active site of the HMGS enzyme. From here, the thioacetate is 
deprotonated to give an enolate which then attacks the ketone of an ACP-bound β-keto thioester in 
an aldol reaction. Hydrolysis of HMGS gives the key carboxylic acid intermediate which is then acted 
upon by the first ECH domain in a dehydration process to give an α,β-unsaturated moiety. Finally, the 
second ECH domain catalyses decarboxylation and subsequent reprotonation to give the β-methyl 
branched product. The exact nature of the β-branch that is formed is however dependent upon the 
specific site at which reprotonation of the enolate occurs. The first, and most commonly observed 
mechanism is reprotonation from the γ-position (C-4) giving a conjugated α,β-unsaturated system 
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(endo-alkene). Alternatively, reprotonation can occur from the α-position (C-2) to give a disubstituted 
β,γ-alkene (exo-alkene).  
 
Scheme 3. Mechanism of β-branch incorporation in polyketides by the five enzyme HSC cassette. 
1.1.6. Kalimantacin Antibiotics 
The kalimantacins are a group of bacterial secondary metabolites first discovered by Tokunaga et al. 
in 1996.81 The family consists of three natural products: kalimantacins A, B, and C (Figure 11), which 
were identified during an antibiotic screening program. These compounds were originally isolated 
from the fermentation broth of the Alcaligenes species YL-02632S which was cultured from a soil 
sample collected from the West Kalimantan province of Borneo, Indonesia.82 In more recent years two 
further bacterial species have been found to produce kalimantacins, namely, Pseudomonas batumici 
and Pseudomonas fluorescens.83,84 Elucidation of the skeletal structure was achieved using 2D NMR 
and MS analysis and revealed a linear polyketide backbone functionalised with a diene, a series of 
β-branches, and three carbonyl groups. Whilst similar in structure, the three products can be 
distinguished by the geometry of the diene (E,Z for A and C, E,E for B), and the presence (A and B) or 
lack of (C) a methyl group at C-27. Absolute structural determination was finally achieved in 2017 
through assignment of the five kalimantacin stereocentres and will be discussed in Section 1.1.9. Due 
to its superior antibiotic profile and higher natural abundance, kalimantacin A 1 was selected as the 




Figure 11: Structures of kalimantacins A, B, and C with their relative natural abundances when isolated from Alcaligenes sp. 
YL-02632S. Corresponding MIC values (against S. aureus FDA 209P) are presented in blue.82  
Kalimantacin A 1 is an interesting antimicrobial in that its spectrum of activity is relatively narrow. It 
shows almost exclusive reactivity towards Gram-positive bacteria with high selectivity for 
staphylococci. This includes potent activity against S. aureus and S. epidermidis84 as well as multi-drug 
resistant strains such as MRSA.82,85 This unique property of kalimantacin A has already been exploited 
in Ukraine where it is employed as a staphylococci detector as part of the ‘Diastaph’ procedure.86 The 
clinical development of these types of narrow-spectrum antibiotics is beneficial as they are intrinsically 
less prone to cross-resistance and are associated with fewer side-effects when compared with 
broad-spectrum drugs.87,88  
It is worth noting that kalimantacin A has been referred to as batumin and kal/bat in the literature. 
These different names derive from the fact that until recently the absolute stereochemistry of the 
antibiotic was unknown, and hence, isolates from different bacterial strains could not be conclusively 
assigned as the same compound. Nevertheless, comparison of the batumin (in Pseudomonas batumici 
UCCM_ID9359) and kal/bat (in Pseudomonas fluorescens BCCM_ID9359) producing gene clusters 
reveals a 100% match, irrefutably proving that both pathways produce the same product.84 For clarity 
and conciseness, the name kalimantacin A will be used exclusively throughout this thesis. 
1.1.7. Mode of Action of Kalimantacin Antibiotics 
The specific mechanism by which kalimantacin antibiotics act is through suppression of fatty acid 
biosynthesis in the target organism. In bacteria, fatty acids are produced by type II synthases (FASII), 
in which the final step of each chain extension cycle is the reduction of an enoyl double bond 
(Scheme 4).89 This is catalysed by a trans-2-enoyl-ACP reductase enzyme called FabI, and it is this site 
that is targeted by the kalimantacins.90 As the FASII pathway is essential for cell growth, inhibition of 




Scheme 4. Kalimantacin A targets a trans-2-enoyl-ACP reductase enzyme (FabI), a key step in fatty acid biosynthesis. 
Self-resistance in kalimantacin producing bacteria stems from the presence of the BatG enzyme. 
Whilst encoded for by the kalimantacin gene cluster, this domain was found (through gene knock-out 
studies) not to be involved in the actual biosynthesis.90 Rather, BatG is an isoform of FabI and is 
responsible for conferring complete resistance to the producing organism. It was also shown to be 
capable of aiding FabI in its role in fatty acid biosynthesis. 
Another potential mechanism of self-resistance is through efflux of an inactive kalimantacin A 
precursor, with transformation to the active antibiotic undertaken once outside the cell. This process 
is very common in nature.91 In the case of kalimantacin A, these late-stage modifications are a 
carbamoylation (BatF) and an oxidation of the C-17 alcohol (BatM) which reverses the action of the 
KR domain in Bat2 module 5 (see Scheme 6, Section 1.1.8.). Prior to this final oxidation the diol 
intermediate displays a drastic drop in activity (~60-fold) compared with the final antibiotic.84 
1.1.8. Kalimantacin Biosynthesis 
In 2010 the gene cluster responsible for kalimantacin A biosynthesis in P. fluorescens was revealed by 
the Lavigne group.84 Elucidation was achieved using BLAST (basic local alignment search tool) analysis 
to identify likely sequences through comparison of the genome with related polyketide producing 
bacteria.92 These bioinformatic predictions were then validated using disruption mutagenesis.93 A 
series of gene knock-out experiments were undertaken and resulted in all mutants displaying a 
complete loss of antibiotic activity, thus confirming their involvement in kalimantacin biosynthesis. 
Sequencing of the kalimantacin A gene cluster revealed a modular type I PKS system, encoded by three 
large open reading frames (ORFs) i.e. translatable sections of a nucleotide sequence that are 
bookended by start and stop codons (Bat1-3). Further analysis also revealed the presence of 
free-standing AT domains, thereby classifying the PKS as trans-AT. 
Although the majority of the kalimantacin A backbone is polyketide in origin, the biosynthetic pathway 
also contains a small cis-acting nonribosomal peptide synthase (NRPS) module, meaning the system is 
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actually a PKS-NRPS hybrid.94 This NRPS module is responsible for the introduction of a glycine moiety 
into the polyketide backbone and is comprised of three domains. Here, the amino acid is activated 
and loaded by an adenylation domain (A) onto a peptidyl carrier protein (PCP), which in this system 
occupies the role of an ACP unit. Amide bond formation is then catalysed by a condensation domain 
(C) to complete the glycine incorporation. The remaining sections of the chain are constructed by the 
PKS and are derived from 11 malonyl-CoA building blocks. 
Alongside the PKS-NRPS, further modifications to the kalimantacin A backbone are performed by a 
series of trans-acting tailoring enzymes. These include a carbamoyl transferase (BatF) and a 
short-chain dehydrogenase (BatM) which finalise the transformation to biologically active 
kalimantacin A,84 as well as an enoylreductase (BatK). Also present is an HCS cassette (BatA-E) 
responsible for the introduction of the four β-branches. This is of particular interest from a mechanistic 
standpoint as the kalimantacins uniquely contain three different types of β-branches, which are 
installed sequentially by the same HCS cassette. An understanding of the underlying mechanism by 
which these processes are controlled was recently achieved through work in our group (Scheme 5).95 
 
Scheme 5. The three mechanisms of β-branch (blue circles) incorporation in kalimantacin A. The standard HCS cassette is 
comprised of five enzymes (BatA-E) and is supplemented by a modular ECH and a trans-acting ER (BatK). 
As discussed previously (Section 1.1.5.), β-branching is generally controlled by a cassette of five 
enzymes. To this end, kalimantacin A is no different, with the standard domains (BatA-E) leading to 
the production of the endo-alkene product, with BatE crucially controlling decarboxylation and 
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subsequent reprotonation at C-4. From here, further reduction is possible through the action of an 
enoylreductase (BatK) which demonstrates remarkable control in acting only at specific points in the 
pathway to give a saturated-β-methyl branch. Most intriguingly however, is the introduction of the 
exo-alkene product. Whilst it was shown that the formation of the exo-alkene branch was catalysed 
by a cis-acting ECH domain, the exact mechanism of action remained unclear, with two different 
pathways possible. The ECH could intercept the dehydrated intermediate before BatE could act, 
thereby catalysing decarboxylation and subsequent reprotonation at C-2. Alternatively, the ECH could 
catalytically isomerise the endo-alkene product to the exo-alkene, once BatE has already acted. 
Through partial reconstitution of the pathway, and a series of in vitro isotope labelled NMR assays, it 
was shown that it is the former route that takes place.95 




Scheme 6. The biosynthetic pathway of kalimantacin A. The gene cluster encodes for three large ORFs (Bat1-3) that constitute 
a type I trans-AT PKS. Also contained within the PKS is an NRPS module which installs a glycine moiety. The PKS is 
supplemented by several trans-acting domains including an AT (BatJ), an ER (BatK), a carbamoyl transferase (BatF), a 
short-chain dehydrogenase (BatM), and an HCS cassette (BatA-E) responsible for β-branching. 
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1.1.9. Elucidation of the Relative and Absolute Stereochemistry of Kalimantacin A 
Owing to its potent and selective antibiotic properties and its unique biosynthesis kalimantacin A has 
attracted significant interest since its discovery in 1996. Despite this attention, the absolute and 
relative stereochemistry of kalimantacin A remained unknown for over 20 years. This is in part due to 
its complex linear structure and also because kalimantacin A exists a viscous oil meaning X-ray 
crystallography has not been possible. 
Initial structural determinations were carried out by Tokunaga et al. who correctly identified the 
skeletal structure of kalimantacin A (as well as B and C).81 Through a combination of simple NMR 
experiments they also assigned the geometry of the three internal double bonds. The trisubstituted 
alkene was assigned as E in accord with an nOe observed between 2-H and 4-H, and the diene moiety 
was characterised as 10Z and 12E based on the magnitude of the coupling constants in the proton 
spectrum (11 Hz and 15 Hz respectively). 
The relative and absolute stereochemistry of kalimantacin A was ultimately determined in 2017 by 
researchers in our group.96 In this work the five remaining unknown stereocentres of kalimantacin A 
were assigned, as well as a sixth stereocentre present in the kalimantacin A precursor, diol 4. This was 
achieved through a combination of NMR spectroscopy, bioinformatics, natural product degradation, 
and target synthesis. The crux of this research was two degradation studies of kalimantacin diol 4: an 
ozonolysis to give lactone 5, and a Grubbs metathesis to give alkene 6 (Scheme 7). Enantioselective 
synthesis of each compound gave standards for comparison of NMR and optical rotation data. For 
lactone 5 all data was a complete match, thus revealing the 15S, 19R, 26R, and 27R stereocentres of 
kalimantacin A, as well as the 17S stereocentre in diol 4. Similarly, the (S)-enantiomer of alkene 6 was 
prepared and was also shown to be an exact match by NMR. However, the optical rotation was found 
in this case to be equal and opposite (+5.0), and therefore, the enantiomer of degradation fragment 
6. Thus, the final stereocentre of kalimantacin A was assigned as 5R. 
 
Scheme 7. Absolute stereochemical elucidation of kalimantacin A was achieved through NMR experiments, degradation 
studies, and target synthesis.97  
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1.2. Project Aims 
With the absolute stereochemistry of kalimantacin A 1 now known, the goal of this project was to 
complete the first enantioselective total synthesis. This was to be undertaken in a convergent fashion 
in order to reduce the overall longest linear sequence and to allow for the rapid production of 
analogues. These are desired for antibacterial studies to assess structure-activity relationships and 
also for use as substrates to further investigate the kalimantacin biosynthetic pathway. In particular, 
it is of interest to further probe the processes responsible for β-branching in order to determine how 
control and selectivity is achieved. The route was to also form the basis of several other total syntheses 
including kalimantacins B (2) and C (3), as well as other minor kalimantacin metabolites that are 
difficult to produce naturally in significant quantities, such as Z,Z-diene 7 (Figure 12). 
 
Figure 12: Initial synthetic target kalimantacin A and some potential future targets of interest. Structural differences to 
kalimantacin A are highlighted in red.
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1.3. Results and Discussion 
 1.3.1. Isolation and Semi-Synthetic Studies of Kalimantacin A 
Prior to commencing work on the total synthesis, it was first decided that synthetic manipulations of 
the natural product itself would provide valuable insights into planned late-stage transformations. For 
this, it was necessary to obtain significant quantities of kalimantacin A. This was achieved through 
slight modifications to a procedure reported by Lavigne and co-workers for the growth, isolation, and 
purification of the natural product from P. fluorescens (strain BCCM_ID9359).84 Firstly, the bacterium 
was grown on a tryptose-agar plate and left to culture for 18 hours (at 25 °C). A single colony was then 
used to inoculate fermentation media (consisting of Lysogeny broth and glucose) which was 
subsequently shaken for a further 24 hours (Figure 13). Aliquots of the preculture were then added to 
250 mL flasks of the media and were shaken for an additional 96 hours (at 16 °C). The cells were then 
separated from the solution through centrifugation and the resulting supernatant was extracted with 
ethyl acetate. At this stage, the original procedure called for purification by HPLC,84 however, this was 
not amenable to large-scale production. Instead, it was found that kalimantacin A could be purified 
effectively through column chromatography (4-10% MeOH in DCM) to provide the product in high 
purity and titres (65 mg/L).  
     
Figure 13. Various stages of the kalimantacin A growth and isolation procedure. A preculture sample (left), growth media 
(middle), and centrifuged cells (right). 
With kalimantacin A 1 in hand, semi-synthetic experiments were undertaken, the first aim of which 
was to develop a protecting group strategy for the total synthesis. If protecting groups could be added 
to the natural product, and then successfully removed, then these could be incorporated into the total 
synthesis with the knowledge that the final steps of the route were already complete. Hence, the 
carboxylic acid was methylated using TMS-diazomethane to give methyl ester 8, and the 19-OH was 
tert-butyldimethylsilyl (TBS) protected under standard conditions to give corresponding silyl ether 9 
in 81% yield over two steps (Scheme 8). 
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Scheme 8. TBS protection and methylation of kalimantacin A, 1. 
Next, conditions for the removal of the protecting groups were investigated. TBS deprotection 
proceeded cleanly with TBAF in 89% yield to give 8, however, hydrolysis of the methyl ester proved 
more challenging (Scheme 9). This is likely to due to the conjugated nature of the ester which 
decreases its electrophilicity compared to the saturated equivalent. When treated with LiOH or 
Ba(OH)2 at room temperature only starting material was recovered, however, reactivity was observed 
upon heating the solution to 60 °C. Interestingly, the methyl ester still remained intact but a retro-aldol 
reaction occurred to give methyl ketone 10. Use of boron tribromide as a more reactive demethylating 
agent was also investigated,98 however, only degradation was observed in this case. 
 
Scheme 9. TBS deprotection of silyl ether 9 and retro-aldol fragmentation of β-hydroxy ketone 8. 
Given the limitations imposed by undesirable chemoselectively and reagent incompatibility, less 
conventional approaches were investigated. Pleasingly, success was achieved using the mild 
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conditions of an esterase enzyme isolated from pig livers (Scheme 10). With the natural product 
successfully regenerated via TBS deprotection and ester hydrolysis, these steps could now be 
incorporated into the total synthesis. 
 
Scheme 10. Hydrolysis of ester 8 using porcine liver esterase. 
A further use of the isolated kalimantacin A was for the preparation of analogues for antibiotic testing 
to give insights into structure-activity relationships. A logical place to begin this work was with the 
interesting retro-aldol reaction observed with methyl ester 8 (Scheme 9). Similarly, treatment of 
kalimantacin 1 with LiOH at 60 °C led to fragmentation to methyl ketone 11, thus allowing the 
bioactivity of the short-chain acid 11, methyl esters 8 and 10, and kalimantacin A 1 to be compared 
(Scheme 11). 
 
Scheme 11. Fragmentations of kalimantacin A to 11 and 12. 
Additionally, heating kalimantacin 1 in toluene at 110 °C for three days gave pyrrole 12 in 56% yield. 
This is proposed to result from attack of the carbamoyl nitrogen into the amide bond (Scheme 12). 
Following cleavage, the resulting amine spontaneously cyclises into the ketone, and from here, 
dehydration and subsequent rearrangement gives the aromatic product.  
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Scheme 12. Proposed mechanism of pyrrole 12 formation. 
Both 11 and 12 may provide a more in-depth understanding of the importance of various structural 
features of kalimantacin A for biological activity. These derivatives also share striking similarities to 
another natural product, fatty acid 13 (Figure 14), isolated from freshwater sponges collected from 
the Sea of Galilee.99 Crucially, the methyl ester of this compound also shows bioactivity against 
Gram-positive bacteria including S. aureus. 
 
Figure 14. Structure of 13, a bioactive product found in freshwater sponges. 
1.3.2. Retrosynthetic Analysis of Kalimantacin A 
Our goal was develop a versatile approach for the synthesis of kalimantacin A, which could be readily 
adapted for the preparation of analogues and putative biosynthetic intermediates. With this in mind, 
retrosynthetic analysis was undertaken (Scheme 13). The first obvious disconnection was that of the 
amide bond, giving carboxylic acid F and amine E, with the alcohol protected as the silyl ether and the 
carboxylic acid masked as the methyl ester. The E,Z-diene could be installed though a 
palladium-catalysed cross-coupling, with a Suzuki reaction selected initially (although Hiyama, Stille, 
and Negishi couplings were also viable). This disconnection gave E-vinyl boronic acid (or ester) C, with 
the amine masked as the azide, and Z-vinyl iodide D as the other coupling partner. The boronic acid 
could undergo one further disconnection to give electrophilic Fragment A as an aldehyde or Weinreb 
amide, and nucleophilic Fragment B as either the Grignard reagent (prepared from the alkyl bromide) 
or the corresponding organolithium species (prepared from the alkyl iodide). 
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Scheme 13. Initial retrosynthetic analysis of kalimantacin A gave six key fragments (A-F). 
1.3.3. Synthesis of Fragments A and B 
Synthesis of the electrophilic A fragments began from ethyl (R)-(+)-4-chloro-3-hydroxybutyrate 14 
(Scheme 14). This relatively cheap ester proved a good starting material as it contained an 
(R)-stereocentre at the site which would become the C-19 position in kalimantacin A. The first step 
was an SN2 substitution of the chloride using sodium azide to introduce the nitrogen functionality, 
which proceeded cleanly at 100 °C to give 15 in 89% yield. This was followed by TBS protection of the 
free hydroxyl to give silyl ether 16. Reduction of the ester using DIBAL at −78 °C gave the first coupling 
partner, aldehyde 17 in 85% yield over three steps. Alternatively, the ester could be hydrolysed to 
carboxylic acid 18 using Ba(OH)2, then coupled with N,O-dimethylhydroxylamine hydrochloride to give 
the second potential coupling partner, Weinreb amide 19 in 70% yield over four steps. 
 
Scheme 14. Synthesis of aldehyde 17 and Weinreb amide 19 (Fragment A). 
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The synthesis of Fragment B was initially undertaken through modification of a procedure reported 
by Ireland,100 starting from (R)-Roche ester 20. Again, this was advantageous as the starting material 
already contained what would become the (15S)-stereocentre of kalimantacin A. The first step was 
protection of the free hydroxyl using freshly prepared benzyl trichloroacetimidate101 to give ether 21 
(Scheme 15). This was followed by reduction of the ester using LiAlH4, and conversion of the resulting 
alcohol, 22, to the corresponding tosylate, 23. 
 
Scheme 15. Synthesis of tosylate 23. 
At this juncture the original Ireland procedure called for substitution of the tosylate using 1.5 
equivalents of an ethylenediamine complex of lithium acetylide to give alkyne 24 in 83% yield.100 When 
this was repeated in our hands however, it was found that a 2:1 mixture of inseparable products was 
obtained. From the 1H NMR of the mixture it could be seen that the major product was indeed the 
desired terminal alkyne and that the minor product, whilst structurally similar, contained an additional 
methyl peak at 1.80 ppm. This could be explained by isomerisation of 24, with the alkyne migrating 
from the terminal to the internal position to give 25 (Scheme 16). 
 
Scheme 16. SN2 substitution of tosylate 23 with lithium acetylide. 
Following this result, the literature was further reviewed and it was found that lithium acetylide can 
catalyse the conversion of 1-alkynes to 2-alkynes at room temperature.102 Furthermore, it was 
reported by Tyman that the main factor influencing isomerisation is the molar excess of the lithium 
acetylide present, and not the concentration.103 With this in mind, the reaction of tosylate 23 was 
repeated using only a single equivalent of the lithium acetylide complex, and pleasingly, it was found 
that desired alkyne 24 was obtained as a single product in 94% yield (Scheme 17). Following the 
successful optimisation of the acetylenation, the alkyne was silyl protected to give TMS-alkyne 26. 
 
Scheme 17. Synthesis of TMS-alkyne 26. 
The next required step was deprotection of the benzyl ether, however, the presence of the alkyne 
moiety now rendered standard hydrogenation conditions unsuitable. Instead, a single electron 
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transfer (SET) reagent was required, with lithium 4,4′-di-tert-butylbiphenylide (LiDBB) 29 used in this 
case. This reagent was freshly prepared and began with a Friedel-Crafts alkylation of biphenyl 27 using 
tert-butyl chloride (Scheme 18A). The resulting biaryl species, (DBB) 28, was then treated with lithium 
metal to produce LiDBB in situ. Formation of the single electron species could be monitored by the 
colour change of the solution from a pale yellow to a deep blue (Scheme 18B). 
 
Scheme 18A. Preparation of LiDBB 29. B. Colour change during LiDBB formation, taken over 15 minutes. 
Once prepared, the LiDBB solution was added slowly to benzyl ether 26. This promoted rapid 
deprotection to alcohol 30, with the reaction deemed complete once the blue colour persisted. Two 
different Appel reactions were then employed to convert alcohol 30 to either alkyl bromide 31 (26% 
over seven steps) as the precursor to the Grignard reagent, or alkyl iodide 32 (31% over seven steps) 
as the precursor to the organolithium species (Scheme 19). 
 
Scheme 19. Synthesis of alkyl bromide 31 and alkyl iodide 32 (Fragment B). 
Whilst these routes provided a robust method for the preparation of the desired organohalides they 
were lengthy and time consuming given the relative simplicity of the target compounds. It was 
therefore desirable to develop a more efficient synthesis containing fewer linear steps, however, the 
available pool of appropriate chiral starting materials was very limited. With this in mind, an 
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enantioselective approach using Evans auxiliary 33 was investigated as a potentially more practical 
option. Gratifyingly, treatment of 33 with NaHMDS and alkyl bromide 34 gave 35 in good yield and 
diastereoselectivity (Scheme 20). Furthermore, both reagents were commercially available, although 
if desired, auxiliary 33 can be prepared from oxazolidinone 36 in a single step and alkyl bromide 34 
can be prepared from propargyl alcohol 37 in two steps to reduce costs. Reductive cleavage of the 
auxiliary using LiBH4 provided alcohol 30, the same intermediate as the original synthetic route 
(Scheme 19), but in four fewer steps. The auxiliary was also recoverable in up to 85% yield if required. 
As before, two different Appel reactions could be performed to provide alkyl bromide 31 (37% over 
three steps) and alkyl iodide 32 (45% over three steps). 
 
Scheme 20A. Optimised syntheses of alkyl bromide 31 and alkyl iodide 32 (Fragment B). B. Synthesis of coupled Evans 
auxiliary 33. C. Synthesis of bromide 34. 
1.3.4. Towards the Synthesis of Fragment C 
With synthetic routes to the two versions of Fragment A (17 and 19) and Fragment B (31 and 32) now 
established, a series of reactions were undertaken to optimise the conditions for coupling. Firstly, the 
use of a Grignard reagent was investigated, which required conversion of bromide 31 to the 
organometallic species using magnesium. Surprisingly, this transformation proved to be unattainable, 
even using a variety of forcing conditions, such as, activating the bromide at elevated temperature 
whilst using magnesium etched either with iodine or 1,2-dibromoethane (DBE). To help determine the 
viability of this route a model study was undertaken with a commercially available and structurally 
similar Grignard reagent, isobutylmagnesium bromide. Interestingly, addition of this species to 
Weinreb amide 19 unexpectedly gave lactam 40 rather than desired ketone 39 (Scheme 21). 
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Scheme 21. Attempted synthesis of ketone 39 resulted in the synthesis of lactam 40.  
This is believed to result from attack of the nucleophile at the internal nitrogen of the azide rather 
than the carbonyl of the amide (Scheme 22). Nitrogen gas is then lost, and the resulting amine adds 
into the carbonyl to form the five-membered ring. This intermediate is stabilised through chelation of 
the methoxy group until aqueous work-up releases the substituted lactam product. 
 
Scheme 22. Proposed mechanism for the synthesis of lactam 40 from 19. 
This result, whilst intriguing, does reveal that the azide moiety is incompatible with Grignard reagents. 
Furthermore, addition of organolithium 41 to Weinreb amide 19 or aldehyde 17 led only to 
degradation, with no discernible products observed (Scheme 23). Due to this functional group 
intolerance it was decided that the azide should be installed later in the route. 
 
Scheme 23. Attempted synthesis of ketone 42 through organolithium addition to Weinreb amide 19 and aldehyde 17. 
The next investigated approach was to use the corresponding chloride, 44. Following the previously 
established procedure, alcohol 44 was again protected as the TBS ether, with subsequent DIBAL 
reduction providing aldehyde 46 in 89% yield over two steps (Scheme 24). Ester 45 was also converted 
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directly to Weinreb amide 47 through activation of the amine using isopropyl magnesium chloride in 
87% yield over two steps.  
 
Scheme 24. Synthesis of aldehyde 46 and Weinreb amide 47 (Fragment A). 
The reactive organolithium species was prepared at low temperature through lithium-halogen 
exchange of iodide 32 with tert-butyllithium. However, addition of this species to amide 47 provided 
no conversion to the desired ketone, 48 (Scheme 25). It could be seen from the 1H NMR that no 
starting iodide was present, implying the organolithium was formed successfully, however, no 
consumption of amide 47 was observed even upon warming to room temperature. The equivalent 
reaction with aldehyde 46 did provide some conversion to alcohol 49, with the resulting mixture of 
diastereomers oxidised to ketone 48 in 24% yield over two steps. 
 
Scheme 25. Synthesis of ketone 48 via organolithium addition to aldehyde 46 followed by DMP oxidation. 
Whilst ketone 48 had now been successfully prepared, the overall yield was poor and needed to be 
optimised. Hence, the reaction was investigated further and a number of interesting observations 
were noted. Firstly, if the reaction was warmed to ~−20 °C during lithium-halogen exchange an 
intramolecular rearrangement occurred to generate two enantiomeric cyclobutylidene organolithium 
species, 50 (Scheme 26). At first this seemed counterintuitive as Baldwin’s rules suggest that the 
5-endo-dig cyclisation should be preferred over the 4-exo-dig, resulting in a lithiocyclopentene.104 
However, recent revisions of these rules have revealed that an obtuse angle of approach (~120°) is 
preferred over the originally assigned acute (~60°) as this better satisfies the stereoelectronic 
requirements of attack into the alkyne π*-orbital (Scheme 26A).105 The resulting thermodynamic 
driving force for both the exo and endo cyclisations are therefore very similar. It is thought that 
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complete regioselectivity is observed in this case as the lithium atom is transferred intramolecularly 
through stereoselective syn-addition, whereas the equivalent transition state for the 5-endo-dig 
process is geometrically unattainable (Scheme 26B).106 It is also worth noting that if the alkyne is 
substituted with an alkyl group rather than a trimethylsilyl (TMS), no cyclisation is observed.106 This 
indicates that the silyl substituent also plays an important role in the stabilisation of the developing 
carbanion. Once formed, the resulting cyclobutylidene organolithium species adds to the aldehyde, 
giving a mixture of diastereomeric enones, 51, after oxidation (Scheme 26C). 
 
Scheme 26A. Proposed attack trajectory in the cyclisation of alkynes by Baldwin (left, 60°) and the more recently revised 
angle of approach (right, 120°).105 B. Intramolecular delivery of the lithium atom results in stereoselective syn-addition.106 
C. Synthesis of enone 51 as a mixture of diastereomers. 
A second observation was that at low temperature (−78 °C) only poor consumption of the aldehyde 
was observed even when two equivalents of the nucleophile were used. It was however found that 
an increase in temperature also led to an increase in conversion, with a temperature of ~0 °C required 
to attain full consumption of the aldehyde. 
Lastly, it was found that even in cases where desired alcohol 49 was formed, a side-reaction occurred 
in which the resulting alkoxide attacked the chloride in an SN2 substitution to give tetrahydrofuran 52 
(Scheme 27). Curiously, only a single diastereomer was isolated from this reaction and so the 1H NMR 
of the crude material was revisited. Indeed, it was found that peaks corresponding to the other 
uncyclised product did appear to be present as approximately 50% of the mixture, although this 
compound was not isolated. This is proposed to result from one of the diastereomers possessing a 
lower activation barrier for cyclisation, and therefore reacting more rapidly. The stereochemistry of 
52 was not elucidated in this case. 
 
Scheme 27. Synthesis of ether 52 as a single but unassigned diastereomer.  
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The main conclusions drawn from these studies are as follows: 
1) That lithium-halogen exchange must occur at <−20 °C to avoid rearrangement. 
2) That the temperature must be raised slowly once the aldehyde has been added to the 
organolithium reagent to maximise conversion. 
3) That the chloride is not compatible with the coupling conditions. 
This will be revisited in Section 1.3.7. 
1.3.5. Synthesis of Fragment D 
The route towards Fragment D was based largely upon previous work in our group for the preparation 
of synthetic standards for the stereochemical elucidation of kalimantacin A 1.96 The synthesis began 
with the cheap starting material γ-butyrolactone 53, which underwent ring-opening in the presence 
of sodium hydroxide to give the linear dianion. This was doubly TBS protected before the silyl ester 
was selectively hydrolysed to give carboxylic acid 54 in 79% yield (Scheme 28). The next stage was the 
stereoselective introduction of a methyl branch that would become the (5R)-centre in kalimantacin A. 
This was achieved using an Evans auxiliary, with the acylation of the oxazolidinone initially investigated 
through activation of acid 54 with ethyl chloroformate, before addition of the deprotonated 
auxiliary.107 Whilst this provided desired product 55 in 61% yield, the procedure was arduous due to 
the requirement of reagents to be transferred at low temperature. This was further exacerbated by 
the poor solubility of the deprotonated oxazolidinone, which was found to precipitate and block 
syringes and cannulas. Instead, an alternative procedure was preferred in which acid 54 was activated 
with pivaloyl chloride before auxiliary 36 and lithium chloride were added in single portions as 
solids.108 This provided an increase in yield to 75%. Methylation of 55 with NaHMDS and methyl iodide 
proceeded with excellent diastereocontrol to give 56. Subsequent cleavage of the auxiliary to alcohol 
57 was followed by an Appel reaction to give alkyl iodide 58 in 67% yield over two steps. 
 
Scheme 28. Synthesis of alkyl iodide 58. 
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The next stage of the synthetic approach required stereoselective formation of the trisubstituted 
E-alkene. This was to be undertaken via carbocupration of methyl but-2-ynoate 61 through adaption 
of a procedure developed by Snyder.109 Firstly, alkyl iodide 58 was converted to the organolithium 
species by lithium-halogen exchange with tBuLi, whilst a trimethylsilylmethylcopper solution was 
prepared by reacting copper iodide with trimethylsilylmethyllithium (Scheme 29A). The resulting 
species, 60, was added to organolithium 59 to produce a new mixed cuprate in which the 
trimethylsilylmethyl group acted as an activating but non-transferable ligand.109,110 Addition of 
but-2-ynoate 61 resulted in syn-addition of the cuprate across the triple bond to give an enolate-like 
intermediate which was quenched at low temperature to give E-alkene 62 as a single isomer. The 
choice of solvent was important for this reaction as it has been shown that the enolate-like 
intermediate equilibrates more rapidly in diethyl ether, resulting in a mixture of isomers 
(Scheme 29B).111,112 The TBS group of 62 was removed under acidic conditions to yield primary alcohol 
63 giving the C-1 to C-7 fragment of kalimantacin A. 
 
Scheme 29A. Stereoselective synthesis of E-alkene 62 and deprotection to alcohol 63. B. Isomerisation of the intermediate 
copper ‘enolate’ occurs under raised temperatures or in diethyl ether. 
The C-8 to C-11 fragment 67 was readily prepared by conversion of alcohol 64 to bromide 67 in three 
steps through TMS protection to 65, formation of tosylate 66, then substitution with lithium bromide 
(Scheme 30A). This could also be achieved in two steps via an Appel reaction, but it was previously 
shown that bromide 67 was difficult to separate from the bromoform by-product, which could 
potentially interfere with the Grignard addition.97  
Alcohol 68 was oxidised to aldehyde 69 using Dess-Martin periodinane (DMP), then treated with the 
Grignard reagent formed from bromide 67 (Scheme 30B). The resultant alcohol, 70, was oxidised using 
DMP to give ketone 71 in 68% yield over three steps. 
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Scheme 30A. Synthesis of alkyl bromide 67. B. Synthesis of ketone 71. 
The next stage was the installation of the exo-alkene through methylenation of ketone 71. This 
conversion had been undertaken previously on this compound, as well as structurally similar 
analogues.97 In this work, organometallic reagents were found to be best suited for this transformation 
rather than other conventional reactions such as the Wittig olefination. A Tour methylenation 
(Cp2ZrCl2, Zn, CH2I2) was employed in these instances, however, yields were inconsistent ranging from 
25-59%.113 It was therefore desirable to establish a more robust approach. Firstly, the use of Petasis 
reagent was investigated which gave desired product 72 but only in 44% yield (Scheme 31).114 More 
success was found using conditions developed by Takai115 and Lombardo116 who employed a 
titanium-based reagent. This reaction provided 72 in a modest yield of 58% but was found to be 
robust, reproducible, and scalable. The drawback to this procedure was that the reaction required 10 
days to reach completion at room temperature. Efforts were made to optimise the reaction time, but 
heating of the solution led only to degradation, and the use of reportedly more reactive conditions117 
(TiCl4, Zn, PbI2, CH2I2) provided no increase in rate. 
 
Scheme 31. Synthesis of alkene 72 via Petasis or Lombardo methylenations. 
TMS-alkyne 72 was converted directly to iodoalkyne 73 using silver trifluoroacetate salt and 
N-iodosuccinimide (NIS) (Scheme 32). Unfortunately, it was found that the subsequent reduction to 
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Z-vinyl iodide 74 using dicyclohexylborane was unsuccessful, with only degradation observed. This is 
likely due to the incompatibility of the exo-methylene to the reductive conditions. Instead it was 
decided that alkyne 75 provided a more practical target for use in a Sonogashira coupling. Thus, the 
silyl group of 72 was removed using potassium carbonate in methanol to give desired product 75 
(Fragment D) in 10% yield over 14 steps. 
 
Scheme 32. Attempted synthesis of vinyl iodide 74 and synthesis of alkyne 75 (Fragment D). 
1.3.6. Revised Retrosynthetic Analysis of Kalimantacin A 
Following the difficulties in synthesising vinyl iodide 74, and the incompatibility of the functional 
groups in the organolithium coupling of Fragments A and B, the synthetic route to kalimantacin A was 
revised (Scheme 33). With alkyne 75 in hand, the obvious answer was to undertake a Sonogashira 
coupling to introduce an enyne moiety, which could in turn be stereoselectively reduced to give the 
E,Z-diene. This also required revision of Fragment C to the vinyl iodide coupling partner. Additionally, 
a redesign of Fragment A was required as both azide 17 and chloride 46 led to degradation 
(Schemes 23 and 25) or unwanted side-reactions (Scheme 27). In this case, a PMB protected alcohol 
was selected which should be stable to the harsh coupling conditions. The strategy was to then install 
the nitrogen functionality later in the route through PMB deprotection, mesylation of the alcohol, and 
SN2 substitution using sodium azide. 
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Scheme 33. Revised retrosynthetic analysis of kalimantacin A, 1. 
1.3.7. Revised Synthesis of Fragments A and C 
The revised synthesis of Fragment A was undertaken in five steps using a procedure developed by 
Solladié (Scheme 34).118 The route began with (S)-glycidol 76, with the stereocentre of the epoxide 
encoding for the stereochemistry of the kalimantacin A 19-OH. The first step was protection of the 
primary alcohol to give PMB ether 77, before the epoxide was ring opened selectively at the terminal 
position using vinyl cuprate. The resulting secondary alcohol, 78, was TBS protected before the alkene 
was transformed to the desired aldehyde. This was undertaken in two steps via a Lemieux-Johnson 
oxidation which proceeded through dihydroxylation of the alkene followed by oxidative cleavage of 
the resultant diol, 80. This gave aldehyde 81 (Fragment A) in five steps and 68% overall yield. 
 
Scheme 34. Synthesis of aldehyde 81 (Fragment A). 
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With aldehyde 81 and alkyl iodide 32 now in hand the organolithium coupling was revisited. Following 
the previously optimised conditions (Section 1.3.4.) the alkyl iodide was maintained at −78 °C during 
lithium-halogen exchange, with the temperature slowly raised after addition of aldehyde 81 
(Scheme 35A). Pleasingly, desired ketone 82 was observed after oxidation, however, a significant 
quantity of an inseparable by-product was also formed as the major component. By 1H NMR a peak 
corresponding to a tert-butyl group was observed indicating that competitive addition of tBuLi to the 
aldehyde had occurred. To verify this, a test reaction was carried out in which tBuLi was added to 
aldehyde 81 in the absence of iodide 32, and indeed, ketone 83 was isolated as the sole product 
following oxidation (Scheme 35B). 
 
Scheme 35A. Synthesis of ketone 82 also gave formation of by-product 83. B. A test reaction showed competitive addition 
of tBuLi to give ketone 83. 
This outcome could only result from significant quantities of tBuLi being present in the solution during 
the aldehyde coupling. This meant that either the organolithium species was not forming fully or that 
too large an excess of tBuLi was being used. Following this, the lithiation time was increased from five 
minutes to one hour (whilst maintaining low temperature) and on a small scale (25 mg of aldehyde) 
this was found to be sufficient to supress the formation of undesired ketone 83. On a larger scale 
however (300 mg of aldehyde), significant quantities of the by-product were still observed. In these 
cases, it was found that lowering the equivalents of tBuLi from two to 1.5 (with respect the aldehyde) 
was sufficient to supress by-product formation. Gratifyingly, following these optimisations desired 
ketone 82 was isolated as a single product in 76% yield over two steps (Scheme 36). 
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Scheme 36. Optimised synthesis of ketone 82. 
With a robust and high yielding route to ketone 82 now developed, attention was turned to the 
installation of the vinyl iodide functionality. This first required deprotection of the TMS group using 
potassium carbonate in methanol to give alkyne 85, which surprisingly only provided a modest yield 
of 54% (Scheme 37A). It transpired that this was due to a side-reaction in which the TBS alcohol 
undergoes an E1CB elimination to the enone, followed by an oxa-Michael addition with the methanol 
solvent to give β-methoxy ketone 86 as mixture of diastereomers (Scheme 37B). 
 
Scheme 37A. Deprotection of TMS-alkyne 82 also showed formation of by-product 86. B. Mechanism of 86 formation.119 
This issue was easily circumvented by changing the order of the reactions such that deprotection was 
undertaken before oxidation of alcohol 88 to ketone 85 (Scheme 38). In this case TMS deprotection 
proceeded cleanly, with subsequent oxidation yielding ketone 85 in 87% yield over two steps.  
 
Scheme 38. Revised synthesis of alkyne 85. 
With alkyne 85 in hand, formation of the vinyl iodide could now be investigated. This was undertaken 
via the formation of vinyl stannane 89 under radical conditions, followed by an in situ quench with 
iodine to give desired E-vinyl iodide 90 with 4.5:1 selectivity (Scheme 39). Conversion of the stannane 
to the iodide was near instantaneous, with reaction progress monitored by the rapid colour change of 
the solution. Once the dark red of the iodine persisted the transformation was deemed complete, 
giving desired coupling partner 90 (Fragment C) in 71% yield. 
Results and Discussion 
39 
 
Scheme 39. Synthesis of vinyl iodide 90 (Fragment C) via the vinyl stannane. 
1.3.8. Synthesis of Fragment E 
With Fragments C (90) and D (75) now in hand, the next key coupling was undertaken, with a 
Sonogashira reaction providing desired enyne 91 in 73% yield (Scheme 40). However, the next stage 
was a PMB deprotection and this unfortunately proved to be unachievable. Various conditions were 
investigated including the use of DDQ,120 ceric ammonium nitrate,121 and TMSI122 with degradation 
observed in each case. It was suspected that the unstable β-hydroxy ketone moiety was once again 
causing issues and so masking of the ketone was also attempted. Again, efforts at reducing (NaBH4) or 
protecting (dithiane, acetonide) the ketone were unsuccessful, with degradation or no reaction 
observed in each instance.  
 
Scheme 40. Synthesis of enyne 91 via a Sonogashira coupling. 
Given the repeated issues caused by the presence of the ketone it was decided that this functionality 
should be masked throughout the majority of the route and released nearer to the end of the 
synthesis. With this in mind, it was decided that alcohol 88 should be protected, rather than oxidised 
to the ketone, even though it meant working with a mixture of diastereomers. The choice of protecting 
group at this stage was important, as it needed to be orthogonal to TBS and PMB, and also be able to 
be deprotected in the presence of a conjugated ester, an enyne, and an exo-methylene. Given these 
limitations, an acetyl group was selected. Pleasingly, esterification of alcohol 88 proceeded in excellent 
yield to give acetate 92 (Scheme 41). Crucially, deprotection could also be undertaken in near 
quantitative yield under mild conditions (K2CO3, MeOH) to regenerate alcohol 88. A model 
deprotection of the PMB group of 92 with DDQ gave primary alcohol 93 in 95% yield which showed 
promise for later stages of the synthesis. As before, alkyne 92 was converted to vinyl iodide 95 via 
stannane 94 in excellent yield. It is worth noting however, that on a larger scale (above 100 mg) a side-
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reaction occurred providing an inseparable by-product. This is thought to result from 
protodestannylation of the vinyl stannane which is a known problem with reactions of this type.123 
Although the by-product was not isolated, key peaks were observed in the 1H NMR of the crude 
material that were indicative of the terminal alkene of 96.  
 
Scheme 41. Synthesis of acetate 92 and deprotection to alcohols 88 and 93. Alkyne 92 was converted to vinyl iodide 95 via 
vinyl stannane 94, which showed significant protodestannylation on a scale greater than 100 mg. 
The Sonogashira coupling was undertaken using the same conditions as before, with enyne 96 isolated 
in 64% yield (Scheme 42). However, it was once again found that PMB deprotection led only to 
degradation, possibly due to the oxidative DDQ conditions being incompatible with the enyne 
system.124 
 
Scheme 42. Synthesis of enyne 96. Attempted PMB deprotections were unsuccessful. 
Again, this issue could be circumvented through a change in the order of the reactions. Thus, first the 
PMB group was removed from vinyl iodide 95 to give alcohol 97, which in turn, was converted to 
mesylate 98 in 75% over two steps (Scheme 43). The Sonogashira reaction between vinyl iodide 98 
and alkyne 75 gave desired enone 99 in 88% yield. Displacement of the mesylate by sodium azide 
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proceeded cleanly at 80 °C to give 100 in 85% yield. This was pleasing as work by Maeda had found 
that the steric bulk of the TBS group had impeded transformation on a structurally similar 
compound.125 Now that the construction of the C-1 to C-20 backbone of kalimantacin A had been 
completed, attention was next turned to reduction of the azide to amine 101. To this end, a Staudinger 
reduction was employed, with a variety of conditions investigated including the use of 
trimethylphosphine,126 tributylphosphine,127 and polymer bound triphenylphosphine,128 however, 
degradation or no reaction was observed in all cases. Interestingly, treatment of 100 with 
triphenylphosphine at first appeared to be successful,129 with all of the anticipated signals accounted 
for by 1H and 13C NMR, as well as the expected molecular ion identified by MS. However, upon 
repeating the reaction a minor product was noted in the 1H NMR of the crude material. Upon closer 
inspection it was revealed that the only major difference in the spectra of the two products was the 
chemical shift of the 20-H2 signals adjacent to the nitrogen. Intriguingly, these proton signals in the 
new minor component were an exact match with what was expected from structurally similar amines 
(~2.70-2.60 ppm).130 Conversely, the same signals in the original product were approximately 0.60 
ppm further downfield than expected (3.40-3.10 ppm). 
 
Scheme 43. Synthesis of azide 100. Attempted Staudinger reduction gave an unidentified dimeric product. 
Reassessment of the MS data also revealed that whilst the mass of the desired product was present 
(m/z of 576), so was a mass approximately double that of the amine (m/z of 1177), implying that some 
form of dimerisation had taken place. Given the complexity of the product, and the number of steps 
required to prepare it, further structural determination was extremely difficult. Instead, it was decided 
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that useful insights into the reaction could be more easily obtained by undertaking model studies on 
azide 16, a structurally similar but less complex analogue.  
To this end, azide 16 was subjected to the same Staudinger conditions as 100 (PPh3, THF, H2O), and as 
before, a mixture of two products resulted (Scheme 44A). The first of these was the desired amine, 
102, but again a by-product was formed with spectral data that closely matched with the dimeric 
product seen previously. Further analysis revealed this compound to be urea 103, with a characteristic 
signal observed in the 13C NMR spectrum at 158 ppm. A review of the literature revealed that 
formation of the urea was possible through an aza-Wittig reaction between the iminophosphorane 
intermediate and carbon dioxide in air.131,132 With this new information to hand, characterisation of 
the reduction product of 100 was revisited, and indeed, further analysis of the spectral data confirmed 
it to be urea 104 (Scheme 44B). 
 
Scheme 44A. Staudinger reduction of azide 16 gave amine 102 and urea 103. B. Staudinger reduction of azide 100. 
A further model reaction with 16 was undertaken in parallel under similar conditions to the Staudinger 
reduction except with the addition of di-tert-butyl dicarbonate (Boc2O) (Scheme 45). The reasoning 
was that if the amine was forming but then undergoing further reactions, then perhaps it could be 
trapped as the Boc protected product before any side-reactions could take place. This proved to be 
partially true with some of carbamate 105 obtained, however, another new by-product was also 
isolated, carbodiimide 106. The key piece of data in this assignment was the diagnostic IR stretching 
frequency at 2136 cm−1. 
 
Scheme 45. Staudinger reduction of azide 16 with Boc2O gave carbamate 105 and carbodiimide 106. 
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A proposed mechanistic explanation for each of these products is given in Scheme 46. All substrates 
initially undergo the desired Staudinger reduction to give the intermediate iminophosphorane 107. 
From here, hydrolysis yields the desired amine 102, and if Boc2O is present then this amine can be 
protected to give carbamate 105. Alternatively, the iminophosphorane can instead undertake an 
aza-Wittig reaction with the carbon dioxide present in air to give the four-membered ring, which in 
turn collapses to isocyanate 108. A molecule of amine 102 then attacks the carbonyl to give 
intermediate 109. In the absence of Boc2O, this species simply protonates at the nitrogen to give urea 
103 but if the anhydride is present then carbonate formation occurs at the oxygen to give 110. With 
the carbonate now constituting a good leaving group, elimination can occur to give carbodiimide 106. 
 
Scheme 46. Proposed mechanism for the formation of the Staudinger reduction products, including urea 103 (red arrows) 
and carbodiimide 106 (blue arrows). 
The conclusion of these studies was that all by-product pathways could be avoided if the reaction was 
conducted in the absence of carbon dioxide. The Staudinger reduction of azide 16 was therefore 
repeated using degassed solvents and a nitrogen atmosphere, and gratifyingly, was found to produce 
amine 102 as the sole product in 60% yield (Scheme 47A). Pleasingly, application of these conditions 
to azide 100 was also successful, giving amine 101 (Fragment E) in 54% yield (Scheme 47B).  
Results and Discussion 
44 
 
Scheme 47A. Staudinger reduction of azide 16 using degassed solvents and an inert atmosphere gave amine 102. B. 
Synthesis of amine 101 (Fragment E). 
1.3.9. Synthesis of Fragment F and Final Steps 
With Fragment E now in hand, attention was next turned to the preparation of Fragment F, the final 
coupling partner which contained the remaining two stereocentres of kalimantacin A. The first of 
these was obtained through the use of a chiral starting material, poly-(R)-3-hydroxybutanoate 111, 
which was hydrolysed under acidic conditions in ethanol and dichloroethane to give the corresponding 
monomer, ester 112.133 The second stereocentre was then set via a Fráter-Seebach methylation,134 
which proceeded with excellent stereocontrol using LDA and methyl iodide to give 113 (Scheme 48). 
At this juncture, the alcohol needed to be protected before the ester was hydrolysed to give the 
corresponding carboxylic acid. Both the PMB (81% yield over two steps)97 and TBS (59% yield over two 
steps)130 protected derivatives have been reported in the literature, however, these groups would be 
incompatible with Fragment E (Scheme 101). PMB deprotection conditions have been shown 
previously to lead to degradation, and the TBS group is already in use so is not orthogonal. It was 
therefore necessary to develop a new protecting group strategy, and thus, the use of TMS and TES 
groups were investigated. Whilst it was found that both silyl ethers could be formed efficiently (114 
and 115 respectively), the subsequent hydrolyses of the ethyl esters were problematic (Scheme 48). 
For both substrates degradation was observed under all trialled conditions (LiOH, NaOH, Ba(OH)2), 
with TESOH the only discernible product isolated from either reaction. This observation indicates that 
E1CB elimination could be a potential competing reaction. 
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Scheme 48. Studies towards the synthesis of Fragment F. 
Following these results, the next logical approach was to attempt a reversal in the order of the 
reactions. Hydrolysis of hydroxy ester 113 proceeded smoothly with Ba(OH)2 to give carboxylic acid 
118 in 78% yield. From here, TMS protection could be undertaken successfully but the reaction 
required purification via column chromatography, after which, only starting alcohol 118 was isolated. 
Switching to the more stable TES group offered a partial solution, with silyl ether 117 now isolated in 
48% yield. However, the reaction was difficult to reproduce, with no product isolated in the majority 
of cases. Finally, formation of protected carbamate 119 was investigated using trichloroacetyl 
isocyanate. As the carbamate functionality is present in kalimantacin A this approach could avoid the 
need for further protecting group manipulations. Whilst it was found that carbamoylation of 118 was 
possible in situ (monitored by 1H NMR), attempted isolation of the product led only to degradation, as 
did efforts to cleave this intermediate to the hydrolysed product, 120.  
Following these difficulties, it was decided that the amide coupling should be attempted with the 
unprotected alcohol, with the logic being that a primary amine should outcompete a secondary 
alcohol as a more effective nucleophile. Upon review of the literature, it was found that couplings of 
this type were indeed possible through the use of COMU® (Scheme 49A).135 
Pleasingly, the reaction between amine 101 (Fragment E) and acid 118 (Fragment F) in the presence 
of COMU® and DIPEA in DMF provided amide 121 in 88% yield (Scheme 49B). This was particularly 
satisfying as it removed the need for protecting groups and the difficulties associated with their 
preparation, and also represented the final proposed key coupling in the synthesis of kalimantacin A. 
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Scheme 49. Synthesis of amide 121. 
Installation of the terminal carbamoyl group was achieved using trichloroacetyl isocyanate, followed 
by hydrolysis of the trichloroacetate in situ (Scheme 50). This was previously shown to be possible 
through the use of aluminium oxide which would give 122,130 however, if potassium carbonate in 
methanol was implemented, then simultaneous deprotection of the acetate could also be achieved to 
give alcohol 123. This was followed by DMP oxidation of the epimeric stereocentre to provide ketone 
124 in 93% yield over three steps. 
 
Scheme 50. Synthesis of ketone 124. 
Next, conditions for the reduction of enyne 124 to the E,Z-diene were investigated. Generally this 
transformation is undertaken through hydrogenation with a sufficiently poisoned palladium 
catalyst,136 however, in this case the presence of an exo- and an endo-alkene made the risk of 
over-reduction a possibility. Instead, partial reduction was investigated using zinc activated with 
copper and silver (Scheme 51).137 At elevated temperatures the reaction proceeded with complete 
stereocontrol to give the Z-alkene exclusively, providing diene 9 in 88% yield. Pleasingly, the optical 
rotation of this compound (+2.0, c 1.00, CHCl3) was an exact match with the reference material 
prepared through semi-synthesis from the natural product (see Scheme 8, Section 1.3.1.). 
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Scheme 51. Synthesis of Kalimantacin A 1. 
From here, TBS deprotection and ester hydrolysis were undertaken using the previously established 
conditions (Schemes 9 and 10). This provided the first ever synthetic sample of kalimantacin A, thereby 
completing the total synthesis in 2.3% overall yield with a longest linear sequence of 24 steps. 
Additionally, the route was undertaken enantioselectively, setting all five stereocentres as well the 
E,Z-diene geometry. HPLC, 1H NMR, and 13C NMR data for both synthetic and natural samples of 
kalimantacin A can be seen in Figures 15, 16, and 17 respectively. 
 
Figure 15. Comparison of HPLC traces for synthetic kalimantacin A (red) and the natural product isolated from 
P. fluorescens (blue). Samples were run on a Phenomenex LUNA column (5 μM, C18, 100 Å, 10 × 250 mm) with a gradient of 
5-95% MeCN in water with 0.05% formic acid. 
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Figure 16. Comparison of 1H NMR spectra for synthetic kalimantacin A (red) and the natural product isolated from 
P. fluorescens (blue). Samples were run on 500 MHz spectrometer in CDCl3. 
 
Figure 17. Comparison of 13C NMR spectra for synthetic kalimantacin A (red) and the natural product isolated from 
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1.4. Conclusions and Future Work 
In conclusion, the first total synthesis of kalimantacin A has been completed with a longest linear 
sequence of 24 steps and an overall yield of 2.3%. This began with investigations into protecting group 
strategy, with semi-synthetic manipulations of the natural product revealing that the hydroxyl and 
carboxylic acid groups could be masked as the TBS ether and methyl ester respectively (Scheme 52).  
 
Scheme 52. Semi-synthetic manipulations and retrosynthesis of kalimantacin A 1. 
Retrosynthetic analysis was undertaken with the goal of creating a convergent synthetic route to 
facilitate the future preparation of derivatives (Scheme 52). This identified three key disconnections: 
the amide bond, adjacent to the ketone, and between the E,Z-diene to provide four starting Fragments 
(A, B, D, and F), each of which were prepared via robust and high yielding synthetic routes. These 
fragments incorporated the five stereocentres of kalimantacin A making the total synthesis 
enantioselective. Two of these stereocentres were obtained by selecting enantiopure starting 
materials, two were set through the use of a chiral auxiliaries, and one was set via a Fráter-Seebach 
methylation. The route also included three key couplings, namely, an organolithium addition to an 
aldehyde to join Fragments A and B, a Sonogashira reaction to join Fragments C and D, and an amide 
coupling to join Fragments E and F. The geometry of the E,Z-diene was also set through stereoselective 
reduction of an enyne using zinc activated with copper and silver. An overview of the total synthesis 
can be seen in Scheme 53.  
With a robust, convergent, and enantioselective synthesis of kalimantacin A achieved, the above 
strategy could now be adapted to allow for the preparation of other interesting natural products such 
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as kalimantacins B (E,E-diene) and C (methylene at C-27), as well as minor metabolites that are difficult 
to produce naturally in significant quantities, such as the Z,Z-diene (7). The modular nature of the 
route should also expedite the synthesis of novel analogues for SAR studies, the design of which will 
be based on X-ray crystallography and molecular dynamics simulations of kalimantacin A with FabI 
(currently unpublished work). Furthermore, preparation of polyketide 13 (Figure 14) should be facile 
using this approach, which would allow access to an additional class of antibiotic. 
 









2. New Strategies to Bioactive Targets 





2.1.1. Terpene Biosynthesis 
One of the largest and most recognisable classes of secondary metabolites are the terpenes, which 
are comprised of repeating five-carbon isoprene units. This unique feature, known as the isoprene 
rule, was first formulated by German Nobel Prize winner Otto Wallach in 1887.138 This research was 
further developed by Leopold Ružička who also won a Nobel Prize for his work in this area.139 
 
Scheme 54A. An overview of the biosynthesis of various classes of terpenes.140 B. The mechanism of chain elongation.141 
As is shown in Scheme 1, terpene biosynthesis occurs through the MVA pathway142 starting from 
acetyl-CoA (although in some plants and bacteria an alternate or secondary process called the methyl 
erythritol 4-phosphate (MEP) pathway may be used143). The function of this pathway is to produce 
two metabolites, isopentenyl pyrophosphate (IPP), and its isomer, dimethylallyl pyrophosphate 
(DMAPP). These two units constitute the building blocks of terpene biosynthesis and combine in an 
iterative fashion to create products of increasing complexity (Scheme 54A).140,144 The mechanism of 
chain elongation has been studied extensively by Cornforth,145 Poulter, and Rilling146 and in simple 
terms begins with elimination of the pyrophosphate of DMAPP to generate a cation via an SN1 type 
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process (Scheme 54B). This is followed by attack by IPP which proceeds with stereospecific 
deprotonation of the pro-R proton. In reality, this mechanism is far more complex with the kinetics 
lying somewhere between an SN1 and SN2’ type procedure, resulting from the influence of enzymes 
on the conformation and stability of the transition states.141 
The simplest terpenes, hemiterpenes (C5), consist of a single isoprene unit and are derived directly 
from DMAPP. Alternatively, condensation of DMAPP and IPP gives geranyl pyrophosphate (GPP) the 
precursor to monoterpenes (C10). From here, further repeated condensations with IPP give farnesyl 
pyrophosphate (FPP), the precursor to sesquiterpenes (C15) and geranylgeranyl pyrophosphate 
(GGPP), the precursor to diterpenes (C20). Further complexity is introduced through combination of 
these larger pyrophosphate intermediates. For example, condensation of two FPP units gives the 
triterpenes (C30) and condensation of two GGPP units gives the tetraterpenes (C40). Representative 
examples of terpenes and terpenoids are shown in Figure 18. 
 
Figure 18. Representative examples of terpenes and terpenoids. 
2.1.2. Pleuromutilin Antibiotics 
Pleuromutilin 125 is an antibiotic secondary metabolite first reported by Kavanagh in 1951 
(Figure 19).147 It was initially isolated from two Basidiomycete species, Pleurotus passeckerianus (now 
Clitopilus passeckerianus) and Pleurotus mutilis (now Clitopilus scyphoides), but has since been found 
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to be produced by 11 different Clitopilus species.148 Kavanagh observed that pleuromutilin was “a 
white, crystalline substance with antibacterial activity” and identified the compounds molecular 
formula (C22H34O5) and molecular weight (378 g/mol).147 In the following year, structural studies were 
published by Anchel, who correctly assigned two of the oxygens as non-phenolic hydroxyls, and one 
as a hindered carbonyl group.149 She tentatively assigned the final two oxygens as lactones, but this 
was incorrect, and they were later revealed to belong to an ester. Around a decade later, the complete 
structural formula was elucidated independently by Birch at Manchester and Arigoni at Zürich.150,151 
This work revealed the unique tricyclic diterpenoid core of pleuromutilin, which consists of fused five-, 
six- and eight-membered rings, and eight stereocentres. The final stereochemistry was assigned in 
1968 using X-ray crystallography and optical rotatory dispersion data of a bromoacetate derivative.152 
 
Figure 19. Structure of pleuromutilin with the Arigoni numbering system. 
The unconventional numbering system Arigoni used to assign pleuromutilin has become 
commonplace in pleuromutilin research and will be employed throughout this report (Figure 19).  
Initial antibacterial tests by Kavanagh showed pleuromutilin was active primarily against 
Gram-positive bacteria, including all tested Staphylococcus, Streptococcus, and Enterococcus 
strains.147 Activity was also observed against certain strains of Gram-negative bacteria, such as 
Klebsiella pneumoniae. Further antibiotic studies were carried out by Knauseder and Brandl in 1976, 
who showed that pleuromutilin was active against drug-resistant bacteria such as penicillin- and 
streptomycin-resistant staphylococci.153 Pleuromutilin also showed high activity against Mycoplasma 
spp., which is important as these bacteria possess an intrinsic resistance to β-lactam antibiotics.154,155 
Pleuromutilin antibiotics have been used extensively in veterinary medicine for nearly 50 years, and 
human medicine for around a decade. All currently marketed pleuromutilin antibiotics are 
semi-synthetic derivatives, synthesised from pleuromutilin naturally produced through the industrial 
fermentation of C. passeckerianus. Since the 1960s over 3000 pleuromutilin analogues have been 
developed, with the aim of increasing the drugs metabolic stability, decreasing its minimum inhibitory 
concentration (MIC), and extending its spectrum of activity.156 Modifications have primarily focused 
on the C-14 ester side-chain, which consists of a glycolic acid residue bound to the core through an 
ester linkage (Scheme 55). This was quickly identified as a good site for modification, as activation and 
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substitution of the primary hydroxyl allows for more complex functionality to be incorporated in a 
short number of synthetic steps, which is ideal for pharmaceutical screening programmes. 
 
Scheme 55. Derivatisation of the C-14 side-chain. LG = OMs, OTs, or I. X = S, NH, or O. Base = NEt3, NaOH, or NaOEt. 
There are currently three marketed pleuromutilin drugs, all of which consist of thioether linkages from 
C-22. Derivatives possessing this thioglycolic acid side-chain show significantly improved MIC values 
relative to pleuromutilin.157 
The first pleuromutilin antibiotic approved for use was tiamulin (Figure 20). It was first synthesised in 
1975 at Sandoz as part of an extensive screening programme and reached the market in 1979.158 It is 
currently sold as the fumarate salt by Novartis under the trade name Denagard®. It possesses a similar 
spectrum of activity to pleuromutilin, targeting Gram-positive bacteria and Mycoplasma spp., 
however, its MIC exceeds that of the parent compound by a factor of 10 to 50.159 In the case of 
Mycoplasma gallisepticum an MIC as low as 0.0039 μg/mL was recorded.158 it has been used 
extensively in veterinary medicine for the treatment of pigs and poultry for Mycoplasma- and 
Brachyspira-related diseases, such as swine dysentery.160,161 
The second analogue approved for commercial use was valnemulin in 1999 (Figure 20). It is marketed 
by Novartis as the hydrochloride salt under the trade name Econor®. Valnemulin is also used in the 
treatment of pigs and poultry for Mycoplasma- and Brachyspira-related diseases, as well as Lawsonia 
intracellularis, a bacterial species that causes porcine proliferative enteropathy (ileitis).162 It has also 
seen sparing use in the treatment of calves with Mycoplasma bovis infections.163 Although both 
antibiotics have a similar spectrum of activity, valnemulin was found to be 100 times more active than 
tiamulin against Mycoplasma hyosynoviae.164 
 
Figure 20. Structures of veterinary pleuromutilin analogues tiamulin and valnemulin. 
Both antibiotics have been used extensively as treatments and preventative medicines since their 
introduction. Tiamulin has also been marketed in the U.S. as a growth promoter.165 The drugs are 
primarily administered orally through drinking water or by premixing into the animals feed, although 
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tiamulin is also available as an injectable formulation for pigs.166 Importantly, resistance to tiamulin 
and valnemulin has been found to develop slowly, and despite the liberal usage of these antibiotics 
for several decades, no significant signs of resistance have yet been observed.164,166 There are however 
a growing number of reports detailing an increase in the MICs of both antibiotics against Brachyspira 
hyodysenteriae strains.167-169 
In 2007 retapamulin became the first, and currently only, pleuromutilin analogue to be approved for 
use in humans (Figure 21). It is a topical antibiotic marketed as Altabax® and Altargo® by 
GlaxoSmithKline and is used in the treatment of impetigo. Its approval for use in 2007 made it the first 
new prescription topical antibiotic to be released in more than 20 years.170 A significant advantage of 
retapamulin is that it shows a low potential for resistance development in S. aureus and S. pyogenes 
strains, a similar trend to that seen with the other marketed pleuromutilin antibiotcs.171,172 This can 
likely be attributed to the unique and highly specific mode of action of pleuromutilin drugs which limits 
the chances of cross-resistance developing from other antibiotic classes (see Section 2.1.4.).170 
 
Figure 21. Structures of topical pleuromutilin analogues retapamulin and BC-7013. 
Further analogues for human use are under development by the biopharmaceutical company Nabriva 
Therapeutics AG, who specialise in pleuromutilin antibiotics. They currently have three pleuromutilin 
drugs in clinical development. The first of these, BC-7013 (Figure 21), is being developed as a topical 
treatment for uncomplicated skin and skin structure infections (uSSSI). It was found to be the most 
active compound against common Gram-positive bacteria such as S. aureus, S. pyogenes and S. 
agalactiae when compared with currently available topical antibiotics.173 It is also shown to be four to 
eight times more potent than retapamulin.173 A second analogue, BC-3205 (Figure 22), possesses a 
similar spectrum of activity and is also in early-stage clinical development. It does however differ in its 
ADMET (absorption, distribution, metabolism, excretion and toxicity) properties, and can 
consequently be developed for oral administration.174 
The third analogue is BC-3781, or lefamulin (Figure 22). It is being developed as the first pleuromutilin 
antibiotic for systemic use in humans, with both intravenous and orals formulations being 
investigated. It has been granted fast track status by the U.S. Food and Drug Administration (FDA), a 
designation reserved for the development of drugs that treat serious conditions and fill an unmet 
medical need.175 It is currently in Phase III clinical trials. Lefamulin is of particular interest for its potent 
Introduction 
57 
activity against community-acquired bacterial pneumonia (CABP) and is the first new antibiotic class 
to reach late-stage clinical development for CABP in over a decade.175 It also shows strong activity 
against staphylococci, streptococci, and enterococci including methicillin- and vancomycin-resistant 
strains.176 The unique mode of action of pleuromutilin drugs means that lefamulins activity is not 
affected by the resistance of bacteria to other antibiotic classes.177 
 
Figure 22. Structures of systemic human pleuromutilin analogues BC-3205 and lefamulin (BC-3781). 
2.1.3. Metabolism of Pleuromutilin Antibiotics 
Initial investigations into the metabolic stability of pleuromutilin were performed by Berner in 1983.178 
He showed that when pleuromutilin was exposed to cytochrome P450 (CYP) oxidation occurred at the 
cyclopentanone and cyclohexane rings. From these studies three metabolites were isolated and 
characterised, and it was found that stereoselective hydroxylation had occurred at C-1, C-2, and C-8. 
Although tiamulin has been a marketed antibiotic since 1979, it was not until 2006 that the first studies 
into its metabolic stability were undertaken. In these experiments Lykkeberg subjected tiamulin 
hydrogen fumarate 126 to pig liver microsomes in order to replicate the conditions encountered 
during veterinary usage.179 In accord with the findings of Berner, hydroxylation was observed at the 
C-2 and C-8 positions (Scheme 56). A third metabolite was also observed in which de-ethylation of the 
ester side-chain had occurred. Importantly, each of these compounds exhibited essentially no 
antibiotic activity.179 This metabolic inactivation of tiamulin has raised concerns about the potential of 
pleuromutilin drugs for use in human medicine. It is hoped that the recent developments of drug 
candidates such as lefamulin will allow these concerns to be dismissed. 
 
Scheme 56. Tiamulin metabolites produced in pig liver microsomes. R = C(O)CH2SCH2CH2NEt2.179 
2.1.4. Mode of Action of Pleuromutilin Antibiotics 
Antibacterial drugs can be broadly categorised based on their mode of action. Most antibiotics fall 
into one of three classes, and target either bacterial cell-wall biosynthesis (e.g. β-lactams and 
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vancomycin), DNA replication and repair (e.g. fluoroquinolones), or protein biosynthesis (e.g. 
tetracyclines and aminoglycosides).180 Pleuromutilins fall into the last of these categories with their 
mode of action revealed by Hodgin and Högenauer at Sandoz in 1974.181 Their results showed that 
pleuromutilins are unable to inhibit the formation of the initiation complexes responsible for protein 
production. In prokaryotes, the 30S pre-initiation complex consists of the 30S ribosomal subunit, 
mRNA, N-formylmethionine (fMet) tRNA, guanosine triphosphate, and three initiation factors. The 
30S complex then associates with the 50S ribosomal subunit to form the 70S initiation complex 
(Figure 23).182 Instead, they found that pleuromutilin antibiotics interfere with the peptidyl 
transferase centre (PTC), the part of the ribosome responsible for forming peptide bonds between 
amino acids.183 With peptide bonds unable to form, protein biosynthesis cannot take place. 
 
Figure 23. Structure of the 70S initiation complex in prokaryotes. 
More recent work using chemical footprinting, molecular docking studies, and X-ray crystallography 
has revealed the specifics of the pleuromutilin binding site.184-187 The binding pocket is located at the 
central part of domain V of 23S rRNA and is occupied by the rigid tricyclic core of the drugs. This section 
of the ribosome is located within the A-site of the 50S subunit. When bound, the mutilin core of the 
antibiotics overlap with the binding pocket of A-site tRNA substrates, furthermore, the C-14 side-chain 
partially extends into the P-tRNA binding site (Figure 24). Both of these factors hamper tRNA 
association in the ribosome, consequentially inhibiting peptide bond formation. 
The binding of pleuromutilins causes a structural rearrangement of rRNA, with two key nucleotides, 
U2506 and U2585 most affected (Figure 24), both of which have been shown to be essential for 
ribosomal activity.188 The induced structural alterations cause U2506 to fold around the bound 
antibiotic, tightening the binding site via an induced-fit mechanism.189 This structural modification is 
stabilised by hydrophobic interactions between U2506 and the tricyclic core. U2506 is further 
stabilised by interactions with U2585, which moves into a more favourable position to avoid the 
pleuromutilin C-14 side-chain. Other important interactions include hydrogen bonding between the 
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carbonyl of C-21 and G2061, and further hydrophobic and hydrogen bonding interactions between 
the tricyclic core and nucleotides A2503, U2504, G2505, and C2452.189 
 
Figure 24. The overlap of lefamulin with the A- and P-sites of the PTC, taken from the Nabrivia website190 (left) and a 
close-up of lefamulin bound in the PTC (right). Dashed lines represent hydrogen bonds. Taken from Eyal (2016).191 
Whilst the specific mode of action of pleuromutilin drugs is unique, other antibiotics such as 
oxazolidinones, lincosamides, phenicols, and streptogramins also target 23S rRNA and have been 
shown to partially overlap with the pleuromutilin binding site.186 This can allow mechanisms to 
develop that mediate cross-resistance to pleuromutilin drugs, although thus far, only limited cases 
have been reported.172,192,193 Resistance can also arise via spontaneous mutation, but again, the 
occurrence rate is very low. When tested against S. aureus, the rate of spontaneous mutation for 
retapamulin was the lowest of all the investigated antibiotics, except for linezolid.171 It also showed 
the single lowest rate of spontaneous mutation when tested against S. pyogenes.171 
2.1.5. Pleuromutilin Biosynthesis 
The first investigations into the biosynthesis of pleuromutilin were undertaken by the groups of 
Birch194 and Arigoni152,195,196 in the 1960s. Using 14C labelled acetic acid and mevalonate lactone Birch 
proved that pleuromutilin is diterpenoid in nature (Scheme 57).194 
 
Scheme 57. Isotopic labelling studies using [1-14C]-acetic acid (red circles) and [2-14C]-mevalonic lactone (blue circles) 
revealed pleuromutilins diterpenoid nature. 
In 1976 Knauseder and Brandl carried out large-scale fermentations of C. passeckerianus with the goal 
of isolating pleuromutilin intermediates or related compounds.153 Culture growth was undertaken in 
a 1000 L fermenter and a time-course was performed to measure the rate at which pleuromutilin was 
produced. Antibiotic production was observed within the first 48 hours during the latter part of the 
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trophophase (the phase in which primary metabolites are formed). Production continued at a 
diminishing rate into the idiophase (the phase in which secondary metabolites are formed) with 
maximum yield achieved after six days. After fermentation was complete, the dried mycelia of the 
fungus were analysed. Several compounds were extracted and characterised, including pleuromutilin 
125, mutilin 129, the novel metabolite 14-O-acetyl-mutilin 132, and a series of pleuromutilin esters.153 
It was incorrectly presumed that mutilin and 14-O-acetyl-mutilin were end products of a secondary 
biosynthetic pathway of pleuromutilin, and not intermediates of the primary pathway as was later 
revealed. 
Further work was undertaken by Hasler in 1979 in which 14C-labelled analogues of 
3-deoxo-11-dehydroxy-mutilin 127, 3-deoxo-mutilin 128, and mutilin 129 were fed to cultures of 
Pleurotus mutilus (Figure 25).197 From each of these experiments 14C-labelled pleuromutilin was 
isolated, providing strong evidence that all three of these compounds were intermediates in the 
biosynthetic pathway. This was further validated in an independent study undertaken by Tsukagoshi 
et al. in 2007 using the same three analogues labelled with 2H rather than 14C.198 The deuterated 
compounds were this time fed into cultures of Clitopilus pseudo-pinsitus, with isotopically labelled 
pleuromutilin again recovered in each case. 
 
Figure 25. Pleuromutilin biosynthetic intermediates proven through 14C (blue circles) and 2H (red circles) labelling studies. 
The final insights into the biosynthetic pathway were revealed by studying of the genes responsible 
for pleuromutilin production. This was largely aided by the existence of gene clusters, a phenomenon 
observed in fungi whereby the genes that encode for a given pathway are often grouped together on 
the chromosome, facilitating their identification and characterisation.199 The putative gene cluster 
responsible for pleuromutilin biosynthesis in C. passeckerianus was elucidated and patented in 2013 
by the Bailey group.200 As pleuromutilin is a diterpenoid it was hypothesised that the gene cluster may 
contain a pathway-specific geranylgeranyl pyrophosphate synthetase gene (ggs). By screening the 
DNA library of C. passeckerianus, four ggs genes were identified, with one being novel. This gene was 
located only once in the genome and was found to be highly expressed under pleuromutilin producing 
conditions meaning it was likely responsible for the production of the pleuromutilin precursor 
geranylgeranyl pyrophosphate 130 (GGPP). Subsequent genome walking and sequencing work 
identified six further genes: a cyclase (cyc), an acetyltransferase (ATF), a short-chain 
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dehydrogenase/reductase (SDR) and three P450s which constituted the putative pleuromutilin gene 
cluster (Figure 26). 
 
Figure 26. The pleuromutilin gene cluster. Adapted from Bailey (2016).201 
Following this, focus was turned to increasing the low titres (8 mg/L) of pleuromutilin obtained from 
the native host. This was initially attempted via genetic manipulation of C. passeckerianus using 
procedures previously established in the Bailey group.202 Using this methodology, transformants of 
C. passeckerianus were created in which the seven genes of the putative gene cluster were 
overexpressed.201 Surprisingly, a decrease or complete loss of pleuromutilin production was observed 
in several cases. This is likely due to co-suppression, a phenomenon which occurs in genetically 
modified plants, animals, and fungi whereby the introduction of a transgenic copy of a gene into the 
organism results in the gene silencing of both the transgene and the endogenous gene. 
Co-suppression has been observed in other basidiomycete species and is a major hinderance to 
genetic manipulation.203,204 Unfortunately, C. passeckerianus also requires long growth times during 
fermentation and proved unamenable to strain improvement techniques.205 
  
Figure 27. The fungi Clitopilus passeckerianus148 (left) and Aspergillus oryzae206 (right). 
To circumvent this issue, pleuromutilin biosynthesis was recreated de novo in a second fungus which 
would act as a heterologous host. Aspergillus oryzae (Figure 27), an ascomycete, was chosen for this 
function as it had been successfully used as a host organism in the recreation of the biosynthesis of 
the secondary metabolites aphidicolin and tenellin.207,208 The putative gene cluster (Figure 26) was 
cloned and expressed in A. oryzae using a multi-gene expression system developed by Pahirulzaman 
et al.209 Using this methodology pleuromutilin production was successfully recreated.201 This was the 
first example of heterologous basidiomycete gene cluster expression in an ascomycete host, and 
crucially, it showed that only seven genes were required to successfully recreate the pleuromutilin 
biosynthetic pathway. Pleuromutilin titres were also found to be much higher in A. oryzae than in the 
native producer. One transformant showed a 10-fold increase in yield relative to C. passeckerianus, 
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and when fermentation times were taken into consideration this rose to 20-fold. Furthermore, 
A. oryzae is more amenable to genetic modification than C. passeckerianus, so yields could potentially 
be increased through further manipulation such as random mutagenesis. Application of heterologous 
expression has also allowed for the investigation of the catalytic function of the enzymes involved in 
the biosynthetic pathway. This led to the isolation and characterisation of each of the biosynthetic 
intermediates, including a previously unreported compound, triol 131 (Scheme 58A). 
The full pleuromutilin biosynthetic pathway and the mechanism of cyclisation is shown in Scheme 58. 
 
Scheme 58A. The biosynthetic pathway of pleuromutilin. Enzymes represented by coloured circles. Adapted from Alberti 
(2015).205 B. The proposed mechanism of cyclisation of GGPP 130 to 3-deoxo-11-dehydroxy-mutilin 127.201  
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2.2. Project Aims 
The aim of this project was to test the substrate specificities of the enzymes involved in pleuromutilin 
125 biosynthesis, with an initial focus on the final two steps of the pathway, acetylation and 
hydroxylation. To achieve this, analogues of the biosynthetic intermediate mutilin 129 were to be 
prepared through semi-synthesis starting from commercially available tiamulin hydrogen fumarate 
126, then fed to A. oryzae transformants containing ATF and P450-3 genes expressed from 
C. passeckerianus (Scheme 59). Enzyme promiscuity could then be assessed by monitoring whether 
biotransformations occurred with the modified derivatives, rather than the native substrates. If found 
to be sufficiently promiscuous then this approach could be expanded to incorporate further enzymes 
from the pathway. 
 
Scheme 59. Proposed semi-synthetic preparation of mutilin 129 from tiamulin hydrogen fumarate 126, chemical 
derivatisations to mutilin derivatives, and biotransformations to novel pleuromutilin analogues.  
The second aim of this project was to use the products of these biotransformations in 
structure-activity relationship (SAR) studies. The antibiotic properties of each novel compound could 
be assessed through disk diffusion assays by measuring relative inhibition zones, with pleuromutilin 
acting as a standard. The results of these screenings could then be used to inform the design of future 
targets. 
If successful, this approach could potentially be used to generate novel pleuromutilin antibiotics from 
easily accessible starting materials. Additionally, it may allow access to targets that would be difficult 
to prepare via standard synthetic methods.
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2.3. Results and Discussion 
2.3.1. Synthesis of Mutilin and Dihydromutilin 
Given the extensive number of studies that have focused on the modification of the pleuromutilin 
C-14 side-chain and given the lack of other functionality present in the molecule the C-2 and C-3 
positions were identified as sites for modification. The ketone of the cyclopentanone ring provides a 
valuable synthetic handle for a range of transformations, whilst alterations at these sites may also 
hinder CYP oxidation at C-2, allowing for pleuromutilins with enhanced metabolic stability. 
Before any synthesis could be performed a convenient starting material needed to be identified and 
sourced. In industry pleuromutilin is produced via large-scale fermentation of Clitopilus 
passeckerianus, however, the natural product is not commercially available at reasonable prices or in 
significant quantities.205 Instead, a more cost-effective source was tiamulin hydrogen fumarate. This 
antibiotic is available as a 12.5% (w/v) aqueous solution which could be concentrated either through 
rotary evaporation or freeze-drying to give tiamulin salt 126 in ~99% purity. The stabilising agents 
methyl p-hydroxybenzoate and propyl p-hydroxybenzoate were also present in trace amounts. The 
C-14 side-chain was then removed though hydrolysis using potassium hydroxide (Scheme 60). 
Large-scale column chromatography was practical for the removal of several impurities, including the 
aforementioned stabilising agents. Recrystallisation completed purification, with mutilin 129 obtained 
as a crystalline white solid. Mutilin offered a good starting point for a range of synthetic modifications, 
however, reduction of the vinyl group was also desirable in certain cases to avoid side-reactions. 
Conveniently, Egger and Reinshagen reported that hydrogenation of the vinyl moiety had no 
significant effect on antibiotic activity.157 Following this procedure, dihydromutilin 133 was acquired 
in excellent yield (Scheme 60).  
 
Scheme 60. Synthesis of mutilin 129 (with X-ray structure) and dihydromutilin 133. 
2.3.2. Protection of the 11- and 14-Hydroxyls 
Before derivatisations could be undertaken, it was first necessary to develop a protecting group 
strategy for the two hydroxyls. There are a number of options available for secondary alcohols, with 
silyl reagents being most commonly employed. With this in mind, protection as the TBS ether was 
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investigated, however, no reaction was observed using TBSCl and imidazole even after 16 hours. 
Subsequently, attention was turned to the less bulky triethylsilyl (TES) derivative. In this case, more 
success was achieved, with full conversion of diol 129 to silyl ether 134 observed after 16 hours at 
60 °C (Scheme 61A). Interestingly, the 14-OH proved to be considerably less reactive than the 11-OH. 
This was attributable to the steric influence of the 16-methyl group on the cyclohexane ring, which 
possesses a pseudo 1,3-diaxial relationship with the 14-OH. Purification of TES-mutilin 134 was 
challenging as its non-polar nature resulted in co-elution with the by-product hexaethyldisiloxane 
(HEDSO) during column chromatography (Scheme 61B). Pleasingly, it was found that HEDSO could be 
removed via recrystallisation from methanol, with purified ketone 134 isolated in 82% yield. 
 
Scheme 61A. TES protection of mutilin 129. B. The structure of hexaethyldisiloxane. 
Further problems were encountered during the subsequent deprotection, with the 14-OTES again 
being slow to react. Treatment of silyl ether 134 with tetrabutylammonium fluoride (TBAF) for 24 
hours led to selective removal of the 11-TES group to give alcohol 129, but cleavage at the more 
hindered 14-OH site took a further 11 days to reach completion (Scheme 62). Some degradation was 
also observed under these conditions and efforts to accelerate the reaction through heating only 
served to exacerbate this issue. Whilst still an effective deprotection, the long reaction times were not 
ideal and so alternative conditions were sought. 
 
Scheme 62. TBAF deprotection of TES-mutilin 134. 
It was proposed that a less hindered fluoride source, such as HF-pyridine, may provide a faster rate of 
reaction. There was some precedence for this in the literature, with deuterated 3-dihydro-mutilin 136 
deprotected under these conditions (Scheme 63A).198 Previous work within our group had also shown 
that this reagent could be used to deprotect 3-deoxo-11-dehydroxy-mutilin 138 (Scheme 63B).210 In 
the case of ketone 134 however, only partial degradation occurred and none of the required product 
was observed (Scheme 63C). This was potentially due to the presence of the ketone which rendered 
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the compound insoluble in acetonitrile. The deprotection was also investigated in tetrahydrofuran in 
which 134 was soluble, however, in this case no reaction was observed. 
 
Scheme 63A. HF-pyridine deprotection of TES analogue 136.198 B. HF-pyridine deprotection of TES analogue 138.210 
C. Attempted HF-pyridine deprotection of TES analogue 134. 
Lastly, deprotection was investigated using concentrated HCl in methanol (Scheme 64). A 4 M solution 
was found to be optimal, with lower concentrations substantially reducing the rate of reaction, and 
higher concentrations leading to considerable degradation of the material. Under these conditions 
mutilin 129 was obtained in 84% yield after two days at room temperature. 
 
Scheme 64. Acid deprotection of TES-mutilin 134. 
In summary, the shorter reaction times required for the HCl deprotection meant that it was more 
convenient than the use of TBAF in most cases. However, in instances where the substrate was acid 
sensitive the fluoride-based conditions proved valuable. 
Whilst the TES protection approach was effective, and was employed successfully through this work, 
the deprotection conditions were still relatively harsh and so a milder protecting group strategy was 
also sought. The obvious next step was to employ a less bulky silyl group, and thus, TMS was 
investigated. This was originally discounted as it was presumed the TMS group would be too labile, 
however, following the unexpected stability of TES-mutilin 134 this was reconsidered. Protection of 
mutilin with TMSCl proceeded smoothly in 92% yield to give 139 (Scheme 65). This compound was 
found to be hygroscopic so required storage under an atmosphere of nitrogen.  
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Scheme 65. TMS protection of mutilin 129. 
As expected, it was found that the TMS group was far easier to remove relative to TES. Complete 
deprotection was observed in one hour using mildly acidic conditions (1.4 M HCl, MeOH), or in 16 
hours using TBAF (Scheme 66). The lability of the TMS group did however cause some minor 
complications during purification. It was found that the mild acidity of the silica used for column 
chromatography was enough to invoke deprotection at C-11, however, providing purification was 
performed swiftly degradation could be kept to a minimum. 
 
Scheme 66A. Acid deprotection of TMS-mutilin 139. B. TBAF deprotection of TMS-mutilin 139. 
It is also worth noting that during deprotection of TES-mutilin 134, TMS-mutilin 139, and their 
respective analogues, some undesired by-products were observed in nearly all cases as a result of a 
[1,5]-hydride shift from C-10 to C-14 with consequent dehydroxylation. An example of this can been 
seen in the deprotection-elimination of silyl ether 140 (Scheme 67A), with the proposed mechanism 
given in Scheme 67B.  
 
Scheme 67A. Acid induced elimination to alkenes 141 and 142. B. Proposed mechanism for the formation of allylic alcohol 
142 in acidic media. 
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A literature review revealed that similar transformations had been reported previously by Birch in 
1966 (Scheme 68A).194 This was later exploited by Kaura in the synthesis of potential serine protease 
inhibitor 147 (Scheme 68B).211 In both cases, phosphoryl chloride was used to activate the hydroxyl, 
so this represent the first instances of these transformations occurring under both acidic and basic 
conditions. 
 
 Scheme 68A. POCl3 induced formation of mutilin derivative 144.194 B. Kaura’s synthesis of potential serine protease 
inhibitor 147.211 
Another approach of interest was the selective protection of the 11-OH. This was accomplished by 
exploiting the differences in reactivity of the two alcohols. By returning to the bulkier TES group, 
mono-protection of the 11-OH was achieved in 63% yield using three equivalents of TESCl at 60 °C 
(Scheme 69). 
 
Scheme 69. Selective TES protection of the 11-OH of mutilin 129. 
An alternative method to differentiate the two alcohols was to mask the 11-OH as a ketone using 
methyl ether 149, known colloquially as 4-epi-mutilin.156 This compound was prepared on scale 
through treatment of tiamulin 126 with trimethyl orthoformate and concentrated H2SO4, which 
invoked a [1,5]-hydride shift from C-11 to C-3 (Scheme 70). The glycolic ester side-chain was then 
cleaved under basic conditions to give desired compound 149 in two steps. Crucially, this hydride shift 
is known to be reversible upon treatment of 149 with zinc chloride and concentrated HCl,212 thus, 
4-epi-mutilin could be employed as a method of reversibly masking the alcohol functionality at C-11. 
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Scheme 70. Synthesis of 4-epi-mutilin 149 with corresponding X-ray crystal structure, and [1,5]-hydride shift to mutilin 129. 
2.3.3. Derivatisation at C-3 
In an effort to hinder CYP oxidation at C-2, synthetic work was aimed at modification of the 
cyclopentanone ring, with preliminary efforts concentrated on the C-3 ketone. Surprisingly, 
nucleophilic addition to the carbonyl proved to be more challenging than initially expected. Reactions 
of mutilin 129 with nucleophiles showed either no conversion to the desired products (EtMgBr, 
TMSCH2MgCl), or in cases where reactivity was observed, the transformations were found to proceed 
slowly (NaBH4, MeMgBr). This is likely due to the steric influence of the fused six- and eight-membered 
rings, which presumably hinder the approach of nucleophiles via the Bürgi-Dunitz angle. This is 
reflected in the stereoselectivity of these transformations, with reactivity occurring exclusively at the 
less hindered Si face (Figure 28). This trend was observed throughout this research. 
  
Figure 28. The steric environment of the cyclopentanone ring. An X-ray crystal structure of mutilin 129 is also provided for 
comparison. Protons are omitted for clarity. 
Despite these steric restrictions nucleophilic attack was observed in cases where the reagents were 
sufficiently small and unhindered. For example, reduction of mutilin to secondary alcohol 131 using 
NaBH4 proceeded in 90% yield, albeit with long reaction times (Scheme 71). As expected, the 
(3R)-alcohol was formed exclusively as confirmed by X-ray crystallography. 
 
Scheme 71. Synthesis of triol 131 with corresponding X-ray crystal structure. 
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Addition of methylmagnesium bromide to TES-protected analogue 134 gave alcohol 150 (Scheme 72). 
Interestingly, no reaction was observed with mutilin 129 even when a large excess of the Grignard 
reagent was employed. Under the established TBAF deprotection conditions triol 151 was obtained in 
62% yield over two steps, or alternatively, if the acid deprotection conditions were utilised then 
elimination to alkene 141 was instead observed in 59% yield over two steps. 
 
Scheme 72. Synthesis of triol 151 and alkene 141. 
The stereochemistry of triol 151 was assigned using a 1D-NOESY NMR experiment through selective 
irradiation of 2’-H3. NOEs were observed to 2-H2, 4-H, and 15-H3 which is in accord with addition having 






Figure 29. Selective 1D-NOESY spectrum of 2’-H3 of triol 151. The observed NOEs are shown on the structure on the right. 
The next target was alkene 154, which was prepared in three steps from TMS-mutilin 139 (Scheme 73). 
First, ketone 139 was reduced to secondary alcohol 152 using NaBH4. Adapting a method developed 
by Duquenne,213 the hydroxyl was converted to the mesylate using MsCl and triethylamine over five 
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days. The transient mesylate eliminated in situ to alkene 153, which was followed by acid mediated 
TMS deprotection to diol 154. Unfortunately, the overall efficiency was low giving alkene 154 in 26% 
yield over three steps. It was difficult to pinpoint at what stage problems were occurring as the 
reactions were performed sequentially and not purified between steps. However, as the reduction 
and silyl deprotection had been performed on the same, or similar substrates in good yield, it is 
presumed that issues arise during mesylation-elimination. 
 
Scheme 73. Synthesis of alkene 154 and methyl ether 156. 
The next selected targets were methyl ethers 156 and 158, which were required for SAR studies to 
compare with the unmethylated products, 131 and 151. Again, both syntheses required the use of a 
protecting group strategy, and so TMS-mutilin 139 was selected as the starting material. The same 
procedures that were employed in the synthesis of triols 131 and 151 were applied in this case to give 
the TMS protected analogues. Reduction of ketone 139 with NaBH4 gave alcohol 152 in 92% yield after 
two days (Scheme 73). Treatment of alcohol 152 with methyl iodide and sodium hydride gave methyl 
ether 155 after 16 hours at 60 °C. This reaction was performed in a sealed tube due to the low boiling 
point of methyl iodide (42 °C). Deprotection was undertaken using TBAF to give methyl ether 156 in 
65% yield over two steps. Tertiary alcohol 140 was similarly synthesised via treatment of ketone 139 
with methylmagnesium bromide over 16 hours (Scheme 73). Interestingly, alcohol 140 was found to 
be unstable, with TMS deprotection observed at C-11 upon exposure to air. This did not occur with 
either TMS-mutilin 139 or TMS-alcohol 152. To circumvent this issue, 140 was purified swiftly 
post-work-up and used immediately in the next step. Pleasingly, the previously established 
methylation conditions were successfully applied to alcohol 140 to give methyl ether 157. Despite the 
mildness of the deprotection (1.4 M HCl, MeOH), some elimination of methyl ether 157 was observed 
to give a 7:2 ratio of methyl ether 158 to alkene 141 by 1H NMR (Scheme 74). This was avoided by 
switching to the use of TBAF, with desired methyl ether 158 now isolated as the sole product in 61% 
yield over three steps. 
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Scheme 74. Synthesis of methyl ether 158. 
As well as nucleophilic additions, methylenation of the C-3 ketone to exo-methylene 159 was also 
investigated (Scheme 75). Firstly, olefination was attempted using Tebbe’s reagent and pyridine,214 
but after 16 hours no reaction was observed at ambient or elevated temperatures. Similarly, a 
Lombardo methylenation using activated zinc, dibromomethane, and titanium tetrachloride also 
returned only starting material.116 The last approach investigated was a Peterson reaction.215 As it had 
previously been found that Grignard addition to the ketone was possible using methylmagnesium 
bromide, it was hoped that nucleophilic attack using TMSCH2MgCl would also be successful. Due to 
the previous observation that Grignard addition was not compatible with diol 129, TES-protected 
mutilin 134 was used, but once again, no reaction was observed. No further conditions were 
investigated, however, future studies could include Wittig,216 Julia,217 or Nysted218 olefinations. 
 
Scheme 75. Conditions investigated in the attempted synthesis of exo-methylene 156. 
Mutilin 129 was next converted to epoxide 161 via a Corey-Chaykovsky reaction of the C-3 ketone 
using trimethylsulfonium iodide and potassium tert-butoxide (Scheme 76A).219 X-ray crystallography 
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revealed that as expected the (3R)-isomer was formed exclusively as a result of nucleophilic attack of 
the Corey-Chaykovsky reagent (Scheme 76B) from the Si face of the cyclopentanone. 
 
Scheme 76A. Synthesis of 161, 162, and 163 via a Corey-Chaykovsky reaction, and allylic alcohol 164 through elimination of 
161. An X-ray crystal structure of 161 is also provided. B. Corey-Chaykovsky reagent 165. 
Whilst the desired epoxide was isolated, several by-products were also identified including the 
analogous 11-methyl ether 162. Additionally, methyl enol ether 163 was isolated in 26% yield 
providing another C-3 modified substrate for biotransformation studies. It is proposed that these 
products result from attack of the alkoxides onto a methyl group of trimethylsulfonium iodide in a 
nucleophilic substitution, releasing dimethyl sulfide. In an effort to improve the yields and selectivity 
a number of modifications to the procedure were investigated. Firstly, trimethylsulfonium iodide and 
the base were premixed to generate Corey-Chaykovsky reagent 165 in situ, prior to the addition of 
mutilin 129. Interestingly, in this case only starting material was returned. Use of TES-protected 
mutilin 134 also failed to improve results, with additional by-products observed in this instance. 
Further trialled conditions included using a mixture of DMSO and THF as the solvent, using 
trimethylsulfoxonium iodide as the oxidising agent, and using sodium hydride as the base, but again, 
these changes gave no increase in the yields of 161 or 163. It was however found that marginally 
better conversion could be attained by quenching the reaction, and resubjecting the crude mixture to 
fresh equivalents of the reagents, but overall the results were variable and difficult to reproduce. 
A further complication was the instability of epoxide 161 under acidic conditions. Attempted 
purification of 161 via high-performance liquid chromatography (HPLC) resulted in complete 
rearrangement to allylic alcohol 164, forming the more substituted alkene (Scheme 77). HPLC 
conditions were recreated in a round bottom flask using a mixture of water, acetonitrile, and formic 
acid, and as anticipated, rearrangement was again observed to give 164 in quantitative yield. Similar 
results were obtained during column chromatography due to the acidity of the silica gel, although in 
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this case rearrangement was slower. Given the poor stability of the epoxide this substrate was clearly 
not appropriate for biological studies, however, allylic alcohol 164 provided a potentially valuable 
alternative. 
Interestingly, allylic alcohol 164 was prone to oxidation to the corresponding aldehyde (Scheme 77). 
An NMR sample of 164 in CDCl3 showed 7% conversion to aldehyde 166 over 27 days. This 
transformation was expedited through reaction of 164 with manganese dioxide to give the aldehyde 
in 85% yield over 16 hours. 
 
Scheme 77. Synthesis of allylic alcohol 164 and aldehyde 166. 
2.3.4. Derivatisation at C-2 
At this juncture, attention was turned to modification of C-2, the major site of metabolism of 
pleuromutilin antibiotics.179 Despite this, to date, surprisingly little synthetic work has focussed on 
derivatisation at this position.156 With this in mind, (2S)-hydroxy mutilin 169 was selected as the next 
target molecule and was prepared in three steps via a Rubottom oxidation procedure developed by 
Wang at GlaxoSmithKline.220 Firstly, the kinetic TMS enol ether 167 was formed selectively using 
LiHMDS and TMSCl at −18 °C (Scheme 78). Oxidation with mCPBA then gave α-hydroxy ketone 168, 
before the TMS groups were cleaved using dilute HCl to provide triol 169 in 61% yield over three steps. 
As seen previously, complete stereoselectivity was obtained with the (2S)-isomer formed exclusively. 
This was confirmed by X-ray crystallography. 
 
Scheme 78. Synthesis of (2S)-hydroxy mutilin 169, its X-ray crystal structure, and an image of the crystals (from DCM). 
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With two of the three hydroxyl groups protected it was possible to selectively oxidise 168 to the 
corresponding diketone, 170, using DMP (Scheme 79). However, deprotection of the TMS groups 
under acidic conditions gave three new products, which were believed to be an interconverting 
mixture of 171, 172, and 173 resulting from tautomerisation of the two ketones, as first noted by 
Berner.221 Deprotected diketone 171 was accessible via the TBAF deprotection conditions, however, 
tautomerisation was again observed during attempted purification via column chromatography. Given 
the instability of the diketone it was not considered appropriate for biological studies. Instead, it was 
found that the equilibrium could be shifted towards the thermodynamic product, enone 173, upon 
treatment with 1 M sodium hydroxide. Unfortunately, tautomerisation was again instigated by column 
chromatography meaning the enone could also not be readily purified. 
 
Scheme 79. Synthesis and deprotection of diketone 170. Attempted methylation of (2S)-hydroxy mutilin 168. 
Synthesis of methyl ether 174 was also attempted, however, this proved problematic (Scheme 79). 
Investigations employing mild conditions (Ag2O, MeI) returned only starting material, even at elevated 
temperatures (75 °C), and upon switching to a stronger base (NaH) only degradation was observed. 
The use of a weaker sterically hindered base (2,6-di-tert-butyl-4-methylpyridine) was also trialled, 
however, under these conditions suspected epimerisation at C-2 occurred, with conversion to the 
same mixture of products obtained even in the absence of a methylating agent. 
Following the theme of modifications at C-2, the synthesis of a series of methylated derivatives was 
investigated by exploiting the previous observation that the kinetic enolate of mutilin 129 could be 
formed selectively when LiHMDS was used as the base.220 Employing these conditions the enolate of 
TES-protected mutilin 134 was formed in situ, with subsequent addition of methyl iodide giving 
α-methylated product 175, with the (2S)-stereocenter formed exclusively (Scheme 80A). This was 
confirmed by NMR with a key NOE observed between 2-H and 8-Hax. Unfortunately, deprotection of 
the silyl ethers using either HCl or TBAF resulted in epimerisation at C-2, giving a ~2:1 ratio of products 
(176 and 177) which were inseparable by column chromatography. In an effort to generate a single 
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epimer the mixture was treated with LiHMDS to reform the sp2 centre at C-2, then reprotonated using 
water. This was found to have no effect, with the same ratio of products returned. Enolisation was 
repeated but in this instance a sterically hindered proton source, butylated hydroxytoluene (BHT), was 
used (Scheme 80B). It was hoped that protonation would occur from the Si face giving better 
selectivity for the (2R)-stereocenter, however, this again provided the same ratio of products. 
Similarly, treatment of the mixture with 0.5 M KOH in methanol gave no improvement. With no 
mechanism for epimerisation synthesis of dimethylated analogue 179 proved more straightforward 
with the product isolated in 67% yield over three steps (Scheme 80C).  
 
Scheme 80A. Synthesis of epimers 176 and 177. B. The structure of butylated hydroxytoluene. C. Synthesis of 2,2-dimethyl 
mutilin 179. 
With (2S)-methyl mutilin 176 still a desirable target methylation was repeated on TMS-mutilin 139. 
Under these mild deprotection conditions it was found that no apparent epimerisation of the C-2 
stereocentre occurred giving 176 in 77% yield over two steps (Scheme 81). 
 
Scheme 81. Synthesis of (2S)-methyl mutilin 176. 
Two further compounds of interest were α-fluorinated derivatives 182 and 184, as the fluorine atom 
is smaller than a proton meaning metabolism at C-2 is blocked but with no increase in steric bulk.222 
For this an electrophilic fluorine source was needed. Initially Selectfluor™, a 
1,4-diazabicyclo[2.2.2]octane (DABCO) derivative, was selected (Scheme 82A) but attempts at 
fluorination using the previously established enolate chemistry (LiHMDS, −18 °C) gave no conversion. 
Upon further review of the literature it was found that another common procedure for fluorination 
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with Selectfluor™ was refluxing in acetonitrile, although again, under these conditions only starting 
material was recovered.223 However, success was achieved upon switching the fluorine source to 
N-fluorobenzenesulfonimide (NFSI) giving (2S)-fluoro mutilin 182 in 72% yield over two steps with no 
apparent epimerisation at C-2 (Scheme 82B). 
 
Scheme 82A. Structures of Selectfluor™, DABCO, and NFSI. B. Synthesis of (2S)-fluoro mutilin 182. 
Next, the synthesis of the difluorinated analogue 184 was investigated, however, in this second 
iteration full conversion was difficult to achieve with a 2:1 ratio of 184 (26%) to 182 (13%) obtained 
over three steps (Scheme 83). The similarity in polarity of the two products made purification 
challenging in this case, resulting in lower yields. 
 
Scheme 83. Synthesis of 2,2-difluoro mutilin 184. 
A further C-2-modified target was cyclopropane 185. The first investigated approach was treatment 
of TMS-mutilin 139 with LiHMDS (two equivalents) and DBE,224 however, only starting material was 
recovered in this instance (Scheme 84). 
 
Scheme 84. Attempted synthesis of cyclopropane 185. 
The second approach involved conversion of mutilin 129 to exocyclic enone 187, followed by a 
Corey-Chaykovsky cyclopropanation. Enone 187 was prepared in two steps by adapting a procedure 
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reported by Berner (Scheme 85).225 Firstly, the Mannich product 186 was formed through reaction of 
dimethylammonium chloride and paraformaldehyde (PFA) with mutilin 129. This gave a 1.6:1 ratio of 
C-2 epimers which decomposed at high temperature (130 °C) to enone 187. The yields for this 
transformation were low (17% over two steps) but were comparable to a similar literature 
procedure.225 The Corey-Chaykovsky cyclopropanation was then performed using 
trimethylsulfoxonium iodide giving 188 in 68% yield (Scheme 85). 
 
Scheme 85. Synthesis of cyclopropane 188. 
2.3.5. Cyclopentenone Synthesis and Derivatisation 
Another avenue of interest was the preparation of cyclopentenone 190 as the enone functionality 
offers a good synthetic handle for further derivatisation. The synthesis began with the formation of 
silyl enol ether 167 from 129 using the previously established LiHMDS/TMSCl procedure.220 167 was 
then treated with palladium(II) acetate to generate enone 189 via a Saegusa-Ito oxidation226 before 
the TMS groups were deprotected using HCl to give 190 (Scheme 86).  
 
Scheme 86. Synthesis of enone 190. 
Unfortunately, the oxidation did not proceed to completion with mutilin 129 also recovered 
post-deprotection. Although 129 only accounted for ~20% of the isolated material, it possessed a 
similar polarity to enone 190, making purification challenging. One possible explanation for this is that 
silyl enol ether 167 is partially hydrolysed by the acetic acid produced as a by-product of the reaction. 
In an effort to prevent this, the reaction was buffered using sodium bicarbonate, but hydrolysis still 
occurred and a significant decrease in the rate of reaction was also observed. Increasing from one to 
two equivalents of palladium(II) acetate also gave no improvement, nor did a catalytic approach 
employing 1,4-benzoquinone as an oxidant to regenerate the active Pd(II) species.226 
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An alternative procedure for the synthesis of enone 190 was a selenoxide elimination (Scheme 87). In 
this reaction the preformed enolate was treated with phenylselenyl chloride to give α-substituted 
mutilin 191. Oxidation and subsequent elimination using mCPBA was investigated, but as with the 
previous studies it was difficult to achieve full conversion leading to problems in obtaining a pure 
sample of enone 192. Ultimately it was found that the original Saegusa-Ito procedure (Scheme 86) 
was the most effective, provided particular care was taken during purification. Although this 
transformation still did not provide full conversion, the yield over three steps was good (71%) and the 
starting ketone, mutilin 129, could be recovered cleanly if so desired.  
 
Scheme 87. Attempted synthesis of enone 192 via a selenoxide elimination. 
With a route to enone 190 now established further derivatives could be prepared. Reduction of enone 
190 to allylic alcohol 193 was investigated via a Luche reduction using NaBH4 and cerium chloride in 
methanol,227 but the reaction was found not reach completion (Scheme 88). Addition of further 
equivalents of reducing agent and cerium chloride had no observable effect, nor did increasing the 
reaction time. Fortunately, the reduction proceeded cleanly meaning starting material could be 
recovered. The desired product 193 was isolated in 43% yield (93% based on recovered starting 
material). 
  
Scheme 88. Synthesis and X-ray crystal structure of allylic alcohol 193. 
The reaction once again proceeded stereoselectively to give a single product, but surprisingly, the 
product showed NOEs from 3-H to 6-H and 8-Hax in accord with the unexpected (3R)-isomer, 193. This 
was confirmed by X-ray crystallography (Scheme 88). Interestingly, this is the opposite 
stereochemistry of alcohol 131 formed by reduction of mutilin 129 using NaBH4 (Scheme 71). 
To investigate this anomaly, mutilin 129 was subjected to the same reaction conditions to ascertain if 
it was the use of cerium chloride that was leading to this reversal of selectivity (Scheme 89). 
Intriguingly, under these conditions the reaction was slow, with only 9% conversion to triol 131 
observed by 1H NMR after two days. The product did however contain the usual (3R)-stereocentre.  
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Scheme 89. Reduction of mutilin 129 under Luche conditions. 
Reduction of enone 190 was also investigated using LiAlH4 (Scheme 90). In this case, a mixture of 
products was obtained with a combination of 1,2- and 1,4-reductions occurring to give mutilin 129, 
allylic alcohol 193, and triol 131. Interestingly, diene 194 (14%) was also isolated which is proposed to 
originate from initial reduction of the ketone to give 193, followed by dehydration to give the 
stabilised conjugated diene. Pleasingly, this by-product could be used as a substrate for biological 
studies. 
 
Scheme 90. LiAlH4 reduction of enone 190. 
It is also worth noting that under these conditions the (3S)-isomer of allylic alcohol 193 was once again 
observed indicating that this unusual reversal of stereoselectivity is due to an intrinsic property of the 
enone rather than the reducing agent employed. One potential explanation is that there is a significant 
conformational change in the five-membered ring of the enone compared with the cyclopentanone, 
such that attack from the Re face is now preferred. To investigate this, enone 190 was recrystallised 
from DCM and an X-ray crystal structure was obtained and compared with mutilin 129 (Figure 30). 
   
Figure 30. Comparison of the X-ray structures of mutilin 129 (left) and enone 190 (middle). The structures are also overlaid 
(right) with protons omitted for clarity and are presented as viewed along the C-4-C-5 bond with the carbonyl groups facing 
downwards. Attack of the Re face would occur from the left of the structures and attack of the Si face from the right. 
Interestingly, the conformations of the two carbon skeletons were almost identical, however, it is 
possible that the steric environment surrounding the carbonyl is significantly altered by the change in 
hybridisation at C-1 and C-2. There may also be a subtle electrostatic effect imposed by the extended 
π-system of the enone. Ultimately, a more in-depth understanding of stereoselectivity would need to 
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be achieved through computational modelling. Whilst a satisfactory rationale is yet to be reached, 
similar reactivity was also observed in the synthesis of punctatin antibiotics.228 
The next target was the tetracyclic product 199, which could be prepared through cyclopropanation 
of the allylic alcohol. To avoid issues with chemoselectivity 19,20-dihydromutilin 133 was selected as 
the starting material in this instance. Saegusa-Ito oxidation was undertaken using the previously 
established procedure to give enone 197 in 71% yield over three steps (Scheme 91). Again, the Luche 
reduction was sluggish and after two days allylic alcohol 198 was isolated in 32% yield, with 31% 
starting material 197 also recovered. In this case, 1,4-reduction was also observed with 
19,20-dihydromutilin 133 isolated in 25% yield. 
 
Scheme 91. Synthesis of enone 197 and subsequent Luche reduction to allylic alcohol 198. 
With allylic alcohol 198 in hand, a Simmons-Smith cyclopropanation was undertaken using diethyl zinc 
and diiodomethane,229 giving a mixture of starting material 198 and cyclopropane 199 after 19 hours 
(Scheme 92). Unfortunately, the two compounds were found to be inseparable by both column 
chromatography and HPLC, thus a pure sample of 199 was not able to be isolated. 
 
Scheme 92. Cyclopropanation of allylic alcohol 198. 
Another enone derived analogue of interest was epoxide 200, which was prepared by treatment of 
190 with hydrogen peroxide under basic conditions (Scheme 93). As a nucleophilic peroxide source 
was used epoxidation could be carried out chemoselectively at the electron-poor enone, leaving the 
vinyl group intact. Interestingly, a small amount of lactone 201 (17%) was also isolated as a minor 
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by-product formed via a Baeyer-Villiger oxidation. Both compounds were isolated as single 
diastereomers, with epoxidation proceeding selectively from the less hindered face. This was 
confirmed using a 1D-NOESY NMR experiment with selective irradiation of 1-H. In both cases NOEs to 
8-H2 were observed. 
 
Scheme 93. Synthesis of α,β-epoxy ketone 200 and lactone 201. 
The formation of lactone 201 was intriguing as previous attempts to perform Baeyer-Villiger 
oxidations on mutilin derivatives were unsuccessful. Following this result, mutilin 129 was subjected 
to these same reaction conditions as enone 190, however, no conversion to lactone 202 was observed, 
with only starting material recovered in this case (Scheme 94). 
 
Scheme 94. Attempted synthesis of lactone 202. 
The rigid structures of pleuromutilins result in well-defined 1H NMR spectra, although, in most 
instances the methylene protons on the cyclohexane ring appear in congested regions of the spectra. 
In the case of diene 194 however, all four of the 7-H2 and 8-H2 signals are well resolved allowing for 
coupling constants to be extracted (Figure 31). These experimental results were compared with the 
expected splitting patterns which were calculated based on three key presumptions: 
1) That geminal couplings (2JHH) on a cyclohexane ring are equal to ~13.0 Hz.230 
2) That in accordance with the Karplus equation, vicinal couplings (3JHH) with a dihedral angle 
of ~180° are also equal to ~13.0 Hz.231 
3) That in accordance with the Karplus equation, vicinal couplings (3JHH) with a dihedral angle 
of ~60° are equal to ~3.5 Hz.231 
Analysis using this model predicted four distinct splitting patterns for the C-7 and C-8 protons, which 
were found to be in good accord with the recorded experimental data (Figure 31). This allowed each 
of the cyclohexane methylene protons to be assigned as either axial or equatorial. 
 







Figure 31. Predictions of the coupling constants and splitting patterns for the methylene protons of diene 194 (top), 
compared with the data extracted from the 1H NMR spectrum (bottom). 
To illustrate one example of this, the equatorial 8-H of diene 194 was predicted to be a doublet of 
triplets based on a geminal coupling of ~13.0 Hz to 8-Hax, and two vicinal couplings of ~3.5 Hz to 7-Hax 
and 7-Heq. Experimentally these couplings were recorded as 13.5 Hz and 3.0 Hz respectively. Whilst 
these data correlate excellently for diene 194, this represented an anomaly, with the 8-Heq signal 
observed as a doublet of quartets in the majority of cases (Figure 32). This was found to result from 
an additional long range ‘W-coupling’ (4JHH) to 4-H. These couplings can be as high as 3 Hz and account 
for the observed change from a triplet to a quartet.232 This interaction was confirmed using COSY NMR 
and from the splitting pattern of the 4-H signal (d, J 3.0 Hz). 
    
Figure 32. If a proton is present at C-4 then an additional W-coupling (orange) is observed for the 8-Heq signal, resulting in 
a doublet of quartets (middle). Additionally, the 4-H signal is observed as a doublet (right). These signals were extracted 
from the 1H NMR of TES-mutilin 134 but are representative of the majority of pleuromutilin products. 
2.3.6. Studies Towards the Synthesis of 14-Epi-Mutilin 
With a sufficiently diverse library of cyclopentanone-modified mutilin derivatives prepared, synthetic 
focus was shifted to the modification of other sites in the molecule. The next selected target was 
14-epi-mutilin 203 (Figure 33), as it was of interest to see if this subtle structural change would impact 
on the ability of the enzymes to catalyse acetylation and hydroxylation during the biotransformations 
and also what effect this would have on antibiotic activity. 
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Figure 33. Structure of 14-epi-mutilin 203. 
The first investigated approach was the Mitsunobu reaction, with both TES-mutilin 148 and 
4-epi-mutilin 149 available as suitable starting materials (Scheme 95). Unfortunately, in both cases, 
the standard conditions of triphenylphosphine, diethyl azodicarboxylate (DEAD), and acetic acid gave 
no reaction at room temperature.233 Similarly, no conversion was achieved under elevated 
temperatures (60 °C), with DEAD substituted in this case for diisopropyl azodicarboxylate (DIAD) due 
to the lower associated explosive risk.234 Lastly, conditions developed specifically for sterically 
congested secondary alcohols were investigated. Tsunoda reported that if a more reactive nucleophile 
(p-anisic acid) and a less bulky phosphine (tributylphosphine) were employed then the steric 
restrictions of the alcohol could be negated.235 Unfortunately, in the case of 148 and 149 still no 
reaction was seen. These observations reflect the previous findings that the 14-OH is significantly 
hindered. 
 
Scheme 95A. Attempted Mitsunobu reaction of TES-mutilin 148. B. Attempted Mitsunobu reaction of 4-epi-mutilin 149. 
The next proposed approach to 14-epi-mutilin was through oxidation-reduction of the 14-OH of 
4-epi-mutilin 149. As a model, 4-epi-mutilin was first reduced using LiAlH4 to give diol 208 in 95% yield 
(Scheme 96). In this case, the (11R)-isomer was formed selectively, which is the opposite 
stereochemistry to that observed in natural mutilin 129. This was not an issue however as C-11 would 
later need to be reoxidised to the ketone to enable the [1,5]-hydride shift to give mutilin analogue 
203. 
 
Scheme 96. LiAlH4 reduction and DMP oxidation of 4-epi-mutilin 149. 
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The next stage was the oxidation of 4-epi-mutilin to diketone 209 which was achieved using DMP in 
quantitative yield (Scheme 96). A crystal structure of diketone 209 was also obtained (Figure 34), and 
from this, the stereochemical outcome of the subsequent reduction could be predicted. 
 
Figure 34. X-ray crystal structure of diketone 209 viewed along the C-13-C-14 bond (left) and from above (right). Protons 
are omitted for clarity. 
It was hypothesised that reduction of the 14-ketone would proceed from the less hindered Re face to 
give the desired (14R)-isomer, 210. Approach of the hydride from the Si face would presumably be 
disfavoured as the angle of approach would be across the eight-membered ring and in close proximity 
to the fused cyclohexane. Pleasingly, reduction of 209 proceeded with complete stereocontrol, but 
surprisingly, the 1H NMR and optical rotation data for the product were an exact match with the 
(14S)-isomer, diol 208 (Scheme 97). 
 
Scheme 97. Reduction of diketone 209. 
The last approach investigated in the pursuit of 14-epi-mutilin 203 was activation of the 14-OH to form 
a good leaving group, followed by an SN2 displacement by an appropriate nucleophile that could be 
subsequently hydrolysed (Scheme 98). 
 
Scheme 98. Proposed synthesis of 14-epimer 211 from 149. 
In the first instance this was attempted through formation of triflate 212, however, it was found that 
treatment of 149 with triflic anhydride and pyridine instead mediated an interesting rearrangement 
to alkene 213 (Scheme 99). 
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Scheme 99. Rearrangement of 4-epi-mutilin 149 to alkene 213 with corresponding X-ray crystal structure. 
The presence of the tetrasubstituted alkene made structural elucidation of this product challenging, 
with success ultimately achieved through the use of an INADEQUATE NMR experiment.236 This 
technique measures 13C couplings between adjacent carbon atoms. Given the low natural abundance 
of 13C (~1%), approximately one in 104 molecules in a given sample will contain the required 13C-13C 
connectivity.237 Hence, the sensitivity of the experiment is poor and requires significant quantities of 
substrate (~30 mg) and long experiment times (~14 hours). However, the advantage of this approach 
is that each C-C bond in the molecule may be explicitly mapped. This is invaluable in the structural 
elucidation of complex organic compounds.238 Structural assignment of alkene 213 was later 
confirmed through X-ray crystallography (Scheme 99). 
A proposed mechanism for this rearrangement is shown in Scheme 100. Firstly, the highly labile triflate 
leaves in an E1 fashion to generate a secondary carbocation, then the 5-methyl group migrates to C-14 
to give the more stable tertiary carbocation at C-5. From the crystal structure of 213 it can be seen 
that this [1,2]-shift proceeds with a retention of stereochemistry. Loss of 6-H then completes the 
transformation to the alkene. 
 
Scheme 100. Proposed mechanism for the formation of alkene 213. 
Next, activation of the 14-OH was instead attempted via formation of the mesylate. This group is four 
orders of magnitude less reactive than the triflate,239 so it was hoped that in this case the activated 
species, 214, could be isolated (Scheme 101). Hence, alcohol 149 was treated with mesyl chloride and 
triethylamine for two days at room temperature. A 5:2:1 ratio of compounds was observed by 1H NMR 
of the crude material and was believed to be a mixture of unreacted alcohol 149, rearrangement 
product 213, and mesylate 214 respectively. The identification of 149 and 213 was achieved through 
comparison with previously collected 1H NMR spectra. The minor product however could not be 
definitively assigned as it was only present in small quantities and was not stable to purification by 
column chromatography. This is likely to be mesylate 214, the proposed intermediate in the formation 
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of alkene 213. Further evidence for this assignment is the presence of a singlet in the 1H NMR at 3.01 
ppm, which corresponds with the methyl group of the mesylate. In summary, mesylate 214, although 
considerably less reactive than the corresponding triflate, is also too unstable to isolate prior to 
rearrangement to alkene 213. 
 
Scheme 101. Attempted mesylation of 4-epi-mutilin 149 and observed rearrangement to alkene 213. 
In order to validate the mechanism of the formation of alkene 213, efforts were made to trap the 
putative C-14 cation. A mild reducing agent (Et3SiH) was selected with the aim of forming 215, 
containing a methylene moiety at C-14 (Scheme 102A). Alcohol 149 was treated with triflic anhydride 
and pyridine as before, however, this time 1.2 equivalents of triethylsilane were also added 
(Scheme 102B). After 16 hours two new compounds were isolated and identified as alkene 216 and 
oxetane 217. The structure of the oxetane was challenging to prove but was ultimately elucidated 
through several key observations. These include the significant change in coupling constant and 
splitting pattern of 14-H in the 1H NMR (Figure 35), the loss of the 4-H signal in the 1H NMR, and the 
absence of an O–H stretch in the IR spectrum. 
 
Scheme 102A. Proposed trapping of the carbocation using triethylsilane. B. Synthesis of alkene 216 and oxetane 217. 
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Figure 35. 1H NMR spectra comparisons of 4-epi-mutilin 149, alkene 216, and oxetane 217 between 5.60 and 2.80 ppm. 
Interestingly, if the reaction time for this procedure was reduced from 16 hours to one hour, then 
demethylated product 218 was instead isolated in near quantitative yield (Scheme 103). Further 
investigations also revealed that pyridine was not required for these transformations, and that triflic 
anhydride could be substituted for triflic acid. As a comparison, demethylation was also investigated 
with boron tribromide, but in this case, after one hour complete conversion to alkene 216 was 
observed instead (Scheme 103). 
 
Scheme 103. Demethylation of 4-epi-mutilin 149 with triethylsilane and formation of alkene 216 using BBr3. 
The mechanism by which demethylation occurs for 149 has not been confirmed, although TESOTf has 
been shown to form under these reaction conditions and could be functioning as a Lewis acid.240 
Elimination of the resultant alcohol to the secondary carbocation can be envisaged via an E1 
mechanism following triflation or activation by a Lewis or Brønsted acid. The E2 route is unlikely in 
this case due to poor alignment of the 3-OH and 4-H orbitals (torsion angle of ~43° based on the X-ray 
crystal structure of 149. From here, loss of 4-H can occur to give alkene 216, or alternatively, a 
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through elimination of 2-H to give alkene 216, or attack by the 14-OH to give oxetane 217 
(Scheme 104). 
 
Scheme 104. Proposed mechanism for the formation of alkene 216 (red) and oxetane 217 (blue). 
2.3.7. Synthesis of Pleuromutilin and 14-O-Acetyl Mutilin  
For the proposed bioassays it was important that good supplies of pleuromutilin 125 and 14-O-acetyl 
mutilin 132 were available as these compounds were required as standards during biotransformation 
studies and antibiotic testing. These targets were prepared from mutilin 129 using a procedure 
developed and patented by GlaxoSmithKline for the installation of the glycolic acid side-chain,241 which 
was also used by Fazakerley in the total synthesis of pleuromutilin.242 This method was again exploited 
for this project and began with the selective protection of the 11-OH with a trifluoroacetate group 
using 1-(trifluoroacetyl)imidazole 219 to give ester 220 (Scheme 105). As an excess of amide 219 was 
used some of the diprotected product, 221, was also formed. 
 
Scheme 105. Synthesis of esters 220 and 221. 
The second step was an EDCI coupling between alcohol 220 and carboxylic acid 224. The preparation 
of 224 was also required as this compound was not commercially available. The original synthesis was 
performed by Iorio and involved the esterification of glycolic acid using 1.3 equivalents of 
trifluoroacetic anhydride (TFAA) in dichloromethane (Scheme 106A).243 After two days, carboxylic acid 
224 was purified by distillation. Following this procedure, a significant amount of by-product was 
formed accounting for around ~28% of the material by 1H NMR. This was also found to be inseparable 
from the desired product meaning characterisation was not possible. The minor component was 
presumed to be the disubstituted derivative 225, resulting from reaction of the carboxylic acid with 
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the excess TFAA, which is supported by the presence of two extra fluorine environments in the 
19F NMR (Scheme 106B). Additionally, the ratio of products is as expected from all 1.3 equivalents of 
TFAA reacting. Reduction of this excess to a single equivalent resulted in complete conversion to 
carboxylic acid 224, with only ~2% by-product formation. Furthermore, cleaner conversion to the 
desired product removed the need for purification, giving a yield of 92%, representing a 10% increase 
over the literature procedure.242 Ester 224 was however found to be very unstable, with 10% 
hydrolysis to glycolic acid observed upon exposure to air for one day. Consequently, 224 was stored 
under an atmosphere of nitrogen at 7 °C. 
 
Scheme 106A. Synthesis of carboxylic acid 224. B. Suspected by-product 225.  
Coupling of 220 and 224 using EDCI proceeded rapidly and was quenched after 30 minutes 
(Scheme 107). The trifluoroacetate groups were then hydrolysed in situ using triethylamine and 
methanol to give pleuromutilin 125. In the literature procedure the reaction was left for 24 hours 
resulting in incomplete hydrolysis with 19% 11-trifluoroacetyl pleuromutilin remaining.242 
Consequently, in our work the reaction was left for 48 hours which gave complete conversion to 125 
in 95% yield (78% over two steps) which was comparable with the literature (75% over two steps).242 
 
Scheme 107. Synthesis of pleuromutilin 125. 
With a route to pleuromutilin now established, this same methodology was adapted to prepare 
14-O-acetyl mutilin 132 (Scheme 108). In this case, alcohol 220 was coupled with acetic acid rather 
than carboxylic acid 224. Surprisingly, the reaction was found to be sluggish and only poor conversion 
was observed, even upon addition of ten equivalents of the acid. Furthermore, deprotection of the 
C-14 ester was arduous, with elevated temperatures and longer reaction times required to reach 
completion. 
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Scheme 108. Attempted synthesis of 14-O-acetyl mutilin 132. 
Instead, a different approach to 14-O-acetyl mutilin 132 was devised starting from 4-epi-mutilin 149 
(Scheme 109). In this case, the 11-OH was masked, and thus, no protecting groups were required. 
Esterification was performed using acetic anhydride to give 226 in 92% yield before the [1,5]-hydride 
shift was instigated to give 14-O-acetyl mutilin 132. 
 
Scheme 109. Synthesis of 14-O-acetyl mutilin 132. 
2.3.8. Biotransformations 
Whilst it had now been shown that the glycolic acid side-chain of pleuromutilin could be installed 
synthetically, this project aimed to determine if this transformation could be performed enzymatically 
on mutilin and its analogues using an A. oryzae transformant (Figure 36) containing ATF and P450 
genes isolated C. passeckerianus (see Section 2.1.5.). If these enzymes were found to be sufficiently 
promiscuous then this methodology could be used to generate novel pleuromutilin derivatives from 
their respective mutilin precursors. This transformant was produced and supplied by our collaborators 
in the Bailey group (Biological Sciences, Bristol).  
  
Figure 36. An agar plate of the A. oryzae transformant (left) and A. oryzae mycelia after two days of growth (right). 
To establish the acetylation and hydroxylation efficiency of the fungal system a time-course was 
undertaken. For this, a CMP (Czapek-dox broth, maltose, and peptone) growth medium was prepared 
(100 mL) and was subsequently inoculated with a small sample of the transformant. Mutilin 129 
(100 mg) was then added in one portion and the culture was incubated at 28 °C for 17 days with 
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shaking (200 rpm). Aliquots of the growth medium (~5 mL) were removed every few days and analysed 
by 1H NMR to compare the relative ratios of mutilin 129, 14-O-acetyl-mutilin 132, and pleuromutilin 
125 present in the spectra (Figure 37). The signals corresponding to 14-H in each of these compounds 
were well resolved and appeared at distinct chemical shifts allowing progress of the reaction to be 
measured readily. From Figure 37 it can be seen that mutilin 129 was entirely consumed within 10 
days of inoculation, and that by day three 14-O-acetyl-mutilin 132 was already the major product. 
Pleuromutilin production began by day five, however, further conversion of 132 to pleuromutilin 125 
was very slow with only marginally more product seen at day 17. This is thought to be due to issues 
with the expression of the P450-3 gene in the A. oryzae transformant, which leads to less efficient 
oxidation compared with the preceding acetylation.205,244 Whilst this system was clearly unsatisfactory 
it was decided that in the interest of time, preliminary biotransformation studies should be 
undertaken concurrently with attempted optimisation of the transformant by our collaborators in the 
Bailey group (Biological Sciences, Bristol). 
 
 
     
 
Figure 37. 1H NMR spectra of the crude organic extracts from the biotransformation time-course. The 14-H peaks 
corresponding to mutilin 129, 14-O-acetyl-mutilin 132, and pleuromutilin 125 are highlighted in blue, red, and green 
respectively. 
To obtain isolated yields the experiment with mutilin 129 was repeated with an incubation time of 10 
days, as this was deemed to be optimal for this particular transformant as it ensured almost full 
consumption of mutilin and near maximum production of pleuromutilin (Scheme 110). Upon 
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completion the mycelia were homogenised using a blender and extracted with ethyl acetate. The 
crude organic extracts were purified by column chromatography to give 14-O-acetyl-mutilin 132 in 
55% yield, pleuromutilin 125 in 19% yield, and unreacted mutilin 129 in 4% yield. 
 
Scheme 110. Products of the biotransformation study of mutilin 129 with the A. oryzae transformant. 
Six mutilin derivatives were subjected to biotransformation studies (Figure 38), with the same growth 
conditions and extraction procedures used as for the native substrate. Purification was undertaken 
either via column chromatography or HPLC depending on the separation of the products. 
 
Figure 38. The six mutilin derivatives selected for initial biotransformation studies. 
Pleasingly, all tested substrates showed at least some conversion to the respective 14-O-acetylated 
derivatives (Figure 39). The best conversion was observed for enone 190, with acetate 232 isolated in 
51% yield. This is perhaps unsurprising given the similarity of 190 to the natural substrate 129 in regard 
to polarity and structure, although 2,2-dimethyl analogue 179 also showed good conversion to 231 
despite the large steric change at C-2. Modifications at the C-3 position were also well tolerated with 
reduction of the ketone (131 and 151) and complete removal of oxygen functionality (141) having no 
observable impact on turnover. Alkene 141 was also interesting as the C-4 position was now an sp2 
centre, which significantly altered the three-dimensional structure of the tricyclic core. Lastly, 
(2S)-hydroxy mutilin 169 showed only poor conversion to 230. This is intriguing given the similarities 
of these compounds to known pleuromutilin metabolites, which also contain a hydroxyl group at C-2. 
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Figure 39. Conversion of the mutilin derivatives to the 14-O-acetylated analogues using the A. oryzae transformant. 
For both 2,2-dimethyl mutilin 179 and enone 190 some conversion to pleuromutilin analogues 233 
and 234 was observed (Figure 40). Although it was disappointing that this transformation was not 
more universally attainable, this can again be attributed to the poor expression of the P450-3 gene in 
the current transformant system. If this can be improved then it is likely that further analogues will be 
compatible. An optimised system will also be required to fully assess the promiscuity of the two 
enzymes, however, these initial experiments certainly demonstrate that significant structural 
modifications can be tolerated. This final hydroxylation is important as 14-O-acetylated mutilin 
exhibits considerably less antibiotic activity than pleuromutilin.210 
 
Figure 40. Conversion of two mutilin derivatives to the pleuromutilin analogues using an A. oryzae transformant. 
2.3.9. Antibiotic Testing 
With some success achieved with the biotransformations, preliminary antibiotic testing was 
performed on the novel derivatives, with enones 232 and 234 selected for these initial studies 
(Figures 28 and 29).210 The antimicrobial activity of these compounds were assessed against the 
Gram-positive bacterium Bacillus subtilis using disk diffusion assays (Figure 41). These were performed 
by inoculating agar plates with the spores of B. subtilis. A piece of sterile filter paper was then placed 
in the centre of each plate before the required amount of substrate was added via pipette. The plates 
were then incubated for two days to allow for bacterial growth, with antimicrobial activity 
subsequently assessed by measuring the relative sizes of the inhibition zones. Each experiment was 
carried out in triplicate, allowing standard deviations to be calculated. 










Figure 41. Comparison of the antibiotic properties of pleuromutilin 125 and 14-O-acetyl mutilin 132 against the unnatural 
enone analogues 234, 232, and 190. Activity was assessed against B. subtilis by measuring the growth inhibition zone. 
It was found that the activity of ester 232 (12.7 ± 0.6 mm) was higher than that of its naturally 
occurring counterpart 14-O-acetyl mutilin 132 (10.3 ± 0.3 mm) and was actually comparable to that of 
pleuromutilin 125 (12.8 ± 0.8 mm). Furthermore, hydroxy ester 234 generated an inhibition zone (15.7 
± 1.8 mm) which was greater than both 14-O-acetyl mutilin 132 and pleuromutilin 125 as well as its 
semi-synthetically derived precursor ester 232. These exciting preliminary results show that there is 
potential for modification around the cyclopentanone ring with retention of (or increase in) activity. 
In the future it would be interesting to determine what effect these modifications have on stability 
with regard to C-2 metabolism. 
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2.4. Conclusions and Future Work 
In conclusion, a semi-synthetic approach was successfully employed to generate a diverse library of 
20 cyclopentanone-modified mutilin analogues (Figure 42). The biosynthetic intermediate mutilin 129 
was used as the starting material for these studies and was accessed from the commercially available 
antibiotic tiamulin hydrogen fumarate 126. 14-O-Acetyl mutilin 132 and pleuromutilin 125 were also 
prepared for use as standards. Several protecting group strategies were developed and employed 
throughout this work including the use of TMS, TES, and TFA groups. Additionally, a [1,5]-hydride shift 
was also exploited as a method of reversibly masking the 11-OH. 
 
Figure 42. The library of semi-synthetically prepared cyclopentanone-modified mutilin derivatives (modifications in red). 
Studies into the derivatisation of the 14-OH of 4-epi-mutilin 149 also provided several interesting 
products. Treatment of 149 with triflic anhydride and pyridine gave alkene 213 via the formation of a 
secondary carbocation followed by a [1,2]-methyl shift (Scheme 111). Furthermore, addition of 
triethylsilane to the reaction instigated demethylation to diol 218 over one hour, or conversion to 
alkene 216 and oxetane 217 over 16 hours. 
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Scheme 111. Reactions observed during investigations into the derivatisation of the 14-OH of 4-epi-mutilin 149. 
The second objective of the project was to assess the promiscuity of the final two enzymes involved 
in the pleuromutilin biosynthetic pathway in order to determine whether this system could be 
exploited to generate novel pleuromutilin derivatives. Six of the prepared mutilin analogues were 
incubated with an A. oryzae transformant containing ATF and P450-3 genes (Scheme 112A). Partial 
conversion to the corresponding 14-O-acetylated derivatives was observed in all cases (Scheme 112B), 
with two analogues also showing further hydroxylation to the full glycolic acid side-chain 
(Scheme 112C). These results demonstrate that the investigated enzymes can tolerate significant 
structural and electronic changes to the five-membered ring. 
 
Scheme 112A. Biotransformation studies of unnatural mutilin analogues with an A. oryzae transformant containing ATF 
and P450 genes. B. Isolated 14-O-acetylated analogues. C. Isolated pleuromutilin analogues. 
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Preliminary antibiotic testing has been undertaken on enones 190, 232, and 234 using disk diffusion 
assays against the Gram-positive bacterium Bacillus subtilis (Figure 43). This provided exciting initial 




   
Figure 43. Comparison of the antibiotic properties of pleuromutilin 125 and unnatural enone analogue 234. Activity was 
assessed against B. subtilis by measuring the growth inhibition zone. 
Future work will need to address the limitations of the current fungal transformant, which are believed 
to result from poor expression of the P450-3 gene. If optimisation of this system can be achieved then 
biotransformations of the remaining library of synthetic analogues of mutilin can be investigated, and 
the resultant products tested for antibiotic activity. It is also of particular interest to determine what 
effects these modifications have on metabolic stability, and specifically, whether hydroxylation at C-2 
by CYP is supressed. The results of these studies can then be used to inform the design of a second 
generation of targets. 
Longer-term, the scope of the project could be expanded to incorporate additional enzymes into the 
transformant system, thus allowing further biosynthetic intermediates to be used as scaffolds for 
synthetic derivatisation. Ideally, this idea would be extended to include all enzymes of the pathway 
allowing modifications to be introduced at the GGPP stage prior to cyclisation. This could potentially 
provide access to analogues that would be difficult to prepare from pleuromutilin itself using standard 
synthetic techniques. In particular, it would be of interest to see if changes could made at the C-8 














3.1. General Experimental Details 
Unless otherwise stated, chemicals were sourced from commercial suppliers and used without further 
purification. All reactions except those employing water as a reagent or solvent were performed under 
anhydrous conditions. Standard Schlenk syringe-septa techniques were used with flame dried 
glassware under a positive pressure of nitrogen. Anhydrous dichloromethane, tetrahydrofuran, 
toluene, hexane, diethyl ether, and acetonitrile were dried by passing through a modified Grubbs 
system of alumina columns, manufactured by Anhydrous Engineering. Ethyl acetate, ethanol, 
methanol, and pentane were dried by stirring with calcium hydride for one hour, distilling onto 3 Å 
molecular sieves, and storing under nitrogen. Petroleum ether is of the 40-60 °C boiling point range. 
Flash column chromatography was performed using silica gel 60 from Sigma Aldrich (40-60 µm) and a 
suitable eluent. TLC was performed with aluminium backed silica TLC plates (Merck-Keiselgel 60 F254) 
with a suitable solvent system. Spots were visualised using ultraviolet (UV) fluorescence (254 nm) 
and/or developed with potassium permanganate solution and heat. Melting points were determined 
on an Electrothermal IA6301 melting point apparatus and are uncorrected. Optical rotations were 
recorded on a Bellingham and Stanley ADP220 polarimeter, irradiating with a sodium D line (λ = 589 
nm). Results are quoted in (° mL)/(g dm). Infrared (IR) spectra were recorded on a Perkin Elmer 
Spectrum 100 FTIR with an attenuated total reflectance (ATR) accessory, frequencies are reported in 
wavenumbers (/cm). 1H and 13C spectra were recorded in CDCl3 solutions on Jeol ECS400 (400 MHz), 
Bruker Nano400 (400 MHz), Varian 400-MR (400 MHz), Jeol ECZ400 (400 MHz), Jeol ECZ400var (400 
MHz), Bruker Avance III HD 500 Cryo (500 MHz), Varian VNMRS500a (500 MHz), Varian VNMRS500b 
(500 MHz), and Varian 600 (600 MHz) spectrometers at ambient temperature and were referenced to 
CHCl3 or CDCl3 (7.26 ppm for 1H and 77.16 ppm for 13C). Chemical shifts (δ) are reported in parts per 
million (ppm) and coupling constants (J) are in hertz (Hz). Peaks were assigned as singlets (s), doublets 
(d), triplets (t), quartets (q), pentets (pent), nonets (non), multiplets (m), or a combination. Peaks could 
also be described as apparent (app.) or broad (br.). COSY, HMBC, HSQC and H2BC NMR spectra were 
routinely used to definitively assign the signals of 1H and 13C NMR spectra. High-resolution mass 
spectrometry (HRMS) was performed using electrospray (ESI) and atmospheric pressure chemical 
(APCI) ionisation, with spectra recorded on a VG Analytical Quattro mass spectrometer. X-ray 
diffraction experiments were performed by Dr H. A. Sparkes and Dr N. E. Pridmore at the University 
of Bristol, using a Bruker Apex II diffractometer with Mo-Kα radiation (λ = 0.71073 Å). Single crystals 
were mounted on glass fibre, and data collected with a CCD area detector. Structures were solved 
using the SIR2004 package within Olex2, using Direct Methods and refinement via the XH refinement 
package (CGLS Minimisation). 
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CuI was purified as follows: CuI was dissolved in a boiling saturated aqueous solution of NaI over 30 
minutes. The solution was cooled to room temperature and diluted with water. The precipitate was 
filtered and washed sequentially with water, EtOH, EtOAc, Et2O, and pentane, then dried under 
vacuum for 24 hours.245 
Zinc powder was activated as follows: The zinc was stirred in aqueous HCl (~4 M) for one minute, then 
filtered through a sinter funnel. The zinc was then resuspended in HCl (~4 M) and stirred for a further 
30 seconds before again filtering. The zinc was then sequentially washed with water (× 3), EtOAc (× 2), 
MeOH (× 2), and Et2O (× 1), then dried under vacuum for at least 30 minutes.245 
Zn(Ag/Cu) was prepared as follows: A flow of nitrogen gas was passed through a suspension of freshly 
activated zinc powder (500 mg) in water (3 mL) for 15 minutes. Copper acetate monohydrate (50 mg) 
was added, followed by silver nitrate (50 mg) after a further 15 minutes. A small exotherm was 
observed and the mixture was stirred for a further 30 minutes, then filtered through a sinter funnel. 





3.2. Experimental for Kalimantacin A Research 
3.2.1. Synthesis of Compounds 
Kalimantacin A 1 
 
Kalimantacin A growth and isolation was undertaken on a 2.4 L scale using an adapted version of a 
procedure reported by Lavigne.84 
Preculture preparation: 
Wild type Pseudomonas fluorescens (strain BCCM_ID9359) was grown on tryptose-agar for 24 hours 
at 28 °C. A single colony was picked and used to inoculate 120 mL of lysogeny broth (20 g 
Bacto™ Tryptone, 10 g yeast extract, and 10 g sodium chloride, per L of deionised water). This was 
incubated at 25 °C whilst being shaken at 200 rpm for 18 hours. 
Fermentation culture: 
The fermentation culture was prepared in 12 × 500 mL conical flasks, with each containing: 
1) 10 mL of preculture 
2) 20 mL sterilised glucose solution (40% w/v) 
3) 170 mL of sterilised lysogeny broth 
Growth was undertaken at 16 °C whilst being shaken at 180 rpm for 96 hours. 
Extraction and purification: 
The cells were separated from the media through centrifugation (8000 rpm, 15 minutes) and resulting 
supernatants were combined. Extraction was performed using EtOAc (3 × 1 L) and the combined 
organic layers were dried over MgSO4, filtered, and concentrated in vacuo. The crude material was 
purified by column chromatography (4-10% MeOH in DCM) to give kalimantacin A 1 (155 mg, 65 mg/L) 
as a pale yellow oil. 
δH (500 MHz, CDCl3) 6.54 (1H, t, J 6.0, NH), 6.24 (1H, dd, J 15.0, 11.0, 12-H), 5.94 (1H, t, J 11.0, 11-H), 
5.68 (1H, q, J 1.0, 2-H), 5.58 (1H, dt, J 15.0, 7.0, 13-H), 5.36 (1H, br. s, COOH), 5.30 (1H, dt, J 11.0, 7.5, 
10-H), 4.89 (1H, dq, J 8.0, 6.5, 27-H), 4.79 (1H, d, J 2.0, 23-HH), 4.73 (1H, d, J 2.0, 23-HH), 4.16 (1H, m, 
19-H), 3.34 (2H, m, 20-H2), 2.59-2.54 (2H, m, 18-H2), 2.48 (1H, m, 26-H), 2.44 (1H, m, 16-HH), 2.32-2.20 
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(3H, m, 9-H2, 16-HH), 2.15 (3H, d, J 1.0, 21-H3), 2.10-2.01 (7H, m, 4-H2, 6-HH, 8-H2, 14-HH, 15-H), 1.96 
(1H, m, 14-HH), 1.89 (1H, m, 5-H), 1.75 (1H, dd, J 14.0, 9.0, 6-HH), 1.27 (3H, d, J 6.5, 28-H3), 1.14 (3H, 
d, J 7.0, 29-H3), 0.88 (3H, d, J 6.5, 24-H3), 0.85 (3H, d, J 6.5, 22-H3). δC (126 MHz, CDCl3) 211.7 (C-17), 
174.7 (C-25), 169.8 (C-1), 160.9 (C-3), 157.4 (C-30), 147.2 (C-7), 132.3 (C-13), 129.9 (C-10), 128.8 (C-11), 
127.6 (C-12), 116.8 (C-2), 111.9 (C-23), 73.5 (C-27), 67.4 (C-19), 50.4 (C-16), 49.0 (C-4), 47.0 (C-26), 
47.0 (C-18), 44.3 (C-20), 43.3 (C-6), 40.1 (C-14), 35.5 (C-8), 29.4 (C-15), 29.0 (C-5), 26.2 (C-9), 19.9 
(C-22), 19.8 (C-24), 19.1 (C-21), 18.0 (C-28), 13.8 (C-29). []D
22 = −24.0 (c 1.00, MeOH) [Lit. −20.0 (c 1.0, 
MeOH)].96 




Kalimantacin A 1 (120 mg, 0.219 mmol) was dissolved in a mixture of DCM (0.8 mL) and MeOH (0.2 mL) 
and cooled to 0 °C. Trimethylsilyldiazomethane (2 M in Et2O, 0.14 mL, 0.280 mmol) was added 
dropwise and the reaction was warmed to room temperature and stirred for one hour. The solution 
was diluted with DCM (2 mL) and quenched with glacial acetic acid (three drops). Solid NaHCO3 (50 mg) 
was added and the solution was filtered through cotton wool and concentrated in vacuo to give ester 
8 (123 mg, quant.) as a yellow oil. 
δH (500 MHz, CDCl3) 6.31 (1H, t, J 5.5, NH), 6.28 (1H, dd, J 15.0, 11.0, 12-H), 5.94 (1H, t, J 11.0, 11-H), 
5.65 (1H, q, J 1.0, 2-H), 5.58 (1H, dt, J 14.5, 7.0, 13-H), 5.30 (1H, dt, J 11.0, 7.5, 10-H), 4.89 (1H, dq, J 
8.0, 6.5, 27-H), 4.80 (1H, s, 23-HH), 4.74 (1H, s, 23-HH), 4.12 (1H, m, 19-H), 3.68 (3H, s, OCH3), 3.43 
(1H, ddd, J 14.0, 6.5, 3.0, 20-HH), 3.21 (1H, ddd, J 14.0, 6.5, 5.5, 20-HH), 2.61-2.52 (2H, m, 18-H2), 2.49 
(1H, m, 26-H), 2.45 (1H, dd, J 16.5, 5.0, 16-HH), 2.33-2.21 (3H, m, 9-H2, 16-HH), 2.18 (1H, dd, J 12.0, 
4.0, 4-HH), 2.13 (3H, d, J 1.0, 21-H3), 2.12-1.97 (6H, m, 6-HH, 8-H2, 14-H2, 15-H), 1.91-1.81 (3H, m, 4-HH, 
5-H, 6-HH), 1.27 (3H, d, J 6.5, 28-H3), 1.16 (3H, d, J 7.0, 29-H3), 0.90 (3H, d, J 6.0, 24-H3), 0.82 (3H, d, J 
6.0, 22-H3). δC (126 MHz, CDCl3) 211.7 (C-17), 174.4 (C-25), 167.2 (C-1), 159.5 (C-3), 156.3 (C-30), 147.2 
(C-7), 132.2 (C-13), 130.1 (C-10), 128.7 (C-11), 127.8 (C-12), 116.7 (C-2), 111.4 (C-23), 73.1 (C-27), 67.4 
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(C-19), 51.0 (OCH3), 50.4 (C-16), 48.7 (C-4), 47.0 (C-18), 46.9 (C-26), 44.4 (C-20), 44.3 (C-6), 40.2 (C-14), 
35.5 (C-8), 29.5 (C-15), 29.1 (C-5), 26.0 (C-9), 20.0 (C-24), 19.5 (C-22), 18.8 (C-21), 17.9 (C-28), 13.8 
(C-29). HRMS (ESI) calc. for C31H50N2O7Na [M+Na]+ 585.3510. Found 585.3496. []D
22 = −22.0 (c 1.00, 
CHCl3). IR (νmax/cm-1) (neat): 3329 (alcohol O–H, carbamoyl N–H, and amide N–H), 2926 (alkane C–H), 




TBSCl (52 mg, 0.345 mmol) and imidazole (30 mg, 0.441 mmol) were added to a solution of ester 8 
(97 mg, 0.172 mmol) in DMF (1 mL). After 16 hours at room temperature further equivalents of TBSCl 
(52 mg, 0.345 mmol) and imidazole (30 mg, 0.441 mmol) were added and the solution was heated to 
60 °C for 16 hours. The reaction was quenched with a saturated aqueous solution of NH4Cl (2 mL) and 
diluted with Et2O (2 mL). The phases were separated and the aqueous layer was extracted with Et2O 
(2 × 2 mL). The combined organic layers were dried over MgSO4, filtered, and concentrated in vacuo. 
The crude material was purified by column chromatography (5% MeOH in DCM) to give silyl ether 9 
(94 mg, 81%) as a yellow oil. 
δH (400 MHz, CDCl3) 6.27 (1H, dd, J 15.0, 11.0, 12-H), 6.05 (1H, t, J 6.0, NH), 5.94 (1H, t, J 11.0, 11-H), 
5.65 (1H, s, 2-H), 5.58 (1H, dt, J 15.0, 7.0, 13-H), 5.30 (1H, dt, J 11.0, 7.5, 10-H), 4.88 (1H, pent, J 6.5, 
27-H), 4.80 (1H, s, 23-HH), 4.74 (1H, s, 23-HH), 4.26 (1H, m, 19-H), 3.68 (3H, s, OCH3), 3.56 (1H, ddd, J 
14.0, 7.5, 4.0, 20-HH), 3.03 (1H, ddd, J 14.0, 6.0, 5.0, 20-HH), 2.54-2.50 (2H, m, 18-H2), 2.45 (1H, m, 
26-H), 2.40 (1H, m, 16-HH), 2.34-2.22 (3H, m, 9-H2, 16-HH), 2.18 (1H, m, 4-HH), 2.13 (3H, s, 21-H3), 
2.09-2.00 (4H, m, 8-H2, 14-HH, 15-H), 2.00-1.94 (2H, m, 6-HH, 14-HH), 1.87-1.80 (3H, m, 4-HH, 5-H, 
6-HH), 1.27 (3H, d, J 6.5, 28-H3), 1.15 (3H, d, J 7.0, 29-H3), 0.89 (3H, d, J 6.0, 24-H3), 0.87 (9H, s, 
SiC(CH3)3), 0.82 (3H, d, J 6.0, 22-H3), 0.10 (3H, s, SiCH3), 0.04 (3H, s, SiCH3). δC (126 MHz, CDCl3) 210.0 
(C-17), 173.7 (C-25), 167.2 (C-1), 159.5 (C-3), 156.1 (C-30), 147.3 (C-7), 132.5 (C-13), 129.9 (C-10), 128.8 
(C-11), 127.6 (C-12), 116.7 (C-2), 111.4 (C-23), 73.2 (C-27), 67.8 (C-19), 51.2 (C-16), 50.9 (OCH3), 48.7 
(C-4), 48.4 (C-18), 46.9 (C-26), 44.6 (C-20), 44.3 (C-6), 40.3 (C-14), 35.5 (C-8), 29.2 (C-15), 29.1 (C-5), 
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26.0 (C-9), 25.9 (SiC(CH3)3), 20.0 (C-24), 19.5 (C-22), 18.8 (C-21), 18.1 (SiC(CH3)3), 17.9 (C-28), 13.9 
(C-29), −4.6 (SiCH3), −4.7 (SiCH3). HRMS (ESI) calc. for C37H64N2O7SiK [M+K]+ 715.4114. Found 715.4124. 
[]D
20 = +2.0 (c 1.00, CHCl3). IR (νmax/cm-1) (neat): 3330 (amine N–H, and amide N–H), 2927 (alkane 
C–H), 1712 (C=O), 1646 (C=O). 
Methyl (2E,5R,10Z,12E,15S,19R)-20-((26R,27R)-27-(carbamoyloxy)-26-methylbutanamido)-19-
hydroxy-3,5,15-trimethyl-7-methylene-17-oxoicosa-2,10,12-trienoate 8  
(Semi-synthetic preparation) 
 
TBAF (1 M, 0.50 mL, 0.50 mmol) was added dropwise to a solution of silyl ether 8 (97 mg, 0.143 mmol) 
in THF (0.5 mL). After 16 hours at room temperature the reaction was quenched with water (1 mL) 
and extracted with Et2O (3 × 1 mL). The combined organic layers were dried over MgSO4, filtered, and 
concentrated in vacuo to give alcohol 9 (72 mg, 89%) as a yellow oil. 
Characterisation as given previously. 
Methyl (2E,5R,10Z,12E,15S)-3,5,15-trimethyl-7-methylene-17-oxooctadeca-2,10,12-trienoate 10 
 
Ester 8 (20 mg, 35.6 µmol) was dissolved in THF (1 mL) and a solution of LiOH (96 mg, 4.01 mmol) in 
water (1 mL) was added. The solution was heated to 60 °C for 16 hours, diluted with water (5 mL), and 
extracted with EtOAc (3 × 5 mL). The combined organic layers were dried over MgSO4, filtered, and 
concentrated in vacuo. The crude material was purified by column chromatography (20% EtOAc in 
petrol) to give ketone 10 (5 mg, 39%) as a colourless oil. 
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δH (500 MHz, CDCl3) 6.28 (1H, dd, J 15.0, 11.0, 12-H), 5.96 (1H, t, J 11.0, 11-H), 5.66 (1H, s, 2-H), 5.61 
(1H, dt, J 14.5, 7.0, 13-H), 5.31 (1H, dt, J 11.0, 7.5, 10-H), 4.81 (1H, s, 21-HH), 4.75 (1H, s, 21-HH), 3.69 
(3H, s, OCH3), 2.44 (1H, dd, J 16.0, 5.0, 16-HH), 2.30-2.27 (2H, m, 9-H2), 2.22 (1H, m, 16-HH), 2.19 (1H, 
m, 4-HH), 2.14 (3H, s, 19-H3), 2.12 (3H, s, 18-H3), 2.10 (1H, m, 15-H), 2.10-2.02 (3H, m, 8-H2, 14-HH), 
2.03-1.97 (2H, m, 6-HH, 14-HH), 1.93-1.82 (3H, m, 4-HH, 5-H, 6-HH), 0.92 (3H, d, J 6.0, 22-H3), 0.83 (3H, 
d, J 6.0, 20-H3). δC (126 MHz, CDCl3) 208.9 (C-17), 167.2 (C-1), 159.5 (C-3), 147.3 (C-7), 132.5 (C-13), 
129.8 (C-10), 128.8 (C-11), 127.6 (C-12), 116.7 (C-2), 111.4 (C-21), 50.9 (OCH3), 50.5 (C-16), 48.7 (C-4), 
44.3 (C-6), 40.3 (C-14), 35.6 (C-8), 30.7 (C-18), 29.6 (C-15), 29.1 (C-5), 26.1 (C-9), 20.0 (C-22), 19.5 
(C-20), 18.8 (C-19). HRMS (ESI) calc. for C23H36O3Na [M+Na]+ 383.2557. Found 383.2569. IR (νmax/cm-1) 
(neat): 2923 (alkane C–H), 1717 (ketone C=O), 1645 (ester C=O). 
Kalimantacin A 1 (semi-synthetic preparation) 
 
Porcine liver esterase (EC 3.1.1.1, Sigma E3019, 25 mg) in potassium phosphate buffer (0.1 M, pH 8.0, 
2.5 mL) was added to a solution kalimantacin A methyl ester 8 (12.0 mg, 21.3 µmol) in MeOH (0.5 mL). 
The reaction was left exposed to air and was heated at 36 °C for 16 hours. The solution was 
concentrated in vacuo and partitioned between a saturated aqueous solution of NH4Cl (1 M, 20 mL) 
and EtOAc (3 × 20 mL). The layers were separated and the aqueous phase was further extracted with 
EtOAc (2 × 20 mL). The combined organic layers were dried over MgSO4, filtered, and concentrated in 
vacuo. The crude material was purified by column chromatography (0-5% MeOH in EtOAc) to give 
kalimantacin A 1 (10.3 mg, 88%) as a pale yellow oil. 







(2E,5R,10Z,12E,15S)-3,5,15-Trimethyl-7-methylene-17-oxooctadeca-2,10,12-trienoic acid 11 
 
Kalimantacin A 1 (15 mg, 27.3 µmol) was dissolved in THF (1 mL) and a solution of LiOH (50 mg, 2.08 
mmol) in water (1 mL) was added. The solution was heated to 60 °C for three hours, diluted with water 
(5 mL), and extracted with EtOAc (3 × 5 mL). The combined organic layers were dried over MgSO4, 
filtered, and concentrated in vacuo. The crude material was purified by column chromatography (0-2% 
MeOH in DCM) to give ketone 11 (3 mg, 32%) as a colourless oil. 
δH (600 MHz, CDCl3) 6.28 (1H, dd, J 15.0, 11.0, 12-H), 5.96 (1H, t, J 11.0, 11-H), 5.69 (1H, s, 2-H), 5.61 
(1H, dt, J 15.0, 7.5, 13-H), 5.31 (1H, dt, J 11.0, 7.5, 10-H), 4.81 (1H, s, 21-HH), 4.75 (1H, s, 21-HH), 2.44 
(1H, dd, J 16.0, 5.5, 16-HH), 2.33-2.27 (2H, m, 9-H2), 2.26-2.19 (2H, m, 4-HH, 16-HH), 2.15 (3H, s, 19-H3), 
2.12 (3H, s, 18-H3), 2.11 (1H, m, 15-H), 2.09-2.04 (3H, m, 8-H2, 14-HH), 2.04-1.98 (2H, m, 6-HH, 14-HH), 
1.93-1.83 (3H, m, 4-HH, 5-H, 6-HH), 0.91 (3H, d, J 6.5, 22-H3), 0.84 (3H, d, J 5.5, 20-H3). δC (151 MHz, 
CDCl3) 209.2 (C-17), 170.4 (C-1), 162.3 (C-3), 147.2 (C-7), 132.5 (C-13), 129.8 (C-10), 128.8 (C-11), 127.6 
(C-12), 116.3 (C-2), 111.5 (C-21), 50.5 (C-16), 48.9 (C-4), 44.2 (C-6), 40.2 (C-14), 35.6 (C-8), 30.7 (C-18), 
29.7 (C-15), 29.2 (C-5), 26.0 (C-9), 20.0 (C-22), 19.6 (C-20), 19.1 (C-19). HRMS (ESI) calc. for C22H33O3 
[M−H]− 345.2435. Found 345.2440. IR (νmax/cm-1) (neat): 3300 (carboxylic acid O–H), 2924 (alkane 




A solution of kalimantacin A 1 (8 mg, 14.6 µmol) in toluene (2 mL) was heated to reflux (111 °C) for 
three days. The solvent was removed under a stream of nitrogen and the crude material was 
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redissolved in DCM (5 mL). The solution was washed with water (5 mL), dried over MgSO4, filtered, 
and concentrated in vacuo. The crude material was purified by column chromatography (2% MeOH in 
DCM) to give pyrrole 12 (3 mg, 56%) as a yellow oil. 
δH (500 MHz, CDCl3) 7.92 (1H, br. s, NH), 6.66 (1H, q, J 2.5, 20-H), 6.29 (1H, dd, J 15.0, 11.0, 12-H), 6.13 
(1H, q, J 2.5, 19-H), 5.97 (1H, t, J 11.0, 11-H), 5.91 (1H, t, J 2.5, 18-H), 5.69 (1H, q, J 1.0, 2-H), 5.67 (1H, 
dt, J 15.0, 7.5, 13-H), 5.31 (1H, dt, J 11.0, 7.5, 10-H), 4.82 (1H, d, J 1.5, 23-HH), 4.75 (1H, d, J 1.5, 23-HH), 
2.61 (1H, dd, J 14.5, 6.0, 16-HH), 2.43 (1H, dd, J 14.5, 8.0, 16-HH), 2.31 (2H, q, J 7.5, 9-H2), 2.22 (1H, m, 
4-HH), 2.17 (1H, m, 14-HH), 2.15 (3H, d, J 1.0, 21-H3), 2.06 (2H, t, J 7.5, 8-H2), 2.06-1.94 (2H, m, 6-HH, 
14-HH), 1.95-1.84 (3H, m, 4-HH, 5-H, 6-HH), 1.80 (1H, q, J 6.5, 15-H), 0.92 (3H, d, J 6.5, 24-H3), 0.84 
(3H, d, J 6.0, 22-H3). δC (126 MHz, CDCl3) 169.8 (C-1), 162.4 (C-3), 147.2 (C-7), 133.2 (C-13), 131.3 (C-17), 
129.5 (C-10), 129.0 (C-11), 127.2 (C-12), 116.2 (C-20), 116.0 (C-2), 111.5 (C-23), 108.4 (C-19), 106.3 
(C-18), 48.9 (C-4), 44.6 (C-6), 40.0 (C-14), 35.6 (C-8), 35.1 (C-16), 34.6 (C-15), 29.2 (C-5), 26.1 (C-9), 19.8 
(C-24), 19.6 (C-22), 19.1 (C-21). HRMS (ESI) calc. for C24H35NO2Na [M+Na]+ 392.2560. Found 392.2547. 
IR (νmax/cm-1) (neat): 2925 (alkane C–H), 1690 (carboxylic acid C=O). 
Ethyl (R)-4-azido-3-hydroxybutanoate 15  
 
Sodium azide (3.83 g, 58.9 mmol) was added to a solution of hydroxybutyrate 14 (4.91 g, 29.5 mmol) 
in DMF (80 mL). The reaction mixture was heated to 100 °C for 22 hours before cooling to room 
temperature and diluting with EtOAc (150 mL) and water (300 mL). The layers were separated and the 
aqueous phase was extracted with EtOAc (2 × 150 mL). The combined organic layers were dried over 
MgSO4, filtered, and concentrated in vacuo. The crude material was purified by column 
chromatography (100% EtOAc) to give azide 15 (4.56 g, 89%) as an orange oil. 
δH (400 MHz, CDCl3) 4.24-4.15 (3H, m, 3-H, OCH2CH3), 3.38 (1H, dd, J 12.5, 5.0, 4-HH), 3.33 (1H, dd, J 
12.5, 6.0, 4-HH), 3.19 (1H, d, J 4.0, OH), 2.56 (1H, dd, J 16.5, 7.5, 2-HH), 2.51 (1H, dd, J 16.5, 5.0, 2-HH), 
1.28 (3H, t, J 7.0, OCH2CH3). δC (101 MHz, CDCl3) 172.2 (C-1), 67.5 (C-3), 61.2 (OCH2CH3), 55.7 (C-4), 
38.5 (C-2), 14.3 (OCH2CH3). []D
22 = +16.0 (c 1.00, CHCl3) [Lit. +15.6 (c 1.00, CHCl3)].246 IR (νmax/cm-1) 
(neat): 3398 (alcohol O–H), 2984 (alkane C–H), 2101 (azide N=N=N), 1719 (ester C=O). 





Ethyl (R)-4-azido-3-((tert-butyldimethylsilyl)oxy)butanoate 16 
 
TBSCl (7.94 g, 52.7 mmol) and imidazole (4.13 g, 60.6 mmol) were added to a solution of ethyl ester 
15 (4.56 g, 26.3 mmol) in DMF (135 mL). The reaction was stirred at room temperature for 16 hours 
then diluted with EtOAc (150 mL) and water (300 mL). The layers were separated and the aqueous 
phase was extracted with EtOAc (2 × 150 mL). The combined organic layers were dried over MgSO4, 
filtered, and concentrated in vacuo. The crude material was purified by column chromatography (10% 
EtOAc in petrol) to give silyl ether 16 (7.57 g, quant.) as a colourless oil. 
δH (400 MHz, CDCl3) 4.25 (1H, tdd, J 6.5, 5.0, 4.5, 3-H), 4.19-4.07 (2H, m, OCH2CH3), 3.37 (1H, dd, 12.5, 
4.5, 4-HH), 3.23 (1H, dd, J 12.5, 5.5, 4-HH), 2.56 (1H, dd, J 15.5, 6.0, 2-HH), 2.51 (1H, dd, J 15.5, 6.5, 
2-HH), 1.26 (3H, t, J 7.0, OCH2CH3), 0.88 (9H, s, SiC(CH3)3), 0.12 (3H, s, SiCH3), 0.08 (3H, s, SiCH3). δC 
(101 MHz, CDCl3) 171.0 (C-1), 68.9 (C-3), 60.8 (OCH2CH3), 56.6 (C-4), 40.3 (C-2), 25.8 (SiC(CH3)3), 18.0 
(SiC(CH3)3), 14.3 (OCH2CH3), −4.6 (SiCH3), −4.9 (SiCH3). []D
23 = +1.0 (c 1.00, CHCl3) [Lit. +2.2 (c 0.33, 
CHCl3)].247 
Spectroscopic data in accord with the literature data.247 
(R)-4-Azido-3-((tert-butyldimethylsilyl)oxy)butanal 17 
 
DIBAL (1 M in hexanes, 1.91 mL, 1.91 mmol) was added dropwise (with the tip of the needle touching 
the inner wall of the flask to pre-cool the DIBAL solution before entering the reaction mixture) to a 
vigorously stirred solution of ester 16 (500 mg, 1.74 mmol) in DCM (25 mL) at −78 °C. After 12 minutes 
the reaction was quenched by sequential addition of MeOH (10 mL, pre-cooled to −78 °C), a saturated 
aqueous solution of Rochelle’s salt (potassium sodium tartrate tetrahydrate, 5 mL), and water (5 mL). 
After vigorous stirring for approximately one hour at room temperature the layers were separated 
and the aqueous phase was extracted with DCM (2 × 20 mL). The combined organic layers were dried 
over MgSO4, filtered, and concentrated in vacuo to give aldehyde 17 (407 mg, 96%) as a colourless oil 
without further need for purification. 
δH (400 MHz, CDCl3) 9.80 (1H, dd, J 2.0, 1.5, 1-H), 4.34 (1H, m, 3-H), 3.38 (1H, dd, J 12.5, 4.5, 4-HH), 
3.22 (1H, dd, J 12.5, 5.0, 4-HH), 2.70 (1H, ddd, J 17.0, 6.0, 1.5, 2-HH), 2.65 (1H, ddd, J 17.0, 6.0, 2.0, 
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2-HH), 0.89 (9H, s, SiC(CH3)3), 0.13 (3H, s, SiCH3), 0.09 (3H, s, SiCH3). δC (101 MHz, CDCl3) 200.4 (C-1), 
67.4 (C-3), 56.7 (C-4), 48.9 (C-2), 25.8 (SiC(CH3)3), 18.1 (SiC(CH3)3), −4.5 (SiCH3), −4.8 (SiCH3). HRMS (ESI) 
calc. for C10H21N3O2SiNa [M+Na]+ 266.1. Found 266.1. []D
23 = −8.0 (c 1.00, CHCl3). IR (νmax/cm-1) (neat): 
2930 (alkane C–H), 2102 (azide N=N=N), 1725 (aldehyde C=O). 
Spectroscopic data in accord with the literature data.248 
Ethyl (R)-4-azido-3-((tert-butyldimethylsilyl)oxy)butanoic acid 18 
 
Ba(OH)2 (1.79 g, 10.5 mmol) was added to a solution of ester 16 (1.00 g, 3.48 mmol) in MeOH (54 mL) 
and water (6 mL) and stirred at room temperature for 16 hours. The MeOH was removed under 
reduced pressure and the solution was diluted with HCl (1 M, 10 mL) and EtOAc (25 mL). The layers 
were separated and the aqueous phase was extracted with EtOAc (2 × 25 mL). The combined organic 
layers were dried over MgSO4, filtered, and concentrated in vacuo. The crude material was purified by 
column chromatography (30% EtOAc in petrol with 1% AcOH) to give carboxylic acid 18 (859 mg, 95%) 
as a colourless oil. 
δH (400 MHz, CDCl3) 4.26 (1H, tdd, J 6.0, 5.0, 4.5, 3-H), 3.38 (1H, dd, J 12.5, 4.5, 4-HH), 3.26 (1H, dd, J 
12.5, 5.0, 4-HH), 2.63 (1H, dd, J 15.5, 6.0, 2-HH), 2.57 (1H, dd, J 15.5, 6.0, 2-HH), 0.89 (9H, s, SiC(CH3)3), 
0.13 (3H, s, SiCH3), 0.10 (3H, s, SiCH3). δC (101 MHz, CDCl3) 176.3 (C-1), 68.6 (C-3), 56.4 (C-4), 39.8 (C-2), 
25.8 (SiC(CH3)3), 18.1 (SiC(CH3)3), −4.5 (SiCH3), −4.9 (SiCH3). HRMS (ESI) calc. for C10H21N3O3SiNa 
[M+Na]+ 282.1244. Found 282.1242. []D
23 = +4.0 (c 1.00, CHCl3) [Lit. of (S)-enantiomer −3.5 (c 1.6, 
CHCl3)].248 IR (νmax/cm-1) (neat): 2930 (alkane C–H), 2103 (azide N=N=N), 1711 (carboxylic acid C=O). 
Spectroscopic data in accord with the literature data.248 
 (R)-4-Azido-3-((tert-butyldimethylsilyl)oxy)-N-methoxy-N-methylbutanamide 19 
 
N,O-Dimethylhydroxylamine hydrochloride (1.53 g, 15.7 mmol), EDCI.HCl (1.20 g, 6.28 mmol), DMAP 
(192 mg, 1.57 mmol), and triethylamine (2.12 mL, 15.71 mmol) were added sequentially to a solution 
of carboxylic acid 18 (815 mg, 3.14 mmol) in DCM (35 mL). The solution stirred at room temperature 
for 4.5 hours, then quenched with a saturated aqueous solution of NH4Cl (35 mL). The phases were 
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separated, and the aqueous layer was extracted with DCM (2 × 30 mL). The combined organic layers 
were dried over MgSO4, filtered, and concentrated in vacuo. The crude material was purified by 
column chromatography (30% EtOAc in petrol) to give amide 19 (787 mg, 83%) as a colourless oil. 
δH (500 MHz, CDCl3) 4.37 (1H, tdd, J 6.5, 4.5, 4.0, 3-H), 3.70 (3H, s, OCH3), 3.43 (1H, dd, J 12.5, 4.0, 
4-HH), 3.20 (1H, dd, J 12.5, 4.5, 4-HH), 3.17 (3H, s, NCH3), 2.75 (1H, dd, J 15.5, 6.5, 2-HH), 2.61 (1H, dd, 
J 15.5, 6.5, 2-HH), 0.89 (9H, s, SiC(CH3)3), 0.13 (3H, s, SiCH3), 0.08 (3H, s, SiCH3). δC (126 MHz, CDCl3) 
171.5 (C-1), 69.0 (C-3), 61.5 (OCH3), 56.8 (C-4), 37.1 (C-2), 32.1 (NCH3), 25.9 (SiC(CH3)3), 18.1 (SiC(CH3)3), 
−4.7 (SiCH3), −4.7 (SiCH3). HRMS (ESI) calc. for C12H26N4O3SiNa [M+Na]+ 325.1666. Found 325.1671. 
[]D
23  = −21.0 (c 1.00, CHCl3). IR (νmax/cm-1) (neat): 2929 (alkane C–H), 2100 (azide N=N=N), 1661 
(amide C=O). 
Benzyl 2,2,2-trichloroacetimidate S1 
 
An aqueous solution of KOH (50%, 10 mL) and tetrabutylammonium hydrogensulfate (15 mg, 
44.2 µmol) were added to a solution of benzyl alcohol (1.00 g, 9.25 mmol) in DCM (10 mL). The mixture 
was cooled to −15 °C and trichloroacetonitrile (1.20 mL, 11.97 mmol) was added dropwise. After 30 
minutes the reaction was warmed to room temperature over another 30 minutes. The layers were 
separated and the aqueous phase was extracted with DCM (2 × 10 mL). The combined organic layers 
were dried over MgSO4, filtered, and concentrated to ~10 mL. The solution was passed through a plug 
of Celite® and concentrated in vacuo to give benzyl 2,2,2-trichloroacetimidate S1 (2.32 g, 99%) as a 
pale yellow oil. The product was used directly without purification. 
δH (400 MHz, CDCl3) 8.40 (1H, br. s, NH), 7.47-7.30 (5H, m, Ar-H), 5.35 (2H, s, CH2). δC (101 MHz, CDCl3) 
162.7 (CNH), 135.6, 128.7, 128.4, and 127.8 (C-Ar), 91.5 (CCl3), 70.9 (CH2). 





To a solution of methyl (R)-(−)-3-hydroxy-2-methylpropionate 20 (0.5 mL, 4.51 mmol) in hexane 
(2.6 mL) and DCM (1.3 mL) was added benzyl 2,2,2-trichloroacetimidate (1.26 mL, 6.77 mmol) and 
triflic acid (10 µL, 0.113 mmol). After five minutes, an exotherm was observed, along with a large 
volume of precipitate. The reaction was stirred for 12 hours, then filtered and the solids washed with 
hexane (10 mL). The filtrate was washed with water (10 mL) and a saturated aqueous solution of 
NaHCO3 (10 mL), dried over MgSO4, filtered, and concentrated in vacuo to give benzyl ether 21. 
The crude benzyl ether was redissolved in Et2O (2 mL) and was added dropwise to a suspension of 
LiAlH4 (200 mg, 5.27 mmol) in of Et2O (15 mL) at 0 °C. The reaction was stirred for two hours at room 
temperature then quenched via dropwise addition of water (0.2 mL), aqueous NaOH (15%, 0.2 mL), 
and further water (0.6 mL). The resulting solids were filtered through Celite® and rinsed with ether 
(15 mL). The filtrate was washed with HCI (0.5 M, 15 mL) and a saturated aqueous solution of NaHCO3 
(15 mL), dried over MgSO4, filtered, and concentrated in vacuo. The crude material was purified by 
column chromatography (10-30% EtOAc in petrol) to give alcohol 22 (708 mg, 87%) as a colourless oil. 
δH (400 MHz, CDCl3) 7.40-7.27 (5H, m, Ar-H), 4.52 (2H, s, 4-H2), 3.62 (2H, m, 1-H2), 3.56 (1H, dd, J 9.0, 
4.5, 3-HH), 3.43 (1H, dd, J 9.0, 8.0, 3-HH), 2.55 (1H, t, J 5.0, OH), 2.08 (1H, m, 2-H), 0.89 (3H, d, J 7.0, 
CH3). δC (101 MHz, CDCl3) 138.2, 128.6, 127.9, and 127.7 (C-Ar), 75.6 (C-3), 73.5 (C-4), 68.0 (C-1), 35.7 
(C-2), 13.6 (CH3). []D
23 = −15.0 (c 1.00, CHCl3) [Lit. −15.9 (c 1.00, CHCl3)].250 
Spectroscopic data in accord with the literature data.251 
(R)-3-(Benzyloxy)-2-methylpropyl 4-methylbenzenesulfonate 23 
 
p-Toluenesulfonyl chloride (17.10 g, 89.7 mmol) and DMAP (456 mg, 3.73 mmol) were added to a 
solution of alcohol 22 (13.5 g, 74.7 mmol) in pyridine (140 mL). The reaction was stirred for 12 hours 
at room temperature then partitioned between water (500 mL) and EtOAc (250 mL). The phases were 
separated, and the organic layer was extracted with a saturated aqueous solution of CuSO4 (500 mL) 
and water (500 mL). The combined organic layers were dried over MgSO4, filtered, and concentrated 
in vacuo to give tosylate 23 (21.0 g, 84%) as a pale orange oil. 
δH (400 MHz, CDCl3) 7.80 (2H, dd, J 8.5, 2.0, Ar-H), 7.38-7.22 (7H, m, Ar-H), 4.42 (2H, s, 4-H2), 4.07 (1H, 
ddd, J 9.5, 5.5, 2.0, 1-HH), 4.01 (1H, ddd, J 9.5, 5.5, 2.0, 1-HH), 3.40-3.31 (2H, m, 3-H2), 2.44 (3H, s, 
Ar-CH3), 2.13 (1H, m, 2-H), 0.96 (3H, dd, J 7.0, 1.5, CHCH3). δC (101 MHz, CDCl3) 144.8, 138.3, 133.1, 
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129.9, 128.4, 128.0, 127.7, and 127.5 (C-Ar), 73.2 (C-4), 72.4 (C-1), 71.2 (C-3), 33.8 (C-2), 21.8 (Ar-CH3), 
13.7 (CHCH3). []D
23 = −4.0 (c 1.00, CHCl3) [Lit. −4.7 (c 1.50, CHCl3)].252 
Spectroscopic data in accord with the literature data.252 
 (S)-(((4-Methylpent-2-yn-2-yl)oxy)methyl)benzene 24 
 
To a solution of tosylate 23 (931 mg, 2.78 mmol) in DMSO (5 mL) was added lithium acetylide 
ethylenediamine complex (LAEDA) (90%, 299 mg, 2.92 mmol) in one portion. The reaction was stirred 
at room temperature for 18 hours before quenching with water (20 mL). The resulting mixture was 
extracted with Et2O (3 × 10 mL) and the combined organic layers were dried over MgSO4, filtered, and 
concentrated in vacuo. The crude material was purified by column chromatography (5% EtOAc in 
petrol) to give acetylene 24 (492 mg, 94%) as a colourless oil. 
δH (400 MHz, CDCl3) 7.39-7.26 (5H, m, Ar-H), 4.52 (2H, s, 6-H2), 3.39 (2H, d, 5-H2), 2.34 (1H, ddd, J 16.5, 
5.5, 2.5, 3-HH), 2.20 (1H, ddd, J 16.5, 7.0, 2.5, 3-HH), 2.02 (1H, m, 4-H), 1.95 (1H, t, J 2.5, 1-H), 1.03 
(3H, d, J 7.0, CH3). δC (101 MHz, CDCl3) 138.7, 128.5, 127.7, and 127.6 (C-Ar), 82.9 (C-2), 74.3 (C-5), 73.2 
(C-6), 69.4 (C-1), 33.0 (C-4), 22.7 (C-3), 16.5 (CH3). []D
24 = −12.0 (c 1.00, CHCl3) [Lit. −15.9 (c 1.05, 
CHCl3)].253 
Spectroscopic data in accord with the literature data.253 
4,4′-Di-tert-butylbiphenyl 28 
 
Biphenyl 27 (60.0 g, 0.389 mol) and anhydrous ferric chloride (312 mg, 1.92 mmol) were dissolved in 
DCM (400 mL) in a two-neck round-bottom flask. A gas bubbler containing a saturated aqueous 
solution of NaHCO3 was connected to the top of the flask. tert-Butyl chloride (90.0 mL, 0.827 mol) was 
added dropwise via a dropping funnel which was replaced with a stopper once addition was complete. 
After 16 hours at room temperature the reaction was quenched with water (400 mL) and the phases 
were separated. The aqueous phase was extracted with hexane (2 × 300 mL) and the combined organic 
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layers were dried over MgSO4, filtered, and concentrated in vacuo to give 4,4′-di-tert-butylbiphenyl 28 
(100 g, 97%) as a pale yellow solid. 
δH (400 MHz, CDCl3) 7.56 (4H, m, 2-H), 7.49 (4H, m, 3-H), 1.40 (18H, s, CH3). δC (101 MHz, CDCl3) 150.0 
(C-4), 138.3 (C-1), 126.8 (C-2), 125.8 (C-3), 34.6 (C-5), 31.5 (C-6). M.p. 124-126 °C (from MeOH) [Lit. 
127 °C].254 
Spectroscopic data in accord with the literature data.255 
Lithium 4,4′-di-tert-butylbiphenylide 29 (LiDBB) 
 
Lithium wire was prepared as follows: strips of wire were sequentially rinsed with petrol to remove 
the mineral oil, submerged in MeOH to clean the surface, rinsed with Et2O, and submerged in 
anhydrous THF. The metal was quickly weighed before resubmerging in anhydrous THF. Once the 
desired quantity was attained the wire was cut into ~0.5 cm long pieces using scissors. Whilst still 
submerged in THF the lithium was also crushed with pliers to increase the surface area. The metal 
(80 mg, 11.53 mmol) was then added to a vigorously stirred solution of 4,4′-di-tert-butylbiphenyl 28 
(2.44 g, 9.16 mmol) in THF (35 mL) which was prepared with careful exclusion of oxygen and moisture. 
After ~15 minutes the solution turned from a pale yellow to a deep green-blue. At this point the 
reaction was cooled to 0 °C and stirred for a further six hours before the reagent was used. 
(S)-2-Methyl-5-(trimethylsilyl)pent-4-yn-1-ol 30 
 
nBuLi (1.48 M in hexanes, 1.86 mL, 2.75 mmol) was added dropwise to a solution of alkyne 24 (431 
mg, 2.29 mmol) in Et2O (4 mL) at −78 °C. After 15 minutes TMSCl (0.44 mmol, 3.47 mmol) was added 
and the solution stirred at −78 °C for a further five minutes, before warming to room temperature 
over 30 minutes. The reaction was quenched with a saturated aqueous solution of NaHCO3 (5 mL) and 
the phases were separated. The aqueous layer was extracted with Et2O (2 × 5 mL). The combined 
organic layers were dried over MgSO4, filtered, and concentrated in vacuo to give silyl alkyne 26. 
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The crude material was redissolved in Et2O (13 mL) and cooled to −78 °C. A solution of LiDBB 29 in THF 
(as prepared above) was added portionwise (~5 mL every 5 minutes) until the green-blue colour 
persisted (~3/4 of the solution was required). The reaction was stirred for a further five minutes 
before quenching with a saturated aqueous solution of NH4Cl (10 mL). The THF was removed in vacuo 
and the product was extracted with Et2O (10 mL). The organic layer was separated and washed with a 
saturated aqueous solution of NaHCO3 (10 mL) and the aqueous phase was extracted with Et2O (2 × 
10 mL). The combined organic layers were dried over MgSO4, filtered, and concentrated in vacuo. The 
crude material was purified by column chromatography (5-30% EtOAc) to give alcohol 30 (214 mg, 
55%) as a pale orange oil. 
δH (400 MHz, CDCl3) 3.60-3.50 (2H, d, J 6.0, 1-H2), 2.29 (1H, dd, J 17.0, 6.5, 3-HH), 2.20 (1H, dd, J 17.0, 
6.0, 3-HH), 1.88 (1H, m, 2-H), 1.73 (1H, s, OH), 0.99 (3H, d, J 7.0, CCH3), 0.14 (9H, s, (SiCH3)3). δC (101 
MHz, CDCl3) 105.6 (C-4), 86.3 (C-5), 67.4 (C-1), 35.2 (C-2), 24.0 (C-3), 16.4 (CCH3), 0.2 (SiCH3). []D
21 = 
−6.0 (c 1.00, CHCl3) [Lit. −6.0 (c 1.00, CHCl3)].256 
Spectroscopic data in accord with the literature data.256 
(S)-1-Bromo-2-methyl-5-(trimethyl)silyl-4-pentyne 31 
 
Triphenylphosphine (462 mg, 1.76 mmol) was added to a solution of alcohol 30 (150 mg, 0.881 mmol) 
and tetrabromomethane (584 mg, 1.76 mmol) in Et2O (5 mL). The reaction was stirred for 16 hours at 
room temperature then quenched with a saturated aqueous solution of NaHCO3 (5 mL). The phases 
were separated and the aqueous layer was extracted with Et2O (2 × 5 mL). The combined organic 
layers were dried over MgSO4, filtered, and concentrated in vacuo. The crude material was purified by 
column chromatography (100% hexane) to give bromide 31 (141 mg, 69%) as a colourless oil.  
δH (400 MHz, CDCl3) 3.46 (1H, dd, J 10.0, 6.0, 1-HH), 3.43 (1H, dd, J 10.0, 5.5, 1-HH), 2.36 (1H, dd, J 
17.0, 6.5, 3-HH), 2.31 (1H, dd, J 17.0, 6.0, 3-HH) 2.04 (1H, m, 2-H), 1.10 (3H, d, J 6.5, CCH3), 0.15 (9H, s, 
(SiCH3)3). δC (101 MHz, CDCl3) 104.4 (C-4), 86.7 (C-5), 39.5 (C-1), 35.0 (C-2), 25.6 (C-3), 18.5 (CCH3), 0.2 
(SiCH3). []D





A solution of triphenylphosphine (1.54 g, 5.87 mmol) in DCM (15 mL) was cooled to 0 °C before iodine 
(1.49 g, 5.87 mmol) and imidazole (600 mg, 8.81 mmol) were added. After 10 minutes a solution of 
alcohol 30 (500 mg, 2.94 mmol) in DCM (10 mL) was added dropwise. The reaction was warmed to 
room temperature and stirred for 3.5 hours before quenching with a saturated aqueous solution of 
Na2S2O3 (5 mL) and water (20 mL). The phases were separated and the aqueous layer was extracted 
with DCM (2 × 10 mL). The combined organic layers were dried over MgSO4, filtered, and concentrated 
in vacuo. The crude material was purified by column chromatography (0-10% EtOAc in petrol) to give 
iodide 32 (681 mg, 83%) as a colourless oil. 
δH (400 MHz, CDCl3) 3.29 (1H, dd, J 9.5, 5.5, 1-HH), 3.26 (1H, dd, J 9.5, 5.5, 1-HH), 2.29 (2H, d, J 6.5, 
3-H2), 1.76 (1H, m, 2-H), 1.08 (3H, d, J 6.5, CCH3), 0.15 (9H, s, (SiCH3)3). δC (101 MHz, CDCl3) 104.4 (C-4), 
86.7 (C-5), 34.7 (C-2), 27.2 (C-3), 20.2 (CCH3), 15.0 (C-1), 0.2 (SiCH3). []D
22 = +5.0 (c 1.00, CHCl3) [Lit. of 
(R)-enantiomer −5.0 (c 1.05, CHCl3)].257 IR (νmax/cm-1) (neat): 2959 (alkane C–H), 2175 (alkyne C≡C). 
Spectroscopic data in accord with the literature data.257 
(R)-5-Benzyl-1-((S)-3’-methyl-6’-(trimethylsilyl)pent-5’-ynoyl)oxazolidin-2-one 35 
 
Oxazolidinone 33 (1.00 g, 4.29 mmol) was dissolved in THF (42 mL) and cooled to −78 °C. NaHMDS 
(1 M in THF, 5.15 mL, 5.15 mmol) was added dropwise and the solution was stirred for two hours 
before bromide 34 (0.84 mL, 5.15 mmol) was added dropwise. After two hours at −78 °C the reaction 
was warmed to 0 °C and stirred for a further two hours, then quenched with a saturated aqueous 
solution of NH4Cl (100 mL). The resulting solution was extracted with DCM (3 × 100 mL) and the 
combined organic layers were dried over MgSO4, filtered, and concentrated in vacuo. The crude 
material was purified by column chromatography (30% Et2O in petrol) to give oxazolidinone 35 (1.09 g, 
74%) as a colourless oil. 
1H NMR analysis revealed a diastereomeric ratio of 10:1. 
δH (400 MHz, CDCl3) 7.37-7.27 (3H, m, Ar-H), 7.25-7.18 (2H, m, Ar-H), 4.70 (1H, m, 5-H), 4.25-4.15 (2H, 
m, 4-H2), 3.94 (1H, m, 3’-H), 3.30 (1H, dd, J 13.5, 3.5, 6-HH), 2.76 (1H, dd, J 13.5, 9.5, 6-HH), 2.62 (1H, 
dd, J 17.0, 6.5, 4’-HH), 2.55 (1H, dd, J 17.0, 7.0, 4’-HH), 1.27 (3H, d, J 7.0, CH3), 0.12 (3H, s, Si(CH3)3). δC 
(101 MHz, CDCl3) 175.3 (C-2’), 153.2 (C-2), 135.4, 129.6, 129.1, and 127.5 (C-Ar), 103.9 (C-5’), 86.7 
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(C-6’), 66.2 (C-4), 55.4 (C-5), 38.2 (C-6), 37.6 (C-3’), 24.2 (C-4’), 16.7 (CH3), 0.2 (Si(CH3)3). []D
23 = −36.0 
(c 1.00, CHCl3). [Lit. of enantiomer +40.7 (c 1.1, CHCl3)].257 
Spectroscopic data in accord with the literature data.257 
(S)-2-Methyl-5-(trimethylsilyl)pent-4-yn-1-ol 30 
 
Oxazolidinone 35 (3.39 g, 9.87 mmol) was dissolved in a mixture of Et2O (120 mL) and water (0.53 mL) 
and cooled to 0 °C. LiBH4 (2 M in THF, 14.8 mL, 29.6 mmol) was added slowly and the solution was 
stirred for one hour. The reaction was quenched with a saturated aqueous solution of NH4Cl (100 mL) 
and the layers were separated. The aqueous phase was extracted with Et2O (2 × 100 mL) and the 
combined organic layers were dried over MgSO4, filtered, and concentrated in vacuo. The crude 
material was purified by column chromatography (20-50% EtOAc in petrol) to give alcohol 30 (1.19 g, 
73%) as a colourless oil. (R)-4-Benzyl-2-oxazolidinone 36 (1.49 g, 85%) was also recovered as a white 
solid. 
(S)-2-Methyl-5-(trimethylsilyl)pent-4-yn-1-ol 30 
Characterisation as given previously. 
(R)-4-Benzyloxazolidin-3-one 36 
δH (400 MHz, CDCl3) 7.37-7.24 (3H, m, Ar-H), 7.21-7.15 (2H, m, Ar-H), 5.66 (1H, br. s, NH), 4.45 (1H, t, 
J 8.5, 4-HH), 4.15 (1H, dd, J 8.5, 5.5, 4-HH), 4.09 (1H, dtd, J 8.5, 7.0, 5.5, 5-H), 2.88 (2H, d, J 7.0, 6-H2). 
δC (101 MHz, CDCl3) 159.4 (C-2), 136.1, 129.1, 129.1, and 127.4 (C-Ar), 69.8 (C-4), 53.9 (C-5), 41.6 (C-6). 
Spectroscopic data in accord with the literature data.258 
(R)-5-Benzyl-1-propionyloxazolidin-2-one 33 
 
Triethylamine (11.8 mL, 84.7 mmol), DMAP (207 mg, 1.69 mmol), and propionyl chloride (4.93 mL, 
56.4 mmol) were added sequentially to a solution of (R)-4-benzyl-2-oxazolidinone 36 (10.0 g, 56.4 
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mmol) in DCM (100 mL) at 0 °C. After one hour the reaction was quenched with a saturated aqueous 
solution of NH4Cl (100 mL) and the phases were separated. The aqueous layer was extracted with DCM 
(2 × 100 mL) and the combined organic layers were dried over MgSO4, filtered, and concentrated in 
vacuo. The crude material was purified by column chromatography (30% EtOAc in petrol) to give 
oxazolidinone 33 (9.16 g, 70%) as a yellow oil. 
δH (400 MHz, CDCl3) 7.38-7.17 (5H, m, Ar-H), 4.67 (1H, ddt, J 9.5, 7.5, 3.5, 5-H), 4.20 (1H, dd, J 9.0, 7.5, 
4-HH), 4.17 (1H, dd, J 9.0, 3.5, 4-HH), 3.31 (1H, dd, J 13.5, 3.5, 6-HH), 3.04-2.88 (2H, m, 3’-H2), 2.77 (1H, 
dd, J 13.5, 9.5, 6-HH), 1.21 (3H, t, J 7.5, 4’-H3). δC (101 MHz, CDCl3) 174.2 (C-2’), 153.7 (C-2), 135.5, 
129.6, 129.1, and 127.5 (C-Ar), 66.4 (C-4), 55.3 (C-5), 38.1 (C-6), 29.3 (C-3’), 8.4 (C-4’). []D
24 = −52.0 
(c 1.00, CHCl3) [Lit. −49.0 (c 4.9, CHCl3)].259 
Spectroscopic data in accord with the literature data.259 
3-(Trimethylsilyl)prop-2-yn-1-ol 38 
 
Propargyl alcohol 37 (3.29 mL, 56.5 mmol) was dissolved in THF (200 mL) and cooled to −78 °C. nBuLi 
(1.47 M in hexanes, 76.4 mL, 112 mmol) was added slowly and the solution was stirred for 30 minutes 
before TMSCl (15.0 mL, 118 mmol) was added dropwise. The reaction was allowed to warm to room 
temperature and stirred for two hours before quenching with water (25 mL) and HCl (1 M, 75 mL). The 
mixture was stirred for a further 1.5 hours and the layers were separated. The aqueous phase was 
extracted with Et2O (5 × 50 mL) and the combined organic layers were dried over MgSO4, filtered, and 
concentrated in vacuo to give alcohol 38 (7.26 g, quant.) as an orange oil without further need for 
purification. 
δH (400 MHz, CDCl3) 4.27 (2H, s, 1-H2), 1.84 (1H, br. s, OH), 0.18 (9H, s, Si(CH3)3). δC (101 MHz, CDCl3) 
103.9 (C-2), 90.9 (C-3), 51.8 (C-1), 0.0 (Si(CH3)3).  





Alcohol 38 (7.26 g, 56.6 mmol) was dissolved in Et2O (40 mL) and a solution of phosphorus tribromide 
(1.86 mL, 19.8 mmol) in Et2O (10 mL) was added slowly. The solution was stirred for 18 hours at room 
temperature before quenching with a saturated aqueous solution of NaHCO3 (10 mL) and diluting with 
water (40 mL). The layers were separated and the aqueous phase was extracted with Et2O (2 × 50 mL). 
The combined organic layers were dried over MgSO4, filtered, and concentrated in vacuo. The crude 
material was purified by column chromatography (100% pentane). The product containing fractions 
were pooled and carefully concentrated in vacuo using a water bath set to 30 °C to give bromide 39 
(6.77 g, 63%) as a colourless oil. 
δH (400 MHz, CDCl3) 3.91 (2H, s, 1-H2), 0.18 (9H, s, Si(CH3)3). δC (101 MHz, CDCl3) 100.1 (C-2), 92.5 (C-3), 
14.9 (C-1), −0.2 (Si(CH3)3). 
Spectroscopic data in accord with the literature data.261 
(R)-4-((tert-Butyldimethylsilyl)oxy)-1-isobutylpyrrolidin-2-one 40 
 
Isobutylmagnesium bromide (2 M in Et2O, 0.25 mL, 0.50 mmol) was added dropwise to a solution of 
Weinreb amide 19 (100 mg, 0.331 mmol) in Et2O (1 mL). The reaction was stirred for 16 hours at room 
temperature then quenched with a saturated aqueous solution of NH4Cl (1 mL). The phases were 
separated and the aqueous layer was extracted with EtOAc (3 × 2 mL). The combined organic layers 
were dried over MgSO4, filtered, and concentrated in vacuo. The crude material was purified by 
column chromatography (20% EtOAc in petrol) to give lactam 40 (34 mg, 38%) as a colourless oil. 
δH (400 MHz, CDCl3) 4.55 (1H, m, 4-H), 3.85 (1H, dd, J 12.0, 6.0, 5-HH), 3.65 (2H, d, J 7.0, 6-H2), 3.59 
(1H, dd, J 12.0, 3.0, 5-HH), 2.87 (1H, dd, J 17.5, 7.0, 3-HH), 2.59 (1H, dd, J 17.5, 3.5, 3-HH), 2.08 (1H, 
app. non, J 7.0, 7-H), 0.97 (6H, d, J 7.0, 8-(CH3)2), 0.87 (9H, s, SiC(CH3)3), 0.08 (3H, s, SiCH3), 0.07 (3H, s, 
SiCH3). δC (101 MHz, CDCl3) 170.7 (C-2), 69.7 (C-6), 63.7 (C-4), 53.2 (C-5), 41.9 (C-3), 28.5 (C-7), 25.8 
(SiC(CH3)3), 20.8 (C-8), 18.1 (SiC(CH3)3), −4.7 (SiCH3), −4.7 (SiCH3). HRMS (ESI) calc. for C14H30NO2Si 
[M+H]+ 272.2040. Found 272.2037. M.p. 58-60 °C (from CHCl3). []D
21  = −20.0 (c 1.00, CHCl3). IR 






Ethyl (R)-3-((tert-butyldimethylsilyl)oxy)-4-chlorobutanoate 45 
 
TBSCl (995 mg, 6.60 mmol) and imidazole (613 mg, 9.00 mmol) were added to a solution of 
hydroxybutyrate 44 (1.00 g, 6.00 mmol) in DMF (6 mL). The solution was stirred at room temperature 
for 16 hours then partitioned between water (100 mL) and EtOAc (100 mL). The layers were separated 
and the aqueous phase was extracted with EtOAc (2 × 100 mL). The combined organic layers were 
dried over MgSO4, filtered, and concentrated in vacuo. The crude material was purified by column 
chromatography (5-10% EtOAc in petrol) to give silyl ether 45 (1.68 g, quant.) as a colourless oil. 
δH (400 MHz, CDCl3) 4.30 (1H, ddt, J 7.0, 6.0, 5.0, 3-H), 4.14 (2H, q, OCH2CH3), 3.53 (1H, dd, J 11.0, 5.0, 
4-HH), 3.49 (1H, dd, J 11.0, 6.0, 4-HH), 2.68 (1H, dd, J 15.5, 5.0, 2-HH), 2.51 (1H, dd, J 15.5, 7.0, 2-HH), 
1.27 (3H, t, J 7.0, OCH2CH3), 0.87 (9H, s, SiC(CH3)3), 0.11 (3H, s, SiCH3), 0.07 (3H, s, SiCH3). δC (101 MHz, 
CDCl3) 171.1 (C-1), 69.6 (C-3), 60.7 (OCH2CH3), 48.2 (C-4), 40.6 (C-2), 25.8 (SiC(CH3)3), 18.1 (SiC(CH3)3), 
14.3 (OCH2CH3), −4.5 (SiCH3), −4.8 (SiCH3). []D
23 = +13.0 (c 1.00, CHCl3) [Lit. +22.2 (c 2.67, CHCl3)].262 
Spectroscopic data in accord with the literature data.262 
 (R)-3-((tert-Butyldimethylsilyl)oxy)-4-chlorobutanal 46 
 
DIBAL (1 M in hexanes, 1.96 mL, 1.96 mmol) was added dropwise (with the tip of the needle touching 
the inner wall of the flask to pre-cool the DIBAL solution before entering the reaction mixture) to a 
vigorously stirred solution of ester 45 (500 mg, 1.78 mmol) in DCM (25 mL) at −78 °C. After 10 minutes 
the reaction was quenched by sequential addition of MeOH (10 mL, pre-cooled to −78 °C), a saturated 
aqueous solution of Rochelle’s salt (potassium sodium tartrate tetrahydrate, 5 mL), and water (5 mL). 
After vigorous stirring for approximately one hour at room temperature the layers were separated 
and the aqueous phase was extracted with DCM (2 × 20 mL). The combined organic layers were dried 
over MgSO4, filtered, and concentrated in vacuo. The crude material was purified by column 
chromatography (2.5% EtOAc in petrol) to give aldehyde 46 (375 mg, 89%) as a colourless oil. 
δH (400 MHz, CDCl3) 9.80 (1H, dd, J 2.5, 1.5, 1-H), 4.39 (1H, tt, J 6.5, 4.5, 3-H), 3.54 (1H, dd, J 11.0, 4.5, 
4-HH), 3.47 (1H, dd, J 11.0, 6.5, 4-HH), 2.78 (1H, ddd, J 16.5, 4.5, 1.5, 2-HH), 2.68 (1H, ddd, J 16.5, 6.5, 
2.5, 2-HH), 0.87 (9H, s, SiC(CH3)3), 0.12 (3H, s, SiCH3), 0.09 (3H, s, SiCH3). δC (101 MHz, CDCl3) 200.5 
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(C-1), 68.1 (C-3), 48.9 (C-4), 48.2 (C-2), 25.8 (SiC(CH3)3), 18.1 (SiC(CH3)3), −4.4 (SiCH3), −4.7 (SiCH3). []D
24 
= +24.0 (c 1.00, CHCl3). [Lit. +17.1 (c 1.01, CHCl3)].263 
Spectroscopic data in accord with the literature data.262 
(R)-3-((tert-Butyldimethylsilyl)oxy)-4-chloro-N-methoxy-N-methylbutanamide 47 
 
Ester 45 (500 mg, 1.78 mmol) and N,O-dimethylhydroxylamine hydrochloride (269 mg, 2.76 mmol) 
were dissolved in THF (4 mL) and cooled to −20 °C. A solution of isopropylmagnesium chloride (2 M in 
THF, 2.67 mL, 5.34 mmol) was added dropwise over 15 minutes ensuring the internal temperature 
remained below −5 °C. The reaction was warmed to −10 °C for 30 minutes, then quenched with a 
saturated aqueous solution of NH4Cl (5 mL) and diluted with Et2O (10 mL). The phases were separated 
and the aqueous layer was extracted with Et2O (2 × 10 mL). The combined organic layers were dried 
over MgSO4, filtered, and concentrated in vacuo. The crude material was purified by column 
chromatography (10-20% EtOAc in petrol) to give amide 47 (460 mg, 87%) as a colourless oil. 
δH (400 MHz, CDCl3) 4.43 (1H, dddd, J 7.0, 5.5, 5.0, 4.5, 3-H), 3.70 (3H, s, OCH3), 3.58 (1H, dd, J 11.0, 
4.5, 4-HH), 3.54 (1H, dd, J 11.0, 5.0, 4-HH), 3.18 (3H, s, NCH3), 2.78 (1H, dd, J 15.5, 7.0, 2-HH), 2.67 (1H, 
dd, J 15.5, 5.5, 2-HH), 0.88 (9H, s, SiC(CH3)3), 0.12 (3H, s, SiCH3), 0.07 (3H, s, SiCH3). δC (126 MHz, CDCl3) 
171.6 (C-1), 69.3 (C-3), 61.5 (OCH3), 49.2 (C-4), 37.5 (C-2), 32.2 (NCH3), 25.9 (SiC(CH3)3), 18.2 (SiC(CH3)3), 
−4.7 (SiCH3), −4.7 (SiCH3). HRMS (ESI) calc. for C12H26ClNO3SiNa [M+Na]+ 318.1263. Found 318.1257. 
[]D
23 = +18.0 (c 1.00, CHCl3). IR (νmax/cm-1) (neat): 2929 (alkane C–H), 1663 (amide C=O). 
(2R,6S)-2-((tert-Butyldimethylsilyl)oxy)-1-chloro-6-methyl-9-(trimethylsilyl)non-8-yn-4-one 48 
 
Iodide 32 (50 mg, 0.178 mmol) was dissolved in a degassed mixture of pentane (1.2 mL) and Et2O 
(0.8 mL) and cooled to −78 °C. tBuLi (1.6 M in pentane, 0.20 mL, 0.32 mmol) was added dropwise and 
the reaction was stirred at −78 °C for one hour before a solution of aldehyde 46 (20 mg, 84.5 µmol) in 
a degassed mixture of pentane (1.2 mL) and Et2O (0.8 mL) was added. The reaction was stirred at 
−78 °C for one hour then quenched with a saturated aqueous solution of NH4Cl (2 mL). The phases 
were separated and the aqueous layer was extracted with Et2O (2 × 5 mL). The combined organic 
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layers were dried over MgSO4, filtered, and concentrated in vacuo to give alcohol 49 as a mixture of 
diastereomers. 
The crude alcohol was redissolved in DCM (0.5 mL) and Dess-Martin periodinane (39 mg, 92.0 µmol) 
was added. After two hours the solvent was removed under a stream of nitrogen and the crude 
material was purified by column chromatography (2% EtOAc in petrol) to give ketone 48 (8 mg, 24%) 
as a colourless oil. 
δH (400 MHz, CDCl3) 4.38 (1H, dddd, J 6.5, 6.0, 5.0, 4.5, 2-H), 3.52 (1H, dd, J 11.0, 4.5, 1-HH), 3.46 (1H, 
dd, J 11.0, 6.0, 1-HH), 2.73 (1H, dd, J 16.5, 5.0, 3-HH), 2.68 (1H, dd, J 16.5, 6.5, 3-HH), 2.59 (1H, dd, J 
17.0, 5.0, 5-HH), 2.33 (1H, dd, J 17.0, 7.5, 5-HH), 2.28-2.14 (3H, m, 6-H, 7-H2), 0.99 (3H, d, J 6.5, CHCH3), 
0.86 (9H, s, SiC(CH3)3), 0.15 (9H, s, Si(CH3)3), 0.11 (3H, s, SiCH3), 0.06 (3H, s, SiCH3). δC (101 MHz, CDCl3) 
208.0 (C-4), 105.1 (C-8), 86.6 (C-9), 68.4 (C-2), 49.9 (C-5), 48.6 (C-1), 48.3 (C-3), 28.3 (C-6), 26.9 (C-7), 
25.9 (SiC(CH3)3), 19.6 (CHCH3), 18.1 (SiC(CH3)3), 0.3 (Si(CH3)3), −4.6 (SiCH3), −4.6 (SiCH3). HRMS (ESI) 
calc. for C19H37O2ClSi [M+H]+ 389.2093. Found 389.2087. IR (νmax/cm-1) (neat): 2957 (alkane C–H), 2173 




Iodide 32 (25 mg, 89.2 µmol) was dissolved in degassed Et2O (1 mL) and cooled to −78 °C before tBuLi 
(1.6 M in pentane, 0.11 mL, 0.176 mmol) was added dropwise. The solution was stirred at −78 °C for 
10 minutes, warmed to room temperature over 20 minutes, and finally recooled to −78 °C. Aldehyde 
46 (21 mg, 88.7 µmol) in degassed Et2O (0.5 mL) was added dropwise and the solution was stirred at 
−78 °C for one hour, then warmed to room temperature for a further 1.5 hours. The reaction was 
quenched with a saturated aqueous solution of NH4Cl (5 mL) and extracted with Et2O (3 × 2 mL). The 
combined organic layers were dried over MgSO4, filtered, and concentrated in vacuo. The crude 
material was purified by column chromatography (5% EtOAc in petrol) to give the allylic alcohol (8 mg, 
23%) as a 1:1:1:1 mixture of diastereomers. 
Dess-Martin periodinane (0.35 M in DCM, 0.12 mL, 42.0 µmol) was added dropwise to a solution of 
the crude alcohol (8 mg, 20.5 µmol) in DCM (0.5 mL) and stirred at room temperature for two hours. 
The reaction was quenched via the addition of saturated aqueous solutions of NaHCO3 (0.5 mL) and 
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Na2S2O3 (0.5 mL) and the phases were separated. The aqueous layer was extracted with DCM (2 × 2 
mL) and the combined organic layers were dried over MgSO4, filtered, and concentrated in vacuo. The 
crude material was purified by column chromatography (2% EtOAc in petrol) to give ketone 51 (8 mg, 
quant.) as a colourless oil as a 1:1 mixture of diastereomers. 
δH (500 MHz, CDCl3) 4.42 (1H, tt, J 6.0, 4.5, 2-H), 4.42 (1H, tt, J 6.0, 4.5, 2-H), 3.53 (2H, d, J 4.5, 1-H2), 
3.53 (2H, d, J 4.5, 1-H2), 3.18-3.07 (2H, m, 7-H2 or 9-H2), 3.07-2.98 (2H, m, 7-H2 or 9-H2), 2.80 (1H, dd, 
J 17.5, 6.0, 3-HH), 2.77 (1H, dd, J 17.5, 6.0, 3-HH), 2.72 (1H, dd, J 17.5, 6.0, 3-HH), 2.70 (1H, dd, J 17.5, 
6.0, 3-HH), 2.61-2.38 (4H, m, 7-H2 × 2 or 9-H2 × 2), 2.43 (2H, m, 8-H × 2), 1.16 (3H, d, J 6.5, CHCH3), 1.15 
(3H, d, J 6.5, CHCH3), 0.87 (18H, s, SiC(CH3)3 × 2), 0.13 (18H, s, Si(CH3)3 × 2), 0.11 (6H, s, SiCH3 × 2), 0.07 
(6H, s, SiCH3 × 2). δC (126 MHz, CDCl3) 205.3 (C-4 × 2), 161.8 (C-6), 161.7 (C-6), 139.0 (C-5), 138.7 (C-5), 
68.3 (C-2), 68.2 (C-2), 49.3 (C-1), 49.3 (C-1), 43.0 (C-7 or C-9), 42.8 (C-7 or C-9), 42.1 (C-7 or C-9), 42.0 
(C-7 or C-9), 25.9 (SiC(CH3)3), 25.9 (SiC(CH3)3), 25.4 (C-8) 25.3 (C-8), 22.0 (CHCH3), 21.9 (CHCH3), 18.2 
(SiC(CH3)3 × 2), 0.1 (Si(CH3)3 × 2), −4.5 (SiCH3), −4.6 (SiCH3), −4.6 (SiCH3 × 2). HRMS (ESI) calc. for 





Iodide 32 (25 mg, 89.2 µmol) was dissolved in degassed Et2O (1 mL) and cooled to −78 °C before tBuLi 
(1.6 M in pentane, 0.11 mL, 0.176 mmol) was added dropwise. The solution was stirred at −78 °C for 
one hour before aldehyde 46 (15 mg, 63.3 µmol) in Et2O (0.5 mL) was added dropwise. The reaction 
was warmed to room temperature for a further 1.5 hours then quenched with a saturated aqueous 
solution of NH4Cl (5 mL) and extracted with Et2O (3 × 2 mL). The combined organic layers were dried 
over MgSO4, filtered, and concentrated in vacuo. The crude material was purified by column 
chromatography (2% EtOAc in petrol) to give tetrahydrofuran 52 (11 mg, 29%) as a colourless oil and 
a single diastereomer. 
δH (500 MHz, CDCl3) 4.42 (1H, m, 2-H), 4.13 (1H, m, 4-H), 3.98 (1H, dd, J 9.0, 5.0, 1-HH), 3.56 (1H, dd, J 
9.0, 3.0, 1-HH), 2.27 (1H, dd, J 17.0, 5.5, 7-HH), 2.13 (1H, dd, J 17.0, 7.0, 7-HH), 1.93-1.83 (2H, m, 3-HH, 
6-H), 1.66-1.54 (2H, m, 3-HH, 5-HH), 1.36 (1H, ddd, J 13.5, 8.5, 4.5, 5-HH), 1.03 (3H, d, J 6.5, CHCH3), 
0.88 (9H, s, SiC(CH3)3), 0.14 (9H, s, Si(CH3)3), 0.06 (3H, s, SiCH3), 0.05 (3H, s, SiCH3). δC (126 MHz, CDCl3) 
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106.2 (C-8), 85.8 (C-9), 76.3 (C-4), 75.8 (C-1), 72.9 (C-2), 42.9 (C-3), 42.0 (C-5), 30.2 (C-6), 27.9 (C-7), 
26.0 (SiC(CH3)3), 19.4 (CHCH3), 18.3 (SiC(CH3)3), 0.3 (Si(CH3)3), −4.6 (SiCH3), −4.6 (SiCH3). HRMS (ESI) 
calc. for C19H38O3Si2Na [M+Na]+ 377.2303. Found 377.2314. IR (νmax/cm-1) (neat): 2928 (alkane C–H), 
2172 (alkyne C≡C). 
4-((tert-Butyldimethylsilyl)oxy)butanoic acid 54 
 
NaOH (3.07 g, 76.8 mmol) was added to a solution of γ-butyrolactone 53 (6.00 g, 69.7 mmol) in MeOH 
(70 mL). After three hours at room temperature the solvent was removed in vacuo. 
The resulting sodium salt was resuspended in DMF (140 mL) and cooled to 0 °C. Imidazole (15.7 g, 
0.231 mol) and TBSCl (23.1 g, 0.153 mol) were added in single portions and the suspension was 
warmed to room temperature and stirred for 16 hours. The reaction was quenched with water 
(400 mL) and extracted with hexane (3 × 150 mL). The combined organic layers were dried over 
MgSO4, filtered, and concentrated in vacuo. 
The crude diprotected product was redissolved in MeOH (70 mL) and THF (70 mL) before an aqueous 
solution of K2CO3 (19.3 g, 0.140 mol, 230 mL) was added. After 16 hours at room temperature the 
solution was acidified to ~pH 2 with HCl (1 M) and extracted with Et2O (4 × 200 mL). The combined 
organic layers were dried over Na2SO4, filtered, and concentrated in vacuo. The resulting oil was 
redissolved in toluene (3 × 25 mL) and concentrated in vacuo to azeotrope TBSOH. This gave carboxylic 
acid 54 (12.0 g, 79%) as a colourless oil without further needed for purification. 
δH (400 MHz, CDCl3) 3.67 (2H, t, J 6.0, 4-H2), 2.46 (2H, t, J 7.0, 2-H2), 1.85 (2H, tt, J 7.0, 6.0, 3-H2), 0.89 
(9H, s, SiC(CH3)3), 0.05 (6H, s, Si(CH3)2). δC (101 MHz, CDCl3) 179.4 (C-1), 62.3 (C-4), 31.0 (C-2), 27.7 
(C-2), 26.0 (SiC(CH3)3), 18.4 (SiC(CH3)3), −5.3 (Si(CH3)2). 










Triethylamine (0.64 mL, 4.59 mmol) was added dropwise to a solution of carboxylic acid 54 (1.00 g, 
4.58 mmol) in Et2O (45 mL). The reaction was stirred at room temperature for 15 minutes then cooled 
to 0 °C. Ethyl chloroformate (0.44 mL, 4.60 mmol) was added dropwise and the mixture was warmed 
to room temperature for one hour. In a separate flask, nBuLi (1.47 M, 3.74 mL, 5.50 mmol) was added 
dropwise to a solution of (4R)-benzyloxazolidone (852 mg, 4.81 mmol) in THF (5 mL) at −78 °C. After 
five minutes the oxazolidinone solution was added dropwise to the reaction mixture at −78 °C. The 
reaction was stirred for one hour, then warmed to room temperature for three hours and quenched 
with a saturated aqueous solution of NH4Cl (100 mL). The solution was extracted with Et2O (3 × 100 mL) 
and the combined organic layers were dried over MgSO4, filtered, and concentrated in vacuo. The 
crude material was purified by column chromatography (10% EtOAc in petrol) to give coupled auxiliary 
55 (1.06 g, 61%) as a colourless oil. 
δH (400 MHz, CDCl3) 7.37-7.26 (3H, m, Ar-H), 7.23-7.18 (2H, m, Ar-H), 4.67 (1H, m, 5-H), 4.22-4.13 (2H, 
m, 4-H2), 3.70 (2H, t, J 7.0, 5’-H2), 3.30 (1H, dd, J 13.5, 3.5, 6-HH), 3.02 (2H, t, J 7.0, 3’-H2), 2.76 (1H, dd, 
J 13.5, 9.5, 6-HH), 1.91 (2H, pent, J 7.0, 4’-H2), 0.90 (9H, s, SiC(CH3)3), 0.06 (6H, s, Si(CH3)2). δC (101 MHz, 
CDCl3) 173.3 (C-2’), 153.6 (C-2), 135.5, 129.6, 129.1, and 127.5 (C-Ar), 66.3 (C-4), 62.2 (C-5’), 55.3 (C-5), 
38.1 (C-6), 32.3 (C-3’), 27.4 (C-4’), 26.1 (SiC(CH3)3), 18.5 (SiC(CH3)3), −5.2 (Si(CH3)2). []D
21  = −33.0 
(c 1.00, CHCl3). [Lit. −32.84 (c 0.81, CHCl3)].107 





Carboxylic acid 54 (1.00 g, 4.58 mmol) was dissolved in THF (37.5 mL) and cooled to −78 °C. 
Trimethylacetyl chloride (0.68 mL, 5.51 mmol) and triethylamine (1.28 mL, 9.18 mmol) were added 
dropwise and the solution stirred for one hour at −78 °C. (4S)-Benzyloxazolidone (893 mg, 5.04 mmol) 
and LiCl (58 mg, 1.37 mmol) were added in single portions and the reaction was stirred for a further 
three hours at −78 °C, then warmed to room temperature over 16 hours. The solution was diluted 
with water (100 mL) and extracted with Et2O (3 × 100 mL). The combined organic layers were dried 
over MgSO4, filtered, and concentrated in vacuo. The crude material was purified by column 
chromatography (10% EtOAc in petrol) to give coupled auxiliary 55 (1.30 g, 75%) as a colourless oil. 
Characterisation as given previously. 
(R)-5-Benzyl-N-((R)-5’-(tert-butyldimethylsilyloxy)-2-methylbutanoyl)oxazolidine-2-one 56 
 
Oxazolidone 55 (1.00 g, 2.65 mmol) was dissolved in THF (7 mL) and cooled to −78 °C. NaHMDS (1 M 
in THF, 3.71 mL, 3.71 mmol) was added dropwise and the solution stirred for one hour at −78 °C. 
Methyl iodide (0.82 mL, 13.2 mmol) was added dropwise and the solution stirred for a further three 
hours at −78 °C. The reaction was quenched via the slow addition of glacial acetic acid (0.2 mL), then 
warmed to room temperature and diluted with EtOAc (50 mL) and water (50 mL). The layers were 
separated and the aqueous phase was extracted with EtOAc (2 × 50 mL). The combined organic layers 
were dried over MgSO4, filtered, and concentrated in vacuo. The crude material was purified by 
column chromatography (10% EtOAc in petrol) to give oxazolidone 56 (798 mg, 77%) as a white solid.  
δH (400 MHz, CDCl3) 7.37-7.24 (3H, m, Ar-H), 7.24-7.18 (2H, m, Ar-H), 4.66 (1H, m, 5-H), 4.21-4.14 (2H, 
m, 4-H2), 3.86 (1H, m, 3’-H), 3.65 (2H, m, 5’-H2), 3.26 (1H, dd, J 13.5, 3.5, 6-HH), 2.76 (1H, dd, J 13.5, 
9.5, 6-HH), 2.04 (1H, m, 4’-HH), 1.64 (1H, m, 4’-HH), 1.25 (3H, d, J 7.0, CHCH3), 0.87 (9H, s, SiC(CH3)3), 
0.03 (3H, s, SiCH3), 0.02 (3H, s, SiCH3). δC (101 MHz, CDCl3) 177.1 (C-2’), 153.1 (C-2), 135.5, 129.6, 129.1, 
and 127.5 (C-Ar), 66.1 (C-4), 61.1 (C-5’), 55.4 (C-5), 38.1 (C-6), 36.1 (C-4’), 34.8 (C-3’), 26.0 (SiC(CH3)3), 
18.4 (SiC(CH3)3), 18.0 (CHCH3), −5.3 (Si(CH3)2). M.p. 50-52 °C (from DCM) [Lit. 51-52 °C].107 []D
21 = −54.0 
(c 1.00, CHCl3). [Lit. −60.37 (c 0.46, CHCl3)].107 







NaBH4 (96%, 7.24 g, 0.184 mol) was added in one portion to a solution of oxazolidone 56 (15.0 g, 38.3 
mmol) in THF (450 mL) and water (150 mL). After 16 hours at room temperature the reaction was 
quenched with a saturated aqueous solution of NH4Cl (300 mL) and diluted with water (200 mL) and 
EtOAc (300 mL). The layers were separated and the aqueous phase was extracted with EtOAc (2 × 
300 mL). The combined organic layers were dried over MgSO4, filtered, and concentrated in vacuo. 
The crude material was purified by column chromatography (10-20% EtOAc in petrol) to give alcohol 
57 (7.74 g, 93%). 
δH (400 MHz, CDCl3) 3.76 (1H, m, 4-HH), 3.66 (1H, m, 4-HH), 3.51 (1H, ddd, J 11.0, 7.0, 5.0, 1-HH), 3.41 
(1H, ddd, J 11.0, 7.0, 4.0, 1-HH), 2.97 (1H, t, J 7.0, OH), 1.80 (1H, m, 2-H), 1.55 (1H, dt, J 6.5, 5.0, 3-H2), 
0.92 (3H, d, J 7.0, CHCH3), 0.90 (9H, s, SiC(CH3)3), 0.07 (6H, s, Si(CH3)2). δC (101 MHz, CDCl3) 68.3 (C-4), 
61.9 (C-1), 37.6 (C-3), 34.6 (C-2), 26.0 (SiC(CH3)3), 18.4 (SiC(CH3)3), 17.5 (CHCH3), −5.3 (SiCH3), −5.3 
(SiCH3). []D
21 = +11.0 (c 1.00, CHCl3). [Lit. +10.6 (c 1.00, CHCl3)].265 
Spectroscopic data in accord with the literature data.265 
 (R)-4-(tert-Butyldimethylsilyloxy)-1-iodo-2-methylbutane 58 
 
Iodine (432 mg, 1.70 mmol) and imidazole (232 mg, 3.41 mmol) were added sequentially to a solution 
of triphenylphosphine (447 mg, 1.70 mmol) in DCM (3 mL) at 0 °C. After 10 minutes a solution of 
alcohol 57 (248 mg, 1.14 mmol) in DCM (1 mL) was added dropwise. The reaction was warmed to 
room temperature and stirred for 16 hours before quenching with a saturated aqueous solution of 
Na2S2O3 (5 mL). The phases were separated and the aqueous layer was extracted with DCM (2 × 5 mL). 
The combined organic layers were dried over MgSO4, filtered, and concentrated in vacuo. The crude 
material was purified by column chromatography (1% Et2O in petrol) to give iodide 58 (268 mg, 72%) 
as a colourless oil. 
δH (400 MHz, CDCl3) 3.64 (2H, td, J 6.0, 2.0, 4-H2), 3.28 (1H, dd, J 9.5, 4.5, 1-HH), 3.20 (1H, dd, J 9.5, 5.5, 
1-HH), 1.70-1.56 (2H, m, 2-H, 3-HH), 1.43 (1H, m, 3-HH), 0.99 (3H, d, J 6.5, CHCH3), 0.89 (9H, s, 
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SiC(CH3)3), 0.05 (6H, s, Si(CH3)2). δC (101 MHz, CDCl3) 60.8 (C-4), 39.3 (C-3), 31.5 (C-2), 26.1 (SiC(CH3)3), 
20.8 (CHCH3), 18.4 (SiC(CH3)3), 18.3 (C-1), −5.2 (Si(CH3)2). []D
21 = −5.0 (c 1.00, CHCl3). [Lit. −4.9 (c 1.00, 
CHCl3)].266 
Spectroscopic data in accord with the literature data.266 
Methyl (S,E)-7-hydroxy-3,5-dimethylhept-2-enoate 63 
 
A solution of alkyl iodide 58 (6.65 g, 20.3 mmol) in pentane (45 mL) and Et2O (75 mL) was cooled to 
−78 °C before tBuLi (1.5 M in pentane, 30.4 mL, 45.6 mmol) was added dropwise. After 15 minutes the 
reaction was warmed to 0 °C (over 30 minutes) and THF (3.3 mL) was added. The solution was stirred 
for a further 30 minutes before cooling to −40 °C. 
Whilst the lithiated species was cooling a trimethylsilylmethylcopper solution was prepared as follows: 
Freshly purified CuI (3.86 g, 20.3 mmol) (see general experimental) was suspended in THF (175 mL) 
and cooled to −78 °C in a three-neck round-bottom flask adapted with a jacketed addition funnel with 
a pressure equalising arm. Trimethylsilylmethyllithium (1.0 M in pentane, 20.3 mL, 20.3 mmol) was 
added dropwise to the suspension which was then immediately warmed to 10 °C and stirred for a 
further 30 minutes, before cooling to −78 °C.  
Organolithium solution 59 was transferred via cannula to the addition funnel, the jacket of which was 
pre-cooled to −40 °C using a combination of dry ice and acetone. After dropwise addition of the 
lithiated species to cuprate 60, the reaction was warmed to 0 °C for 30 minutes, then cooled to −78 °C 
before a solution of methyl 2-butynoate 61 (2.03 mL, 20.3 mmol) in THF (20 mL) was added dropwise. 
The solution was stirred for two hours then quenched with a saturated aqueous solution of NH4Cl 
(75mL) and allowed to warm to room temperature over one hour. The solution was diluted with water 
(300 mL) and extracted with Et2O (3 × 300 mL). The combined organic layers were dried over MgSO4, 
filtered, and concentrated in vacuo to give silyl ether 62. 
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The crude silyl ether was redissolved in MeOH (400 mL) and HCl (12 M, 3 mL) was added. The solution 
was stirred for 16 hours at room temperature, diluted with water (500 mL), and extracted with EtOAc 
(3 × 500 mL). The combined organic layers were dried over MgSO4, filtered, and concentrated in vacuo. 
The crude material was purified by column chromatography (20% EtOAc in petrol) to give alcohol 63 
(3.14 g, 83%) as a colourless oil. 
δH (400 MHz, CDCl3) 5.65 (1H, J 1.5, 2-H), 3.75-3.62 (2H, m, 7-H2), 3.67 (3H, s, OCH3), 2.16 (1H, dd, J 
12.5, 6.0, 4-HH), 2.13 (3H, d, J 1.5, CCH3), 1.99-1.86 (2H, m, 4-HH, 5-H), 1.58 (1H, m, 6-HH), 1.37 (1H, 
m, 6-HH), 0.88 (3H, d, J 6.5, CHCH3). δc (101 MHz, CDCl3) 167.2 (C-1), 159.2 (C-3), 116.8 (C-2), 60.9 (C-7), 
50.9 (OCH3), 49.1 (C-4), 39.7 (C-6), 27.7 (C-5), 19.5 (CHCH3), 18.7 (CCH3). []D
20 = −5.0 (c 1.00, CHCl3). 
[Lit. −5.0 (c 1.0, CHCl3)].96 
Spectroscopic data in accord with the literature data.96 
4-(Trimethylsilyl)but-3-yn-1-ol 65 
 
3-Butyn-1-ol 64 (4.63 mL, 61.2 mmol) was dissolved in THF (250 mL) and cooled to −78 °C. nBuLi 
(1.52 M in hexanes, 94 mL, 143 mmol) was added (in 5 mL portions) and the resulting suspension was 
stirred for one hour at −78 °C. TMSCl (19.02 mL, 150 mmol) was added and the solution was allowed 
to warm to room temperature over two hours. The reaction was quenched with water (200 mL) and 
HCl (6 M, 20 mL), then diluted with EtOAc (200 mL). The layers were separated and the aqueous phase 
was extracted with EtOAc (2 × 200 mL). The combined organic layers were dried over MgSO4, filtered, 
and concentrated in vacuo to give alcohol 65 (8.66 g, quant.) as a yellow oil. 
δH (400 MHz, CDCl3) 3.71 (2H, t, J 6.5, 1-H2), 2.50 (2H, t, J 6.5, 2-H2), 0.15 (9H, s, Si(CH3)3). δc (101 MHz, 
CDCl3) 103.5 (C-3), 87.2 (C-4), 61.0 (C-1), 24.4 (C-2), 0.2 (Si(CH3)3). 
Spectroscopic data in accord with the literature data.267 
1-p-Toluenesulfonyloxy-4-trimethylsilyl-3-butyne 66 
 
Alcohol 65 (8.66 g, 60.9 mmol) was dissolved in pyridine (40 mL) and cooled to 0 °C. pTsCl (12.8 g, 67.1 
mmol) was added and the solution was warmed to room temperature for a further 16 hours. The 
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reaction was quenched with a saturated aqueous solution of NaHCO3 (50 mL), diluted with water 
(200 mL), and extracted with Et2O (3 × 200 mL). The combined organic layers were washed with HCl 
(1 M, 4 × 100 mL), a saturated aqueous solution of NaCl (100 mL), and a saturated aqueous solution of 
NaHCO3 (100 mL), dried over MgSO4, filtered, and concentrated in vacuo to give tosylate 66 (13.3 g, 
74%) as a colourless oil without further need for purification. 
δH (400 MHz, CDCl3) 7.80 (2H, d, J 8.0, Ar-H), 7.35 (2H, d, J 8.0, Ar-H), 4.08 (2H, t, J 7.5, 1-H2), 2.59 (2H, 
t, J 7.5, 2-H2), 2.45 (3H, s, Ar-CH3), 0.12 (9H, s, Si(CH3)3). δc (101 MHz, CDCl3) 145.1, 133.1, 130.0, and 
128.1 (C-Ar), 100.4 (C-3), 87.6 (C-4), 67.7 (C-1), 21.8 (C-2), 20.9 (Ar-CH3), 0.0 (Si(CH3)3). 
Spectroscopic data in accord with the literature data.268 
1-Bromo-4-trimethylsilyl but-3-yne 67 
 
Lithium bromide (7.76 g, 89.3 mmol) was added in one portion to a solution of tosylate 66 (13.25 g, 
44.7 mmol) in acetone (300 mL). The reaction was stirred at room temperature for 12 hours, then 
heated to reflux (56 °C) for 24 hours. The reaction was diluted with water (300 mL) and extracted with 
Et2O (3 × 300 mL). The combined organic layers were dried over MgSO4, filtered, and concentrated in 
vacuo. The crude material was purified by column chromatography (1% Et2O in petrol) to give bromide 
67 (7.69 g, 84%) as a colourless oil. 
The product also contained 6% of the chloride analogue by 1H NMR, presumably due to LiCl present 
in the commercially purchased LiBr. 
1-Bromo-4-trimethylsilyl but-3-yne 67 
δH (400 MHz, CDCl3) 3.42 (2H, t, J 7.5, 1-H2), 2.77 (2H, t, J 7.5, 2-H2), 0.16 (9H, s, Si(CH3)3). δc (101 MHz, 
CDCl3) 103.3 (C-3), 87.2 (C-4), 29.3 (C-1), 24.4 (C-2), 0.1 (Si(CH3)3). 
Spectroscopic data in accord with the literature data.269 
1-Chloro-4-trimethylsilyl but-3-yne 
δH (400 MHz, CDCl3) 3.58 (2H, t, J 7.5, 1-H2), 2.68 (2H, t, J 7.5, 2-H2), 0.16 (9H, s, Si(CH3)3). 





Methyl (S,E)-3,5-dimethyl-7-oxo-11-(trimethylsilyl)undec-2-en-10-ynoate 71 
 
Dess-Martin periodinane (3.77 g, 8.89 mmol) was added to a solution of alcohol 68 (1.38 g, 7.41 mmol) 
in DCM (60 mL). The reaction was stirred at room temperature for one hour then quenched via the 
addition of saturated aqueous solutions of NaHCO3 (20 mL) and Na2S2O3 (20 mL). The phases were 
separated and the aqueous layer was extracted with DCM (2 × 50 mL). The combined organic layers 
were dried over MgSO4, filtered, and concentrated in vacuo. The crude material was redissolved in 
Et2O (15 mL) and filtered through cotton wool to remove insoluble impurities. The solution was 
concentrated in vacuo to give aldehyde 69. 
Magnesium turnings (1.19 g, 49.0 mmol) were added to a two-neck round-bottom flask and flame 
dried before being placed under vacuum. The magnesium was further heated for five minutes under 
vacuum using a heat gun. The metal was suspended in THF (50 mL) and was heated to reflux (66 °C). 
Dibromoethane (0.64 mL, 7.43 mmol) was added and the suspension was maintained at reflux for a 
further 10 minutes. A solution of bromide 67 (3.04 g, 14.8 mmol) in THF (10 mL) was added dropwise 
and the solution was refluxed for a further hour before cooling to room temperature. The Grignard 
reagent was added dropwise to a solution of crude aldehyde 69 in THF (10 mL) at 0 °C. Upon complete 
addition the reaction was warmed to room temperature and stirred for a further two hours. The 
reaction was quenched with a saturated aqueous solution of NH4Cl (100 mL) and diluted with DCM 
(150 mL). The phases were separated and the aqueous layer was extracted with DCM (2 × 100 mL). 
The combined organic layers were dried over MgSO4, filtered, and concentrated in vacuo. The crude 
material was purified by column chromatography (20% EtOAc in petrol) to give alcohol 70 as a 1:1 
mixture of diastereomers. 
Alcohol 70 was redissolved in DCM (60 mL). Dess-Martin periodinane (3.77 g, 8.89 mmol) was added 
dropwise and the solution stirred at room temperature for three hours. The reaction was quenched 
via the addition of saturated aqueous solutions of NaHCO3 (20 mL) and Na2S2O3 (20 mL) and the phases 
were separated. The aqueous layer was extracted with DCM (2 × 50 mL) and the combined organic 
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layers were dried over MgSO4, filtered, and concentrated in vacuo. The crude material was purified by 
column chromatography (15% EtOAc in petrol) to give ketone 71 (1.56 g, 68%) as a colourless oil. 
δH (400 MHz, CDCl3) 5.64 (1H, s, 2-H), 3.68 (3H, s, OCH3), 2.65-2.57 (2H, m, 8-H2), 2.50-2.43 (2H, m, 
9-H2), 2.42-2.22 (3H, m, 5-H, 6-H2), 2.14 (3H, s, CCH3), 2.12 (1H, dd, J 13.0, 6.0, 4-HH), 1.96 (1H, dd, J 
13.0, 7.5, 4-HH), 0.88 (3H, d, J 6.0, CHCH3), 0.12 (9H, s, (Si(CH3)3). δC (101 MHz, CDCl3) 208.0 (C-7), 167.0 
(C-1), 158.4 (C-3), 117.2 (C-2), 105.7 (C-10), 85.3 (C-11), 51.0 (OCH3), 49.6 (C-6), 48.5 (C-4), 42.3 (C-8), 
27.3 (C-5), 19.9 (CHCH3), 18.7 (CCH3), 14.5 (C-9), 0.2 (Si(CH3)3). HRMS (ESI) calc. for C17H28O3SiNa 
[M+Na]+ 331.1700. Found 331.1703. []D
23 = +3.0 (c 1.00, CHCl3) [Lit. +5.0 (c 1.0, CHCl3)].96 IR (νmax/cm-1) 
(neat): 2956 (alkane C–H), 2176 (alkyne C≡C), 1715 (ketone C=O), 1646 (ester C=O). 
Spectroscopic data in accord with the literature data.96 
Methyl (R,E)-3,5-dimethyl-7-methylene-11-(trimethylsilyl)undec-2-en-10-ynoate 72 
Method One 
 
Petasis reagent (0.21 M, 2.32 mL, 0.487 mmol) was added to a solution of ketone 71 (50 mg, 
0.162 mmol) in THF (3 mL). The reaction was heated to reflux (66 °C) for 16 hours then cooled to room 
temperature and diluted with petrol (5 mL). The solution was passed through a plug of Celite® and 
concentrated in vacuo. The crude material was purified by column chromatography (2% EtOAc in 
petrol) to give exo-methylene 72 (22 mg, 44%) as a colourless oil. 
δH (400 MHz, CDCl3) 5.65 (1H, s, 2-H), 4.82 (1H, s, 7-CHH), 4.76 (1H, s, 7-CHH), 3.68 (3H, s, OCH3), 
2.38-2.31 (2H, m, 9-H2), 2.24-2.16 (3H, m, 4-HH, 8-H2), 2.14 (3H, s, CCH3), 2.00 (1H, J 12.0, 4.5, 6-HH), 
1.94-1.80 (3H, m, 4-HH, 5-H, 6-HH), 0.82 (3H, d, J 6.0, CHCH3), 0.14 (9H, s, (Si(CH3)3). δC (101 MHz, 
CDCl3) 167.2 (C-1), 159.4 (C-3), 146.1 (C-7), 116.7 (C-2), 112.0 (7-CH2), 107.0 (C-10), 85.0 (C-11), 50.9 
(OCH3), 48.7 (C-4), 44.1 (C-6), 34.8 (C-8), 29.2 (C-5), 19.5 (CHCH3), 18.9 (CCH3), 18.8 (C-9), 0.3 (Si(CH3)3). 
HRMS (ESI) calc. for C18H31O2Si [M+H]+ 307.2088. Found 307.2088. []D
23  = −5.0 (c 1.00, CHCl3). IR 
(νmax/cm-1) (neat): 2923 (alkane C–H), 2176 (alkyne C≡C), 1645 (ester C=O). 




TiCl4 (1 M in DCM, 0.18 mL, 0.180 mmol) was added dropwise to a solution of freshly activated zinc 
powder (47 mg, 0.719 mmol) (see general experimental) and dibromomethane (17 µL, 0.242 mmol) 
in THF (1.5 mL). After 15 minutes a solution ketone 71 (50 mg, 0.162 mmol) in THF (1 mL) was added 
dropwise and the mixture stirred for 10 days at room temperature. The reaction was quenched with 
HCl (1 M, 5 mL) and diluted with Et2O (5 mL). The layers were separated and the aqueous phase was 
extracted with Et2O (2 × 5 mL). The combined organic layers were dried over MgSO4, filtered, and 
concentrated in vacuo. The crude material was purified by column chromatography (2% EtOAc in 
petrol) to give exo-methylene 72 (29 mg, 58%) as a colourless oil. 
Characterisation as given previously. 
Methyl (R,E)-11-iodo-3,5-dimethyl-7-methyleneundec-2-en-10-ynoate 73 
 
Silver trifluoroacetate (12 mg, 54.3 µmol) and NIS (40 mg, 0.178 mmol) were added to a solution of 
TMS-alkyne 72 (27 mg, 88.1 µmol) in acetone (2 mL). After one hour the reaction was concentrated in 
vacuo and the crude material was purified by column chromatography (2-5% EtOAc in petrol) to give 
iodoalkyne 73 (18 mg, 57%) as a colourless oil. 
δH (500 MHz, CDCl3) 5.65 (1H, s, 2-H), 4.82 (1H, s, 7-CHH), 4.79 (1H, s, 7-CHH), 3.69 (3H, s, OCH3), 2.49 
(2H, t, J 7.5, 9-H2), 2.25-2.16 (3H, m, 4-HH, 8-H2), 2.14 (3H, s, CCH3), 2.00 (1H, m, 6-HH), 1.94-1.80 (3H, 
m, 4-HH, 5-H, 6-HH), 0.82 (3H, d, J 6.0, CHCH3). δC (101 MHz, CDCl3) 167.2 (C-1), 159.3 (C-3), 145.8 
(C-7), 116.8 (C-2), 112.2 (7-CH2), 94.2 (C-10), 50.9 (OCH3), 48.7 (C-4), 44.1 (C-6), 34.5 (C-8), 29.2 (C-5), 
19.8 (C-9), 19.5 (CHCH3), 18.8 (CCH3), −6.5 (C-9). HRMS (ESI) calc. for C16H22IO2 [M+H]+ 361.0659. Found 
361.0661. IR (νmax/cm-1) (neat): 2922 (alkane C–H), 1644 (ester C=O). 
Methyl (R,E)-3,5-dimethyl-7-methyleneundec-2-en-10-ynoate 75 
 
Alkyne 72 (26 mg, 84.8 µmol) was dissolved in MeOH (1 mL). K2CO3 (18 mg, 0.127 mmol) was added 
and the solution was stirred at room temperature for 16 hours. The reaction was acidified with HCl 
(1 M, 1 mL) and diluted with DCM (2 mL) and water (2 mL). The layers were separated and the aqueous 
phase was extracted with DCM (2 × 2 mL). The combined organic layers were dried over MgSO4, 
filtered, and concentrated in vacuo to give alkyne 75 (20 mg, quant.) as a colourless oil. 
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δH (400 MHz, CDCl3) 5.65 (1H, s, 2-H), 4.84 (1H, s, 7-CHH), 4.79 (1H, s, 7-CHH), 3.68 (3H, s, OCH3), 
2.36-2.29 (2H, m, 9-H2), 2.25-2.15 (3H, m, 4-HH, 8-H2), 2.14 (3H, s, CCH3), 2.02 (1H, dd, J 12.5, 4.5, 
6-HH), 1.96 (1H, t, J 2.5, 11-H), 1.94-1.80 (3H, m, 4-HH, 5-H, 6-HH), 0.83 (3H, d, J 6.0, CHCH3). δC (101 
MHz, CDCl3) 167.2 (C-1), 159.3 (C-3), 145.9 (C-7), 116.8 (C-2), 112.0 (7-CH2), 84.2 (C-10), 68.7 (C-11), 
51.0 (OCH3), 48.7 (C-4), 44.1 (C-6), 34.5 (C-8), 29.1 (C-5), 19.5 (CHCH3), 18.8 (CCH3), 17.3 (C-9). HRMS 
(ESI) calc. for C16H23O2 [M+H]+ 235.1693. Found 235.1686. []D
21 = −3.0 (c 1.00, CHCl3). IR (νmax/cm-1) 
(neat): 3299 (alkyne C≡C), 2924 (alkane C–H), 1645 (ester C=O). 
(R)-2-(((4-Methoxybenzyl)oxy)methyl)oxirane 77 
 
Sodium hydride (60% dispersion in mineral oil, 1.48 g, 37.0 mmol) was slowly dissolved in DMF (50 mL) 
at 0 °C before 4-methoxybenzyl chloride (5.03 mL, 37.1 mmol) was added dropwise. After 25 minutes 
(S)-glycidol 76 (2.50 g, 33.7 mmol) was added dropwise and the solution was warmed to room 
temperature for a further 16 hours. The reaction was quenched with a saturated aqueous solution of 
NH4Cl (100 mL) and diluted with EtOAc (100 mL). The layers were separated and the aqueous phase 
was extracted with EtOAc (2 × 100 mL). The combined organic layers were dried over MgSO4, filtered, 
and concentrated in vacuo. The crude material was purified by column chromatography (10-30% 
EtOAc in petrol) to give epoxide 77 (5.95 g, 91%) as a colourless oil. 
δH (400 MHz, CDCl3) 7.28 (2H, d, J 8.5, Ar-H), 6.88 (2H, d, J 8.5, Ar-H), 4.55 (1H, d, J 11.5, PMPCHH), 
4.49 (1H, d, J 11.5, PMP-CHH), 3.81 (3H, s, OCH3), 3.73 (1H, dd, J 11.5, 3.0, 1-HH), 3.41 (1H, dd, J 11.5, 
6.0, 1-HH), 3.18 (1H, ddt, J 6.0, 4.0, 3.0, 2-H), 2.80 (1H, dd, J 5.0, 4.0, 3-HH), 2.61 (1H, dd, J 5.0, 3.0, 
3-HH). δC (101 MHz, CDCl3) 159.4, 130.1, 129.6, and 114.0 (C-Ar), 73.1 (PMPCH2), 70.6 (C-1), 55.4 
(OCH3), 51.0 (C-2), 44.5 (C-3). []D
24 = +4.0 (c 1.00, CHCl3) [Lit. +4.2 (c 0.95, CHCl3)].271 
Spectroscopic data in accord with the literature data.272 
 (R)-1-((4-Methoxybenzyl)oxy)pent-4-en-2-ol 78 
 
CuI (532 mg, 2.79 mmol) and vinylmagnesium bromide (1 M in THF, 13.4 mL, 13.4 mmol) were added 
sequentially to a solution of epoxide 77 (2.17 g, 11.1 mmol) in THF (50 mL) at −78 °C. The reaction was 
stirred for three hours before quenching with a 4:1 saturated aqueous solution of NH4Cl/NH4OH 
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(100 mL). The mixture was diluted with DCM (50 mL) and the layers were separated. The aqueous 
phase was extracted with DCM (2 × 50 mL) and the combined organic layers were dried over MgSO4, 
filtered, and concentrated in vacuo. The crude material was purified by column chromatography (60% 
Et2O in petrol) to give alcohol 78 (2.35 g, 95%) as a colourless oil. 
δH (400 MHz, CDCl3) 7.26 (2H, d, J 8.5, Ar-H), 6.85 (2H, d, J 8.5, Ar-H), 5.82 (1H, ddt, J 17.0, 10.0, 7.0, 
4-H), 5.15-5.06 (2H, m, 5-H2), 4.49 (2H, s, PMPCH2), 3.87 (1H, qt, J 7.0, 3.5, 2-H), 3.81 (3H, s, OCH3), 
3.49 (1H, dd, J 9.5, 3.5, 1-HH), 3.34 (1H, dd, J 9.5, 7.0, 1-HH), 2.34 (1H, d, J 3.5, OH), 2.25 (2H, t, J 7.0, 
3-H2). δC (101 MHz, CDCl3) 159.5 (C-Ar), 134.4 (C-4), 130.2 (C-Ar), 129.5 (C-Ar), 117.8 (C-5), 114.0 (C-Ar), 
73.7 (C-1), 73.2 (PMPCH2), 69.9 (C-2), 55.4 (OCH3), 38.0 (C-3). []D
24 = −2.0 (c 1.00, CHCl3) [Lit. −2.2 
(c 1.1, CHCl3)].273 
Spectroscopic data in accord with the literature data.273 
(R)-1-((4-Methoxybenzyl)oxy)-2-((tert-butyldimethylsilyl)oxy)pent-4-ene 79 
 
Alcohol 78 (2.35 g, 10.6 mmol) was dissolved in DCM (100 mL) and cooled to 0 °C. Imidazole (1.44 g, 
21.2 mmol) and TBSCl (2.39 g, 15.9 mmol) were added sequentially and the solution was warmed to 
room temperature for 16 hours. The reaction was diluted with water (100 mL) and the layers were 
separated. The aqueous phase was extracted with DCM (2 × 100 mL) and the combined organic layers 
were dried over MgSO4, filtered, and concentrated in vacuo. The crude material was purified by 
column chromatography (5% EtOAc in petrol). The resulting oil was redissolved in toluene (3 × 25 mL) 
and concentrated in vacuo to azeotrope TBSOH. This gave silyl ether 79 (3.07 g, 86%) as a colourless 
oil. 
δH (400 MHz, CDCl3) 7.25 (2H, d, J 8.5, Ar-H), 6.85 (2H, d, J 8.5, Ar-H), 5.82 (1H, ddt, J 17.0, 10.0, 7.0, 
4-H), 5.09-5.00 (2H, m, 5-H2), 4.45 (2H, s, PMPCH2), 3.86 (1H, dq, J 6.5, 5.5, 2-H), 3.81 (3H, s, OCH3), 
3.37 (1H, dd, J 9.5, 5.5, 1-HH), 3.35 (1H, dd, J 9.5, 5.5, 1-HH), 2.34 (1H, dddt, J 13.5, 7.0, 5.5, 1.5, 3-HH), 
2.21 (1H, dddt, J 13.5, 7.0, 6.5, 1.0, 3-HH), 0.88 (9H, s, SiC(CH3)3), 0.05 (3H, s, SiCH3), 0.04 (3H, s, SiCH3). 
δC (101 MHz, CDCl3) 159.3 (C-Ar), 135.2 (C-4), 130.7 (C-Ar), 129.3 (C-Ar), 117.1 (C-5), 113.9 (C-Ar), 74.1 
(C-1), 73.1 (PMPCH2), 71.4 (C-2), 55.4 (OCH3), 39.5 (C-3), 26.0 (SiC(CH3)3), 18.3 (SiC(CH3)3), −4.3 (SiCH3), 
−4.6 (SiCH3). []D
25 = +3.0 (c 1.00, CHCl3) [Lit. +3.0 (c 2.01, CHCl3)].274 





Potassium osmate dihydrate (81 mg, 0.220 mmol) and N-methylmorpholine N-oxide (3.84 g, 32.8 
mmol) were sequentially added to a solution of alkene 79 (7.36 g, 21.9 mmol) in a mixture of acetone 
(45 mL) and water (5 mL). After 16 hours at room temperature the reaction was diluted with EtOAc 
(100 mL) and water (100 mL) and the layers were separated. The aqueous phase was extracted with 
EtOAc (2 × 100 mL) and the combined organic layers were dried over MgSO4, filtered, and 
concentrated in vacuo. 
The crude diol was redissolved in a mixture of THF (70 mL) and water (50 mL) before NaIO4 (6.56 g, 
30.7 mmol) was added slowly. After two hours at room temperature the reaction was filtered through 
Celite® and the filtrate was diluted with DCM (200 mL) and a 10% aqueous solution of Na2S2O3 (150 
mL). The layers were separated and the aqueous phase was extracted with DCM (2 × 200 mL). The 
combined organic layers were dried over MgSO4, filtered, and concentrated in vacuo to give aldehyde 
81 (6.73 g, 91%) as an orange oil without further need for purification. 
δH (400 MHz, CDCl3) 9.79 (1H, t, J 2.5, 1-H), 7.23 (2H, d, J 8.5, Ar-H), 6.88 (2H, d, J 8.5, Ar-H), 4.45 (2H, 
s, PMPCH2), 3.34 (1H, tt, J 6.5, 5.5, 3-H), 3.81 (3H, s, OCH3), 3.48 (1H, dd, J 9.5, 5.0, 4-HH), 3.36 (1H, dd, 
J 9.5, 6.5, 4-HH), 2.64 (1H, ddd, J 16.0, 5.0, 2.5, 2-HH), 2.56 (1H, ddd, J 16.0, 6.5, 2.5, 2-HH), 0.86 (9H, 
s, SiC(CH3)3), 0.06 (6H, s, Si(CH3)2). δC (101 MHz, CDCl3) 201.7 (C-1), 159.4, 130.2, 129.4, and 114.0 
(C-Ar), 73.8 (C-4), 73.2 (PMPCH2), 67.5 (C-3), 55.4 (OCH3), 49.1 (C-2), 25.9 (SiC(CH3)3), 18.2 (SiC(CH3)3), 
−4.3 (SiCH3), −4.8 (SiCH3). []D
23 = +15.0 (c 1.00, CHCl3). 
Spectroscopic data in accord with the literature data.275 
(R)-2-((tert-Butyldimethylsilyl)oxy)-1-((4-methoxybenzyl)oxy)-5,5-dimethylhexan-4-one 83 
 
Aldehyde 81 (50 mg, 0.148 mmol) was dissolved in a degassed mixture of pentane (0.6 mL) and Et2O 
(0.4 mL) and cooled to −78 °C. tBuLi (1.5 M in pentane, 0.49 mL, 0.735 mmol) was added dropwise and 
the solution was stirred for one hour before warming to 0 °C for an additional hour. The reaction was 
quenched with a saturated aqueous solution of NH4Cl (1 mL) and the layers were separated. The 
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aqueous phase was extracted with Et2O (2 × 1 mL) and the combined organic layers were dried over 
MgSO4, filtered, and concentrated in vacuo. 
The crude alcohol was redissolved in DCM (2 mL) and Dess-Martin periodinane (94 mg, 0.222 mmol) 
was added. After two hours the solvent was removed under a stream of nitrogen and the crude 
material was purified by column chromatography (5-10% EtOAc in petrol) to give ketone 83 (33 mg, 
57%) as a colourless oil. 
δH (400 MHz, CDCl3) 7.24 (2H, d, J 8.5, Ar-H), 6.87 (2H, d, J 8.5, Ar-H), 4.45 (2H, s, PMPCH2), 4.41 (1H, 
dddd, J 7.5, 6.0, 5.0, 4.5, 2-H), 3.80 (3H, s, OCH3), 3.41 (1H, dd, J 10.0, 5.0, 1-HH), 3.33 (1H, dd, J 10.0, 
6.0, 1-HH), 2.75 (1H, dd, J 17.0, 7.5, 3-HH), 2.62 (1H, dd, J 17.0, 4.5, 3-HH), 1.11 (9H, s, 6-H9), 0.83 (9H, 
s, SiC(CH3)3), 0.06 (3H, s, SiCH3), 0.02 (3H, s, SiCH3). δC (101 MHz, CDCl3) 213.9 (C-4), 159.3, 130.5, 129.4, 
and 113.8 (C-Ar), 73.9 (C-1), 73.0 (PMPCH2), 67.7 (C-2), 55.4 (OCH3), 44.3 (C-5), 41.9 (C-3), 26.2 (C-6), 
26.0 (SiC(CH3)3), 18.2 (SiC(CH3)3), −4.5 (SiCH3), −4.7 (SiCH3). HRMS (ESI) calc. for C22H38O4SiNa [M+Na]+ 
417.2432. Found 417.2429. []D





Iodide 81 (1.40 g, 5.00 mmol) was dissolved in a degassed mixture of pentane (15 mL) and Et2O (10 mL) 
and cooled to −78 °C. tBuLi (1.5 M in pentane, 4.89 mL, 7.34 mmol) was added dropwise and the 
reaction was stirred at −78 °C for one hour before a solution of aldehyde 32 (825 mg, 2.44 mmol) in a 
degassed mixture of pentane (6 mL) and Et2O (4 mL) was added. The reaction was stirred at −78 °C for 
one hour then warmed to 0 °C for an additional hour before quenching with a saturated aqueous 
solution of NH4Cl (20 mL). The phases were separated and the aqueous layer was extracted with Et2O 
(2 × 25 mL). The combined organic layers were dried over MgSO4, filtered, and concentrated in vacuo. 
The crude material was purified by column chromatography (10% EtOAc in petrol) to give alcohol 84 
(1.20 g, 83%) as a colourless oil and a mixture of diastereomers. 
δH (400 MHz, CDCl3) 7.24 (4H, d, J 8.5, Ar-H × 2), 6.88 (4H, d, J 8.5, Ar-H × 2), 4.52-4.38 (4H, m, PMPCH2 
× 2), 4.12 (1H, m, 2-H), 4.04 (1H, m, 2-H), 3.99-3.83 (2H, m, 4-H × 2), 3.81 (6H, s, OCH3 × 2), 3.49-3.40 
(3H, m, 1-HH, 1-H2), 3.35 (1H, dd, J 9.5, 6.0, 1-HH), 3.27 (1H, d, J 2.5, OH), 3.12 (1H, d, J 2.5, OH), 
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2.30-2.06 (4H, m, 7-H2 × 2), 1.97-1.81 (2H, m, 6-H × 2), 1.77-1.67 (2H, m, 3-HH × 2), 1.65-1.51 (3H, m, 
3-HH × 2, 5-HH), 1.46-1.38 (2H, m, 5-HH, 5-HH), 1.22 (1H, m, 5-HH), 1.01 (3H, d, J 6.5, CHCH3), 1.00 
(3H, d, J 6.5, CHCH3), 0.88 (9H, s, SiC(CH3)3), 0.88 (9H, s, SiC(CH3)3), 0.14 (18H, s, Si(CH3)3 × 2), 0.09 (3H, 
s, SiCH3), 0.09 (3H, s, SiCH3), 0.07 (3H, s, SiCH3), 0.06 (3H, s, SiCH3). δC (101 MHz, CDCl3) 159.4, 130.2, 
129.5, and 113.9 (C-Ar × 2), 106.4 (C-8), 106.2 (C-8), 85.9 (C-9), 85.7 (C-9), 74.7 (C-1), 73.1 (C-1), 73.1 
(PMPCH2 × 2), 71.6 (C-2), 70.6 (C-2), 67.7 (C-4), 66.3 (C-4), 55.4 (OCH3 × 2), 44.2 (C-5 × 2), 42.8 (C-3), 
41.0 (C-3), 29.0 (C-6 × 2), 28.1 (C-7), 26.7 (C-7), 25.9 (SiC(CH3)3 × 2), 20.3 (CHCH3), 19.0 (CHCH3), 18.1 
(SiC(CH3)3 × 2), 0.3 (Si(CH3)3 × 2), −4.1 (SiCH3), −4.4 (SiCH3), −4.7 (SiCH3), −4.9 (SiCH3). HRMS (ESI) calc. 
for C27H48O4Si2Na [M+Na]+ 515.2983. Found 515.2987. IR (νmax/cm-1) (neat): 3674 (O–H), 2928 (alkane 




Iodide 32 (50 mg, 0.178 mmol) was dissolved in a degassed mixture of pentane (0.6 mL) and Et2O 
(0.4 mL) and cooled to −78 °C. tBuLi (1.6 M in pentane, 0.20 mL, 0.32 mmol) was added dropwise and 
the reaction was stirred at −78 °C for one hour before a solution of aldehyde 81 (28 mg, 82.7 µmol) in 
a mixture of pentane (0.6 mL) and Et2O (0.4 mL) was added. The reaction was stirred at −78 °C for one 
hour then warmed to 0 °C for a further hour before quenching with a saturated aqueous solution of 
NH4Cl (2 mL). The phases were separated and the aqueous layer was extracted with Et2O (2 × 5 mL). 
The combined organic layers were dried over MgSO4, filtered, and concentrated in vacuo to give 
alcohol 84. 
The crude alcohol was redissolved in DCM (2 mL) and Dess-Martin periodinane (53 mg, 0.125 mmol) 
was added. After two hours the solvent was removed under a stream of nitrogen and the crude 
material was purified by column chromatography (10% EtOAc in petrol) to give ketone 82 (31 mg, 
76%) as a colourless oil. 
δH (500 MHz, CDCl3) 7.23 (2H, d, J 8.5, Ar-H), 6.87 (2H, d, J 8.5, Ar-H), 4.44 (2H, s, PMPCH2), 4.34 (1H, 
ddt, J 7.0, 6.0, 5.0, 2-H), 3.80 (3H, s, OCH3), 3.41 (1H, dd, J 9.5, 5.0, 1-HH), 3.31 (1H, dd, J 9.5, 6.0, 1-HH), 
2.63 (1H, dd, J 16.0, 5.0, 3-HH), 2.58 (1H, dd, J 16.0, 7.0, 3-HH), 2.56 (1H, dd, J 17.0, 5.0, 5-HH), 2.31 
(1H, dd, J 17.0, 7.0, 5-HH), 2.24-2.15 (3H, m, 6-H, 7-H2), 0.97 (3H, d, J 6.5, CHCH3), 0.84 (9H, s, SiC(CH3)3), 
0.14 (9H, s, Si(CH3)3), 0.05 (3H, s, SiCH3), 0.04 (3H, s, SiCH3). δC (126 MHz, CDCl3) 208.5 (C-4), 159.3, 
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130.4, 129.4, and 113.9 (C-Ar), 105.3 (C-8), 86.4 (C-9), 73.9 (C-1), 73.1 (PMPCH2), 67.9 (C-2), 55.4 
(OCH3), 50.0 (C-5), 48.5 (C-3), 28.2 (C-6), 27.0 (C-7), 26.0 (SiC(CH3)3), 19.6 (CHCH3), 18.2 (SiC(CH3)3), 0.3 
(Si(CH3)3), −4.4 (SiCH3), −4.8 (SiCH3). HRMS (ESI) calc. for C27H46O4Si2 [M+H]+ 491.3007. Found 491.3003. 
[]D
24 = +4.0 (c 1.00, CHCl3). IR (νmax/cm-1) (neat): 2928 (alkane C–H), 2173 (alkyne C≡C), 1715 (ketone 
C=O). 
(2R,6S)-2-((tert-Butyldimethylsilyl)oxy)-1-((4-methoxybenzyl)oxy)-6-methylnon-8-yn-4-one 85 and 
(6S)-2-Methoxy-1-((4-methoxybenzyl)oxy)-6-methylnon-8-yn-4-one 86 
 
K2CO3 (141 mg, 1.02 mmol) was added to a solution of alkyne 82 (100 mg, 0.204 mmol) in MeOH 
(2.5 mL). After 4.5 hours at room temperature the reaction was diluted with DCM (5 mL) and a 
saturated aqueous solution of NH4Cl (5 mL). The layers were separated and the aqueous phase was 
extracted with DCM (2 × 5 mL). The combined organic layers were dried over MgSO4, filtered, and 
concentrated in vacuo. The crude material was purified by column chromatography (10-20% EtOAc in 
petrol) to give alkynes 85 (46 mg, 54%) and 86 (19 mg, 29%) as colourless oils. 
1H NMR analysis revealed alkyne 86 was isolated as a 1:1 mixture of diastereomers. 
(2R,6S)-2-((tert-Butyldimethylsilyl)oxy)-1-((4-methoxybenzyl)oxy)-6-methylnon-8-yn-4-one 85 
δH (500 MHz, CDCl3) 7.23 (2H, d, J 8.5, Ar-H), 6.87 (2H, d, J 8.5, Ar-H), 4.44 (2H, s, PMPCH2), 4.33 (1H, 
m, 2-H), 3.80 (3H, s, OCH3), 3.41 (1H, dd, J 9.5, 5.0, 1-HH), 3.31 (1H, dd, J 9.5, 6.0, 1-HH), 2.66-2.54 (3H, 
m, 3-H2, 5-HH), 2.34 (1H, dd, J 17.0, 7.0, 5-HH), 2.29-2.14 (3H, m, 6-H, 7-H2), 1.96 (1H, t, J 2.5, 9-H), 
0.98 (3H, d, J 6.5, CHCH3), 0.84 (9H, s, SiC(CH3)3), 0.05 (3H, s, SiCH3), 0.04 (3H, s, SiCH3). δC (101 MHz, 
CDCl3) 208.5 (C-4), 159.3, 130.4, 129.4, and 113.9 (C-Ar), 82.5 (C-8), 73.9 (C-1), 73.1 (PMPCH2), 70.0 
(C-9), 68.0 (C-2), 55.4 (OCH3), 49.9 (C-5), 48.4 (C-3), 28.0 (C-6), 26.0 (SiC(CH3)3), 25.5 (C-7), 19.6 
(CHCH3), 18.2 (SiC(CH3)3), −4.4 (SiCH3), −4.8 (SiCH3). HRMS (ESI) calc. for C24H38O4SiNa [M+Na]+ 
441.2432. Found 441.2442. []D
22 = +49.0 (c 1.00, CHCl3). IR (νmax/cm-1) (neat): 2929 (alkane C–H), 1714 
(ketone C=O). 
(6S)-2-Methoxy-1-((4-methoxybenzyl)oxy)-6-methylnon-8-yn-4-one 86 
δH (500 MHz, CDCl3) 7.24 (4H, d, J 8.5, Ar-H × 2), 6.87 (4H, d, J 8.5, Ar-H × 2), 4.48 (2H, d, J 11.5, PMPCHH 
× 2), 4.44 (2H, d, J 11.5, PMPCHH × 2), 3.86 (2H, m, 2-H × 2), 3.80 (6H, s, ArOCH3 × 2), 3.50-3.43 (4H, 
m, 1-H2 × 2), 3.37 (3H, s, OCH3), 3.37 (3H, s, OCH3), 2.72-2.65 (2H, m, 3-HH × 2), 2.65-2.53 (4H, m, 3-HH 
× 2, 5-HH × 2), 2.37-2.29 (2H, m, 5-HH × 2), 2.29-2.11 (6H, m, 6-H × 2, 7-H2 × 2), 1.96 (2H, m, 9-H × 2), 
Experimental 
140 
0.99 (3H, d, J 6.5, CHCH3), 0.98 (3H, d, J 6.5, CHCH3). δC (126 MHz, CDCl3) 208.5 (C-4 × 2), 159.3, 130.3, 
129.5, and 113.9 (C-Ar × 2), 82.4 (C-8 × 2), 76.3 (C-2), 76.2 (C-2), 73.2 (PMPCH2 × 2), 70.6 (C-1 × 2), 70.0 
(C-9 × 2), 57.9 (OCH3 × 2), 55.4 (ArOCH3 × 2), 49.4 (C-5 × 2), 45.6 (C-3), 45.5 (C-3), 28.0 (C-6), 28.0 (C-6), 
25.4 (C-7), 25.4 (C-7), 19.5 (CHCH3), 19.5 (CHCH3). HRMS (ESI) calc. for C19H26O4Na [M+Na]+ 341.1723. 
Found 341.1726. IR (νmax/cm-1) (neat): 2927 (alkane C–H), 1710 (ketone C=O). 
(2R,6S)-2-((tert-Butyldimethylsilyl)oxy)-1-((4-methoxybenzyl)oxy)-6-methylnon-8-yn-4-ol 88 
 
K2CO3 (211 mg, 1.53 mmol) was added to a solution of alkyne 84 (153 mg, 0.310 mmol) in MeOH 
(2.5 mL). After 16 hours at room temperature the reaction was diluted with DCM (5 mL) and a 
saturated aqueous solution of NH4Cl (5 mL). The layers were separated and the aqueous phase was 
extracted with DCM (2 × 5 mL). The combined organic layers were dried over MgSO4, filtered, and 
concentrated in vacuo. The crude material was purified by column chromatography (10-20% EtOAc in 
petrol) to give alkyne 88 (131 mg, quant.) as a colourless oil and a mixture of diastereomers. 
δH (400 MHz, CDCl3) 7.24 (4H, d, J 8.5, Ar-H × 2), 6.88 (4H, d, J 8.5, Ar-H × 2), 4.51-4.40 (4H, m, PMPCH2 
× 2), 4.13 (1H, m, 2-H), 4.04 (1H, m, 2-H), 4.00-3.85 (2H, m, 4-H × 2), 3.81 (6H, s, OCH3 × 2), 3.49-3.40 
(3H, m, 1-HH, 1-H2), 3.35 (1H, dd, J 9.5, 6.0, 1-HH), 3.26 (1H, d, J 2.5, OH), 3.12 (1H, d, J 2.0, OH), 
2.26-2.15 (3H, m, 7-HH, 7-H2), 2.11 (1H, ddd, J 17.0, 6.5, 2.5, 7-HH), 1.98-1.84 (4H, m, 6-H × 2, 9-H × 
2), 1.76-1.69 (2H, m, 3-HH × 2), 1.66-1.55 (3H, m, 3-HH × 2, 5-HH), 1.46-1.41 (2H, m, 5-HH, 5-HH), 1.23 
(1H, m, 5-HH), 1.02 (6H, d, J 6.5, CHCH3 × 2), 0.88 (9H, s, SiC(CH3)3), 0.88 (9H, s, SiC(CH3)3), 0.09 (3H, s, 
SiCH3), 0.09 (3H, s, SiCH3), 0.07 (3H, s, SiCH3), 0.06 (3H, s, SiCH3). δC (101 MHz, CDCl3) 159.4 (C-Ar × 2), 
130.2 (C-Ar), 130.1 (C-Ar), 129.5 (C-Ar), 129.5 (C-Ar), 113.9 (C-Ar × 2), 83.3 (C-8), 83.1 (C-8), 74.7 (C-1), 
73.2 (PMPCH2 × 2), 73.1 (C-1), 71.6 (C-2), 70.5 (C-2), 69.6 (C-9), 69.4 (C-9), 67.6 (C-4), 66.2 (C-4), 55.4 
(OCH3 × 2), 44.0 (C-5 × 2), 42.8 (C-3), 40.9 (C-3), 28.8 (C-6), 28.7 (C-6), 26.7 (C-7) 25.9 (SiC(CH3)3 × 2), 
25.1 (C-7), 20.2 (CHCH3), 19.0 (CHCH3), 18.1 (SiC(CH3)3 × 2), −4.1 (SiCH3), −4.4 (SiCH3), −4.7 (SiCH3), −4.9 
(SiCH3). HRMS (ESI) calc. for C24H41O4Si [M+H]+ 421.2769. Found 421.2748. IR (νmax/cm-1) (neat): 3302 
(O–H), 2923 (alkane C–H). 




K2CO3 (414 mg, 3.00 mmol) was added to a solution of alkyne 84 (295 mg, 0.599 mmol) in MeOH 
(10 mL). The reaction was stirred at room temperature for 16 hours then diluted with DCM (40 mL) 
and a saturated aqueous solution of NH4Cl (40 mL). The layers were separated and the aqueous phase 
was extracted with DCM (2 × 25 mL). The combined organic layers were dried over MgSO4, filtered, 
and concentrated in vacuo. 
The crude material redissolved in DCM (10 mL) and Dess-Martin periodinane (381 mg, 0.898 mmol) 
was added. After two hours the solvent was removed in vacuo. The crude product was purified by 
column chromatography (5-10% EtOAc in petrol) to give ketone 85 (218 mg, 87%) as a colourless oil. 




Azobisisobutyronitrile (16 mg, 97.4 µmol) was added to a solution of alkyne 85 (207 mg, 0.494 mmol) 
in benzene (5 mL). nTributyltin hydride (0.27 mL, 1.00 mmol) was added and the mixture was heated 
to 80 °C for two hours. The reaction was cooled to room temperature and a solution of iodine (1 M in 
Et2O) was added dropwise until the red colour persisted. An additional 0.25 mL of the iodine solution 
was added and the solution was stirred for further 15 minutes. The reaction was quenched with a 
saturated aqueous solution of Na2S2O3 (5 mL) and diluted with Et2O (10 mL). The layers were separated 
and the organic phase was washed with an aqueous solution of KF (1 M, 3 × 10 mL) with each extracting 
shaken vigorous for 30 seconds. The organic layer was then dried over MgSO4, filtered, and 
concentrated in vacuo. The crude material was purified by column chromatography (0-10% EtOAc in 
petrol) to give vinyl iodide 90 (177 mg, 71%) as a colourless oil. 
1H NMR analysis revealed an E/Z ratio of 4.5:1. 
δH (500 MHz, CDCl3) 7.23 (2H, d, J 8.5, Ar-H), 6.87 (2H, d, J 8.5, Ar-H), 6.44 (1H, dt, J 14.5, 7.5, 8-H), 
5.99 (1H, d, J 14.5, 9-H), 4.44 (2H, s, PMPCH2), 4.32 (1H, ddt, J 7.0, 6.0, 5.0, 2-H), 3.81 (3H, s, OCH3), 
3.41 (1H, dd, J 9.5, 5.0, 1-HH), 3.31 (1H, dd, J 9.5, 6.0, 1-HH), 2.60 (1H, dd, J 16.0, 5.0, 3-HH), 2.55 (1H, 
dd, J 16.0, 7.0, 3-HH), 2.37 (1H, dd, J 17.0, 5.5, 5-HH), 2.24 (1H, dd, J 17.0, 7.5, 5-HH), 2.10 (1H, m, 6-H), 
2.02 (1H, m, 7-HH), 1.92 (1H, m, 7-HH), 0.88 (3H, d, J 6.5, CHCH3), 0.84 (9H, s, SiC(CH3)3), 0.05 (3H, s, 
SiCH3), 0.03 (3H, s, SiCH3). δC (126 MHz, CDCl3) 208.6 (C-4), 159.3 (C-Ar), 144.6 (C-8), 130.4, 129.4, and 
113.9 (C-Ar), 76.2 (C-9), 73.9 (C-1), 73.1 (PMPCH2), 68.1 (C-2), 55.4 (OCH3), 50.7 (C-5), 48.5 (C-3), 43.1 
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(C-7), 28.3 (C-6), 26.0 (SiC(CH3)3), 19.7 (CHCH3), 18.2 (SiC(CH3)3), −4.4 (SiCH3), −4.8 (SiCH3). HRMS (ESI) 
calc. for C24H39O4SiINa [M+Na]+ 569.1555. Found 569.1528. []D
21 = +14.0 (c 1.00, CHCl3). IR (νmax/cm-1) 




CuI (12.4 mg, 65.1 µmol) and Pd(PPh3)2Cl2 (15.4 mg, 21.9 µmol) were added sequentially to a solution 
of vinyl iodide 90 (143 mg, 0.262 mmol) and alkyne 75 (51 mg, 0.218 mmol) in degassed triethylamine 
(5 mL). The reaction was stirred for one hour then quenched with a saturated aqueous solution of 
NH4Cl (5 mL), diluted with Et2O (10 mL), and the layers were separated. The aqueous phase was 
extracted with Et2O (2 × 10 mL) and the combined organic layers were washed with HCl (1 M, 15 mL) 
then dried over MgSO4, filtered, and concentrated in vacuo. The crude material was purified by column 
chromatography (2-10% EtOAc in petrol) to give enyne 91 (104 mg, 73%) as a colourless oil. 
δH (500 MHz, CDCl3) 7.23 (2H, d, J 8.5, Ar-H), 6.87 (2H, d, J 8.5, Ar-H), 5.96 (1H, dt, J 16.0, 7.5, 13-H), 
5.65 (1H, s, 2-H), 5.43 (1H, d, J 16.0, 12-H), 4.83 (1H, s, 23-CHH), 4.78 (1H, s, 23-CHH), 4.43 (2H, s, 
PMPCH2), 4.32 (1H, ddt, J 7.0, 6.0, 5.0, 19-H), 3.80 (3H, s, ArOCH3), 3.68 (3H, s, CO2CH3), 3.40 (1H, dd, 
J 9.5, 5.0, 20-HH), 3.31 (1H, dd, J 9.5, 6.0, 20-HH), 2.60 (1H, dd, J 16.0, 5.0, 18-HH), 2.55 (1H, dd, J 16.0, 
7.0, 18-HH), 2.49-2.35 (3H, m, 9-H2, 16-HH), 2.27-2.16 (4H, m, 4-HH, 8-H2, 16-HH), 2.14 (3H, s, 21-H3), 
2.12-1.91 (4H, m, 6-HH, 14-H2, 15-H), 1.90-1.81 (3H, m, 4-HH, 5-H, 6-HH), 0.87 (3H, d, J 6.5, 24-H3), 
0.84 (9H, s, SiC(CH3)3), 0.82 (3H, d, J 6.0, 22-H3), 0.05 (3H, s, SiCH3), 0.03 (3H, s, SiCH3). δC (126 MHz, 
CDCl3) 208.8 (C-17), 167.2 (C-1), 159.4 (C-3), 159.3 (C-Ar), 146.2 (C-7), 141.1 (C-13), 130.4 (C-Ar), 129.4 
(C-Ar), 116.7 (C-2), 113.9 (C-Ar), 111.9 (C-23), 111.8 (C-12), 88.5 (C-10), 79.5 (C-11), 73.9 (C-20), 73.1 
(PMPCH2), 68.1 (C-19), 55.4 (ArOCH3), 50.9 (CO2CH3), 50.9 (C-16), 48.7 (C-4), 48.4 (C-18), 44.2 (C-6), 
40.2 (C-14), 34.8 (C-8), 29.1 (C-5), 28.8 (C-15), 26.0 (SiC(CH3)3), 19.8 (C-24), 19.5 (C-22), 18.8 (C-21), 
18.3 (SiC(CH3)3), 18.2 (C-9), −4.4 (SiCH3), −4.8 (SiCH3). HRMS (ESI) calc. for C39H64O6NSi [M+NH4]+ 
670.4497. Found 670.4472. []D
21 = +14.0 (c 1.00, CHCl3). IR (νmax/cm-1) (neat): 2926 (alkane C–H), 1716 






DMAP (2 mg, 16.4 µmol), triethylamine (0.34 mL, 2.44 mmol), and acetic anhydride (0.19 mL, 
2.01 mmol) were added sequentially to a solution of alcohol 88 (171 mg, 0.406 mmol) in DCM (10 mL). 
The reaction was stirred at room temperature for 16 hours then quenched with a statured aqueous 
solution of NH4Cl (10 mL). The layers were separated and the aqueous phase was extracted with DCM 
(2 × 10 mL). The combined organic layers were dried over MgSO4, filtered, and concentrated in vacuo. 
The crude material was purified by column chromatography (5-10% EtOAc in petrol) to give ester 92 
(183 mg, 97%) as a colourless oil and a mixture of diastereomers. 
δH (400 MHz, CDCl3) 7.25 (4H, d, J 8.5, Ar-H × 2), 6.88 (2H, d, J 8.5, Ar-H), 6.87 (2H, d, J 8.5, Ar-H), 5.11 
(1H, m, 4-H), 5.04 (1H, m, 4-H), 4.48-4.41 (4H, m, PMPCH2 × 2), 3.84 (2H, m, 2-H × 2), 3.81 (3H, s, OCH3), 
3.80 (3H, s, OCH3), 3.43-3.34 (3H, m, 1-HH, 1-H2), 3.30 (1H, dd, J 9.5, 5.5, 1-HH), 2.18-2.15 (3H, m, 7-HH, 
7-H2), 2.12 (1H, ddd, J 10.5, 6.0, 2.5, 7-HH), 2.01 (6H, s, O2CCH3 × 2), 1.97 (1H, t, J 2.5, 9-H), 1.94 (1H, 
t, J 2.5, 9-H), 1.84-1.37 (10H, m, 3-H2 × 2, 5-H2 × 2, 6-H × 2), 1.02 (3H, d, J 6.5, CHCH3), 0.99 (3H, d, J 
6.5, CHCH3), 0.88 (9H, s, SiC(CH3)3), 0.87 (9H, s, SiC(CH3)3), 0.06 (3H, s, SiCH3), 0.04 (3H, s, SiCH3), 0.02 
(3H, s, SiCH3), 0.02 (3H, s, SiCH3). δC (101 MHz, CDCl3) 170.7 (O2CCH3), 170.6 (O2CCH3), 159.3 (C-Ar), 
159.2 (C-Ar), 130.6 (C-Ar), 130.5 (C-Ar), 129.4 (C-Ar × 2), 113.9 (C-Ar), 113.8 (C-Ar), 82.9 (C-8), 82.8 
(C-8), 74.8 (C-1), 74.1 (C-1), 73.1 (PMPCH2 × 2), 70.0 (C-4), 69.7 (C-4), 69.7 (C-9), 69.6 (C-9), 68.9 (C-2), 
68.2 (C-2), 55.4 (OCH3 × 2), 41.0 (C-5), 40.8 (C-5), 40.4 (C-3), 39.7 (C-3), 29.1 (C-6 × 2), 26.6 (C-7) 26.0 
(SiC(CH3)3 × 2), 25.8 (C-7), 21.5 (O2CCH3), 21.4 (O2CCH3), 19.6 (CHCH3), 19.1 (CHCH3), 18.3 (SiC(CH3)3), 
18.2 (SiC(CH3)3), −4.0 (SiCH3), −4.1 (SiCH3), −4.7 (SiCH3), −5.0 (SiCH3). HRMS (ESI) calc. for C26H43O5Si 
[M+H]+ 463.2874. Found 463.2865. IR (νmax/cm-1) (neat): 2928 (alkane C–H), 1733 (ester C=O). 
Hydrolysis of ester 92 
 
K2CO3 (15 mg, 0.109 mmol) was added to a solution of ester 92 (10 mg, 21.6 µmol) in MeOH (1 mL). 
The reaction was stirred at room temperature for 16 hours then diluted with DCM (5 mL) and a 
saturated aqueous solution of NH4Cl (5 mL). The layers were separated and the aqueous phase was 
extracted with DCM (2 × 5 mL). The combined organic layers were dried over MgSO4, filtered, and 
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concentrated in vacuo to give alcohol 88 (9 mg, 99%) as a colourless oil without further need for 
purification. 
Characterisation as given previously. 
(2R,6S)-4-Acetoxy-2-((tert-butyldimethylsilyl)oxy)-1-hydroxy-6-methylnon-8-yne 93 
 
DDQ (7 mg, 30.8 µmol) was added to a solution of ether 92 (10 mg, 21.6 µmol) in DCM (1 mL) and 
water (0.1 mL). The reaction was stirred for two hours at room temperature before quenching with a 
saturated aqueous solution of NaHCO3 (1 mL). The layers were separated and the aqueous phase was 
extracted with DCM (2 × 1 mL). The combined organic layers were dried over MgSO4, filtered, and 
concentrated in vacuo. The crude material was purified by column chromatography (10-20% EtOAc in 
petrol) to give alcohol 93 (7 mg, 95%) as a colourless oil. 
δH (400 MHz, CDCl3) 5.04 (1H, m, 4-H), 4.98 (1H, m, 4-H), 3.78 (2H, m, 2-H × 2), 3.62 (2H, m, 1-HH × 2), 
3.53 (1H, ddd, J 11.5, 7.5, 4.5, 1-HH), 3.47 (1H, ddd, J 11.5, 7.5, 4.0, 1-HH), 2.18 (2H, td, J 6.0, 2.5, 7-HH 
× 2), 2.13 (2H, ddd, J 9.0, 6.0, 2.5, 7-HH × 2), 2.04 (3H, s, O2CCH3), 2.03 (3H, s, O2CCH3), 1.98 (1H, t, J 
2.5, 9-H), 1.96 (1H, t, J 2.5, 9-H), 1.87-1.61 (8H, m, 3-H2 × 2, 5-HH × 2, 6-H × 2), 1.57 (1H, m, 5-HH), 1.42 
(1H, ddd, J 13.5, 9.0, 3.5, 5-HH), 1.03 (3H, d, J 6.5, CHCH3), 1.00 (3H, d, J 6.5, CHCH3), 0.90 (18H, s, 
SiC(CH3)3), 0.10-0.05 (12H, m, SiCH3 × 4). δC (101 MHz, CDCl3) 171.0 (O2CCH3), 170.8 (O2CCH3), 82.8 
(C-8), 82.5 (C-8), 70.3 (C-4), 69.9 (C-2), 69.8 (C-2), 69.8 (C-9 × 2), 69.4 (C-4), 67.1 (C-1), 65.6 (C-1), 41.4 
(C-5), 40.7 (C-5), 39.4 (C-3), 39.1 (C-3), 29.1 (C-6), 29.0 (C-6), 26.6 (C-7) 26.0 (SiC(CH3)3), 25.9 (SiC(CH3)3), 
25.7 (C-7), 21.5 (O2CCH3), 21.3 (O2CCH3), 19.7 (CHCH3), 19.1 (CHCH3), 18.2 (SiC(CH3)3 × 2), −4.2 (SiCH3), 
−4.5 (SiCH3 × 2), −4.8 (SiCH3). HRMS (ESI) calc. for C19H34O4Si [M+H]+ 343.2299. Found 343.2291. IR 




Azobisisobutyronitrile (7 mg, 42.6 µmol) was added to a solution of alkyne 92 (68 mg, 0.147 mmol) in 
benzene (2 mL). nTributyltin hydride (79.0 µL, 0.294 mmol) was added dropwise and the solution was 
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heated to 80 °C for two hours. The reaction was cooled to room temperature and a solution of iodine 
(1 M in Et2O) was added dropwise until the red colour persisted. An additional 0.25 mL of the iodine 
solution was added and the solution was stirred for further 15 minutes. The reaction was quenched 
with a saturated aqueous solution of Na2S2O3 (2.5 mL) and diluted with Et2O (10 mL). The layers were 
separated and the organic phase was washed with an aqueous solution of KF (1 M, 3 × 10 mL) with 
each extracting shaken vigorous for 30 seconds. The organic layer was then dried over MgSO4, filtered, 
and concentrated in vacuo. The crude material was purified by column chromatography (10-20% 
EtOAc in petrol) to give vinyl iodide 95 (83 mg, 96%) as a colourless oil. 
1H NMR analysis revealed an E/Z ratio of 5:1. 
Note: if the reaction was scaled above 100 mg (of alkyne) partial protodestannylation to the 
corresponding alkene was observed. 
δH (500 MHz, CDCl3) 7.25 (4H, d, J 8.5, Ar-H × 2), 6.91-6.85 (4H, m, Ar-H), 6.44 (2H, m, 8-H × 2), 5.97 
(2H, m, 9-H × 2), 5.06 (2H, m, 4-H × 2), 4.45 (4H, s, PMPCH2 × 2), 3.84 (2H, m, 2-H × 2), 3.81 (3H, s, 
OCH3), 3.81 (3H, s, OCH3), 3.44-3.34 (3H, m, 1-HH, 1-H2), 3.30 (1H, dd, J 9.5, 5.5, 1-HH), 2.12-2.18 (2H, 
m, 7-HH × 2), 2.01 (6H, s, O2CCH3 × 2), 1.95-1.83 (2H, m, 7-HH × 2), 1.84-1.25 (10H, m, 3-H2 × 2, 5-H2 × 
2, 6-H × 2), 0.92 (3H, d, J 6.5, CHCH3), 0.90-0.85 (21H, m, SiC(CH3)3 × 2, CHCH3), 0.05 (3H, s, SiCH3), 0.04 
(3H, s, SiCH3), 0.02 (3H, s, SiCH3), 0.02 (3H, s, SiCH3). δC (126 MHz, CDCl3) 170.7 (O2CCH3), 170.6 
(O2CCH3), 159.3 (C-Ar × 2), 144.9 (C-8 × 2), 130.6 (C-Ar), 130.5 (C-Ar), 129.5 (C-Ar), 129.4 (C-Ar), 113.9 
(C-Ar × 2), 75.8 (C-9 × 2), 74.8 (C-1), 74.0 (C-1), 73.2 (PMPCH2), 73.1 (PMPCH2), 70.0 (C-4), 69.6 (C-4), 
68.9 (C-2), 68.2 (C-2), 55.4 (OCH3 × 2), 43.8 (C-7), 43.4 (C-7), 41.5 (C-5), 41.5 (C-5), 40.4 (C-3), 39.7 (C-3), 
29.4 (C-6), 29.1 (C-6), 26.0 (SiC(CH3)3 × 2), 21.5 (O2CCH3), 21.4 (O2CCH3), 19.5 (CHCH3), 19.3 (CHCH3), 
18.3 (SiC(CH3)3), 18.2 (SiC(CH3)3), −4.0 (SiCH3), −4.2 (SiCH3), −4.6 (SiCH3), −4.9 (SiCH3). HRMS (ESI) calc. 







CuI (2.4 mg, 12.6 µmol) and Pd(PPh3)2Cl2 (3.0 mg, 4.27 µmol) were added sequentially to a solution of 
vinyl iodide 95 (30 mg, 50.8 µmol) and alkyne 75 (10 mg, 42.7 µmol) in degassed triethylamine (1 mL). 
The reaction was stirred for 16 hours then quenched with a saturated aqueous solution of NH4Cl 
(5 mL), diluted with Et2O (5 mL), and the layers were separated. The aqueous phase was extracted 
with Et2O (2 × 5 mL) and the combined organic layers were washed with HCl (1 M, 5 mL) then dried 
over MgSO4, filtered, and concentrated in vacuo. The crude material was purified by column 
chromatography (2-10% EtOAc in petrol) to give enyne 76 (19 mg, 64%) as a colourless oil. 
δH (500 MHz, CDCl3) 7.27 (4H, m, Ar-H), 6.91-6.84 (4H, m, Ar-H), 5.98 (2H, m, 13-H × 2), 5.65 (2H, s, 2-H 
× 2), 5.43 (2H, d, J 15.5, 12-H × 2), 5.06 (2H, m, 17-H × 2), 4.83 (2H, s, 23-CHH × 2), 4.78 (2H, s, 23-CHH 
× 2), 4.45 (4H, s, PMPCH2 × 2), 3.84 (2H, m, 19-H × 2), 3.81 (3H, s, OCH3), 3.80 (3H, s, OCH3), 3.68 (6H, 
s, CO2CH3 × 2), 3.44-3.34 (3H, m, 20-HH, 20-H2), 3.29 (1H, dd, J 9.5, 5.5, 20-HH), 2.47-2.36 (4H, m, 9-H2 
× 2), 2.25-2.17 (6H, m, 4-HH × 2, 8-H2 × 2), 2.14 (6H, s, 21-H3 × 2), 2.13-1.98 (10H, m, 6-HH × 2, 14-HH 
× 2, O2CCH3 × 2), 1.98-1.81 (8H, m, 4-HH × 2, 5-H × 2, 6-HH × 2, 14-HH × 2), 1.80-1.70 (3H, m, 18-HH, 
18-H2), 1.64-1.38 (6H, m, 15-H × 2, 16-HH, 16-H2, 18-HH), 1.27 (1H, m, 16-HH), 0.87 (6H, d, J 6.5, 24-H3 
× 2), 0.88 (9H, s, SiC(CH3)3), 0.86 (9H, s, SiC(CH3)3), 0.82 (6H, d, J 6.0, 22-H3 × 2), 0.05 (3H, s, SiCH3), 0.04 
(3H, s, SiCH3), 0.02 (3H, s, SiCH3), 0.01 (3H, s, SiCH3). δC (126 MHz, CDCl3) 170.7 (O2CCH3), 170.6 
(O2CCH3), 167.2 (C-1 × 2), 159.4 (C-Ar or C-3), 159.4 (C-Ar or C-3), 159.3 (C-Ar or C-3), 159.2 (C-Ar or 
C-3), 146.3 (C-7 × 2), 141.5 (C-13), 141.5 (C-13), 130.6 (C-Ar), 130.5 (C-Ar), 129.4 (C-Ar), 129.4 (C-Ar), 
116.7 (C-2× 2), 113.9 (C-Ar), 113.8 (C-Ar), 111.9 (C-23), 111.9 (C-23), 111.5 (C-12), 111.5 (C-12), 88.3 
(C-10), 88.2 (C-10), 79.7 (C-11), 79.7 (C-11), 74.9 (C-20), 74.0 (C-20), 73.1 (PMPCH2), 73.1 (PMPCH2), 
70.2 (C-17), 69.6 (C-17), 68.9 (C-19), 68.2 (C-19), 55.4 (ArOCH3), 55.4 (ArOCH3), 50.9 (CO2CH3 × 2), 48.7 
(C-4 × 2), 44.2 (C-6 × 2), 41.7 (C-16), 41.6 (C-16), 41.0 (C-14), 40.6 (C-14), 40.4 (C-18), 39.6 (C-18), 34.9 
(C-8 × 2), 29.8 (C-15), 29.5 (C-15), 29.1 (C-5 × 2), 26.0 (SiC(CH3)3), 26.0 (SiC(CH3)3), 21.5 (O2CCH3), 21.4 
(O2CCH3), 19.5 (C-24), 19.4 (C-22 × 2), 19.3 (C-24), 18.8 (C-21 × 2), 18.3 (C-9 × 2), 18.3 (SiC(CH3)3), 18.2 
(SiC(CH3)3), −4.0 (SiCH3), −4.2 (SiCH3), −4.7 (SiCH3), −5.0 (SiCH3). HRMS (ESI) calc. for C41H65O7Si [M+H]+ 







DDQ (12 mg, 52.9 µmol) was added to a solution of ether 95 (20 mg, 33.9 µmol) in DCM (1 mL) and 
water (0.1 mL). The reaction was stirred for two hours at room temperature before quenching with a 
saturated aqueous solution of NaHCO3 (1 mL). The layers were separated and the aqueous phase was 
extracted with DCM (2 × 1 mL). The combined organic layers were dried over MgSO4, filtered, and 
concentrated in vacuo. 
The crude alcohol was redissolved in DCM (1 mL) before methanesulfonyl chloride (4 µL, 51.7 µmol) 
and triethylamine (9 µL, 64.6 µmol) were added sequentially. The reaction was stirred for 1.5 hours at 
room temperature before quenching with a saturated aqueous solution of NH4Cl (1 mL). The layers 
were separated and the aqueous phase was extracted with DCM (2 × 1 mL). The combined organic 
layers were dried over MgSO4, filtered, and concentrated in vacuo. The crude material was purified by 
column chromatography (5-15% EtOAc in petrol) to give mesylate 98 (14 mg, 75%) as a colourless oil. 
1H NMR analysis revealed an E/Z ratio of 5:1. 
δH (400 MHz, CDCl3) 6.45 (2H, m, 8-H × 2), 6.00 (2H, m, 9-H × 2), 5.07 (1H, m, 4-H), 5.02 (1H, m, 4-H), 
4.21 (1H, dd, J 10.5, 3.5, 1-HH), 4.15-4.03 (3H, m, 1-HH, 1-H2), 3.94 (2H, m, 2-H × 2), 3.03 (3H, s, 
SO2CH3), 3.03 (3H, s, SO2CH3), 2.17-1.86 (10H, m, 7-H2 × 2, O2CCH3 × 2), 1.84-1.60 (5H, m, 3-H2 × 2, 
5-HH), 1.60-1.37 (4H, m, 5-H2, 6-H × 2), 1.25 (1H, m, 5-HH), 0.93 (3H, d, J 6.0, CHCH3), 0.91-0.82 (21H, 
m, SiC(CH3)3 × 2, CHCH3), 0.10 (3H, s, SiCH3), 0.09 (3H, s, SiCH3), 0.09 (3H, s, SiCH3), 0.06 (3H, s, SiCH3). 
δC (126 MHz, CDCl3) 170.8 (O2CCH3), 170.7 (O2CCH3), 144.6 (C-8), 144.6 (C-8), 76.1 (C-9), 76.1 (C-9), 
72.7 (C-1), 72.5 (C-1), 69.6 (C-4), 68.7 (C-4), 67.6 (C-2), 67.3 (C-2), 43.8 (C-7), 43.3 (C-7), 41.7 (C-5), 41.4 
(C-5), 39.3 (C-3), 39.1 (C-3), 37.6 (SO2CH3), 37.6 (SO2CH3), 29.4 (C-6), 29.1 (C-6), 25.9 (SiC(CH3)3), 25.9 
(SiC(CH3)3), 21.5 (O2CCH3), 21.3 (O2CCH3), 19.4 (CHCH3), 19.2 (CHCH3), 18.2 (SiC(CH3)3), 18.1 (SiC(CH3)3), 
−4.1 (SiCH3), −4.4 (SiCH3), −4.7 (SiCH3), −4.9 (SiCH3). HRMS (ESI) calc. for C19H41NO6ISSi [M+NH4]+ 






CuI (11 mg, 57.8 µmol) and Pd(PPh3)2Cl2 (13 mg, 18.5 µmol) were added sequentially to a solution of 
vinyl iodide 98 (100 mg, 0.182 mmol) and alkyne 75 (42 mg, 0.179 mmol) in degassed triethylamine (7 
mL). The reaction was stirred for one hour then quenched with HCl (1 M, 10 mL) and diluted with water 
(10 mL) and Et2O (10 mL). The layers were separated and the aqueous phase was extracted with Et2O 
(2 × 10 mL). The combined organic layers were washed with HCl (1 M, 15 mL) then dried over MgSO4, 
filtered, and concentrated in vacuo. The crude material was purified by column chromatography 
(5-20% EtOAc in petrol) to give enyne 99 (103 mg, 88%) as a colourless oil. 
δH (500 MHz, CDCl3) 5.97 (2H, m, 13-H × 2), 5.65 (2H, s, 2-H × 2), 5.44 (2H, m, 12-H × 2), 5.07 (1H, m, 
17-H), 5.00 (1H, m, 17-H), 4.83 (2H, s, 23-CHH × 2), 4.77 (2H, s, 23-CHH × 2), 4.21 (1H, dd, J 10.5, 3.5, 
20-HH), 4.15-4.02 (3H, m, 20-HH, 20-H2), 3.95 (1H, m, 19-H), 3.92 (1H, m, 19-H), 3.68 (6H, s, CO2CH3 × 
2), 3.03 (3H, s, SO2CH3), 3.02 (3H, s, SO2CH3), 2.44-2.38 (4H, m, 9-H2 × 2), 2.24-2.16 (6H, m, 4-HH × 2, 
8-H2 × 2), 2.13 (6H, s, 21-H3 × 2), 2.11-1.90 (12H, m, 6-HH × 2, 14-H2 × 2, O2CCH3 × 2), 1.90-1.77 (8H, 
m, 4-HH × 2, 5-H × 2, 6-HH × 2, 18-HH × 2), 1.76-1.64 (3H, m, 16-HH, 18-HH × 2), 1.57-1.40 (4H, m, 15-H 
× 2, 16-H2), 1.25 (1H, m, 16-HH), 0.94-0.87 (24H, m, SiC(CH3)3 × 2, 24-H3 × 2), 0.82 (6H, d, J 5.5, 22-H3 
× 2), 0.09 (3H, s, SiCH3), 0.08 (3H, s, SiCH3), 0.08 (3H, s, SiCH3), 0.06 (3H, s, SiCH3). δC (126 MHz, CDCl3) 
170.8 (O2CCH3), 170.7 (O2CCH3), 167.2 (C-1 × 2), 159.4 (C-3), 159.4 (C-3), 146.3 (C-7 × 2), 141.2 (C-13 × 
2), 116.7 (C-2 × 2), 111.9 (C-23 × 2), 111.7 (C-12), 111.7 (C-12), 88.5 (C-10), 88.4 (C-10), 79.6 (C-11 × 
2), 72.7 (C-20), 72.5 (C-20), 69.7 (C-17), 68.7 (C-17), 67.6 (C-19), 67.3 (C-19), 50.9 (CO2CH3 × 2), 48.7 
(C-4 × 2), 44.2 (C-6 × 2), 41.8 (C-16), 41.5 (C-16), 40.9 (C-14), 40.5 (C-14), 39.9 (C-18), 39.0 (C-18), 37.6 
(SO2CH3), 37.5 (SO2CH3), 34.9 (C-8 × 2), 29.8 (C-15), 29.5 (C-15), 29.2 (C-5 × 2), 25.9 (SiC(CH3)3), 25.9 
(SiC(CH3)3), 21.5 (O2CCH3), 21.2 (O2CCH3), 19.5 (C-24 ×2), 19.4 (C-22), 19.3 (C-22), 18.8 (C-21 × 2), 18.3 
(C-9 × 2), 18.2 (SiC(CH3)3), 18.1 (SiC(CH3)3), −4.2 (SiCH3), −4.4 (SiCH3), −4.7 (SiCH3), −5.0 (SiCH3). HRMS 
(ESI) calc. for C34H62NO8SSi [M+NH4]+ 672.3960. Found 672.3956. IR (νmax/cm-1) (neat): 2928 (alkane 






Sodium azide (6.3 mg, 96.9 µmol) was added to a solution of mesylate 99 (32 mg, 48.9 µmol) in DMF 
(2 mL). The reaction was heated to 80 °C for 16 hours then cooled to room temperature and quenched 
with water (10 mL). The solution was extracted with Et2O (3 × 10 mL) and the combined organic layers 
were dried over MgSO4, filtered, and concentrated in vacuo. The crude material was purified by 
column chromatography (2-10% EtOAc in petrol) to give azide 100 (25 mg, 85%) as a colourless oil. 
δH (500 MHz, CDCl3) 5.98 (2H, m, 13-H × 2), 5.65 (2H, s, 2-H × 2), 5.44 (2H, m, 12-H × 2), 4.98 (2H, m, 
17-H × 2), 4.83 (2H, s, 23-CHH × 2), 4.78 (2H, s, 23-CHH × 2), 3.81 (2H, m, 19-H × 2), 3.69 (6H, s, CO2CH3 
× 2), 3.37 (1H, dd, J 12.5, 3.5, 20-HH), 3.32 (1H, dd, J 12.5, 5.0, 20-HH), 3.17 (1H, dd, J 12.5, 5.0, 20-HH), 
3.14 (1H, dd, J 12.5, 5.0, 20-HH), 2.52-2.37 (4H, m, 9-H2 × 2), 2.27-2.16 (6H, m, 4-HH × 2, 8-H2 × 2), 2.14 
(6H, s, 21-H3 × 2), 2.11-1.90 (12H, m, 6-HH × 2, 14-H2 × 2, O2CCH3 × 2), 1.90-1.60 (11H, m, 4-HH × 2, 
5-H × 2, 6-HH × 2, 16-HH, 18-H2 × 2), 1.54-1.39 (4H, m, 15-H × 2, 16-H2), 1.25 (1H, m, 16-HH), 0.94-0.87 
(24H, m, SiC(CH3)3 × 2, 24-H3 × 2), 0.82 (6H, d, J 6.0, 22-H3 × 2), 0.10 (3H, s, SiCH3), 0.09 (3H, s, SiCH3), 
0.09 (3H, s, SiCH3), 0.06 (3H, s, SiCH3). δC (126 MHz, CDCl3) 170.8 (O2CCH3), 170.6 (O2CCH3), 167.2 (C-1 
× 2), 159.4 (C-3), 159.4 (C-3), 146.3 (C-7 × 2), 141.3 (C-13 × 2), 116.7 (C-2 × 2), 111.9 (C-23), 111.9 
(C-23), 111.7 (C-12), 111.7 (C-12), 88.5 (C-10), 88.4 (C-10), 79.6 (C-11 × 2), 70.2 (C-17 × 2), 69.1 (C-19), 
68.6 (C-19), 57.3 (C-20), 56.0 (C-20), 51.0 (CO2CH3 × 2), 48.7 (C-4 × 2), 44.2 (C-6 × 2), 41.9 (C-16), 41.5 
(C-16), 40.9 (C-14), 40.6 (C-14), 40.6 (C-18), 39.9 (C-18), 34.9 (C-8 × 2), 29.5 (C-15 × 2), 29.2 (C-5 × 2), 
25.9 (SiC(CH3)3), 25.9 (SiC(CH3)3), 21.5 (O2CCH3), 21.3 (O2CCH3), 19.5 (C-24), 19.5 (C-24), 19.5 (C-22), 
19.4 (C-22), 18.8 (C-21 × 2), 18.3 (C-9 × 2), 18.1 (SiC(CH3)3), 18.1 (SiC(CH3)3), −4.1 (SiCH3), −4.5 (SiCH3), 
−4.6 (SiCH3), −4.9 (SiCH3). HRMS (ESI) calc. for C33H59N4O5Si [M+NH4]+ 619.4249. Found 619.4250. IR 
(νmax/cm-1) (neat): 2926 (alkane C–H), 2101 (azide N=N=N), 1736 (ester C=O), 1644 (ester C=O). 
Ethyl (R)-4-azido-3-((tert-butyldimethylsilyl)oxy)butanoate 102 and 1,3-bis[ethyl (R)-3-((tert-
butyldimethylsilyl)oxy)butanoate]-4-yl urea 103 
 
Triphenylphosphine (137 mg, 0.522 mmol) was added to a solution of azide 16 (100 mg, 0.348 mmol) 
in THF (2.5 mL) and water (0.25 mL). The solution was stirred for 16 hours at room temperature before 
diluting with Et2O (5 mL) and water (5 mL). The phases were separated and the aqueous phase was 
extracted with Et2O (2 × 5 mL). The combined organic layers were dried over MgSO4, filtered, and 
concentrated in vacuo. The crude material was purified by column chromatography (20-50% EtOAc in 




Ethyl (R)-4-azido-3-((tert-butyldimethylsilyl)oxy)butanoate 102 
δH (400 MHz, CDCl3) 4.16-4.03 (3H, m, 3-H, OCH2CH3), 2.77 (1H, dd, 13.0, 4.5, 4-HH), 2.68 (1H, dd, J 
13.0, 5.0, 4-HH), 2.48 (2H, d, J 6.5, 2-H2), 1.44 (2H, br. s, NH2), 1.25 (3H, t, J 7.0, OCH2CH3), 0.87 (9H, s, 
SiC(CH3)3), 0.08 (3H, s, SiCH3), 0.05 (3H, s, SiCH3). δC (101 MHz, CDCl3) 171.7 (C-1), 70.9 (C-3), 60.6 
(OCH2CH3), 47.9 (C-4), 40.4 (C-2), 25.9 (SiC(CH3)3), 18.1 (SiC(CH3)3), 14.3 (OCH2CH3), −4.5 (SiCH3), −4.7 
(SiCH3). HRMS (ESI) calc. for C12H28NO3Si [M+H]+ 262.1833. Found 262.1841. []D
22  = +9.0 (c 1.00, 
CHCl3). IR (νmax/cm-1) (neat): 2929 (alkane C–H), 1736 (ester C=O). 
1,3-Bis[ethyl (R)-3-((tert-butyldimethylsilyl)oxy)butanoate]-4-yl urea 103 
δH (400 MHz, CDCl3) 4.74 (2H, t, J 5.0, NH), 4.22 (2H, m, 3-H), 4.11 (4H, q, J 7.0, OCH2CH3), 3.33 (2H, 
ddd, 13.5, 6.5, 5.0, 4-HH), 3.21 (2H, dt, J 13.0, 5.0, 4-HH), 2.48 (2H, dd, J 15.0, 5.5, 2-HH), 2.43 (2H, dd, 
J 15.0, 6.5, 2-HH), 1.25 (6H, t, J 7.0, OCH2CH3), 0.86 (18H, s, SiC(CH3)3), 0.08 (6H, s, SiCH3), 0.05 (6H, s, 
SiCH3). δC (101 MHz, CDCl3) 171.5 (C-1), 158.2 (CO(NH)2), 68.7 (C-3), 60.7 (OCH2CH3), 46.1 (C-4), 40.4 
(C-2), 25.9 (SiC(CH3)3), 18.1 (SiC(CH3)3), 14.3 (OCH2CH3), −4.5 (SiCH3), −4.8 (SiCH3). HRMS (ESI) calc. for 
C25H52N2O7Si2Na [M+Na]+ 571.3211. Found 571.3201. []D
21  = +18.0 (c 1.00, CHCl3). IR (νmax/cm-1) 
(neat): 3335 (urea N–H), 2929 (alkane C–H), 1741 (ester C=O) 1621 (urea N–H). 
1,3-Bis[methyl (2E,5R,12E,15S,19R)-17-acetoxy-19-((tert-butyldimethylsilyl)oxy)-3,5,15-trimethyl-
7-methyleneicosa-2,12-dien-10-ynoate]-20-yl urea 104 
 
Triphenylphosphine (16 mg, 61.0 µmol) was added to a solution of azide 100 (25 mg, 41.5 µmol) in 
THF (3.4 mL) and water (0.6 mL). The solution was stirred for 16 hours at room temperature before 
diluting with Et2O (5 mL) and water (5 mL). The layers were separated and the aqueous phase was 
extracted with Et2O (2 × 5 mL). The combined organic layers were dried over MgSO4, filtered, and 
concentrated in vacuo. The crude material was purified by column chromatography (20% EtOAc in 
petrol) to give urea 104 (19 mg, 78%) as a colourless oil and a mixture of diastereomers. 
For simplicity 1H NMR integrals presented as a single isomer. 
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δH (500 MHz, CDCl3) 5.97 (2H, m, 13-H × 2), 5.65 (2H, s, 2-H × 2), 5.42 (2H, m, 12-H × 2), 5.03 (1H, m, 
17-H), 4.97 (1H, m, 17-H), 4.83 (2H, s, 23-CHH × 2), 4.77 (2H, s, 23-CHH × 2), 4.61 (1H, m, NH), 3.81 
(2H, m, 19-H × 2), 3.68 (6H, s, CO2CH3 × 2), 3.40-3.12 (4H, m, 20-H2 × 2), 2.45-2.37 (4H, m, 9-H2 × 2), 
2.25-2.16 (6H, m, 4-HH × 2, 8-H2 × 2), 2.13 (6H, s, 21-H3 × 2), 2.12 (1H, m, 14-HH), 2.07-1.99 (9H, m, 
6-HH × 2, 14-HH, O2CCH3 × 2), 1.98-1.79 (8H, m, 4-HH × 2, 5-H × 2, 6-HH × 2, 14-HH × 2), 1.98-1.60 (5H, 
m, 16-HH, 18-H2 × 2), 1.59-1.39 (4H, m, 15-H × 2, 16-H2), 1.35 (1H, m, 16-HH), 0.92-0.86 (24H, m, 
SiC(CH3)3 × 2, 24-H3 × 2), 0.82 (6H, d, J 5.5, 22-H3 × 2), 0.09-0.05 (12H, s, SiCH3 × 4). δC (126 MHz, CDCl3) 
170.8 (O2CCH3), 170.8 (O2CCH3), 167.2 (C-1), 167.2 (C-1), 159.4 (C-3), 159.4 (C-3), 158.2 (CO(NH)2), 
146.3 (C-7), 146.3 (C-7), 141.4 (C-13), 141.3 (C-13), 116.7 (C-2), 116.7 (C-2), 111.9 (C-23 × 2), 111.6 
(C-12), 111.6 (C-12), 88.4 (C-10), 88.3 (C-10), 79.6 (C-11), 79.6 (C-11), 70.3 (C-17), 69.6 (C-17), 68.6 
(C-19), 68.4 (C-19), 50.9 (CO2CH3 ), 50.9 (CO2CH3 ), 48.6 (C-4 × 2), 46.6 (C-20), 45.2 (C-20), 44.2 (C-6 × 
2), 42.0 (C-16), 41.6 (C-16), 41.1 (C-14), 40.4 (C-14), 40.3 (C-18), 40.0 (C-18), 34.9 (C-8 × 2), 29.8 (C-15), 
29.8 (C-15), 29.1 (C-5 × 2), 26.0 (SiC(CH3)3), 26.0 (SiC(CH3)3), 21.5 (O2CCH3), 21.4 (O2CCH3), 19.4 (C-22 × 
2 and C-24 × 2), 18.8 (C-21), 18.8 (C-21), 18.3 (C-9 × 2), 18.1 (SiC(CH3)3), 18.1 (SiC(CH3)3), −4.2 (SiCH3), 
−4.4 (SiCH3), −4.6 (SiCH3), −4.8 (SiCH3). HRMS (ESI) calc. for C67H113N2O11Si2 [M+H]+ 1177.7883. Found 
1177.7880. IR (νmax/cm-1) (neat): 2928 (alkane C–H), 1733 (ester C=O), 1644 (ester C=O). 
Ethyl (R)-4-((tert-butoxycarbonyl)amino)-3-((tert-butyldimethylsilyl)oxy)butanoate 105 and 
Bis(ethyl (R)-3-((tert-butyldimethylsilyl)oxy)butanoate]-4-yl-carbodiimide 106 
 
Triphenylphosphine (137 mg, 0.522 mmol) and Boc2O (152 mg, 0.696 mmol) were added to a solution 
of azide 16 (100 mg, 0.348 mmol) in THF (2.5 mL) and water (0.25 mL). The solution was stirred for 16 
hours at room temperature before diluting with Et2O (5 mL) and water (5 mL). The layers were 
separated and the aqueous phase was extracted with Et2O (2 × 5 mL). The combined organic layers 
were dried over MgSO4, filtered, and concentrated in vacuo. The crude material was purified by 
column chromatography (5-10% EtOAc in petrol) to give carbamate 105 (27 mg, 21%) and 
carbodiimide 106 (52 mg, 56%) as colourless oils. 
Ethyl (R)-4-((tert-butoxycarbonyl)amino)-3-((tert-butyldimethylsilyl)oxy)butanoate 105 
δH (400 MHz, CDCl3) 4.75 (1H, br. s, NH), 4.22 (1H, m, 3-H), 4.12 (2H, q, J 7.0, OCH2CH3), 3.32-3.14 (2H, 
m, 4-H2), 2.48-2.42 (2H, m, 2-H2), 1.44 (9H, s, 7-H9) 1.26 (3H, t, J 7.0, OCH2CH3), 0.87 (9H, s, SiC(CH3)3), 
0.09 (3H, s, SiCH3), 0.05 (3H, s, SiCH3). δC (126 MHz, CDCl3) 171.3 (C-1), 156.1 (C-5), 79.5 (C-6), 68.6 
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(C-3), 60.7 (OCH2CH3), 46.2 (C-4), 40.5 (C-2), 28.5 (C-7), 25.9 (SiC(CH3)3), 18.1 (SiC(CH3)3), 14.3 
(OCH2CH3), −4.6 (SiCH3), −4.8 (SiCH3). HRMS (ESI) calc. for C17H35NO5SiNa [M+Na]+ 384.2177. Found 
384.2167. []D
21 = +13.0 (c 1.00, CHCl3). IR (νmax/cm-1) (neat): 2929 (alkane C–H), 1735 (ester C=O) 1721 
(carbamate C=O). 
Bis(ethyl (R)-3-((tert-butyldimethylsilyl)oxy)butanoate]-4-yl-carbodiimide 106 
δH (400 MHz, CDCl3) 4.21-4.05 (6H, m, 3-H, OCH2CH3), 3.35-3.25 (4H, m, 4-H2), 2.57 (2H, J 15.0, 5.0, 
2-HH), 2.45 (2H, J 15.0, 7.5, 2-HH), 1.26 (6H, t, J 7.0, OCH2CH3), 0.87 (18H, s, SiC(CH3)3), 0.09 (6H, s, 
SiCH3), 0.05 (6H, s, SiCH3). δC (101 MHz, CDCl3) 171.5 (C-1), 139.2 (C-5), 69.3 (C-3), 60.6 (OCH2CH3), 52.1 
(C-4), 40.5 (C-2), 25.9 (SiC(CH3)3), 18.1 (SiC(CH3)3), 14.3 (OCH2CH3), −4.4 (SiCH3), −4.9 (SiCH3). HRMS 
(ESI) calc. for C25H51N2O6Si2 [M+H]+ 531.3280. Found 531.3276. []D
21  = +13.0 (c 1.00, CHCl3). IR 
(νmax/cm-1) (neat): 2929 (alkane C–H), 2136 (carbodiimide, N=C=N), 1735 (ester C=O). 
Ethyl (R)-4-amino-3-((tert-butyldimethylsilyl)oxy)butanoate 102 
 
Under a nitrogen atmosphere, triphenylphosphine (137 mg, 0.522 mmol) was added to a solution of 
azide 16 (100 mg, 0.348 mmol) in a degassed mixture of THF (2.5 mL) and water (0.25 mL). The solution 
was stirred for 16 hours at room temperature before diluting with Et2O (5 mL) and water (5 mL). The 
layers were separated and the aqueous phase was extracted with Et2O (2 × 5 mL). The combined 
organic layers were dried over MgSO4, filtered, and concentrated in vacuo. The crude material was 
purified by column chromatography (0-20% MeOH in EtOAc) to give amine 102 (55 mg, 60%) as a 
colourless oil. 






Under a nitrogen atmosphere, triphenylphosphine (87 mg, 0.332 mmol) was added to a solution of 
azide 100 (133 mg, 0.221 mmol) in a degassed mixture of THF (5 mL) and water (0.5 mL). The solution 
was stirred for 16 hours at room temperature before diluting with Et2O (10 mL) and water (10 mL). 
The layers were separated and the aqueous phase was extracted with Et2O (2 × 10 mL). The combined 
organic layers were dried over MgSO4, filtered, and concentrated in vacuo. The crude material was 
purified by column chromatography (0-20% MeOH in EtOAc) to give amine 101 (47% w/w, 145 mg, 
54%) and triphenylphosphine oxide as an inseparable mixture. 
δH (500 MHz, CDCl3) 5.98 (2H, m, 13-H × 2), 5.65 (2H, s, 2-H × 2), 5.44 (2H, m, 12-H × 2), 5.04 (1H, m, 
17-H), 4.97 (1H, m, 17-H), 4.83 (2H, s, 23-CHH × 2), 4.78 (2H, s, 23-CHH × 2), 3.72-3.61 (8H, m, 19-H 
× 2, CO2CH3 × 2), 2.80 (1H, dd, J 13.0, 4.0, 20-HH), 2.76 (1H, dd, J 13.0, 5.0, 20-HH), 2.63 (1H, dd, J 13.0, 
4.0, 20-HH), 2.63 (1H, dd, J 13.0, 5.0, 20-HH), 2.49-2.39 (4H, m, 9-H2 × 2), 2.26-2.17 (6H, m, 4-HH × 2, 
8-H2 × 2), 2.14 (6H, s, 21-H3 × 2), 2.12-1.91 (12H, m, 6-HH × 2, 14-H2 × 2, O2CCH3 × 2), 1.90-1.82 (11H, 
m, 4-HH × 2, 5-H × 2, 6-HH × 2), 1.77-1.59 (5H, m, 16-HH, 18-H2 × 2), 1.54 (2H, m, 15-H × 2), 1.52-1.39 
(2H, m, 16-H2), 1.26 (1H, m, 16-HH), 0.94-0.87 (24H, m, SiC(CH3)3 × 2, 24-H3 × 2), 0.82 (6H, d, J 6.0, 
22-H3 × 2), 0.07 (3H, s, SiCH3), 0.07 (3H, s, SiCH3), 0.06 (3H, s, SiCH3), 0.05 (3H, s, SiCH3). δC (126 MHz, 
CDCl3) 170.8 (O2CCH3), 170.7 (O2CCH3), 167.2 (C-1 × 2), 159.4 (C-3 × 2), 146.3 (C-7 × 2), 141.4 (C-13), 
141.4 (C-13), 116.7 (C-2 × 2), 111.9 (C-23 × 2) 111.6 (C-12), 111.5 (C-12), 88.3 (C-10 × 2), 79.6 (C-11 × 
2), 71.0 (C-19), 70.6 (C-17), 70.4 (C-19), 69.5 (C-17), 50.9 (CO2CH3 × 2), 48.7 (C-4 × 2), 48.3 (C-20), 47.2 
(C-20), 44.2 (C-6 × 2), 41.9 (C-16), 41.6 (C-16), 41.0 (C-14), 40.5 (C-14 and C-18), 39.5 (C-18 × 2), 34.9 
(C-8 × 2), 29.9 (C-15 × 2), 29.2 (C-5 × 2), 26.0 (SiC(CH3)3), 26.0 (SiC(CH3)3), 21.5 (O2CCH3), 21.3 (O2CCH3), 
19.6 (C-24), 19.5 (C-22 and C-24), 19.4 (C-22), 18.8 (C-21 × 2), 18.3 (C-9 × 2), 18.2 (SiC(CH3)3), 18.2 
(SiC(CH3)3), −4.1 (SiCH3), −4.3 (SiCH3), −4.4 (SiCH3), −4.7 (SiCH3). HRMS (ESI) calc. for C33H58NO5Si [M+H]+ 
576.4079. Found 576.4098. IR (νmax/cm-1) (neat): 3523 (amine N–H), 2928 (alkane C–H), 1730 (ester 
C=O), 1644 (ester C=O). 
Ethyl (R)-3-hydroxybutanoate 112 
 
H2SO4 (18 M, 2.00 mL, 36.0 mmol) was added to a solution of poly-(R)-3-hydroxybutanoate 111 (5.00 
g, 58.1 mmol) in DCE (30 mL) and EtOH (35 mL). The reaction was heated at 80 °C for five days, cooled 
to room temperature, and partitioned between DCM (200 mL) and water (200 mL). The layers were 
separated and the aqueous phase was extracted with DCM (2 × 150 mL). The combined organic layers 
were washed with a saturated aqueous solution of NaHCO3 (250 mL), dried over MgSO4, filtered, and 
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concentrated in vacuo to give alcohol 112 (7.26 g, 95%) as an orange oil without further need for 
purification. 
δH (400 MHz, CDCl3) 4.18 (1H, m, 3-H), 4.16 (2H, q, J 7.0, OCH2CH3), 3.02 (1H, d, J 3.5, OH), 2.48 (1H, 
dd, J 16.5, 3.5, 2-HH), 2.40 (1H, dd, J 16.5, 8.5, 2-HH), 1.27 (3H, t, J 7.0, OCH2CH3), 1.22 (3H, d, J 6.5, 
4-H3). δC (101 MHz, CDCl3) 173.1 (C-1), 64.4 (C-3), 60.8 (OCH2CH3), 42.9 (C-2), 22.5 (C-4), 14.3 
(OCH2CH3). []D
23 = −30.0 (c 1.00, CHCl3). [Lit. −36.9 (c 1.00, CHCl3)].276 
Spectroscopic data in accord with the literature data.276 
Ethyl (2R,3R)-3-hydroxy-2-methylbutanoate 112 
 
Diisopropylamine (3.50 mL, 24.97 mmol) was dissolved in THF (15 mL) and cooled to −78 °C. nBuLi (1 M 
in hexane, 15.99 mL, 23.8 mmol) was added and the solution stirred for one hour. A solution of ester 
112 (1.50 g, 11.4 mmol) in THF (3 mL) was added dropwise before the cooling bath was removed. After 
20 minutes the cooling bath was replaced and the reaction was allowed to cool for 30 minutes. Methyl 
iodide (0.70 mL, 11.24 mmol) was added dropwise and the solution was warmed to 0 °C for four hours. 
The reaction was quenched with a saturated aqueous solution of NH4Cl (5 mL) and HCl (6 M, 5 mL). 
The solution was extracted with Et2O (3 × 50 mL) and the combined organic layers were dried over 
MgSO4, filtered, and concentrated in vacuo. The crude material was purified by column 
chromatography (25-40% Et2O in petrol) to give ester 113 (1.63 g, 98%) as a colourless oil. 
1H NMR analysis revealed a diastereomeric ratio of 14:1. 
δH (400 MHz, CDCl3) 4.17 (2H, q, J 7.0, OCH2CH3), 3.87 (1H, m, 3-H), 2.71 (1H, d, J 6.5, OH), 2.43 (1H, 
m, 2-H), 1.27 (3H, t, J 7.0, OCH2CH3), 1.21 (3H, d, J 6.5, 4-H3), 1.18 (3H, d, J 7.0, 3’-H3). δC (101 MHz, 
CDCl3) 176.1 (C-1), 69.6 (C-3), 60.7 (OCH2CH3), 47.0 (C-2), 20.9 (C-4), 14.3 (OCH2CH3), 14.3 (C-3’). []D
23 
= −23.0 (c 1.00, CHCl3). [Lit. −30.0 (c 1.0, CHCl3)].277 
Spectroscopic data in accord with the literature data.277 




TMSCl (0.61 mL, 4.81 mmol) and triethylamine (1.00 mL, 7.17 mmol) were added sequentially to a 
solution of ester 113 (350 mg, 2.39 mmol) in DCM (30 mL). The reaction was stirred for 16 hours at 
room temperature before quenching with a saturated aqueous solution of NH4Cl (20 mL). The layers 
were separated and the aqueous phase was extracted with DCM (2 × 30 mL). The combined organic 
layers were dried over MgSO4, filtered, and concentrated in vacuo. The crude material was purified by 
column chromatography (5-10% EtOAc in petrol) to give silyl ether 114 (522 mg, quant.) as a colourless 
oil. 
δH (400 MHz, CDCl3) 4.12 (2H, m, OCH2CH3), 3.98 (1H, dq, J 8.0, 6.0, 3-H), 2.46 (1H, m, 2-H), 1.26 (3H, 
t, J 7.0, OCH2CH3), 1.13 (3H, d, J 6.0, 4-H3), 1.07 (3H, d, J 7.0, 3’-H3), 0.09 (9H, s, Si(CH3)3). δC (101 MHz, 
CDCl3) 175.4 (C-1), 70.5 (C-3), 60.3 (OCH2CH3), 48.5 (C-2), 20.8 (C-4), 14.4 (OCH2CH3), 13.1 (C-3’), 0.29 
(Si(CH3)3). HRMS (ESI) calc. for C10H23O3Si [M+H]+ 219.1411. Found 219.1409. []D
22 = −37.0 (c 1.00, 
CHCl3). IR (νmax/cm-1) (neat): 2976 (alkane C–H), 1735 (ester C=O). 
Ethyl (2R,3R)-2-methyl-3-((triethylsilyl)oxy)butanoate 115 
 
Pyridine (0.28 mL, 3.46 mmol) and TESCl (0.29 mL, 1.73 mmol) were added sequentially to a solution 
of ester 113 (100 mg, 0.684 mmol) in DCM (2.5 mL). The reaction was stirred for one hour at room 
temperature before quenching with a saturated aqueous solution of NaHCO3 (2.5 mL). The layers were 
separated and the aqueous phase was extracted with DCM (2 × 5 mL). The combined organic layers 
were dried over MgSO4, filtered, and concentrated in vacuo. The crude material was purified by 
column chromatography (0-10% EtOAc in petrol). The resulting oil was redissolved in toluene (2 × 15 
mL) and concentrated in vacuo to azeotrope TESOH. This gave silyl ether 115 (154 mg, 86%) as a 
colourless oil. 
δH (400 MHz, CDCl3) 4.12 (2H, q, J 7.0, OCH2CH3), 4.05 (1H, m, 3-H), 2.49 (1H, m, 2-H), 1.25 (3H, t, J 7.0, 
OCH2CH3), 1.13 (3H, d, J 6.0, 4-H3), 1.08 (3H, d, J 7.0, 3’-H3), 0.94 (9H, t, J 8.0, SiCH2CH3), 0.58 (6H, q, J 
8.0, SiCH2CH3). δC (126 MHz, CDCl3) 175.3 (C-1), 70.1 (C-3), 60.3 (OCH2CH3), 48.3 (C-2), 20.6 (C-4), 14.3 
(OCH2CH3), 12.6 (C-3’), 6.9 (SiCH2CH3), 5.1 (SiCH2CH3). HRMS (ESI) calc. for C13H29O3Si [M+H]+ 261.1880. 
Found 261.1880. []D
22 = −36.0 (c 1.00, CHCl3) [Lit. −35.2 (c 1.1, CHCl3)].278 IR (νmax/cm-1) (neat): 2877 
(alkane C–H), 1736 (ester C=O). 




(2R,3R)-3-Hydroxy-2-methylbutanoic acid 118 
 
Ba(OH)2 (1.17 g, 6.83 mmol) was added to a solution of ester 113 (500 mg, 3.42 mmol) in MeOH 
(30 mL) and water (3 mL). The reaction was stirred for three hours at room temperature then acidified 
to ~pH 2 with HCl (1 M) and extracted with Et2O (5 × 50 mL). The combined organic layers were dried 
over MgSO4, filtered, and concentrated in vacuo to give carboxylic acid 118 (315 mg, 78%) as a 
colourless oil without further need for purification. 
1H NMR analysis revealed a diastereomeric ratio of 11:1. 
δH (400 MHz, CDCl3) 6.67 (1H, br. s, COOH), 3.92 (1H, m, 3-H), 2.48 (1H, m, 2-H), 1.25 (3H, d, J 6.5, 
4-H3), 1.20 (3H, d, J 7.0, 3’-H3). δC (101 MHz, CDCl3) 180.8 (C-1), 69.6 (C-3), 47.0 (C-2), 20.8 (C-4), 14.1 
(C-3’). HRMS (APCI) calc. for C5H9O2 [M+H−H2O]+ 101.0597. Found 101.0600. []D
24 = −29.0 (c 1.00, 
CHCl3). IR (νmax/cm-1) (neat): 3384 (alcohol O–H), 2580 (carboxylic acid O–H), 1707 (carboxylic acid 
C=O). 
Spectroscopic data in accord with the literature data. 
(2R,3R)-2-Methyl-3-((triethylsilyl)oxy)butanoic acid 117 
 
TESCl (0.10 mL, 0.596 mmol) and pyridine (0.10 mL, 1.24 mmol) were added sequentially to a solution 
of carboxylic acid 118 (30 mg, 0.254 mmol) in DCM (1 mL). The reaction was stirred for 16 hours at 
room temperature then quenched with a saturated aqueous solution of NH4Cl (20 mL). The layers 
were separated and the aqueous phase was extracted with DCM (2 × 30 mL). The combined organic 
layers were dried over MgSO4, filtered, and concentrated in vacuo. The crude material was purified by 
column chromatography (0-20% EtOAc in petrol) to give silyl ether 117 (28 mg, 47%) as a colourless 
oil. 
1H NMR analysis revealed a diastereomeric ratio of 16:1. 
δH (400 MHz, CDCl3) 4.02 (1H, pent, J 6.0, 3-H), 2.52 (1H, qd, J 7.0, 6.0, 2-H), 1.23 (3H, d, J 6.0, 4-H3), 
1.20 (3H, d, J 7.0, 3’-H3), 0.97 (9H, t, J 8.0, SiCH2CH3), 0.64 (6H, q, J 8.0, SiCH2CH3). δC (126 MHz, CDCl3) 
178.3 (C-1), 70.5 (C-3), 47.7 (C-2), 21.5 (C-4), 14.0 (C-3’), 6.9 (SiCH2CH3), 5.0 (SiCH2CH3). HRMS (ESI) 
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calc. for C11H23O3Si [M−H]− 231.1416. Found 231.1410. []D
24  = −11.0 (c 1.00, CHCl3). IR (νmax/cm-1) 
(neat): 2877 (alkane C–H), 1709 (carboxylic acid C=O). 
(2R,3R)-2-Methyl-3-(((2,2,2-trichloroacetyl)carbamoyl)oxy)butanoic acid 119 
 
In an NMR tube carboxylic acid 118 (10 mg, 84.7 µmol) was dissolved in CDCl3 (0.5 mL). Trichloroacetyl 
isocyanate (96%, 11 µL, 88.6 µmol) was added, the tube was sealed, shaken, and left for 20 minutes 
at room temperature. Complete conversion to N-protected carbamate 119 was observed in situ via 1H 
and 13C NMR. 
δH (500 MHz, CDCl3) 5.24 (1H, m, 3-H), 2.82 (1H, m, 2-H), 1.38 (3H, d, J 6.5, 4-H3), 1.25 (3H, d, J 7.0, 
3’-H3). δC (126 MHz, CDCl3) 178.7 (C-1), 157.9 (C-5), 149.4 (C-6), 91.9 (C-7), 75.2 (C-3), 44.2 (C-2), 16.9 




DIPEA (43 µL, 0.247 mmol) and COMU® (23 mg, 53.7 µmol) were added sequentially to a solution of 
carboxylic acid 118 (5.8 mg, 49.1 µmol) in DMF (0.75 mL). After 30 minutes at room temperature the 
mixture was added dropwise to a solution of amine 101 (47% w/w, 20.0 mg, 16.3 µmol) in DMF (0.75 
mL). The reaction was stirred for one hour then quenched with a saturated aqueous solution of 
NaHCO3 (5 mL) and diluted with EtOAc (5 mL). The layers were separated and the aqueous phase was 
extracted with EtOAc (2 × 5 mL). The combined organic layers were dried over MgSO4, filtered, and 
concentrated in vacuo. The crude material was purified by column chromatography (10-60% EtOAc in 
petrol) to give amide 121 (9.7 mg, 88%) as a colourless oil. 
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δH (500 MHz, CDCl3) 6.19 (1H, m, NH), 6.02 (1H, m, NH), 5.97 (2H, m, 13-H × 2), 5.65 (2H, s, 2-H × 2), 
5.44 (2H, m, 12-H × 2), 5.04 (1H, m, 17-H), 4.95 (1H, pent, J 6.5, 17-H), 4.83 (2H, s, 23-CHH × 2), 4.78 
(2H, s, 23-CHH × 2), 3.89-3.79 (4H, m, 19-H × 2, 27-H × 2), 3.69 (6H, s, CO2CH3 × 2), 3.63 (2H, m, 20-HH 
× 2), 3.25-3.11 (2H, m, 20-HH × 2), 2.50-2.38 (4H, m, 9-H2 × 2), 2.25-2.16 (8H, m, 4-HH × 2, 8-H2 × 2, 
26-H × 2), 2.14 (6H, s, 21-H3 × 2), 2.11-1.91 (12H, m, 6-HH × 2, 14-H2 × 2, O2CCH3 × 2), 1.90-1.82 (6H, 
m, 4-HH × 2, 5-H × 2, 6-HH × 2), 1.76-1.60 (5H, m, 16-HH, 18-H2 × 2), 1.55-1.39 (4H, m, 15-H × 2, 16-H2), 
1.31 (1H, m, 16-HH), 1.24 (6H, d, J 6.5, 28-H3 × 2), 1.22 (6H, d, J 7.5, 29-H3 × 2), 0.92-0.87 (24H, m, 
SiC(CH3)3 × 2, 24-H3 × 2), 0.83 (6H, d, J 6.0, 22-H3 × 2), 0.10-0.06 (12H, s, SiCH3 × 4). δC (126 MHz, CDCl3) 
176.2 (C-25), 176.1 (C-25), 170.9 (O2CCH3 × 2), 167.2 (C-1 × 2), 159.5 (C-3 × 2), 146.3 (C-7 × 2), 141.4 
(C-13), 141.3 (C-13), 116.7 (C-2 × 2), 111.9 (C-23 × 2) 111.7 (C-12), 111.6 (C-12), 88.4 (C-10 × 2), 79.6 
(C-11 × 2), 70.3 (C-17), 70.0 (C-27 × 2), 69.6 (C-17), 68.0 (C-19), 67.8 (C-19), 51.0 (CO2CH3 × 2), 48.7 (C-4 
× 2), 48.1 (C-26 × 2), 45.0 (C-20 × 2), 44.2 (C-6 × 2), 41.9 (C-16), 41.4 (C-16), 41.1 (C-14), 40.4 (C-14), 
39.7 (C-18 × 2), 34.9 (C-8 × 2), 29.9 (C-15 × 2), 29.2 (C-5 × 2), 26.0 (SiC(CH3)3), 25.9 (SiC(CH3)3), 21.7 
(C-28), 21.6 (C-28), 21.5 (O2CCH3), 21.4 (O2CCH3), 19.6 (C-24 × 2), 19.5 (C-22 × 2), 18.8 (C-21 × 2), 18.3 
(C-9 × 2), 18.2 (SiC(CH3)3), 18.1 (SiC(CH3)3), 15.5 (C-29 × 2), −4.3 (SiCH3), −4.5 (SiCH3), −4.5 (SiCH3), −4.8 
(SiCH3). HRMS (ESI) calc. for C38H65NO7SiNa [M+Na]+ 698.4423. Found 698.4439. IR (νmax/cm-1) (neat): 




Trichloroacetyl isocyanate (96%, 6.7 µL, 54.0 µmol) was added to a vial containing a solution of amine 
121 (25.5 mg, 37.7 µmol) in DCM (2 mL). The reaction was stirred for 30 minutes at room temperature 
before the solvent was removed under a stream of nitrogen. The crude material was resuspended in 
MeOH (2 mL) and K2CO3 (50 mg, 0.265 mmol) was added. After 16 hours at room temperature the 
solvent was removed under a stream of nitrogen and the crude material was partitioned between 
DCM (2.5 mL) and water (2.5 mL). The layers were separated and the aqueous phase was extracted 
with DCM (2 × 2.5 mL). The combined organic layers were dried over MgSO4, filtered, and 
Experimental 
159 
concentrated in vacuo. The crude material was purified by column chromatography (50-80% EtOAc in 
petrol) to give carbamoyl 123 (25.5 mg, quant.) as a colourless oil. 
δH (500 MHz, CDCl3) 6.07 (1H, m, NH × 2), 5.99 (2H, m, 13-H × 2), 5.65 (2H, s, 2-H × 2), 5.44 (2H, m, 
12-H × 2), 4.87 (2H, m, 27-H × 2), 4.83 (2H, s, 23-CHH × 2), 4.78 (2H, s, 23-CHH × 2), 4.06 (2H, m, 19-H 
× 2), 3.88 (2H, m, 17-H × 2), 3.68 (6H, s, CO2CH3 × 2), 3.58 (2H, m, 20-HH × 2), 3.18 (2H, m, 20-HH × 2), 
2.50-2.38 (6H, m, 9-H2 × 2, 26-H × 2), 2.25-2.15 (7H, m, 4-HH × 2, 8-H2 × 2, 14-HH), 2.14 (6H, s, 21-H3 × 
2), 2.04-1.80 (11H, m, 4-HH × 2, 5-H × 2, 6-H2 × 2, 14-HH, 14-H2), 1.71 (2H, m, 15-H × 2), 1.63-1.45 (5H, 
m, 16-HH, 18-H2 × 2), 1.33 (2H, m, 16-H2), 1.29 (6H, d, J 6.5, 28-H3 × 2), 1.16 (3H, d, J 7.0, 29-H3), 1.16 
(3H, d, J 7.0, 29-H3), 1.06 (1H, m, 16-HH), 0.92-0.88 (24H, m, SiC(CH3)3 × 2, 24-H3 × 2), 0.82 (6H, d, J 6.0, 
22-H3 × 2), 0.13 (3H, s, SiCH3), 0.13 (3H, s, SiCH3), 0.12 (3H, s, SiCH3), 0.11 (3H, s, SiCH3). δC (126 MHz, 
CDCl3) 174.0 (C-25), 173.9 (C-25), 167.2 (C-1 × 2), 159.5 (C-3), 159.5 (C-3), 156.2 (C-30), 156.1 (C-30), 
146.3 (C-7), 146.3 (C-7), 141.8 (C-13), 141.6 (C-13), 116.7 (C-2 × 2), 111.9 (C-23 × 2) 111.5 (C-12), 111.4 
(C-12), 88.5 (C-10), 88.4 (C-10), 79.6 (C-11 × 2), 73.2 (C-27), 73.2 (C-27), 70.4 (C-19), 69.8 (C-19), 67.1 
(C-17), 66.9 (C-17), 51.0 (CO2CH3 × 2), 48.7 (C-4 × 2), 47.0 (C-26), 46.9 (C-26), 45.3 (C-16 × 2), 45.1 (C-20 
× 2), 44.2 (C-6 × 2), 41.9 (C-18), 41.8 (C-18), 41.2 (C-14), 40.0 (C-14), 34.9 (C-8), 34.8 (C-8), 29.6 (C-15 
× 2), 29.2 (C-5 × 2), 26.0 (SiC(CH3)3), 25.9 (SiC(CH3)3), 20.2 (C-24 × 2), 19.5 (C-22 × 2), 18.8 (C-21 × 2), 
18.3 (C-9), 18.3 (C-9), 18.1 (SiC(CH3)3 × 2), 17.9 (C-28), 17.8 (C-28), 14.0 (C-29), 13.8 (C-29), −4.3 (SiCH3), 
−4.4 (SiCH3), −4.6 (SiCH3), −4.7 (SiCH3). HRMS (ESI) calc. for C37H65N2O7Si [M+H]+ 677.4561. Found 





Dess-Martin periodinane (24.0 mg, 56.6 µmol) was added to a solution of alcohol 123 (25.5 mg, 
37.7 µmol) in DCM (2 mL). After one hour at room temperature the solvent was removed under a 
stream of nitrogen and the crude material was partitioned between DCM (2.5 mL), water (2.5 mL), 
and a saturated aqueous solution of Na2S2O3 (0.5 mL). The layers were separated and the aqueous 
phase was extracted with DCM (2 × 2.5 mL). The combined organic layers were dried over MgSO4, 
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filtered, and concentrated in vacuo. The crude material was purified by column chromatography 
(40-80% EtOAc in petrol) to give ketone 124 (23.7 mg, 93%) as a colourless oil. 
δH (400 MHz, CDCl3) 6.04 (1H, m, NH), 5.95 (1H, dt, J 15.0, 7.5, 13-H), 5.65 (1H, s, 2-H), 5.43 (1H, d, J 
15.0, 12-H), 4.89 (1H, pent, J 6.5, 27-H), 4.83 (1H, s, 23-HH), 4.78 (1H, s, 23-HH), 4.26 (1H, m, 19-H), 
3.68 (3H, s, OCH3), 3.56 (1H, ddd, J 13.5, 7.5, 3.5, 20-HH), 3.02 (1H, ddd, J 13.5, 6.5, 4.5, 20-HH), 
2.56-2.49 (2H, m, 18-H2), 2.46 (1H, pent, J 7.0, 26-H), 2.43-2.37 (3H, m, 9-H2, 16-HH), 2.27 (1H, dd, J 
17.0, 8.0, 16-HH), 2.24-2.16 (3H, m, 4-HH, 8-H2), 2.14 (3H, s, 21-H3), 2.11-1.94 (4H, m, 6-HH, 14-H2, 
15-H), 1.92-1.81 (3H, m, 4-HH, 5-H, 6-HH), 1.28 (3H, d, J 6.5, 28-H3), 1.16 (3H, d, J 7.0, 29-H3), 0.89 (3H, 
d, J 6.0, 24-H3), 0.88 (9H, s, SiC(CH3)3), 0.82 (3H, d, J 6.0, 22-H3), 0.11 (3H, s, SiCH3), 0.06 (3H, s, SiCH3). 
δC (126 MHz, CDCl3) 209.7 (C-17), 173.7 (C-25), 167.2 (C-1), 159.4 (C-3), 156.1 (C-30), 146.2 (C-7), 141.0 
(C-13), 116.2 (C-2), 112.0 (C-23), 111.9 (C-12), 88.7 (C-10), 79.5 (C-11), 73.2 (C-27), 67.7 (C-19), 51.0 
(C-16), 51.0 (OCH3), 48.7 (C-4), 48.3 (C-18), 46.9 (C-26), 44.6 (C-20), 44.2 (C-6), 40.2 (C-14), 34.8 (C-8), 
29.2 (C-5), 28.7 (C-15), 25.9 (SiC(CH3)3), 19.9 (C-24), 19.5 (C-22), 18.8 (C-21), 18.3 (C-9), 18.1 (SiC(CH3)3), 
17.9 (C-28), 13.9 (C-29), −4.6 (SiCH3), −4.7 (SiCH3). HRMS (ESI) calc. for C37H62N2O7SiNa [M+Na]+ 
697.4218. Found 697.4227. []D
23  = +42.0 (c 1.00, CHCl3). IR (νmax/cm-1) (neat): 3299 (N–H), 2923 




Enyne 124 (23.7 mg, 35.0 µmol) was suspended in a degassed mixture of water (1.5 mL) and MeOH 
(1.5 mL) in a sealed tube. Freshly prepared Zn(Cu/Ag) (350 mg, 5.35 mmol) (see general experimental) 
was added and the suspension was heated to 65 °C for 20 hours. The slurry was passed through a plug 
Celite® and the filtrate was diluted with EtOAc (10 mL) and water (10 mL). The layers were separated 
and the aqueous phase was extracted with EtOAc (2 × 10 mL). The combined organic layers were dried 
over MgSO4, filtered, and concentrated in vacuo to give diene 9 (21.0 mg, 88%) as a colourless oil 
without further need for purification. 
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Characterisation as given previously. 
Methyl (2E,5R,10Z,12E,15S,19R)-20-((26R,27R)-27-(carbamoyloxy)-26-methylbutanamido)-19-
hydroxy-3,5,15-trimethyl-7-methylene-17-oxoicosa-2,10,12-trienoate 8 (Synthetic preparation) 
 
TBAF (1 M, 93.1 µL, 93.1 µmol) was added dropwise to a solution of silyl ether 9 (21.0 mg, 31.0 µmol) 
in THF (0.5 mL). After 16 hours at room temperature the reaction was quenched with water (1 mL) 
and extracted with Et2O (3 × 1 mL). The combined organic layers were dried over MgSO4, filtered, and 
concentrated in vacuo. The crude material was purified by column chromatography (0-5% MeOH in 
DCM) to give alcohol 8 (6.0 mg, 46%) as a yellow oil. 
Characterisation as given previously. 
Kalimantacin A 1 (Synthetic preparation) 
 
Porcine liver esterase (EC 3.1.1.1, Sigma E3019, 25 mg) in potassium phosphate buffer (0.1 M, pH 8.0, 
2.5 mL) was added to a solution kalimantacin A methyl ester 8 (6.0 mg, 10.7 µmol) in MeOH (0.5 mL). 
The reaction was left exposed to air and was heated at 36 °C for 16 hours. The solution was 
concentrated in vacuo and partitioned between a saturated aqueous solution of NH4Cl (1 M, 20 mL) 
and EtOAc (3 × 20 mL). The layers were separated and the aqueous phase was further extracted with 
EtOAc (2 × 20 mL). The combined organic layers were dried over MgSO4, filtered, and concentrated in 
vacuo. The crude material was purified by HPLC (47% MeCN in water with 0.05% formic acid, 30 
minutes) to give kalimantacin A 1 (1.9 mg, 32%) as a pale yellow oil. 
Characterisation as given previously.  
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3.3. Experimental for Pleuromutilin Research 
3.3.1. Purification via Preparative HPLC 
Preparative HPLC was performed using a Waters mass-directed autopurification system with a Waters 
2767 autosampler and Waters 2545 pump system, a Phenomenex LUNA column (5 μM, C18, 100 Å, 10 
× 250 mm) for reverse-phase chromatography, equipped with a Phenomenex Security Guard 
precolumn (Luna C5 300 Å) eluted at 16 mL/min. UV absorbance was detected between 200 and 400 
nm with a Waters 2998 diode array detector, mass spectrometry was performed with a Waters 
Quattro Micro, and the approximate amount of compound eluted was evaluated with a Waters 2424 
evaporative light scattering detector (ELSD). For the reverse-phase chromatography a gradient of 
MeCN in water was used, with both solvents containing 0.05% formic acid. All gradients were run over 
a 20 minute period. Specific gradients are given next to the relevant compounds. Products were 
collected in glass tubes, pooled in pre-weighed glass vials, and dried under a flow of dry nitrogen gas. 
3.3.2. Synthesis of Compounds 
Isolation of tiamulin hydrogen fumarate 126 
 
A solution of tiamulin hydrogen fumarate (20 mL, 12.5% w/v Denagard®) was concentred in vacuo. 
Removal of the water was accelerated by using toluene (3 × 25 mL) to form an azeotrope, giving 
tiamulin hydrogen fumarate 126 (3.50 g) as a white solid. 
δH (400 MHz, CDCl3) 6.75 (2H, s, 2’-H2), 6.45 (1H, dd, J 17.5, 11.0, 19-H), 5.70 (1H, d, J 8.5, 14-H), 5.29 
(1H, dd, J 11.0, 1.5, 20-HH), 5.19 (1H, dd, J 17.5, 1.5, 20-HH), 3.37 (1H, d, J 6.5, 11-H), 3.19 (2H, d, J 2.5, 
22-H2), 3.18-3.13 (2H, m, 24-H2), 3.06 (4H, q, J 7.5, 25-H4), 2.96-2.89 (2H, m, 23-H2), 2.36-2.02 (5H, m, 
10-H, 2-H2, 4-H, 13-HH), 1.76 (1H, dd, J 14.5, 3.0, 8-HH), 1.71-1.59 (2H, m, 1-H2), 1.53 (1H, m, 6-H), 1.43 
(3H, s, 15-H3), 1.42-1.28 (3H, m, 7-H2, 13-HH), 1.25 (6H, t, J 7.5, 26-H6), 1.16 (3H, s, 18-H3), 1.11 (1H, 
m, 8-HH), 0.87 (3H, d, J 7.0, 17-H3), 0.71 (3H, d, J 7.0, 16-H3). δC (101 MHz, CDCl3) 217.1 (C-3), 170.5 
(C-21), 168.9 (C-1’),139.4 (C-19), 135.4 (C-2’), 117.2 (C-20), 74.7 (C-11), 69.8 (C-14), 58.3 (C-4), 50.7 
(C-24), 46.2 (C-25), 45.6 (C-9), 44.9 (C-13), 44.1 (C-12), 41.9 (C-5), 36.9 (C-6), 36.1 (C-10), 34.6 (C-22), 




Spectroscopic data in accord with the literature data.179 
Synthesis of mutilin 129 
 
Potassium hydroxide (7.50 g, 134 mmol) was added to a solution of tiamulin hydrogen fumarate 126 
(3.45 g, 5.65 mmol) in MeOH (100 mL). The reaction was heated to reflux (65 °C) for 18 hours, before 
cooling to room temperature and pouring into water (50 mL). The resulting solution was extracted 
with DCM (3 × 50 mL) and the combined organic layers were washed with a saturated aqueous 
solution of NaHCO3 (50 mL), dried over MgSO4, filtered, and concentrated in vacuo. The crude material 
was purified by column chromatography (20% EtOAc in petrol) to give mutilin 129 (1.22 g, 68%) as a 
white solid. 
δH (400 MHz, CDCl3) 6.15 (1H, ddd, J 18.0, 11.0, 0.5, 19-H), 5.36 (1H, dd, J 18.0, 1.5, 20-HH), 5.29 (1H, 
dd, J 11.0, 1.5, 20-HH), 4.35 (1H, dd, J 8.0, 6.0, 14-H), 3.41 (1H, dd, J 7.5, 5.5, 11-H), 2.29-2.10 (3H, m, 
2-H2, 10-H), 2.05 (1H, d, J 3.0, 4-H), 1.91 (1H, dd, J 16.0, 8.0, 13-HH), 1.74 (1H, dq, J 14.5, 3.0, 8-HH), 
1.67 (1H, m, 6-H), 1.63-1.42 (5H, m, 1-H2, 7-HH, 13-HH, OH), 1.39 (1H, m, 7-HH), 1.36 (3H, s, 15-H3), 
1.26 (1H, d, J 5.5, OH), 1.12 (1H, m, 8-HH), 1.15 (3H, s, 18-H3), 0.96 (3H, d, J 7.0, 16-H3), 0.92 (3H, d, J 
7.0, 17-H3). δC (101 MHz, CDCl3) 217.7 (C-3), 139.5 (C-19), 116.0 (C-20), 75.3 (C-11), 66.9 (C-14), 59.2 
(C-4), 45.5 (C-9), 45.4 (C-12), 45.2 (C-13), 42.5 (C-5), 37.0 (C-6), 36.6 (C-10), 34.6 (C-2), 30.5 (C-8), 28.7 
(C-18), 27.3 (C-7), 25.2 (C-1), 18.3 (C-16), 13.6 (C-15), 11.4 (C-17). HRMS (ESI) calc. for C20H32O3Na 
[M+Na]+ 343.2244. Found 343.2245. M.p. 190-191 °C (from EtOH) [Lit. 
192 °C].153 []D
21 = +31.0 (c 1.00, CHCl3) [Lit. +69 (c 0.07, CHCl3)].242 IR 
(νmax/cm-1) (neat): 3471 (alcohol O–H), 2929 (alkane C–H), 1727 
(ketone C=O). 
Spectroscopic data in accord with the literature data.279 
X-ray crystal structure obtained following recrystallisation from DCM. 





Synthesis of 19,20-dihydromutilin 133 
 
10% palladium on carbon (50% water, 1.00 g, 0.940 mmol) was added to a degassed solution of mutilin 
129 (1.00 g, 3.12 mmol) in EtOH (38 mL). The solution was subjected to a positive pressure of hydrogen 
gas and stirred for 16 hours. The reaction mixture was filtered through Celite® and the plug was rinsed 
with DCM (50 mL). The filtrate was concentrated in vacuo to give diol 133 (978 mg, 97%) as a white 
solid. 
δH (400 MHz, CDCl3) 4.24 (1H, d, J 7.5, 14-H), 3.39 (1H, d, J 7.0, 11-H), 2.31 (1H, pent, J 7.0, 10-H), 
2.26-2.10 (2H, m, 2-H2), 2.06 (1H, d, J 3.0, 4-H), 1.75 (1H, dq, J 14.5, 3.0, 8-HH), 1.71-1.36 (10H, m, 1-H2, 
6-H, 7-H2, 13-H2, 19-H2, OH), 1.33 (3H, s, 15-H3), 1.12 (1H, td, J 14.0, 4.5, 8-HH), 1.00 (3H, s, 18-H3), 
0.99-0.94 (6H, m, 16-H3, 20-H3), 0.92 (3H, d, J 7.0, 17-H3). δC (101 MHz, CDCl3) 217.8 (C-3), 76.9 (C-11), 
66.7 (C-14), 59.3 (C-4), 45.6 (C-9), 43.5 (C-13), 42.6 (C-5), 40.9 (C-12), 36.9 (C-6), 34.6 (C-2), 34.5 (C-10), 
30.5 (C-8), 27.3 (C-7), 26.8 (C-18), 25.1 (C-1), 21.3 (C-19), 18.3 (C-16), 13.4 (C-15), 11.2 (C-17), 8.3 
(C-20). HRMS (ESI) calc. for C20H34O3Na [M+Na]+ 345.2400. Found 345.2412. M.p. 222-225 °C (from 
MeOH). [Lit. 223-224 °C].194 []D
21 = +29.0 (c 1.00, CHCl3). IR (νmax/cm-1) (neat): 3513 (alcohol O–H), 
2955 (alkane C–H), 1726 (ketone C=O). 
Synthesis of TES-mutilin 134 
 
Mutilin 129 (2.00 g, 6.25 mmol), imidazole (1.27 g, 18.7 mmol) and DMAP (76 mg, 0.622 mmol) were 
dissolved in DMF (50 mL). TESCl (5.24 mL, 31.2 mmol) was added and the solution was heated to 60 °C 
for 16 hours. The reaction mixture was diluted with DCM (100 mL) and extracted with water 
(2 × 100 mL) and a saturated aqueous solution of NaCl (100 mL). The organic layer was dried over 
MgSO4, filtered, and concentrated in vacuo. The crude material was purified by column 
chromatography (0-5% EtOAc in petrol) followed by a recrystallisation from MeOH to give ketone 134 
(2.81 g, 79%) as a white solid. 
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δH (400 MHz, CDCl3) 6.15 (1H, dd, J 17.5, 11.0, 19-H), 5.26 (1H, dd, J 17.5, 1.5, 20-HH), 5.21 (1H, dd, J 
11.0, 1.5, 20-HH), 4.47 (1H, d, J 8.0, 14-H), 3.54 (1H, d, J 6.0, 11-H), 2.30 (1H, app. pent, J 7.0, 10-H), 
2.24-2.19 (2H, m, 2-H2), 2.02 (1H, d, J 3.0, 4-H), 1.86 (1H, dd, J 16.0, 8.0, 13-HH), 1.74 (1H, dq, J 14.5, 
3.0, 8-HH), 1.58 (1H, m, 6-H), 1.56-1.42 (3H, m, 1-H2, 7-HH), 1.39 (1H, d, J 16.0, 13-HH), 1.34 (3H, s, 
15-H3), 1.31 (1H, m, 7-HH), 1.11 (1H, m, 8-HH), 1.09 (3H, s, 18-H3), 0.97 (9H, t, J 8.0, SiCH2CH3), 0.95 
(9H, t, J 8.0, SiCH2CH3), 0.87 (3H, d, J 7.0, 16-H3), 0.85 (3H, d, J 7.0, 17-H3), 0.63 (12H, app. pent, J 8.0, 
SiCH2CH3). δC (101 MHz, CDCl3) 218.2 (C-3), 141.1 (C-19), 116.1 (C-20), 77.5 (C-11), 67.5 (C-14), 59.5 
(C-4), 47.4 (C-13), 45.7 (C-9), 45.2 (C-12), 43.8 (C-5), 37.6 (C-6), 36.5 (C-10), 34.9 (C-2), 31.1 (C-8), 29.0 
(C-18), 27.4 (C-7), 25.6 (C-1), 18.5 (C-16), 14.5 (C-15), 12.1 (C-17), 7.4 and 7.3 (SiCH2CH3), 6.2 and 5.9 
(SiCH2CH3). HRMS (ESI) calc. for C32H60O3Si2Na [M+Na]+ 571.3973. Found 571.3971. M.p. 106-108 °C 
(from MeOH). []D
23 = +30.0 (c 0.98, CHCl3) [Lit. +27.9 (c 1.25, CHCl3)].198 IR (νmax/cm-1) (neat): 2953 
(alkane C–H), 1733 (ketone C=O). 
1H NMR data in accord with the literature data.198 
TBAF deprotection of TES-mutilin 134 
 
TES-mutilin 134 (100 mg, 0.182 mmol) was dissolved in a solution of TBAF in THF (1 M, 1.08 mL, 1.08 
mmol) and stirred for 12 days at room temperature. The solution was diluted with water (5 mL) and 
extracted with Et2O (3 × 5 mL). The combined organic layers were dried over MgSO4, filtered, and 
concentrated in vacuo. The crude material was purified by column chromatography (20% EtOAc in 
petrol) to give mutilin 129 as a white solid (41 mg, 70%). 
Characterisation as given previously. 
Acid deprotection of TES-mutilin 134 
 
TES-mutilin 134 (100 mg, 0.182 mmol) was dissolved in a solution of HCl in MeOH (1.4 M, 5 mL) and 
stirred for two days at room temperature. The reaction was quenched with a saturated aqueous 
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solution of NaHCO3 (5 mL) and diluted with DCM (5 mL). The layers were separated and the aqueous 
phase was extracted with DCM (2 × 5 mL). The combined organic layers were dried over MgSO4, 
filtered, and concentrated in vacuo. The crude material was purified by column chromatography (20% 
EtOAc in petrol) to give mutilin 129 as a white solid (49 mg, 84%). 
Characterisation as given previously. 
Synthesis of TMS-mutilin 139 
 
Mutilin 129 (500 mg, 1.56 mmol) and TMSCl (0.99 mL, 7.80 mmol) were dissolved in DCM (10 mL). 
Triethylamine (1.08 mL, 7.80 mmol) was added dropwise and the solution stirred for 16 hours at room 
temperature. A saturated aqueous solution of NaHCO3 (10 mL) was added to the reaction mixture and 
the layers were separated. The aqueous phase was extracted with DCM (3 × 10 mL) and the combined 
organic layers were dried over MgSO4, filtered, and concentrated in vacuo. The crude material was 
purified by column chromatography (5% EtOAc in petrol) to give TMS-mutilin 139 (668 mg, 92%) as a 
colourless oil. 
δH (400 MHz, CDCl3) 6.16 (1H, dd, J 17.5, 11.0, 19-H), 5.26 (1H, dd, J 17.5, 1.5, 20-HH), 5.22 (1H, dd, J 
11.0, 1.5, 20-HH), 4.44 (1H, d, J 8.0, 14-H), 3.48 (1H, d, J 6.0, 11-H), 2.33 (1H, app. pent, J 7.0, 10-H), 
2.25-2.12 (2H, m, 2-H2), 2.04 (1H, d, J 3.0, 4-H), 1.88 (1H, dd, J 16.0, 8.0, 13-HH), 1.75 (1H, dq, J 14.5, 
3.0, 8-HH), 1.57 (1H, m, 6-H), 1.55-1.39 (2H, m, 1-H2, 7-HH), 1.42 (1H, d, J 16.0, 13-HH), 1.35 (1H, m, 
7-HH), 1.34 (3H, s, 15-H3), 1.12 (1H, td, J 14.0, 4.5, 8-HH), 1.07 (3H, s, 18-H3), 0.85 (3H, d, J 7.0, 16-H3), 
0.85 (3H, d, J 7.0, 17-H3), 0.13 (9H, s, (SiCH3)3), 0.11 (9H, s, (SiCH3)3). δC (101 MHz, CDCl3) 218.2 (C-3), 
141.1 (C-19), 116.3 (C-20), 77.6 (C-11), 67.5 (C-14), 59.4 (C-4), 47.5 (C-13), 45.8 (C-9), 44.9 (C-12), 43.5 
(C-5), 37.6 (C-6), 36.5 (C-10), 34.9 (C-2), 31.0 (C-8), 29.2 (C-18), 27.3 (C-7), 25.6 (C-1), 18.5 (C-16), 14.6 
(C-15), 12.2 (C-17), 1.5 and 1.1 (SiCH3). HRMS (ESI) calc. for C26H48O2Si2Na [M+Na]+ 487.3034. Found 
487.3045. []D
21 = +44.0 (c 0.75, CHCl3). IR (νmax/cm-1) (neat): 2956 (alkane C–H), 1736 (ketone C=O). 





Acid deprotection of TMS-mutilin 139 
 
TMS-mutilin 139 (100 mg, 0.215 mmol) was dissolved in a solution of HCl in MeOH (1.4 M, 5 mL) and 
stirred for one hour at room temperature. The reaction was quenched with a saturated aqueous 
solution of NaHCO3 (5 mL) and diluted with DCM (5 mL). The layers were separated and the aqueous 
phase was extracted with DCM (2 × 5 mL). The combined organic layers were dried over MgSO4, 
filtered, and concentrated in vacuo. The crude material was purified by column chromatography (20% 
EtOAc in petrol) to give mutilin 129 as a white solid (50 mg, 73%). 
Characterisation as given previously. 
TBAF deprotection of TMS-mutilin 139 
 
TMS-mutilin 139 (100 mg, 0.215 mmol) was dissolved in a solution of TBAF in THF (1 M, 1.08 mL, 1.08 
mmol) and stirred for 16 hours at room temperature. The solution was diluted with water (5 mL) and 
extracted with Et2O (3 × 5 mL). The combined organic layers were dried over MgSO4, filtered, and 
concentrated in vacuo. The crude material was purified by column chromatography (40% EtOAc in 
petrol) to give mutilin 129 as a white solid (60 mg, 87%). 
Characterisation as given previously. 




TMS-mutilin 139 (400 mg, 0.861 mmol) was dissolved in THF (10 mL) and cooled to 0 °C. A solution of 
methylmagnesium bromide in Et2O (3 M, 1.43 mL, 4.30 mmol) was added dropwise and the solution 
warmed to room temperature and stirred for 16 hours. The reaction was quenched with water (20 mL) 
and extracted with DCM (3 × 20 mL). The combined organic layers were dried over MgSO4, filtered, 
and concentrated in vacuo. 
The resulting material was dissolved in a solution of HCl in MeOH (4 M, 7.5 mL) and stirred for 16 hours 
at room temperature. The reaction mixture was neutralised with aqueous NaOH solution and 
extracted with DCM (3 × 15 mL). The combined organic layers were dried over MgSO4, filtered, and 
concentrated in vacuo. The crude material was purified by column chromatography (20% EtOAc in 
petrol) to give alkene 141 (153 mg, 56%) as a white solid and exo-methylene 142 (34 mg, 13%) as a 
colourless oil. 
Alkene 141 
δH (400 MHz, CDCl3) 6.12 (1H, dd, J 18.0, 11.0, 19-H), 5.29 (1H, dd, J 18.0, 1.5, 20-HH), 5.25 (1H, dd, J 
11.0, 1.5, 20-HH), 4.34 (1H, d, J 8.0, 14-H), 3.06 (1H, d, J 5.5, 11-H), 2.35 (1H, ddd, J 17.0, 11.0, 4.5, 
2-HH), 2.25 (1H, ddd, J 17.0, 10.0, 7.0, 2-HH), 2.10 (1H, qd, J 7.0, 5.5, 10-H), 1.98-1.77 (3H, m, 1-HH, 
8-HH, 13-HH), 1.89 (3H, s, 2’-H3), 1.56-1.32 (5H, m, 6-H, 7-H2, 2 × OH), 1.52 (1H, d, J 15.0, 13-HH), 1.31 
(3H, s, 15-H3), 1.30-1.17 (2H, m, 1-HH, 8-HH), 1.05 (3H, s, 18-H3), 1.01 (3H, d, J 6.5, 16-H3), 0.83 (3H, d, 
J 6.5, 17-H3). δC (101 MHz, CDCl3) 141.8 (C-4), 139.9 (C-19), 133.3 (C-3), 115.8 (C-20), 76.3 (C-11), 68.3 
(C-14), 57.3 (C-9), 48.4 (C-5), 47.2 (C-13), 45.3 (C-12), 43.8 (C-6), 41.0 (C-2), 38.4 (C-8), 37.1 (C-10), 30.2 
(C-1), 28.6 and 28.5 (C-7 and C-18), 19.9 (C-15), 18.2 (C-16), 17.8 (C-2’), 11.3 (C-17). HRMS (ESI) calc. 
for C21H34O2Na [M+Na]+ 341.2451. Found 341.2467. M.p. 118-120 °C (from CHCl3). []D
22 = −55.0 (c 
1.00, CHCl3). IR (νmax/cm-1) (neat): 3466 (alcohol O–H), 2921 (alkane C–H). 
Exo-methylene 142 
δH (400 MHz, CDCl3) 6.22 (1H, dd, J 17.5, 11.0, 19-H), 5.15 (1H, dd, J 11.0, 2.0, 20-HH), 5.04 (1H, dd, J 
17.5, 2.0, 20-HH), 5.03 (1H, s, 17-HH), 4.94 (1H, s, 17-HH), 3.64 (1H, s, 14-H), 2.48-2.31 (2H, m, 2-H2), 
2.23 (1H, dt, J 13.0, 3.0, 8-HH), 1.86 (3H, s, 2’-H3), 1.77-1.66 (2H, m, 1-HH, 14-HH), 1.65-1.40 (5H, m, 
1-HH, 6-H, 7-HH, 8-HH, 13-HH), 1.31 (1H, m, 7-HH), 1.20 (3H, s, 15-H3), 1.17 (1H, m, 13-HH), 1.13 (3H, 
s, 18-H3), 0.93 (1H, m, 14-HH), 0.76 (3H, d, J 6.5, 16-H3). δC (101 MHz, CDCl3) 159.7 (C-10), 140.7 (C-4), 
140.6 (C-19), 133.6 (C-3), 114.3 (C-20), 105.8 (C-17), 76.6 (C-11), 58.5 (C-9), 45.7 (C-12), 44.4 and 44.3 
(C-5 and C-6), 40.7 (C-2), 37.9 (C-1), 37.6 (C-8), 33.1 (C-13), 28.6 (C-7), 27.8 (C-18), 26.4 (C-14), 25.6 
(C-15), 16.8 (C-2’), 15.8 (C-16). HRMS (ESI) calc. for C21H32ONa [M+Na]+ 323.2345. Found 323.2357. 
[]D
23 = −25.0 (c 1.00, CHCl3). IR (νmax/cm-1) (neat): 2921 (alkane C–H). 
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Synthesis of 11-TES-mutilin 148 
 
Mutilin 129 (250 mg, 0.780 mmol), imidazole (159 mg, 2.34 mmol) and DMAP (9.5 mg, 77.8 µmol) 
were dissolved in DMF (5 mL). TESCl (0.39 mL, 2.34 mmol) was added and the solution stirred at room 
temperature for 16 hours. The reaction mixture was diluted with Et2O (20 mL) and extracted with 
water (3 × 100 mL). The organic layer was dried over MgSO4, filtered, and concentrated in vacuo. The 
crude material was purified by column chromatography (15% EtOAc in petrol) to give 11-TES-mutilin 
148 (214 mg, 63%) as a colourless oil. 
δH (400 MHz, CDCl3) 6.26 (1H, dd, J 17.5, 11.0, 19-H), 5.39 (1H, dd, J 11.0, 1.5, 20-HH), 5.32 (1H, 
dd, J 17.5, 1.5, 20-HH), 4.55 (1H, d, J 8.0, 14-H), 3.34 (1H, d, J 6.5, 11-H), 2.28 (1H, app. pent, J 7.5, 
10-H), 2.24-2.11 (2H, m, 2-H2), 2.02 (1H, d, J 2.5, 4-H), 1.98 (1H, dd, J 16.5, 8.5, 13-HH), 1.75 (1H, 
dq, J 14.5, 3.0, 8-HH), 1.68-1.53 (2H, m, 1-HH, 6-H), 1.55-1.31 (3H, m, 1-HH, 7-H2), 1.41 (1H, d, J 16.5, 
13-HH), 1.35 (3H, s, 15-H3), 1.18 (3H, s, 18-H3), 1.12 (1H, m, 8-HH), 0.95 (9H, t, J 8.0, Si(CH2CH3)3), 0.89 
(3H, d, J 7.0, 16-H3), 0.88 (3H, d, J 7.0, 17-H3), 0.61 (6H, q, J 8.0, Si(CH2CH3)3). δC (101 MHz, CDCl3) 218.1 
(C-3), 139.5 (C-19), 118.0 (C-20), 75.1 (C-11), 66.7 (C-14), 59.3 (C-4), 46.9 (C-13), 45.6 (C-9), 44.4 (C-12), 
43.8 (C-5), 37.7 (C-6), 36.0 (C-10), 34.8 (C-2), 31.0 (C-8), 27.4 (C-7), 26.6 (C-18), 25.1 (C-1), 18.5 (C-16), 
14.4 (C-15), 11.7 (C-17), 7.3 (Si(CH2CH3)3), 6.2 (Si(CH2CH3)3). HRMS (ESI) calc. for C26H46O3SiNa 
[M+Na]+ 457.3108. Found 457.3126. []D
23 = +40.0 (c 1.00, CHCl3). IR (νmax/cm-1) (neat): 3537 (alcohol 
O–H), 2933 (alkane C–H), 1731 (ketone C=O). 
Synthesis of 4-epi-mutilin 149 
 
A commercial solution of aqueous tiamulin hydrogen fumarate 126 (150 mL, 12.5% w/v Denagard®) 
was diluted with water (100 mL) and a saturated aqueous solution of NaHCO3 (100 mL). The aqueous 
solution was extracted with EtOAc (3 × 100 mL) and the organic phases dried over MgSO4, filtered and 
concentrated in vacuo to give tiamulin (14.0 g) as a pale yellow oil. 
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The crude material was redissolved in MeOH (50 mL) and trimethyl orthoformate (13.96 mL, 127.6 
mmol) was added. The solution was cooled to 0 °C and H2SO4 (18 M, 3.94 mL, 70.9 mmol) was added 
dropwise. The reaction was heated at 55 °C for six hours then cooled to room temperature. KOH 
(24.0 g, 0.428 mol) was added and the solution heated to reflux (65 °C) for 16 hours. The solution was 
diluted with water (50 mL) and extracted with Et2O (3 × 50 mL). The combined organic layers were 
dried over MgSO4, filtered, and concentrated in vacuo. The crude material was purified by column 
chromatography (10-20% EtOAc in petrol) to give 4-epi-mutilin 149 (7.51 g, 79%) as a white solid. 
δH (400 MHz, CDCl3) 6.00 (1H, dd, J 17.5, 11.0, 19-H), 5.26 (1H, d, J 11.0, 20-HH), 5.23 (1H, d, J 17.5, 
20-HH), 4.63 (1H, d, J 9.0, 14-H), 3.47 (1H, ddd, J 11.5, 8.0, 5.5, 3-H), 3.21 (3H, s, OCH3), 2.91 (1H, q, J 
6.5, 10-H), 2.41 (1H, dd, J 15.5, 9.5, 13-HH), 2.18 (1H, ddd, J 13.5, 10.0, 3.0, 1-HH), 2.05-1.90 (2H, m, 
2-HH, 8-HH), 1.81 (1H, d, J 15.5, 13-HH), 1.71 (1H, d, 11.5, 4-H), 1.60-1.41 (2H, m, 7-H2), 1.34 (1H, m, 
6-H), 1.22 (1H, m, 2-HH), 1.16 (3H, s, 18-H3), 1.14 (1H, m, 1-HH), 1.14 (3H, s, 15-H3), 1.07 (1H, m, 8-HH), 
1.06 (3H, d, J 7.0, 16-H3), 0.96 (3H, d, J 6.5, 17-H3). δC (101 MHz, CDCl3) 216.9 (C-11), 140.7 (C-19), 
117.1 (C-20), 83.4 (C-3), 69.3 (C-14), 64.4 (C-4), 56.9 (OCH3), 54.6 (C-12), 47.8 (C-9), 45.6 (C-6), 44.9 
(C-13), 44.3 (C-5 and C-10), 40.7 (C-8), 30.8 (C-1), 29.6 (C-2), 29.0 (C-7), 25.9 (C-18), 19.0 (C-15), 18.1 
(C-16), 15.3 (C-17). HRMS (ESI) calc. for C21H35O3 [M+H]+ 335.2581. Found 335.2579. M.p. 78-80 °C 
(from petrol). []D
24  = −179.0 (c 1.00, CHCl3). IR (νmax/cm-1) (neat): 
3514(alcohol O–H), 2924 (alkane C–H), 1698 (ketone C=O). 
Spectroscopic data in accord with the literature data.280 
X-ray crystal structure obtained following recrystallisation from 
petrol. 
Space Group: P21 (monoclinic). 
Synthesis of triol 131 
 
Mutilin 129 (100 mg, 0.312 mmol) was dissolved in THF (5 mL) and EtOH (5 mL). NaBH4 (96%, 123 mg, 
3.12 mmol) was added and the reaction stirred for three days at room temperature. The reaction was 
cooled to 0 °C before a saturated aqueous solution of NH4Cl (50 mL) was added slowly. The resulting 
solution was extracted with DCM (3 × 50 mL) and the combined organic layers were dried over MgSO4, 
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filtered, and concentrated in vacuo. The crude material was purified by column chromatography 
(10-20% EtOAc in petrol) to give triol 131 (90 mg, 90%) as a white solid. 
δH (400 MHz, CDCl3) 6.15 (1H, dd, J 18.0, 11.0, 19-H), 5.31 (1H, dd, J 18.0, 1.5, 20-HH), 5.26 (1H, dd, J 
11.0, 1.5, 20-HH), 4.53 (1H, t, J 6.0, 3-H), 4.32 (1H, d, J 8.5, 14-H), 3.23 (1H, d, J 6.0, 11-H), 2.22 (1H, m, 
6-H), 2.04 (1H, app. pent, J 7.0, 10-H), 1.96 (1H, m, 2-HH), 1.96 (1H, dd, J 15.5, 8.5, 13-HH), 1.84 (1H, 
td, J 13.5, 5.5, 8-HH), 1.68 (1H, dq, J 13.5, 3.0, 8-HH), 1.67-1.29 (8H, m, 1-H2, 2-HH, 4-H, 7-H2, 8-HH, 2 
× OH), 1.59 (1H, d, J 15.5, 13-HH), 1.14 (3H, s, 18-H3), 1.12 (3H, s, 15-H3), 0.96 (3H, d, J 7.0, 16-H3), 0.85 
(3H, d, J 7.0, 17-H3). δC (101 MHz, CDCl3) 140.1 (C-19), 115.7 (C-20), 77.6 (C-3), 75.6 (C-11), 68.2 (C-14), 
52.0 (C-4), 46.1 (C-9), 45.8 (C-12), 45.7 (C-13), 42.1 (C-5), 36.8 (C-6), 36.1 (C-10), 34.2 (C-2), 32.5 (C-8), 
32.1 (C-1), 28.6 (C-18), 28.0 (C-7), 18.7 (C-16), 16.6 (C-15), 12.1 (C-17). 
HRMS (ESI) calc. for C20H34O3Na [M+Na]+ 345.2400. Found 345.2395. M.p. 
178-180 °C (from CHCl3). []D
24  = −54.0 (c 0.74, DCM:MeOH [1:1]). IR 
(νmax/cm-1) (neat): 3458 (alcohol O–H), 2934 (alkane C–H). 
X-ray crystal structure obtained following recrystallisation from CHCl3. 
Space Group: P213 (cubic). 
Synthesis of triol 151 
 
Mutilin 134 (200 mg, 0.350 mmol) was dissolved in THF (5 mL) and cooled to 0 °C. A solution of 
methylmagnesium bromide in Et2O (3 M, 0.58 mL, 1.74 mmol) was added dropwise and the solution 
warmed to room temperature and stirred for 16 hours. The reaction was quenched with water (20 mL) 
and extracted with EtOAc (3 × 20 mL). The combined organic layer was then dried over MgSO4, filtered, 
and concentrated in vacuo. 
The resulting material was redissolved in THF (5 mL) and a solution of TBAF in THF (1 M, 10.0 mL, 10.0 
mmol) was added. The solution was stirred for 12 days at room temperature before water (50 mL) 
was added. The solution was extracted with EtOAc (3 × 50 mL) and the combined organic layers were 
dried over MgSO4, filtered, and concentrated in vacuo. The crude material was purified by column 
chromatography (20-33% EtOAc in petrol, then 10-15% EtOAc in petrol) to give triol 151 (76 mg, 62%) 
as a white solid. 
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δH (400 MHz, CDCl3) 6.15 (1H, dd, J 18.0, 11.0, 19-H), 5.32 (1H, dd, J 18.0, 1.5, 20-HH), 5.26 (1H, dd, J 
11.0, 1.5, 20-HH), 4.33 (1H, d, J 8.0, 14-H), 3.26 (1H, br. s, 11-H), 2.29 (1H, m, 6-H), 2.06 (1H, pent, J 
7.0, 10-H), 1.98 (1H, dd, J 15.5, 8.0, 13-HH), 1.98-1.82 (2H, m, 2-H2), 1.75-1.64 (2H, m, 8-HH, OH), 1.59 
(1H, m, 8-HH), 1.58 (1H, d, J 15.5, 13-HH), 1.47 (3H, s, 2’-H3), 1.51-1.38 (3H, m, 4-H, 7-H2), 1.30-1.24 
(4H, m, 1-H2, 2 × OH), 1.18 (3H, s, 15-H3), 1.15 (3H, s, 18-H3), 0.95 (3H, d, J 7.0, 16-H3), 0.83 (3H, d, J 
7.0, 17-H3). δC (101 MHz, CDCl3) 140.0 (C-19), 115.7 (C-20), 83.2 (C-3), 75.2 (C-11), 68.2 (C-14), 54.0 
(C-4), 48.7 (C-9), 46.0 (C-13), 45.4 (C-12), 43.7 (C-2), 43.5 (C-5), 36.0 (C-10), 35.8 (C-6), 35.2 (C-2’), 29.8 
(C-1), 29.2 (C-8), 28.7 (C-18), 27.6 (C-7), 18.7 (C-16), 15.2 (C-15), 12.2 (C-17). HRMS (ESI) calc. for 
C21H36O3Na [M+Na]+ 359.2557. Found 359.2555. M.p. 162-163 °C (from petrol/EtOAc). []D
22 = −10.2 
(c 0.68, CHCl3). IR (νmax/cm-1) (neat): 3367 (alcohol O–H), 2952 (alkane C–H). 
Synthesis of alkene 141 
 
TES-mutilin 134 (500 mg, 0.911 mmol) was dissolved in THF (10 mL) and cooled to 0 °C. A solution of 
methylmagnesium bromide in Et2O (3 M, 1.52 mL, 4.56 mmol) was added dropwise and the solution 
warmed to room temperature and stirred for 16 hours. The reaction was quenched with water (20 mL) 
and extracted with DCM (3 × 20 mL). The combined organic layers were then dried over MgSO4, 
filtered, and concentrated in vacuo. 
The resulting material was dissolved in a solution of HCl in MeOH (4 M, 10 mL) and stirred for two days 
at room temperature. The reaction mixture was diluted with water (15 mL) and extracted with DCM 
(3 × 15 mL). The combined organic layers were washed with a saturated aqueous solution of NaHCO3 
(15 mL), dried over MgSO4, filtered, and concentrated in vacuo. The crude material was purified by 
column chromatography (20% EtOAc in petrol) to give alkene 141 (170 mg, 59%) as a white solid. 
Characterisation as given previously. 




TMS-mutilin 139 (470 mg, 1.01 mmol) was dissolved in THF (5 mL) and EtOH (5 mL). NaBH4 (96%, 398 
mg, 10.1 mmol) was added and the reaction stirred for two days at room temperature. The reaction 
was cooled to 0 °C before a saturated aqueous solution of NH4Cl (50 mL) was added slowly. The 
resulting solution was extracted with DCM (3 × 20 mL) and the combined organic layers were dried 
over MgSO4, filtered, and concentrated in vacuo. The crude material was purified by column 
chromatography (2% EtOAc in petrol) to give alcohol 152 (435 mg, 92%) as a white solid. 
δH (400 MHz, CDCl3) 6.19 (1H, m, 19-H), 5.23-5.17 (2H, m, 20-H2), 4.53 (1H, t, J 5.0, 3-H), 4.39 (1H, d, J 
9.0, 14-H), 3.33 (1H, d, J 5.5, 11-H), 2.15 (1H, qd, J 7.0, 5.5, 10-H), 2.07 (1H, m, 6-H), 1.92 (1H, dd, J 
16.0, 9.0, 13-HH), 1.91-1.62 (4H, m, 2-H2, 8-H2), 1.59-1.32 (7H, m, 1-H2, 4-H, 7-H2, 13-HH, OH), 1.08 
(3H, s, 15-H3), 1.05 (3H, s, 18-H3), 0.86 (3H, d, J 7.0, 16-H3), 0.80 (3H, d, J 7.0, 17-H3), 0.11 (9H, s, 
Si(CH3)3), 0.10 (9H, s, Si(CH3)3). δC (101 MHz, CDCl3) 142.0 (C-19), 115.5 (C-20), 78.1 (C-3), 78.0 (C-11), 
69.1 (C-14), 51.7 (C-4), 48.1 (C-13), 46.0 (C-9), 45.8 (C-12), 42.8 (C-5), 37.7 (C-6), 36.1 (C-10), 34.4 (C-2), 
34.0 (C-8), 32.7 (C-1), 29.2 (C-18), 28.2 (C-7), 18.9 (C-16), 17.9 (C-15), 13.0 (C-17), 1.6 (Si(CH3)3), 1.0 
(Si(CH3)3). HRMS (ESI) calc. for C26H50O3Si2Na [M+Na]+ 489.3191. Found 489.3171. M.p. 127-129 °C 
(from MeOH). []D
20 = −9.0 (c 1.00, CHCl3). IR (νmax/cm-1) (neat): 3627 (alcohol O–H), 2954 (alkane 
C–H). 
Reaction performed by Jennifer Anderson. 
Synthesis of alkene 154 
 
TMS-mutilin 139 (250 mg, 0.538 mmol) was dissolved in THF (2 mL) and EtOH (2 mL). NaBH4 (96%, 212 
mg, 5.38 mmol) was added and the reaction stirred for two days at room temperature. The reaction 
was cooled to 0 °C before a saturated aqueous solution of NH4Cl (10 mL) was added slowly. The 
resulting solution was extracted with DCM (3 × 10 mL) and the combined organic layers were dried 
over MgSO4, filtered, and concentrated in vacuo. 
The crude alcohol was redissolved in DCM (3 mL) and methanesulfonyl chloride (0.12 mL, 1.61 mmol) 
was added. Triethylamine (0.22 mL, 1.61 mmol) was added dropwise and the solution was stirred for 
five days at room temperature. The reaction was quenched with water (5 mL) and the layers were 
separated. The aqueous phase was extracted with DCM (2 × 5 mL) and the combined organic layers 
were dried over MgSO4, filtered, and concentrated in vacuo. 
Experimental 
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The crude material was dissolved in a solution of HCl in MeOH (1.4 M, 7.5 mL) and stirred for 1.5 hours 
at room temperature. The reaction was quenched with a saturated aqueous solution of NaHCO3 
(15 mL) and diluted with DCM (15 mL). The layers were separated and the aqueous phase was 
extracted with DCM (2 × 15 mL). The combined organic layers were dried over MgSO4, filtered, and 
concentrated in vacuo. The crude material was purified by HPLC (70-95% MeCN in water with 0.05% 
formic acid) to give alkene 154 (42 mg, 26%) as a colourless oil. 
δH (400 MHz, CDCl3) 6.11 (1H, dd, J 18.0, 11.0, 19-H), 5.48 (1H, t, J 2.5, 3-H), 5.28 (1H, dd, J 18.0, 1.5, 
20-HH), 5.24 (1H, dd, J 11.0, 1.5, 20-HH), 4.34 (1H, d, J 8.0, 14-H), 3.07 (1H, d, J 5.5, 11-H), 2.27 (2H, m, 
2-H2), 2.11 (1H, qd, J 7.0, 5.5, 10-H), 1.99 (1H, dt, J 13.0, 3.0, 8-HH), 1.93 (1H, ddd, J 14.0, 10.0, 6.0, 
1-HH), 1.83 (1H, dd, J 15.0, 8.0, 13-HH), 1.54 (1H, qd, J 13.0, 3.0, 7-HH), 1.46 (1H, d, J 15.0, 13-HH), 
1.45-1.17 (4H, m, 1-HH, 6-H, 7-HH, 8-HH), 1.12 (3H, s, 15-H3), 1.04 (3H, s, 18-H3), 1.02 (3H, d, J 7.0, 
16-H3), 0.87 (3H, d, J 7.0, 17-H3). δC (101 MHz, CDCl3) 153.8 (C-4), 140.1 (C-19), 124.9 (C-3), 115.6 
(C-20), 76.4 (C-11), 67.2 (C-14), 54.5 (C-9), 46.5 (C-13), 46.2 (C-5), 45.2 (C-12), 44.5 (C-6), 38.2 (C-8), 
36.8 (C-10), 32.6 (C-1), 30.5 (C-2), 28.5 (C-18), 28.3 (C-7), 18.5 (C-16), 18.2 (C-15), 11.6 (C-17). HRMS 
(ESI) calc. for C20H32O2Na [M+Na]+ 327.2295. Found 327.2294. M.p. 96-98 °C (from CHCl3). []D
24 = 
−32.0 (c 1.00, CHCl3). IR (νmax/cm-1) (neat): 3483 (alcohol O–H), 2923 (alkane C–H). 
Synthesis of methyl ether 156 
 
Alcohol 152 (390 mg, 0.835 mmol) was dissolved in THF (5 mL) in a pressure tube. Methyl iodide 
(0.26 mL, 4.18 mmol) was added, followed by sodium hydride (60% dispersion in mineral oil, 167 mg, 
4.18 mmol). The tube was quickly sealed, and the reaction heated to 60 °C for 16 hours. After cooling 
to room temperature, the reaction was quenched with water (20 mL) and extracted with DCM (3 × 
20 mL). The combined organic layers were dried over MgSO4, filtered, and concentrated in vacuo. 
The resulting material was redissolved in a solution of TBAF in THF (1 M, 5.00 mL, 5.00 mmol) and 
stirred at room temperature for 16 hours. The reaction was quenched with water (10 mL) and 
extracted with DCM (3 × 20 mL). The combined organic layers were dried over MgSO4, filtered, and 
concentrated in vacuo. The crude material was purified by column chromatography (15% EtOAc in 
petrol) to give methyl ether 156 (182 mg, 65%) as a white solid. 
Experimental 
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δH (400 MHz, CDCl3) 6.15 (1H, dd, J 18.0, 11.0, 19-H), 5.31 (1H, d, J 18.0, 20-HH), 5.26 (1H, d, J 11.0, 
1.5, 20-HH), 4.30 (1H, d, J 8.5, 14-H), 3.79 (1H, t, J 6.0, 3-H), 3.23 (1H, d, J 6.0, 11-H), 3.19 (3H, s, OCH3), 
2.26 (1H, m, 6-H), 2.03 (1H, app. pent, J 7.0, 10-H), 1.95 (dd, J 15.5, 8.5, 13-HH), 1.83-1.73 (2H, m, 
7-HH, 8-HH), 1.72-1.63 (1H, m, 7-HH), 1.60-1.48 (3H, m, 2-HH, 4-H, 8-HH), 1.59 (1H, d, J 15.5, 13-HH) 
1.44-1.24 (3H, m, 1-H2, 2-HH), 1.14 (3H, s, 18-H3), 1.02 (3H, s, 15-H3), 0.92 (3H, d, J 7.0, 16-H3), 0.84 
(3H, d, J 7.0, 17-H3). δC (101 MHz, CDCl3) 140.2 (C-19), 115.6 (C-20), 86.7 (C-3), 75.5 (C-11), 68.2 (C-14), 
56.3 (OCH3), 52.0 (C-4), 46.1 (C-5), 45.7 (C-13), 45.6 (C-12), 42.1 (C-9), 37.6 (C-6), 35.9 (C-10), 32.1 
(C-2), 31.7 (C-8), 28.6 (C-18), 28.0 (C-7), 28.0 (C-1), 18.6 (C-16), 16.0 (C-15), 12.2 (C-17). HRMS (ESI) 
calc. for C21H36O3Na [M+Na]+ 359.2557. Found 359.2566. M.p. 109-111 °C (from MeOH). []D
21 = −50.0 
(c 1.00, CHCl3). IR (νmax/cm-1) (neat): 3473 (alcohol O–H), 2890 (alkane C–H). 
Reactions performed by Jennifer Anderson. 
Synthesis of methyl ether 158 
 
TMS-mutilin 139 (300 mg, 0.645 mmol) was dissolved in THF (5 mL) and cooled to 0 °C. A solution of 
methylmagnesium bromide in Et2O (3 M, 1.08 mL, 3.22 mmol) was added dropwise and the solution 
warmed to room temperature and stirred for 16 hours. The reaction was quenched with water (20 mL) 
and extracted with DCM (3 × 20 mL). The combined organic layers were then dried over MgSO4, 
filtered, and concentrated in vacuo. 
The resulting material was transferred to a pressure tube and redissolved in THF (3 mL). Methyl iodide 
(0.20 mL, 3.23 mmol) was added, followed by sodium hydride (60% dispersion in mineral oil, 129 mg, 
3.23 mmol). The tube was quickly sealed, and the reaction heated to 60 °C for 16 hours. After cooling 
to room temperature, the reaction was quenched with water (10 mL) and extracted with DCM (3 × 
10 mL). The combined organic layers were dried over MgSO4, filtered, and concentrated in vacuo. 
The resulting material was redissolved in a solution of TBAF in THF (1 M, 3.22 mL, 3.22 mmol) and 
stirred at room temperature for 16 hours. The reaction was quenched with water (10 mL) and 
extracted with DCM (3 × 10 mL). The combined organic layers were dried over MgSO4, filtered, and 
concentrated in vacuo. The crude material was purified by column chromatography (20% EtOAc in 
petrol) to give methyl ether 158 (138 mg, 61%) as a white solid. 
Experimental 
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δH (400 MHz, CDCl3) 6.14 (1H, dd, J 18.0, 11.0, 19-H), 5.32 (1H, dd, J 18.0, 1.5, 20-HH), 5.24 (1H, dd, J 
11.0, 1.5, 20-HH), 4.30 (1H, d, J 8.0, 14-H), 3.26 (1H, d, J 6.0, 11-H), 3.15 (3H, s, OCH3), 2.33 (1H, m, 
6-H), 2.08 (1H, m, 2-HH), 2.04 (1H, app. pent, J 7.0, 10-H), 1.96 (1H, dd, J 15.5, 8.0, 13-HH), 1.70 (1H, 
td, J 13.0, 5.5, 8-HH), 1.57 (1H, d, J 15.5, 13-HH), 1.55-1.42 (3H, m, 2-HH, 4-H, 8-HH), 1.40-1.31 (2H, m, 
7-H2), 1.37 (3H, s, 2’-H3), 1.32-1.22 (2H, m, 1-H2), 1.14 (3H, s, 18-H3), 1.12 (3H, s, 15-H3), 0.91 (3H, d, J 
7.0, 16-H3), 0.81 (3H, d, J 7.0, 17-H3). δC (101 MHz, CDCl3) 140.1 (C-19), 115.6 (C-20), 87.4 (C-3), 75.2 
(C-11), 68.4 (C-14), 55.9 (C-4), 49.3 (OCH3), 48.3 (C-9), 45.9 (C-13), 45.3 (C-12), 43.6 (C-5), 36.5 (C-2), 
35.8 (C-10), 35.3 (C-6), 30.1 (C-1), 28.9 (C-8), 28.6 (C-18), 27.9 (C-2’), 27.6 (C-7), 18.7 (C-16), 14.7 (C-15), 
12.2 (C-17). HRMS (ESI) calc. for C22H38O3Na [M+Na]+ 373.2713. Found 373.2730. M.p. 84-86 °C (from 
CHCl3). []D
23 = −23.0 (c 1.00, CHCl3). IR (νmax/cm-1) (neat): 3485 (alcohol O–H), 2955 (alkane C–H). 
Corey-Chaykovsky reaction of mutilin 129 
 
In three parallel reactions mutilin 129 (100 mg (× 3), 0.312 mmol (× 3)) was dissolved in DMF (3 × 5 
mL). trimethylsulfonium iodide (96 mg (× 3), 0.470 mmol (× 3)) was added to each reaction and the 
resulting solutions were stirred for 10 minutes at room temperature. KOtBu (53 mg (× 3), 0.472 mmol 
(× 3)) was then added and the solutions stirred for 16 hours. Further equivalents of trimethylsulfonium 
iodide (96 mg (× 3), 0.470 mmol (× 3)) and KOtBu (53 mg, 0.472 mmol (× 3)) were added and the 
reactions stirred for 24 hours. The reactions were quenched with water (25 mL (× 3)) and combined 
for the work-up. The resulting aqueous phase was extracted with EtOAc (3 × 25 mL). The combined 
organic layers were washed with water (25 mL) and brine (25 mL), dried over MgSO4, filtered, and 
concentrated in vacuo. 
The resulting material was redissolved in DMF (15 mL) before trimethylsulfonium iodide was added 
(288 mg, 1.41 mmol). The reaction was stirred for 10 minutes before KOtBu (159 mg, 1.41 mmol) was 
added in three portions over 1.5 hours. The reaction was stirred for 16 hours before quenching with 
water (75 mL). The resulting aqueous phase was extracted with EtOAc (3 × 75 mL). The combined 
organic layers were washed with water (75 mL) and brine (75 mL), dried over MgSO4, filtered, and 
concentrated in vacuo. The crude material was purified by column chromatography (10-50% EtOAc in 
petrol) to give epoxide 161 (109 mg, 35%) as a white solid, epoxide 162 (34 mg, 10%) as a colourless 




δH (400 MHz, CDCl3) 6.15 (1H, dd, J 18.0, 11.0, 19-H), 5.33 (1H, dd, J 18.0, 1.5, 20-HH), 5.26 (1H, dd, J 
11.0, 1.5, 20-HH), 4.39 (1H, d, J 8.0, 14-H), 3.34 (1H, d, J 6.5, 11-H), 2.98 (1H, d, J 5.0, 2’-HH), 2.56 (1H, 
d, J 5.0, 2’-HH), 2.15 (1H, app. pent, J 7.0, 10-H), 2.06 (1H, m, 6-H), 1.99 (1H, d, J 3.0, 4-H), 1.96-1.87 
(3H, m, 2-H2, 13-HH), 1.67 (1H, dq, J 13.5, 3.0, 8-HH), 1.53 (1H, d, J 16.0, 13-HH), 1.47-1.41 (2H, m, 
7-H2), 1.37-1.29 (2H, m, 1-H2), 1.25 (1H, m, 8-HH), 1.14 (3H, s, 18-H3), 0.92 (3H, d, J 7.0, 16-H3), 0.88 
(3H, d, J 7.0, 17-H3), 0.87 (3H, s, 15-H3).δC (101 MHz, CDCl3) 139.9 (C-19), 115.8 (C-20), 75.0 (C-11), 67.4 
(C-14), 66.5 (C-3), 53.0 (C-2’), 48.3 (C-9), 46.8 (C-4), 45.5 (C-12), 45.2 (C-13), 43.2 (C-5), 36.8 (C-6), 36.5 
(C-10), 32.2 (C-2), 29.8 (C-8), 29.5 (C-1), 28.6 (C-18), 27.4 (C-7), 18.5 (C-16), 13.3 (C-17), 12.4 (C-15). 
HRMS (ESI) calc. for C21H34O3Na [M+Na]+ 357.2400. Found 357.2405. 
M.p. 110-111 °C (from petrol/EtOAc). []D
23 = −4.9 (c 1.01, CHCl3). IR 
(νmax/cm-1) (neat): 3497 (alcohol O–H), 2932 (alkane C–H). 
X-ray crystal structure obtained following recrystallisation from 
petrol/EtOAc. 
Space Group: P212121 (orthorhombic). 
Methyl ether 162 
δH (400 MHz, CDCl3) 6.07 (1H, dd, J 18.0, 11.0, 19-H), 5.31 (1H, dd, J 18.0, 1.5, 20-HH), 5.17 (1H, dd, J 
11.0, 1.5, 20-HH), 4.30 (1H, dd, J 8.0, 4.5, 14-H), 3.36 (3H, s, OCH3), 2.98 (1H, d, J 5.0, 2’-HH), 2.67 (1H, 
d, J 6.5, 11-H), 2.59 (1H, d, J 5.0, 2’-HH), 2.12 (1H, app. pent, J 7.0, 10-H), 2.04 (1H, m, 6-H), 1.99-1.89 
(3H, m, 4-H, 2-H2), 1.84 (1H, dd, J 16.0, 8.0, 13-HH), 1.65 (1H, m, 8-HH), 1.63-1.53 (1H, m, 8-HH), 1.58 
(1H, d, J 16.0, 13-HH), 1.53-1.36 (3H, m, 1-HH, 7-H2), 1.32 (1H, m, 1-HH), 1.19 (1H, d, J 4.5, OH), 1.11 
(3H, s, 18-H3), 0.91 (3H, d, J 7.0, 16-H3), 0.87 (3H, s, 15-H3), 0.86 (3H, d, J 7.0, 17-H3). δC (101 MHz, 
CDCl3) 141.3 (C-19), 114.4 (C-20), 86.0 (C-11), 67.6 (C-14), 66.4 (C-3), 61.2 (OCH3), 53.3 (C-2’), 47.7 
(C-9), 46.9 (C-4), 46.4 (C-12), 44.7 (C-13), 43.2 (C-5), 38.1 (C-10), 36.8 (C-6), 32.3 (C-2), 30.1 (C-1), 29.8 
(C-8), 29.3 (C-18), 27.5 (C-7), 18.5 (C-16), 13.2 (C-17), 12.0 (C-15). HRMS (ESI) calc. for C22H35O2 
[M+H−H2O]+ 331.2632. Found 331.2637. []D
23  = +15.0 (c 1.13, CHCl3). IR (νmax/cm-1) (neat): 3527 
(alcohol O–H), 2923 (alkane C–H). 
Methyl enol ether 163 
δH (400 MHz, CDCl3) 6.11 (1H, dd, J 18.0, 11.0, 19-H), 5.28 (1H, dd, J 18.0, 1.5, 20-HH), 5.24 (1H, dd, J 
11.0, 1.5, 20-HH), 4.21 (1H, d, J 7.5, 14-H), 3.52 (3H, s, OCH3), 3.10 (1H, d, J 5.5, 11-H), 2.50 (1H, ddd, J 
16.0, 11.5, 4.5, 2-HH), 2.37 (1H, ddd, J 16.0, 10.5, 6.5, 2-HH), 2.05 (1H, qd, J 7.0, 5.5, 10-H), 1.98 (1H, 
dd, J 15.0, 8.0, 13-HH), 1.94 (1H, dt, J 13.0, 3.0, 8-HH), 1.82 (1H, ddd, J 14.0, 10.5, 4.5, 1-HH), 1.49 (1H, 
Experimental 
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d, J 15.0, 13-HH), 1.49-1.31 (3H, m, 6-H, 7-H2), 1.29 (3H, s, 15-H3), 1.28-1.18 (3H, m, 1-HH, 8-HH), 1.07 
(3H, s, 18-H3), 0.98 (3H, d, J 6.5, 16-H3), 0.81 (3H, d, J 7.0, 17-H3). δC (101 MHz, CDCl3) 151.7 (C-4), 139.9 
(C-19), 122.5 (C-3), 115.8 (C-20), 76.3 (C-11), 68.2 (C-14), 56.3 (OCH3), 51.5 (C-9), 47.4 (C-13), 46.5 
(C-12), 45.4 (C-5), 43.6 (C-6), 38.5 (C-8), 37.3 (C-10), 28.8 (C-2), 28.5 (C-18), 28.5 (C-7), 27.6 (C-1), 18.0 
(C-16), 17.8 (C-15), 11.0 (C-17). HRMS (ESI) calc. for C21H34O3Na [M+Na]+ 357.2400. Found 357.2397. 
M.p. 120-121 °C (from CHCl3). []D
23 = −44.5 (c 1.03, CHCl3). IR (νmax/cm-1) (neat): 3473 (alcohol O–H), 
2927 (alkane C–H), 1648 (alkene C=C). 
Allylic alcohol 164 
δH (400 MHz, CDCl3) 6.11 (1H, dd, J 18.0, 11.0, 19-H), 5.28 (1H, dd, J 18.0, 1.5, 20-HH), 5.24 (1H, dd, J 
11.0, 1.5, 20-HH), 4.56 (1H, d, J 12.5, 2’-HH), 4.36 (1H, d, J 12.5, 2’-HH), 4.35 (1H, d, J 7.5, 14-H), 3.10 
(1H, d, J 5.5, 11-H), 2.56 (1H, ddd, J 17.0, 11.5, 5.0, 2-HH), 2.45 (1H, ddd, J 17.0, 10.5, 6.5, 2-HH), 2.12 
(1H, qd, J 7.0, 5.5, 10-H), 1.96 (1H, dt, J 13.0, 2.5, 8-HH), 1.91-1.81 (2H, m, 1-HH, 13-HH), 1.52 (1H, d, J 
15.0, 13-HH), 1.48-1.25 (5H, m, 1-HH, 6-H, 7-H2, 8-HH), 1.31 (3H, s, 15-H3), 1.04 (3H, s, 18-H3), 1.01 
(3H, d, J 6.5, 16-H3), 0.84 (3H, d, J 7.0, 17-H3). δC (101 MHz, CDCl3) 145.9 (C-4), 139.8 (C-19), 137.0 (C-3), 
115.8 (C-20), 76.0 (C-11), 67.7 (C-14), 61.2 (C-2’), 57.7 (C-9), 49.0 (C-5), 47.2 (C-13), 45.1 (C-12), 44.1 
(C-6), 38.2 (C-8), 37.0 (C-10), 35.6 (C-2), 29.9 (C-1), 28.4 (C-18), 28.3 (C-7), 19.6 (C-15), 18.2 (C-16), 11.3 
(C-17). HRMS (ESI) calc. for C21H34O3Na [M+Na]+ 357.2400. Found 357.2396. M.p. 136-138 °C (from 
CHCl3). []D
23 = −50.4 (c 0.83, CHCl3). IR (νmax/cm-1) (neat): 3399 (alcohol O–H), 2924 (alkane C–H). 
Rearrangement of epoxide 161 under acidic conditions 
 
Epoxide 161 (10 mg, 29.9 µmol) was dissolved in a mixture of MeCN (1.5 mL) and water (0.5 mL). 
Formic acid (one drop) was added and the solution stirred for 16 hours at room temperature. The 
solvent was removed under a stream of nitrogen to give allylic alcohol 164 (10 mg, quant.) as a white 
solid. 





Synthesis of aldehyde 166 
 
MnO2 (390 mg, 4.48 mmol) was added to a solution of 164 (25 mg, 74.7 µmol) in DCM (10 mL). The 
reaction was stirred for 16 hours at room temperature then filtered through Celite®. The plug was 
rinsed with DCM (20 mL) and the filtrate was concentrated in vacuo to give aldehyde 166 (21 mg, 85%) 
as a white solid. 
δH (400 MHz, CDCl3) 10.48 (1H, s, 2’-H), 6.11 (1H, dd, J 18.0, 11.0, 19-H), 5.31 (1H, dd, J 18.0, 1.5, 
20-HH), 5.27 (1H, dd, J 11.0, 1.5, 20-HH), 4.49 (1H, d, J 7.5, 14-H), 3.06 (1H, d, J 5.5, 11-H), 2.66 (1H, 
ddd, J 17.0, 10.5, 6.5, 2-HH), 2.58 (1H, ddd, J 17.0, 11.0, 5.5, 2-HH), 2.28 (1H, qd, J 7.0, 5.5, 10-H), 2.06 
(1H, dt, J 13.0, 3.0, 8-HH), 1.89 (1H, m, 1-HH), 1.83 (1H, dd, J 15.0, 8.0, 13-HH), 1.65 (1H, d, J 15.0, 
13-HH), 1.61-1.51 (2H, m, 6-H, 7-HH), 1.49 (3H, s, 15-H3), 1.48-1.32 (3H, m, 1-HH, 7-HH, 8-HH), 1.08 
(3H, d, J 6.5, 16-H3), 1.04 (3H, s, 18-H3), 0.89 (3H, d, J 7.0, 17-H3). δC (101 MHz, CDCl3) 193.1 (C-2’), 
168.0 (C-4), 140.7 (C-3), 139.5 (C-19), 116.0 (C-20), 76.1 (C-11), 67.1 (C-14), 59.9 (C-9), 52.0 (C-5), 47.2 
(C-13), 45.4 (C-6), 44.8 (C-12), 37.6 (C-8 and C-10), 31.1 (C-2), 29.5 (C-1), 28.4 (C-18), 27.8 (C-7), 22.9 
(C-15), 18.1 (C-16), 11.2 (C-17). HRMS (ESI) calc. for C21H32O3Na [M+Na]+ 355.2244. Found 355.2240. 
M.p. 97-98 °C (from petrol/EtOAc). []D
23 = −110.0 (c 0.5, CHCl3). IR (νmax/cm-1) (neat): 3466 (alcohol 
O–H), 2923 (alkane C–H), 1637 (alkene C=C). 
Synthesis of TMS-protected (2S)-hydroxymutilin 168 
 
A solution of mutilin 129 (500 mg, 1.56 mmol) and TMSCl (0.71 mL, 5.62 mmol) in THF (5 mL) was 
cooled to −18 °C. LiHMDS (1 M, 5.15 mL, 5.15 mmol) was added dropwise and the solution stirred for 
two hours ensuring the internal temperature remained below −8 °C. The reaction mixture was diluted 
with cyclohexane (5 mL) before quenching with a saturated aqueous solution of NaHCO3 (5 mL). The 
layers were separated and the organic phase washed with a saturated aqueous solution of NaHCO3 (5 
mL). The organic layer was dried over MgSO4, filtered, and concentrated in vacuo. 
Experimental 
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A solution of mCPBA (∼77%, 524 mg, 2.34 mmol) in DCM (9 mL) was cooled to −25 °C. Acetic acid 
(2.05 mL, 35.9 mmol) and pyridine (0.69 mL, 8.58 mmol) were added at a rate that maintained an 
internal temperature of less than −20 °C. The mixture was then added to a solution of silyl enol ether 
167 in DCM (2.5 mL) over 100 minutes whilst maintaining an internal temperature of less than −20 °C. 
After 30 minutes, the solution was raised to −10 °C and stirred for a further 75 minutes before 
quenching with 10% aqueous Na2SO3 solution (2 mL). After 30 minutes at room temperature the 
organic phase was separated and washed with water (2 × 5 mL), then concentrated to a volume of 
∼4 mL. EtOAc (4.5 mL) was added and the mixture was again concentrated to a volume of ∼4 mL. The 
organic solution was then diluted with cyclohexane (4.5 mL), washed with a saturated aqueous 
solution of NaHCO3 (2 × 3.5 mL), dried over MgSO4, filtered, and concentrated in vacuo. The crude 
material was purified by column chromatography (10-20% EtOAc in petrol) to give (2S)-hydroxymutilin 
168 (602 mg, 80%) as a white solid. 
Spectroscopic data in accord with the literature data.220 
δH (400 MHz, CDCl3) 6.15 (1H, dd, J 18.0, 11.0, 19-H), 5.26 (1H, dd, J 18.0, 1.5, 20-HH), 5.23 (1H, dd, J 
11.0, 1.5, 20-HH), 4.43 (1H, d, J 8.0, 14-H), 3.99 (1H, t, J 8.5, 2-H), 3.43 (1H, d, J 6.0, 11-H), 2.54 (1H, br. 
s, OH), 2.27 (1H, app. pent, J 7.0, 10-H), (1H, d, J 3.0, 4-H), 2.07 (1H, dd, J 13.0, 8.5, 1-HH), 1.96-1.87 
(2H, m, 8-HH, 13-HH), 1.51 (1H, m, 7-HH), 1.46 (1H, d, J 16.0, 13-HH), 1.38 (1H, m, 6-H), 1.35 (3H, s, 
15-H3), 1.35-1.25 (2H, m, 1-HH, 7-HH), 1.08 (3H, s, 18-H3), 1.01 (1H, td, J 13.0, 3.0, 8-HH), 0.88 (3H, d, 
J 7.0, 16-H3), 0.87 (3H, d, J 7.0, 17-H3), 0.13 (9H, s, (SiCH3)3), 0.12 (9H, s, (SiCH3)3). δC (101 MHz, CDCl3) 
219.3 (C-3), 141.0 (C-19), 116.4 (C-20), 77.3 (C-11), 72.8 (C-2), 67.6 (C-14), 57.6 (C-4), 47.6 (C-13), 45.2 
(C-12), 44.0 (C-5), 42.3 (C-9), 39.1 (C-6), 36.5 (C-10), 35.3 (C-1), 33.2 (C-8), 29.2 (C-18), 27.1 (C-7), 18.4 
(C-15), 15.0 (C-17), 12.5 (C-16), 1.5 and 1.1 (SiCH3). HRMS (ESI) calc. for C26H48O4Si2Na [M+Na]+ 
503.2983. Found 503.2960. M.p. 70-72 °C (from CHCl3). []D
23 = +19.0 (c 1.00, CHCl3). IR (νmax/cm-1) 
(neat): 2958 (alkane C–H), 1737 (ketone C=O). 
Synthesis of (2S)-hydroxymutilin 169 
 
A solution of mutilin 129 (100 mg, 0.314 mmol) and TMSCl (0.14 mL, 1.13 mmol) in THF (2 mL) was 
cooled to −18 °C. LiHMDS (1 M, 1.04 mL, 1.04 mmol) was added dropwise and the solution stirred for 
two hours ensuring the internal temperature remained below −8 °C. The reaction mixture was diluted 
Experimental 
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with cyclohexane (2 mL) before quenching with a saturated aqueous solution of NaHCO3 (2 mL). The 
layers were separated and the organic phase washed with a saturated aqueous solution of NaHCO3 (2 
mL). The organic layer was dried over MgSO4, filtered, and concentrated in vacuo. 
A solution of mCPBA (~77%, 105 mg, 0.471 mmol) in DCM (1 mL) was cooled to −25 °C. Acetic acid 
(0.41 mL, 7.22 mmol) and pyridine (0.14 mL, 1.73 mmol) were added at a rate that maintained an 
internal temperature of less than −20 °C. The mixture was then added to a solution of silyl enol ether 
167 in DCM (1 mL) over 100 minutes whilst maintaining an internal temperature of less than −20 °C. 
After 30 minutes, the solution was raised to −10 °C and stirred for a further 75 minutes before 
quenching with 10% aqueous Na2SO3 solution (0.3 mL). After 30 minutes at room temperature the 
organic phase was separated and washed with water (2 × 2 mL), then concentrated to a volume of 
∼1 mL. EtOAc (1 mL) was added and the mixture was again concentrated to a volume of ∼1 mL. The 
organic solution was then diluted with cyclohexane (1 mL), washed with a saturated aqueous solution 
of NaHCO3 (2 × 1 mL), dried over MgSO4, filtered, and concentrated in vacuo. 
The crude material was redissolved in a solution of HCl in MeOH (1.4 M, 2 mL) and stirred for 1.5 hours 
at room temperature. The reaction was quenched with a saturated aqueous solution of NaHCO3 (5 mL) 
and diluted with DCM (5 mL). The layers were separated and the aqueous phase was extracted with 
DCM (2 × 5 mL). The combined organic layers were dried over MgSO4, filtered, and concentrated in 
vacuo. The crude material was purified by column chromatography (50% EtOAc in petrol) to give 
(2S)-hydroxymutilin 169 (64 mg, 61%) as a white solid. 
δH (400 MHz, CDCl3) 6.15 (1H, dd, J 1 8.0, 11.0, 19-H), 5.35 (1H, d, J 18.0, 20-HH), 5.28 (1H, d, J 11.0, 
20-HH), 4.32 (1H, d, J 7.5, 14-H), 3.97 (1H, t, J 8.5, 2-H), 3.37 (1H, d, J 6.5, 11-H), 2.78 (1H, br. s, OH), 
2.19 (1H, d, J 3.0, 4-H), 2.13 (1H, app. pent, J 7.0, 10-H), 2.07 (1H, dd, J 13.0, 8.5, 1-HH), 1.98-1.85 (2H, 
m, 8-HH, 13-HH), 1.63 (1H, d, J 16.0, 13-HH), 1.54-1.41 (2H, m, 6-H, 7-HH), 1.38 (3H, s, 15-H3), 1.35 
(1H, m, 7-HH), 1.35 (1H, d, J 13.0, 8.5, 1-HH), 1.14 (3H, s, 18-H3), 0.98 (1H, m, 8-HH), 0.97 (3H, d, J 7.0, 
16-H3), 0.95 (3H, d, J 7.0, 17-H3). δC (101 MHz, CDCl3) 218.9 (C-3), 139.7 (C-19), 115.8 (C-20), 74.8 
(C-11), 72.4 (C-2), 67.0 (C-14), 57.5 (C-4), 45.6 (C-13), 45.5 (C-12), 43.0 (C-5), 42.1 (C-9), 38.3 (C-6), 36.8 
(C-10), 35.0 (C-1), 32.7 (C-8), 28.9 (C-18), 27.1 (C-7), 18.2 (C-16), 14.0 (C-15), 11.8 (C-17). HRMS (ESI) 
calc. for C20H32O4Na [M+Na]+ 359.2193. Found 359.2201. M.p. 180-182 °C (from DCM). []D
23 = +2.6 
(c 1.13, CHCl3). IR (νmax/cm-1) (neat): 3406 (alcohol O–H), 2930 (alkane C–H), 1736 (ketone C=O). 
Spectroscopic data in accord with the literature data.220 
Experimental 
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X-ray crystal structure obtained following recrystallisation from DCM. 





Synthesis of (2S)-methylmutilin 175 
 
A solution of ketone 134 (100 mg, 0.182 mmol) in THF (2.5 mL) was cooled to −18 °C. LiHMDS (1 M, 
0.22 mL, 0.220 mmol) was added dropwise and the solution stirred for 45 minutes ensuring the 
temperature remained below −8 °C. Methyl iodide (13 µL, 0.209 mmol) was added dropwise and the 
solution stirred for a further 1.5 hours. The reaction was quenched with water (10 mL) and extracted 
with DCM (3 × 10 mL). The combined organic layers were dried over MgSO4, filtered, and concentrated 
in vacuo to give (2S)-methylmutilin 175 (100 mg, 98%) as a white solid. 
δH (400 MHz, CDCl3) 6.15 (1H, dd, J 17.5, 11.0, 19-H), 5.26 (1H, dd, J 17.5, 1.5, 20-HH), 5.21 (1H, dd, J 
11.0, 1.5, 20-HH), 4.47 (1H, d, J 8.0, 14-H), 3.51 (1H, d, J 6.0, 11-H), 2.27 (1H, app. pent, J 7.0, 10-H), 
2.20 (1H, m, 2-H), 2.00 (1H, d, J 3.0, 4-H), 1.86 (1H, dd, J 16.0, 8.0, 13-HH), 1.81-1.71 (2H, m, 1-HH, 
8-HH), 1.56-1.42 (2H, m, 6-H, 7-HH), 1.39 (1H, d, J 16.0, 13-HH), 1.34 (3H, s, 15-H3), 1.31 (1H, m, 7-HH), 
1.16-1.07 (2H, m, 1-HH, 8-HH), 1.10 (3H, d, J 7.5, 3’-H3), 1.09 (3H, s, 18-H3), 0.97 (9H, t, J 8.0, SiCH2CH3), 
0.95 (9H, t, J 8.0, SiCH2CH3), 0.87 (3H, d, J 6.5, 16-H3), 0.85 (3H, d, J 7.0, 17-H3), 0.65 (6H, q, J 8.0, 
SiCH2CH3), 0.62 (6H, q, J 8.0, SiCH2CH3). δC (101 MHz, CDCl3) 221.5 (C-3), 141.2 (C-19), 116.1 (C-20), 
77.5 (C-11), 67.6 (C-14), 58.1 (C-4), 47.4 (C-13), 45.2 (C-12), 44.4 (C-9), 43.9 (C-5), 40.1 (C-2), 38.0 (C-6), 
36.5 (C-10), 35.5 (C-1), 31.8 (C-8), 29.0 (C-18), 27.3 (C-7), 18.5 (C-16), 18.1 (C-3’), 14.5 (C-15), 12.2 
(C-17), 7.5 and 7.3 (SiCH2CH3), 6.3 and 5.9 (SiCH2CH3). HRMS (ESI) calc. for C33H62O3Si2Na [M+Na]+ 
585.4130. Found 585.4138. M.p. 58-60 °C (from MeOH). []D
20 = +33.0 (c 1.00, CHCl3). IR (νmax/cm-1) 




Synthesis of 2,2-dimethylmutilin 179 
 
A solution of ketone 134 (200 mg, 0.364 mmol) in THF (5 mL) was cooled to −18 °C. LiHMDS (1 M, 
0.44 mL, 0.440 mmol) was added dropwise and the solution stirred for 45 minutes ensuring the 
temperature remained below −8 °C. Methyl iodide (27 µL, 0.433 mmol) was added dropwise and the 
solution stirred for a further 1.5 hours. The reaction was quenched with water (10 mL) and extracted 
with DCM (3 × 10 mL). The combined organic layers were dried over MgSO4, filtered, and concentrated 
in vacuo. 
The crude material was redissolved in THF (5 mL) and cooled to −18 °C. LiHMDS (1 M, 0.44 mL, 
0.440 mmol) was added dropwise and the solution stirred for 45 minutes ensuring the temperature 
remained below −8 °C. Methyl iodide (27 µL, 0.433 mmol) was added dropwise and the solution stirred 
for a further 1.5 hours. The reaction was quenched with water (10 mL) and extracted with DCM (3 × 
10 mL). The combined organic layers were dried over MgSO4, filtered, and concentrated in vacuo.  
The crude material was dissolved in a solution of HCl in MeOH (4 M, 10 mL) and stirred for two days at 
room temperature. The reaction mixture was diluted with water (15 mL) and extracted with DCM (3 × 
15 mL). The combined organic layers were washed with a saturated aqueous solution of NaHCO3 
(15 mL), dried over MgSO4, filtered, and concentrated in vacuo. The crude material was purified by 
column chromatography (8-15% EtOAc in petrol) to give 2,2-dimethylmutilin 179 (85 mg, 67%) as a 
white solid. 
δH (400 MHz, CDCl3) 6.14 (1H, dd, J 18.0, 11.0, 19-H), 5.36 (1H, dd, J 18.0, 1.5, 20-HH), 5.28 (1H, dd, J 
11.0, 1.5, 20-HH), 4.33 (1H, dd, J 8.0, 5.0, 14-H), 3.36 (1H, t, J 6.5, 11-H), 2.40 (1H, d, J 3.0, 4-H), 2.13 
(1H, app. pent, J 7.0, 10-H), 1.90 (1H, dd, J 16.0, 8.0, 13-HH), 1.72 (1H, dq, J 14.5, 3.0, 8-HH), 1.60 (1H, 
d, J 16.0, 13-HH), 1.56 (1H, d, J 13.5, 1-HH), 1.52 (1H, d, J 7.0, OH), 1.43 (1H, m, 7-HH), 1.35 (1H, m, 
7-HH), 1.35 (1H, d, J 13.5, 1-HH), 1.32 (3H, s, 15-H3), 1.28 (1H, d, J 5.0, OH), 1.16 (3H, s, 18-H3), 1.12 
(3H, s, 3’-H3 or 3’’-H3), 1.07 (3H, s, 3’-H3 or 3’’-H3), 1.05 (1H, m, 8-HH), 0.96 (3H, d, J 7.0, 16-H3), 0.87 
(3H, d, J 7.0, 17-H3). δC (101 MHz, CDCl3) 220.8 (C-3), 139.6 (C-19), 116.0 (C-20), 75.9 (C-11), 67.1 (C-14), 
55.9 (C-4), 45.3 and 45.2 (C-12 and C-13), 42.7 (C-9), 42.2 (C-1), 41.8 and 41.7 (C-2 and C-5), 36.2 (C-10), 
36.1 (C-6), 32.4 (C-8), 30.7 (C-3’ or C-3’’), 28.8 (C-18), 27.4 (C-3’ or C-3’’), 27.1 (C-7), 18.3 (C-16), 13.5 
(C-15), 11.1 (C-17). HRMS (ESI) calc. for C22H36O3Na [M+Na]+ 371.2557. Found 371.2556. M.p. 
Experimental 
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192-194 °C (from toluene). []D
21 = +28.3 (c 0.74, CHCl3). IR (νmax/cm-1) (neat): 3544 (alcohol O–H), 3419 
(alcohol O–H), 2931 (alkane C–H), 1721 (ketone C=O). 
Synthesis of (2S)-methylmutilin 176 
 
A solution of TMS-mutilin 139 (125 mg, 0.269 mmol) in THF (3 mL) was cooled to −18 °C. LiHMDS (1 
M, 0.32 mL, 0.320 mmol) was added dropwise and the solution stirred for 45 minutes ensuring the 
temperature remained below −8 °C. Methyl iodide (20 µL, 0.323 mmol) was added dropwise and the 
solution stirred for a further 1.5 hours. The reaction was quenched with water (5 mL) and extracted 
with DCM (3 × 5 mL). The combined organic layers were dried over MgSO4, filtered, and concentrated 
in vacuo. 
The crude material was dissolved in a solution of HCl in MeOH (1.4 M, 3 mL) and stirred for 75 minutes 
at room temperature. The reaction was quenched with a saturated aqueous solution of NaHCO3 (5 mL) 
and extracted with DCM (3 × 10 mL). The combined organic layers were dried over MgSO4, filtered, 
and concentrated in vacuo. The crude material was purified by column chromatography (15% EtOAc 
in petrol) to give (2S)-methylmutilin 176 (69 mg, 77%) as a white solid. 
δH (400 MHz, CDCl3) 6.14 (1H, dd, J 18.0, 11.0, 19-H), 5.36 (1H, dd, J 18.0, 1.5, 20-HH), 5.28 (1H, dd, J 
11.0, 1.5, 20-HH), 4.34 (1H, d, J 7.5, 14-H), 3.33 (1H, d, J 6.5, 11-H), 2.20 (1H, tq, J 9.5, 7.5, 2-H), 2.15 
(1H, app. pent, J 7.0, 10-H), 2.01 (1H, d, J 3.0, 4-H), 1.90 (1H, dd, J 16.0, 7.5, 13-HH), 1.81-1.70 (2H, m, 
1-HH, 8-HH), 1.60 (1H, m, 6-H), 1.59 (1H, d, J 16.0, 13-HH), 1.51-1.32 (2H, m, 7-H2), 1.36 (3H, s, 15-H3), 
1.18-1.06 (2H, m, 1-HH, 8-HH), 1.15 (3H, s, 18-H3), 1.10 (3H, d, J 7.5, 3’-H3), 0.96 (3H, d, J 7.0, 16-H3), 
0.91 (3H, d, J 7.0, 17-H3). δC (101 MHz, CDCl3) 221.1 (C-3), 139.6 (C-19), 116.0 (C-20), 75.2 (C-11), 67.0 
(C-14), 57.9 (C-4), 45.5 (C-13), 45.2 (C-12), 44.2 (C-9), 42.6 (C-5), 39.9 (C-2), 37.3 (C-6), 36.6 (C-10), 35.1 
(C-1), 31.2 (C-8), 28.7 (C-18), 27.2 (C-7), 18.3 (C-16), 18.1 (C-3’), 13.6 (C-15), 11.6 (C-17). HRMS (ESI) 
calc. for C21H34O3Na [M+Na]+ 357.2400. Found 357.2401. M.p. 232-234 °C (from CHCl3). []D
23 = +47.0 






Synthesis of (2S)-fluoromutilin 182 
 
A solution of TMS-mutilin 139 (150 mg, 0.323 mmol) in THF (3 mL) was cooled to −18 °C. LiHMDS (1 
M, 0.39 mL, 0.390 mmol) was added dropwise and the solution stirred for 45 minutes ensuring the 
temperature remained below −8 °C. N-Fluorobenzenesulfonimide (97%, 126 mg, 0.387 mmol) was 
added and the solution was warmed to room temperature for 16 hours. The reaction was quenched 
with water (10 mL) and extracted with DCM (3 × 10 mL). The combined organic layers were dried over 
MgSO4, filtered, and concentrated in vacuo. The crude material was purified by column 
chromatography (5% EtOAc in petrol) to give fluorinated mutilin 181. 
Mutilin 181 was dissolved in a solution of HCl in MeOH (1.4 M, 3 mL) and stirred for one hour at room 
temperature. The reaction was quenched with a saturated aqueous solution of NaHCO3 (5 mL) and 
extracted with DCM (3 × 10 mL). The combined organic layers were dried over MgSO4, filtered, and 
concentrated in vacuo. The crude material was purified by column chromatography (15% EtOAc in 
petrol) to give (2S)-fluoromutilin 182 (79 mg, 72%) as a white solid. 
δH (400 MHz, CDCl3) 6.14 (1H, dd, J 18.0, 11.0, 19-H), 5.36 (1H, dd, J 18.0, 1.5, 20-HH), 5.29 (1H, dd, J 
11.0, 1.5, 20-HH), 4.65 (1H, ddd, J 52.0, 8.5, 6.5, 2-H), 4.31 (1H, d, J 7.5, 14-H), 3.35 (1H, d, J 6.0, 11-H), 
2.29 (1H, d, J 2.5, 4-H), 2.15 (2H, m, 1-HH, 10-H), 1.92 (2H, m, 8-HH, 13-HH), 1.64 (1H, d, J 16.0, 13-HH), 
1.74 (1H, dq, J 14.5, 3.0, 8-HH), 1.67 (1H, m, 6-H), 1.64-1.41 (3H, m, 1-HH, 6-H, 7-HH), 1.38 (3H, s, 
15-H3), 1.36 (1H, m, 7-HH), 1.16 (3H, s, 18-H3), 0.97 (3H, d, J 6.5, 16-H3), 0.94 (3H, d, J 7.0, 17-H3) 0.81 
(1H, ddd, J 14.5, 13.0, 4.5, 8-HH). δC (101 MHz, CDCl3) 210.9 (d, J 13.5, C-3), 139.4 (C-19), 116.1 (C-20), 
90.2 (d, J 182.0, C-2), 75.0 (C-11), 66.9 (C-14), 45.4 (C-12 and C-13), 42.7 (C-5), 41.8 (d, J 4.0, C-9), 37.3 
(C-6), 36.5 (C-10), 34.1 (d, J 18.5, C-1), 33.4 (C-8), 28.7 (C-18), 27.0 (C-7), 18.1 (C-16), 13.8 (C-15), 11.5 
(C-17). δF (376 MHz, CDCl3) −180.9 (ddd, J 52.0, 35.0, 7.5, 2-F). HRMS (ESI) calc. for C20H31O3FNa 
[M+Na]+ 361.2149. Found 361.2153. M.p. 208-210 °C (from CHCl3). []D
21 = +17.0 (c 1.00, CHCl3). IR 






Synthesis of 2,2-difluoromutilin 184 
 
A solution of TMS-mutilin 139 (150 mg, 0.323 mmol) in THF (3 mL) was cooled to −18 °C. LiHMDS (1 
M, 0.39 mL, 0.3 mmol) was added dropwise and the solution stirred for 45 minutes ensuring the 
temperature remained below −8 °C. N-Fluorobenzenesulfonimide (97%, 126 mg, 0.387 mmol) was 
added and the solution was warmed to room temperature for 16 hours. The reaction was quenched 
with water (10 mL) and extracted with DCM (3 × 10 mL). The combined organic layers were dried over 
MgSO4, filtered, and concentrated in vacuo.  
The material was redissolved in THF (3 mL) and cooled to −18 °C. LiHMDS (1 M, 0.39 mL, 0.39 mmol) 
was added dropwise and the solution stirred for 45 minutes ensuring the temperature remained 
below −8 °C. N-Fluorobenzenesulfonimide (97%, 126 mg, 0.387 mmol) was added and the solution 
was warmed to room temperature for 16 hours. The reaction was quenched with water (10 mL) and 
extracted with DCM (3 × 10 mL). The combined organic layers were dried over MgSO4, filtered, and 
concentrated in vacuo. The crude material was purified by column chromatography (5% EtOAc in 
petrol) to give fluorinated mutilins 181 and 183 as an inseparable mixture. 
The mixture of fluorinated mutilins was dissolved in a solution of HCl in MeOH (1.4 M, 3 mL) and stirred 
for one hour at room temperature. The reaction was quenched with a saturated aqueous solution of 
NaHCO3 (5 mL) and extracted with DCM (3 × 10 mL). The combined organic layers were dried over 
MgSO4, filtered, and concentrated in vacuo. The crude material was purified by HPLC (70-95% MeCN 
in water with 0.05% formic acid) to give (2S)-fluoromutilin 182 (23 mg, 13%) and 2,2-difluoromutilin 
184 (49 mg, 26%) as white solids. 
(2S)-Fluoromutilin 182 
Characterisation as given previously. 
2,2-Difluoromutilin 184 
δH (400 MHz, CDCl3) 6.12 (1H, dd, J 18.0, 11.0, 19-H), 5.37 (1H, dd, J 18.0, 1.0, 20-HH), 5.30 (1H, dd, J 
11.0, 1.0, 20-HH), 4.31 (1H, dd, J 8.0, 4.0, 14-H), 3.31 (1H, t, J 6.0, 11-H), 2.44 (1H, q, J 3.0, 4-H), 2.17 
(1H, app. pent, J 7.0, 10-H), 2.08-1.95 (2H, m, 1-H2), 1.94-1.84 (2H, m, 8-HH, 13-HH), 1.71 (1H, m, 6-H), 
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1.67 (1H, d, J 16.0, 13-HH), 1.61 (1H, br. d, J 6.0, OH), 1.52-1.37 (2H, m, 7-H2), 1.36 (3H, s, 15-H3), 1.31 
(1H, br. d, J 4.0, OH), 1.16 (3H, s, 18-H3), 1.08 (1H, m, 8-HH), 0.98 (3H, d, J 7.0, 16-H3), 0.91 (3H, d, J 
7.0, 17-H3). δC (101 MHz, CDCl3) 203.0 (t, J 25.0, C-3), 139.0 (C-19), 116.4 (C-20), 115.9 (dd, J 260.5, 
252.5, C-2), 75.1 (C-11), 66.7 (C-14), 45.3 (C-12), 45.1 (C-13), 42.3 (C-5), 40.6 (d, J 5.0, 3.5, C-9), 38.4 (t, 
J 20.5, C-1), 36.2 (C-6), 36.1 (C-10), 32.4 (C-8), 28.6 (C-18), 26.8 (C-7), 18.1 (C-16), 13.7 (C-15), 11.1 
(C-17). δF (376 MHz, CDCl3) −94.4 (ddd, J 276.0, 21.0, 10.0, 2-FF), −104.5 (dt, J 276.0, 17.5, 2-FF). HRMS 
(ESI) calc. for C20H30O3F2Na [M+Na]+ 379.2055. Found 379.2067. M.p. 227-229 °C (from CHCl3). []D
23 
= +31.0 (c 1.00, CHCl3). IR (νmax/cm-1) (neat): 3569 (alcohol O–H), 2933 (alkane C–H), 1763 (ketone 
C=O). 
Synthesis of enone 187 
 
Mutilin 129 (500 mg, 1.56 mmol), paraformaldehyde (96%, 60 mg, 1.92 mmol), and dimethylamine 
hydrochloride (168 mg, 2.06 mmol) were dissolved in 1,4-dioxane (10 mL). HCl (12 M, 80 µL) was added 
and the reaction heated to reflux (101 °C) for 20 hours. The reaction was cooled to room temperature, 
diluted with HCl (0.05 M, 20 mL), and extracted with EtOAc (3 × 10 mL). The aqueous phase was 
basified using a saturated aqueous solution of NaHCO3 (10 mL) and again extracted with EtOAc (3 × 
10 mL). The combined organic layers were dried over MgSO4, filtered, and concentrated in vacuo to 
give amine 186 as a mixture of epimers. 
The crude material was redissolved in xylene (10 mL) and was heated to reflux (140 °C) for 20 hours. 
The reaction was cooled to room temperature and concentrated in vacuo. The crude material was 
purified by column chromatography (20% EtOAc in petrol) to give enone 187 (86 mg, 17%) as a 
colourless oil. Mutilin 129 was also recovered (368 mg, 74%). 
δH (400 MHz, CDCl3) 6.15 (1H, dd, J 18.0, 11.0, 19-H), 6.04 (1H, dt, J 3.5, 1.5, 3’-HH), 5.37 (1H, dd, J 
18.0, 1.5, 20-HH), 5.29 (1H, dd, J 11.0, 1.5, 20-HH), 5.26 (1H, m, 3’-HH), 4.38 (1H, d, J 7.5, 14-H), 3.40 
(1H, d, J 6.5, 11-H), 2.31 (1H, dt, J 16.5, 3.5, 1-HH), 2.24-2.14 (3H, m, 1-HH, 4-H, 10-H), 1.94 (1H, dd, J 
16.0, 7.5, 13-HH), 1.74 (1H, dq, J 14.5, 3.0, 8-HH), 1.64 (1H, m, 6-H), 1.61 (1H, d, J 16.0, 13-HH), 1.46 
(1H, m, 7-HH), 1.43 (3H, s, 15-H3), 1.35 (1H, m, 7-HH), 1.14 (3H, s, 18-H3), 1.07 (1H, td, J 14.0, 4.5, 
8-HH), 0.97 (3H, d, J 7.0, 16-H3), 0.93 (3H, d, J 7.0, 17-H3). δC (101 MHz, CDCl3) 205.6 (C-3), 143.6 (C-2), 
139.5 (C-19), 118.4 (C-3’), 116.0 (C-20), 75.2 (C-11), 66.9 (C-14), 59.7 (C-4), 45.5 (C-13), 45.2 (C-12), 
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43.2 (C-9), 42.9 (C-5), 37.1 (C-6), 36.3 (C-10), 34.9 (C-1), 31.6 (C-8), 28.7 (C-18), 27.2 (C-7), 18.3 (C-16), 
13.7 (C-15), 11.6 (C-17). HRMS (ESI) calc. for C21H32O3Na [M+Na]+ 355.2244. Found 355.2261. []D
22 = 
−36.0 (c 1.00, CHCl3). IR (νmax/cm-1) (neat): 3493 (alcohol O–H), 2927 (alkane C–H), 1716 (enone C=O). 
Cyclopropanation of enone 187 
 
Sodium hydride (60% dispersion in mineral oil, 9 mg, 0.225 mmol) was added to a solution of 
trimethylsulfoxonium iodide (48 mg, 0.218 mmol) in DMSO (2 mL). After 15 minutes a solution of 
enone 187 (69 mg, 0.208 mmol) in THF (2 mL) was added dropwise. The reaction was stirred for 16 
hours at room temperature before quenching with water (10 mL). The solution was extracted with 
DCM (3 × 10 mL) and the combined organic layers were dried over MgSO4, filtered, and concentrated 
in vacuo. The crude material was purified by column chromatography (20% EtOAc in petrol) to give 
cyclopropane 188 (49 mg, 68%) as a white solid. 
δH (400 MHz, CDCl3) 6.16 (1H, dd, J 18.0, 11.0, 19-H), 5.37 (1H, dd, J 18.0, 1.5, 20-HH), 5.29 (1H, dd, J 
11.0, 1.5, 20-HH), 4.38 (1H, d, J 7.5, 14-H), 3.49 (1H, d, J 6.5, 11-H), 2.29 (1H, d, J 3.0, 4-H), 2.20 (1H, 
app. pent, J 7.0, 10-H), 1.96 (1H, dd, J 15.5, 7.5, 13-HH), 1.94 (1H, d, J 12.5, 1-HH), 1.81 (1H, dt, J 10.5, 
2.5, 8-HH), 1.61 (1H, m, 6-H), 1.61 (1H, d, J 15.5, 13-HH), 1.52-1.46 (2H, m, 7-HH, 8-HH), 1.38 (1H, m, 
7-HH), 1.38 (3H, s, 15-H3), 1.32 (1H, d, J 12.5, 1-HH), 1.27 (1H, m, 3’-HH or 3’’-HH), 1.16 (3H, s, 18-H3), 
1.08 (1H, m, 3’-HH or 3’’-HH), 0.97 (3H, d, J 7.0, 16-H3), 0.90 (3H, d, J 7.0, 17-H3), 0.81-0.72 (2H, m, 
3’-HH, 3’’-HH). δC (101 MHz, CDCl3) 218.3 (C-3), 139.6 (C-19), 116.0 (C-20), 75.2 (C-11), 67.0 (C-14), 
59.8 (C-4), 45.5 (C-13), 45.3 and 45.2 (C-9 and C-12), 42.8 (C-5), 37.4 (C-6), 36.9 (C-1), 36.6 (C-10), 31.5 
(C-8), 28.7 (C-18), 27.3 (C-7), 21.0 (C-3’ or C-3’’), 18.4 (C-16), 17.2 (C-3’ or C-3’’), 13.6 (C-2), 13.6 (C-15), 
11.6 (C-17). HRMS (ESI) calc. for C22H34O3Na [M+Na]+ 369.2400. Found 369.2409. M.p. 250-252 °C 
(from CHCl3). []D
22 = −16.0 (c 0.05, CHCl3). IR (νmax/cm-1) (neat): 3475 (alcohol O–H), 2928 (alkane 







Synthesis of enone 190 
 
A solution of mutilin 129 (1.00 g, 3.12 mmol) and TMSCl (1.42 mL, 11.2 mmol) in THF (20 mL) was 
cooled to −18 °C. LiHMDS (1 M, 10.3 mL, 10.3 mmol) was added dropwise and the solution stirred for 
two hours ensuring the temperature remained below −8 °C. The reaction mixture was diluted with 
cyclohexane (20 mL) before quenching with a saturated aqueous solution of NaHCO3 (20 mL). The 
layers were separated and the organic phase washed with a saturated aqueous solution of NaHCO3 
(20 mL). The organic layer was dried over MgSO4, filtered, and concentrated in vacuo. 
The crude silyl enol ether was redissolved in MeCN (20 mL) before Pd(OAc)2 (98%, 930 mg, 4.06 mmol) 
was added. The solution was stirred for two hours at room temperature then filtered through Celite® 
and concentrated in vacuo.  
The crude material was dissolved in a solution of HCl in MeOH (1.4 M, 10 mL) and stirred for 1.5 hours 
at room temperature. The reaction mixture was partitioned between DCM (20 mL) and water (20 mL) 
and the phases were separated. The aqueous phase was extracted with DCM (2 × 20 mL). The 
combined organic layers were washed with a saturated aqueous solution of NaHCO3 (20 mL), dried 
over MgSO4, filtered, and concentrated in vacuo. The crude material was purified by column 
chromatography (20% EtOAc in petrol) to give enone 190 (705 mg, 71%) as a white solid. 
δH (400 MHz, CDCl3) 7.71 (1H, d, J 6.0, 1-H), 6.16 (1H, dd, J 18.0, 11.0, 19-H), 6.02 (1H, d, J 6.0, 2-H), 
5.36 (1H, dd, J 18.0, 1.5, 20-HH), 5.30 (1H, dd, J 11.0, 1.0, 20-HH), 4.33 (1H, d, J 8.0, 14-H), 3.09 (1H, d, 
J 7.0, 11-H), 2.25-2.18 (2H, m, 4-H, 8-HH), 2.13 (1H, pent, J 7.0, 10-H), 2.01 (1H, dd, J 16.0, 8.0, 13-HH), 
1.65 (1H, m, 6-H), 1.63 (1H, d, J 16.0, 13-HH), 1.59-1.47 (2H, m, 7-HH, OH), 1.45 (3H, s, 15-H3), 1.38 
(1H, dq, J 14.0, 4.5, 7-HH), 1.12 (3H, s, 18-H3), 1.11 (3H, d, J 7.0, 16-H3), 1.02 (3H, d, J 7.0, 17-H3), 0.95 
(1H, td, J 14.0, 4.5, 8-HH). δC (101 MHz, CDCl3) 208.1 (C-3), 165.2 (C-1), 139.5 (C-19), 133.0 (C-2), 116.2 
(C-20), 76.4 (C-11), 67.2 (C-14), 59.8 (C-4), 51.3 (C-9), 46.1 (C-13), 45.8 (C-12), 42.8 (C-5), 39.1 (C-8), 
38.4 (C-6), 36.0 (C-10), 28.6 (C-18), 27.4 (C-7), 17.8 (C-16), 13.2 (C-15), 12.1 (C-17). HRMS (ESI) calc. for 
C20H30O4Na [M+Na]+ 341.2087. Found 341.2097. M.p. 184-186 °C (from CHCl3). []D
23 = −59.4 (c 0.82, 
CHCl3). IR (νmax/cm-1) (neat): 3464 (alcohol O–H), 2928 (alkane C–H), 1699 (enone C=O). 
1H NMR data in accord with the literature data.220 
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X-ray crystal structure obtained following recrystallisation from 
DCM. 




Luche reduction of enone 190 
 
Enone 190 (100 mg, 0.314 mmol) and CeCl3.7H2O (234 mg, 0.628 mmol) were dissolved in MeOH 
(10 mL). NaBH4 (96%, 37 mg, 0.953 mmol) was added slowly and the reaction was heated to 60 °C for 
two days. The solution was diluted with water (20 mL) and extracted with DCM (3 × 20 mL). The 
organic layer was dried over MgSO4, filtered, and concentrated in vacuo. The crude material was 
purified by column chromatography (50% EtOAc in petrol) to give allylic alcohol 193 (43 mg, 43%) as 
a white solid. Enone 190 was also recovered (54 mg, 54%). 
δH (400 MHz, CDCl3) 6.17 (1H, dd, J 18.0, 11.0, 19-H), 6.00 (1H, dd, J 6.0, 1.5, 1-H), 5.69 (1H, dd, J 6.0, 
1.5, 2-H), 5.31 (1H, dd, J 18.0, 1.5, 20-HH), 5.27 (1H, dd, J 11.0, 1.5, 20-HH), 4.86 (1H, d, J 8.0, 3-H), 
4.29 (1H, dd, J 8.5, 4.5, 14-H), 3.40 (1H, t, J 6.5, 11-H), 2.12 (1H, dd, J 15.5, 8.5, 13-HH), 1.96 (1H, qd, J 
14.0, 3.0, 8-HH), 1.91 (1H, app. pent, J 7.0, 10-H), 1.74 (1H, d, J 8.0, 4-H), 1.72-1.62 (3H, m, 6-H, 2 × 
OH), 1.58 (1H, d, J 15.5, 13-HH), 1.52 (1H, br. d, J 6.5, OH), 1.43 (1H, qd, J 14.0, 3.5, 7-HH), 1.32 (1H, 
dq, J 14.0, 3.5, 7-HH), 1.16 (3H, s, 18-H3), 1.10 (3H, s, 15-H3), 1.06 (3H, d, J 7.0, 16-H3), 0.98 (3H, d, J 
7.0, 17-H3), 0.97 (1H, m, 8-HH). δC (101 MHz, CDCl3) 140.3 (C-19), 139.8 (C-1), 133.6 (C-2), 115.6 (C-20), 
78.6 (C-3), 75.5 (C-11), 67.9 (C-14), 59.0 (C-4), 52.1 (C-9), 46.1 (C-13), 45.7 (C-12), 41.5 (C-5), 38.1 (C-6), 
35.9 (C-8), 35.7 (C-10), 28.7 (C-18), 26.9 (C-7), 18.0 (C-16), 17.8 (C-15), 12.5 (C-17). HRMS (ESI) calc. for 
C20H32O3Na [M+Na]+ 343.2244. Found 343.2251. M.p. 123-125 °C (from CHCl3). []D
25 = +28.0 (c 1.00, 





X-ray crystal structure obtained following recrystallisation from 
CHCl3. 




Reduction of enone 190 using LiAlH4 
 
A solution of enone 190 (75 mg, 0.236 mmol) in Et2O (5 mL) was added to a suspension of LiAlH4 (18 
mg, 0.471 mmol) in Et2O (5 mL) at 0 °C. The reaction was allowed to warm to room temperature and 
was stirred for 16 hours. LiAlH4 (18 mg, 0.471 mmol) was added to the solution in one portion and the 
reaction was stirred for a further three days at room temperature. The reaction was quenched with 
HCl (1 M, 2 mL) and the layers were separated. The aqueous phase was extracted with Et2O (2 × 5 mL) 
and the combined organic layers were dried over MgSO4, filtered, and concentrated in vacuo. The 
crude material was purified by column chromatography (30-60% EtOAc in petrol) to give mutilin 129 
(11 mg, 14%), allylic alcohol 193 (4 mg, 6%), and triol 131 (16 mg, 21%) as white solids, and diene 194 
(10 mg, 14%) as a colourless oil. 
Mutilin 129, allylic alcohol 193, and triol 131 
Characterisations as given previously. 
Diene 194 
δH (400 MHz, CDCl3) 6.42 (1H, dd, J 5.5, 2.0, 1-H), 6.37 (1H, dd, J 5.5, 2.0, 2-H), 6.12 (1H, t, J 2.0, 3-H), 
6.10 (1H, dd, J 18.0, 11.0, 19-H), 5.28 (1H, dd, J 18.0, 1.5, 20-HH), 5.23 (1H, dd, J 11.0, 1.5, 20-HH), 4.40 
(1H, d, J 8.0, 14-H), 2.30 (1H, dt, J 14.0, 3.5, 8-HH), 2.20 (1H, app. pent, J 7.0, 10-H), 1.91 (1H, d, J 6.0, 
11-H), 1.79 (1H, dd, J 15.0, 8.0, 13-HH), 1.65 (1H, qd, J 14.0, 3.5, 7-HH), 1.50 (1H, d, J 15.0, 13-HH), 1.43 
(1H, dq, J 14.0, 3.5, 7-HH), 1.24 (3H, s, 15-H3), 1.22 (1H, m, 6-H), 1.10 (3H, d, J 7.0, 16-H3), 1.06 (3H, d, 
J 7.0, 17-H3), 0.97 (3H, s, 18-H3), 0.72 (1H, td, J 14.0, 3.5, 8-HH). δC (101 MHz, CDCl3) 162.0 (C-4), 141.1 
(C-1), 140.0 (C-19), 130.9 (C-2), 125.0 (C-3), 115.3 (C-20), 75.3 (C-11), 66.5 (C-14), 60.4 (C-9), 47.0 (C-5 
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and C-13), 45.6 (C-12), 45.4 (C-6), 34.1 (C-10), 33.5 (C-8), 28.6 (C-18), 28.3 (C-7), 17.7 and 17.6 (C-15 
and C-16), 13.7 (C-17). HRMS (ESI) calc. for C20H30O2Na [M+Na]+ 325.2138. Found 325.2154. []D
22 = 
−56.5 (c 0.23, CHCl3). IR (νmax/cm-1) (neat): 3472 (alcohol O–H), 2924 (alkane C–H). 
Synthesis of enone 197 
 
A solution of 19,20-dihydromutilin 133 (200 mg, 0.620 mmol) and TMSCl (0.28 mL, 2.23 mmol) in THF 
(20 mL) was cooled to −18 °C. LiHMDS (1 M, 2.04 mL, 2.04 mmol) was added dropwise and the solution 
stirred for two hours ensuring the temperature remained below −8 °C. The reaction mixture was 
diluted with cyclohexane (5 mL) before quenching with a saturated aqueous solution of NaHCO3 
(5 mL). The layers were separated and the organic phase washed with a saturated aqueous solution 
of NaHCO3 solution (20 mL). The organic layer was dried over MgSO4, filtered, and concentrated in 
vacuo. 
The crude silyl enol ether was redissolved in MeCN (5 mL) before Pd(OAc)2 (98%, 185 mg, 0.806 mmol) 
was added. The solution was stirred for 16 hours at room temperature then filtered through Celite® 
and concentrated in vacuo.  
The crude material was dissolved in a solution of HCl in MeOH (1.4 M, 5 mL) and stirred for 1.5 hours 
at room temperature. The reaction mixture was partitioned between DCM (5 mL) and water (5 mL) 
and the phases were separated. The aqueous phase was extracted with DCM (2 × 5 mL) and the 
combined organic layers were washed with a saturated aqueous solution of NaHCO3 (5 mL), dried over 
MgSO4, filtered, and concentrated in vacuo. The crude material was purified by column 
chromatography (20% EtOAc in petrol) to give enone 197 (157 mg, 71%) as a white solid. Ketone 133 
was also recovered (18 mg, 9%). 
δH (400 MHz, CDCl3) 7.72 (1H, d, J 6.0, 1-H), 6.01 (1H, d, J 6.0, 2-H), 4.21 (1H, d, J 8.0, 14-H), 3.08 (1H, 
d, J 7.0, 11-H), 2.30-2.17 (3H, m, 4-H, 8-HH, 10-H), 1.73 (1H, dd, J 16.0, 8.0, 13-HH), 1.68-1.50 (4H, m, 
6-H, 7-HH, 19-H2), 1.47 (1H, d, J 16.0, 13-HH), 1.43 (3H, s, 15-H3), 1.39 (1H, m, 7-HH), 1.11 (3H, d, J 7.0, 
17-H3), 1.02 (3H, d, J 7.0, 16-H3), 1.02 (3H, d, J 7.0, 17-H3), 0.96 (3H, s, 18-H3), 0.94 (1H, m, 8-HH), 0.94 
(3H, t, J 8.0, 20-H3). δC (101 MHz, CDCl3) 208.2 (C-3), 165.1 (C-1), 133.0 (C-2), 78.1 (C-11), 67.1 (C-14), 
59.9 (C-4), 51.4 (C-9), 43.9 (C-13), 43.0 (C-5), 41.4 (C-12), 39.3 (C-8), 38.4 (C-6), 34.0 (C-10), 27.5 (C-7), 
26.8 (C-18), 21.1 (C-19), 17.8 (C-16), 13.1 (C-15), 11.9 (C-17), 8.3 (C-20). HRMS (ESI) calc. for C20H33O3 
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[M+H]+ 321.2424. Found 321.2411. M.p. 218-220 °C (from CHCl3). []D
24 = −56.0 (c 1.00, CHCl3). IR 
(νmax/cm-1) (neat): 3417 (alcohol O–H), 2952 (alkane C–H), 1698 (enone C=O). 
Luche reduction of enone 197 
 
Enone 197 (155 mg, 0.484 mmol) and CeCl3.7H2O (360 mg, 0.966 mmol) were dissolved in MeOH 
(10 mL). NaBH4 (96%, 57 mg, 1.45 mmol) was slowly added and the solution was heated to 60 °C for 
two days. The solution was diluted with water (20 mL) and extracted with DCM (3 × 20 mL). The 
organic layer was dried over MgSO4, filtered, and concentrated in vacuo. The crude material was 
purified by column chromatography (50% EtOAc in petrol) to give allylic alcohol 198 (50 mg, 32%) and 
19,20-dihydromutilin 133 (48 mg, 25%) as white solids. Enone 197 was also recovered (48 mg, 31%). 
Allylic alcohol 198 
δH (400 MHz, CDCl3) 6.00 (1H, dd, J 6.0, 1.5, 1-H), 5.68 (1H, dd, J 6.0, 1.5, 2-H), 4.84 (1H, d, J 8.0, 3-H), 
4.17 (1H, d, J 8.5, 14-H), 3.38 (1H, d, J 7.0, 11-H), 2.06-1.92 (2H, m, 8-HH, 10-H), 1.83 (1H, dd, J 16.0, 
8.5, 13-HH), 1.76 (1H, d, J 8.0, 4-H), 1.65-1.38 (4H, m, 6-H, 7-HH, 19-H2), 1.42 (1H, d, J 15.5, 13-HH), 
1.34 (1H, dq, J 14.0, 3.5, 7-HH), 1.08 (3H, s, 15-H3), 1.05 (3H, d, J 7.0, 16-H3), 0.99 (3H, s, 18-H3), 0.98 
(3H, d, J 7.0, 17-H3), 0.97 (1H, m, 8-HH), 0.92 (3H, t, J 7.5, 20-H3). δC (101 MHz, CDCl3) 139.8 (C-1), 133.7 
(C-2), 78.6 (C-3), 77.1 (C-11), 67.8 (C-14), 59.0 (C-4), 52.1 (C-9), 43.6 (C-13), 41.7 (C-5), 41.3 (C-12), 38.1 
(C-6), 35.9 (C-8), 33.7 (C-10), 26.9 (C-7 and C-18), 21.3 (C-19), 18.0 (C-16), 17.8 (C-15), 12.3 (C-17), 8.3 
(C-20). HRMS (ESI) calc. for C20H33O2 [M+H−H2O]+ 305.2475. Found 305.2477. M.p. 138-140 °C (from 
CHCl3). []D
22 = +29.0 (c 1.00, CHCl3). IR (νmax/cm-1) (neat): 3343 (alcohol O–H), 2933 (alkane C–H). 
19,20-Dihydromutilin 133 
Characterisation as given previously. 




Hydrogen peroxide (30%, 1.5 mL) was added to a solution of enone 190 (150 mg, 0.471 mmol) in 
MeOH. The solution was cooled to 0 °C and an aqueous solution of NaOH (1 M, 0.3 mL) was added 
dropwise. When addition was complete the reaction was heated at 50 °C for 16 hours, cooled to room 
temperature, and quenched with a saturated aqueous solution of NH4Cl (3 mL). The resulting mixture 
was extracted with DCM (3 × 5 mL) and the organic layers combined, dried over MgSO4, filtered, and 
concentrated in vacuo. The crude material was purified by column chromatography (15-30%) to give 
epoxide 200 (128 mg, 82%) as a white solid and lactone 201 (27 mg, 17%) as a colourless oil.  
Epoxide 200 
δH (400 MHz, CDCl3) 6.15 (1H, ddd, J 18.0, 11.0, 1.0, 19-H), 5.35 (1H, dd, J 18.0, 1.5, 20-HH), 5.28 (1H, 
dd, J 11.0, 1.5, 20-HH), 4.21 (1H, d, J 7.5, 14-H), 3.83 (1H, d, J 7.0, 11-H), 3.64 (1H, d, J 3.0, 1-H), 3.17 
(1H, d, J 3.0, 2-H), 2.51 (1H, d, J 3.5, 4-H), 2.12 (1H, pent, J 7.0, 10-H), 1.93-1.84 (2H, m, 8-HH, 13-HH), 
1.71 (1H, ddq, J 14.0, 7.0, 3.5, 6-H), 1.60 (1H, d, J 16.0, 13-HH), 1.48-1.33 (2H, m, 7-H2), 1.28 (1H, s, 
15-H3), 1.17 (3H, d, J 7.0, 17-H3), 1.15 (3H, s, 18-H3), 0.98 (3H, d, J 7.0, 16-H3), 0.92 (1H, m, 8-HH). δC 
(101 MHz, CDCl3) 210.1 (C-3), 139.7 (C-19), 115.9 (C-20), 74.8 (C-11), 67.2 (C-14), 60.1 (C-1), 51.8 (C-2), 
48.6 (C-4), 45.6 (C-12), 45.2 (C-13), 43.7 (C-9), 40.7 (C-5), 36.9 (C-6), 36.4 (C-10), 31.1 (C-8), 29.1 (C-18), 
26.3 (C-7), 18.1 (C-16), 14.0 (C-15), 12.1 (C-17). HRMS (ESI) calc. for C20H30O4Na [M+Na]+ 357.2036. 
Found 357.2049. M.p. 142-144 °C (from CHCl3). []D
24 = −51.0 (c 1.00, CHCl3). IR (νmax/cm-1) (neat): 3477 
(alcohol O–H), 2928 (alkane C–H), 1741 (ketone C=O). 
Lactone 201 
δH (400 MHz, CDCl3) 6.13 (1H, dd, J 18.0, 11.0, 1.0, 19-H), 5.34 (1H, dd, J 18.0, 1.5, 20-HH), 5.29 (1H, 
dd, J 11.0, 1.5, 20-HH), 4.33 (1H, d, J 8.5, 14-H), 4.30 (1H, d, J 1.5, 4-H), 3.78 (1H, d, J 5.0, 11-H), 3.51 
(1H, d, J 4.0, 1-H), 3.45 (1H, d, J 4.0, 2-H), 2.24 (1H, qd, J 7.0, 5.0, 10-H), 1.91 (1H, dd, J 16,.0, 8.5, 
13-HH), 1.85-1.68 (2H, m, 6-H, 8-HH), 1.70 (1H, d, J 16.0, 13-HH), 1.46-1.35 (2H, m, 7-H2), 1.23 (1H, m, 
8-HH), 1.14 (1H, s, 15-H3), 1.12 (3H, s, 18-H3), 1.10 (3H, d, J 7.0, 17-H3), 0.98 (3H, d, J 7.0, 16-H3). δC 
(101 MHz, CDCl3) 167.3 (C-3), 138.8 (C-19), 116.1 (C-20), 81.3 (C-4), 73.0 (C-11), 66.7 (C-14), 57.2 (C-1), 
47.6 (C-2), 45.5 (C-12), 45.1 (C-5), 44.3 (C-13), 39.4 (C-9), 35.2 (C-6), 34.5 (C-10), 28.4 (C-18), 26.0 (C-8), 
25.6 (C-7), 17.8 (C-16), 15.1 (C-15), 11.1 (C-17). HRMS (ESI) calc. for C20H30O5Na [M+Na]+ 373.1985. 
Found 373.1998. []D
22 = −37.0 (c 1.00, CHCl3). IR (νmax/cm-1) (neat): 3495 (alcohol O–H), 2931 (alkane 






Reduction of 4-epi-mutilin 149 using LiAlH4 
 
To a suspension of LiAlH4 (227 mg, 5.97 mmol) in 1,4-dioxane (10 mL) was added 4-epi-mutilin 149 
(100 mg, 0.299 mmol) in one portion. The solution was heated to 90 °C for two hours, then cooled to 
room temperature. The reaction mixture was added dropwise to a saturated aqueous solution of 
NH4Cl (50 mL) then extracted with EtOAc (3 × 50 mL). The combined organic layers were dried over 
MgSO4, filtered, and concentrated in vacuo. The crude material was purified by column 
chromatography (15% EtOAc in petrol) to give diol 208 (96 mg, 95%) as a white solid.  
δH (400 MHz, CDCl3) 5.92 (1H, dd, J 18.0, 11.5, 19-H), 5.18 (1H, d, J 18.0, 20-HH), 5.15 (1H, d, J 11.5, 
20-HH), 4.59 (1H, ddd, J 11.0, 7.5, 5.5, 3-H), 4.04 (1H, d, J 6.0, 14-H), 3.59 (1H, br. s, 11-H), 3.30 (3H, s, 
OCH3), 2.67 (1H, dd, J 15.5, 6.5, 13-HH), 2.25 (1H, dddd, J 12.0, 10.5, 7.5, 5.5, 2-HH), 2.10-1.98 (3H, m, 
1-HH, 8-HH, 10-H), 1.73 (1H, d, J 11.0, 4-H), 1.52 (1H, qd, J 15.0, 4.0, 7-HH), 1.40 (1H, d, J 15.0, 4.0, 
7-HH), 1.35 (1H, m, 6-H), 1.24 (1H, m, 2-HH), 1.22 (1H, d, J 15.5, 13-HH), 1.16-1.08 (2H, m, 1-HH, 8-HH), 
1.11 (3H, s, 15-H3), 1.06 (3H, d, J 7.0, 17-H3), 1.02 (3H, s, 18-H3), 0.96 (3H, d, J 7.0, 16-H3). δC (101 MHz, 
CDCl3) 146.0 (C-19), 113.6 (C-20), 85.6 (C-3), 83.2 (C-11), 70.1 (C-14), 64.9 (C-4), 56.7 (OCH3), 46.6 (C-6), 
45.7 (C-9), 45.5 (C-8), 44.7 (C-12), 43.9 (C-5), 42.0 (C-13), 36.9 (C-10), 32.2 (C-1), 31.6 (C-2), 29.9 (C-7), 
28.6 (C-18), 22.4 (C-17), 18.2 (C-15 and C-16). HRMS (ESI) calc. for C21H36O3Na [M+Na]+ 359.2557. 
Found 359.2559. M.p. 126-128 °C (from CHCl3) [Lit. 120-121 °C].281 []D
23 = −58.0 (c 1.00, CHCl3). IR 
(νmax/cm-1) (neat): 3435 (alcohol O–H), 2927 (alkane C–H). 
Spectroscopic data in accord with the literature data.281 
Synthesis of diketone 209 
 
4-epi-mutilin 149 (500 mg, 1.49 mmol) was dissolved in DCM (10 mL). A solution of Dess-Martin 
periodinane in DCM (0.35 M, 6.34 mL, 2.24 mmol) was added slowly and the reaction stirred for 16 
hours at room temperature. The solution was concentrated in vacuo and the crude material was 
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purified by column chromatography (15% EtOAc in petrol) to give diketone 209 (496 mg, quant.) as a 
white solid.  
δH (400 MHz, CDCl3) 6.38 (1H, dd, J 17.5, 10.5, 19-H), 5.23 (1H, d, J 10.5 20-HH), 5.10 (1H, d, J 17.5, 
20-HH), 3.69 (1H, dt, J 12.5, 7.0, 3-H), 3.27 (3H, s, OCH3), 3.01 (1H, d, J 12.0, 13-HH), 2.75 (1H, q, J 6.5, 
10-H), 2.31 (1H, d, J 12.0, 13-HH), 2.25 (1H, ddd, J 14.0, 10.5, 4.0, 1-HH), 2.05 (1H, m, 2-HH), 2.01 (1H, 
dt, J 13.5, 3.5, 8-HH), 1.75 (1H, d, J 11.5, 4-H), 1.69 (1H, m, 7-HH), 1.42 (1H, dq, J 15.0, 3.5, 7-HH), 
1.38-1.17 (9H, m, 1-HH, 2-HH, 6-H, 16-H3, 18-H3), 1.33 (3H, s, 15-H3), 1.10 (1H, td, J 13.5, 4.5, 8-HH), 
0.93 (3H, d, J 6.5, 17-H3). δC (101 MHz, CDCl3) 215.5 (C-14), 215.2 (C-11), 138.7 (C-19), 117.8 (C-20), 
83.0 (C-3), 63.3 (C-4), 57.0 (OCH3), 56.3 (C-12), 53.9 (C-5), 48.7 (C-13), 48.1 (C-9), 46.2 (C-6), 43.7 (C-10), 
40.5 (C-8), 29.9 (C-1), 29.6 (C-2), 28.3 (C-7), 24.6 (C-18), 22.6 (C-15), 16.5 
(C-16), 15.8 (C-17). HRMS (ESI) calc. for C21H32O3Na [M+Na]+ 355.2244. 
Found 355.2260. M.p. 118-120 °C (from CHCl3). []D
22 = −110.0 (c 1.00, 
CHCl3). IR (νmax/cm-1) (neat): 2978 (alkane C–H), 1702 (ketone C=O), 1686 
(ketone C=O). 
X-ray crystal structure obtained following recrystallisation from toluene. 
Space Group: P43212 (tetragonal). 
Reduction of diketone 209 using LiAlH4 
 
LiAlH4 (228 mg, 6.01 mmol) was added in one portion to a solution of diketone 209 (100 mg, 0.299 
mmol) in 1,4-dioxane (10 mL). The solution was heated to 90 °C for two hours, then cooled to room 
temperature. The reaction mixture was added dropwise to a saturated aqueous solution of NH4Cl (50 
mL) then extracted with EtOAc (3 × 50 mL). The combined organic layers were dried over MgSO4, 
filtered, and concentrated in vacuo. The crude material was purified by column chromatography (15% 
EtOAc in petrol). Further purification was performed via HPLC (70-95% MeCN in water with 0.05% 
formic acid) to give diol 208 (31 mg, 31%) as a white solid. 





Rearrangement of 4-epi-mutilin 149 
 
4-Epi-mutilin 149 (100 mg, 0.299 mmol) was dissolved in DCM (3 mL). Triflic anhydride (60 µL, 
0.357 mmol) was added, followed by pyridine (46 µL, 0.569 mmol). The reaction mixture was stirred 
at room temperature for 16 hours before quenching with water (10 mL). The solution was extracted 
with DCM (3 × 10 mL) and the combined organic layers were dried over MgSO4, filtered, and 
concentrated in vacuo. The crude material was purified by column chromatography (7.5% EtOAc in 
petrol) to give mutilin alkene 213 (36 mg, 38%) as a white solid. 
δH (400 MHz, CDCl3) 6.36 (1H, dd, J 17.5, 11.0, 19-H), 5.17 (1H, dd, J 11.0, 1.0, 20-HH), 5.10 (1H, dd, J 
17.5, 1.0, 20-HH), 3.89 (1H, dt, J 10.5, 6.5, 3-H), 3.27 (1H, m, 14-H), 3.26 (3H, s, 21-H3), 3.09 (1H, q, J 
7.0, 10-H), 2.40 (1H, d, J 10.5, 4-H), 2.34-2.17 (3H, m, 1-HH, 2-HH, 7-HH), 2.01 (1H, dd, J 14.5, 12.5, 
13-HH), 1.97 (1H, ddd, J 17.5, 9.0, 3.5, 7-HH), 1.78 (3H, s, 16-H3), 1.73 (1H, dd, J 14.5, 6.5, 13-HH), 1.63 
(1H, m, 8-HH), 1.48-1.30 (3H, m, 1-HH, 2-HH, 8-HH), 1.13 (3H, s, 18-H3), 1.10 (3H, d, J 7.0, 15-H3), 0.82 
(3H, d, J 7.0 17-H3). δC (101 MHz, CDCl3) 222.4 (C-11), 141.1 (C-19), 134.4 (C-5), 129.4 (C-6), 115.4 
(C-20), 81.1 (C-3), 57.7 (C-4), 56.7 (OCH3), 54.9 (C-12), 53.0 (C-9), 48.9 (C-13), 45.4 (C-10), 37.0 (C-8), 
31.8 (C-14), 31.3 (C-2), 30.6 (C-7), 29.3 (C-1), 26.0 (C-18), 19.9 (C-15), 19.1 (C-16), 13.0 (C-17). HRMS 
(ESI) calc. for C21H32O2Na [M+Na]+ 339.2295. Found 339.2305. M.p. 72-74 °C (from EtOH). []D
22 = 
−248.0 (c 1.00, CHCl3). IR (νmax/cm-1) (neat): 2925 (alkane C–H), 1689 
(ketone C=O). 
Reaction performed by Jennifer Anderson. 
X-ray crystal structure obtained following recrystallisation from 
EtOH. 







Synthesis of alkene 216 and oxetane 217 
 
4-Epi-mutilin 149 (200 mg, 0.598 mmol) and triethylsilane (0.11 mL, 0.717 mmol) were dissolved in 
DCM (5 mL). Triflic anhydride (0.12 mL, 0.717 mmol) was added, followed by pyridine (97 µL, 
1.20 mmol). The reaction mixture was stirred at room temperature for 16 hours before quenching 
with water (10 mL). The solution was extracted with DCM (3 × 10 mL) and the combined organic layers 
were dried over MgSO4, filtered, and concentrated in vacuo. The crude material was purified by 
column chromatography (15% EtOAc in petrol) to give alkene 216 (90 mg, 50%) as a white solid and 
oxetane 217 (20 mg, 11%) as a pale yellow oil. 
Alkene 216 
δH (400 MHz, CDCl3) 6.03 (1H, dd, J 17.5, 11.0, 19-H), 5.41 (1H, t, J 2.5, 3-H), 5.26 (1H, d, J 11.0, 20-HH), 
5.20 (1H, d, J 17.5, 20-HH), 4.64 (1H, d, J 8.0, 14-H), 3.12 (1H, q, J 6.5, 10-H), 2.59 (1H, ddd, J 13.0, 7.5, 
5.0, 1-HH), 2.15-2.06 (2H, m, 2-H2), 1.97 (1H, dt, J 13.5, 3.0, 8-HH), 1.91 (1H, dd, J 14.5, 8.5, 13-HH), 
1.66 (1H, qd, 14.0, 3.5, 7-HH), 1.58 (1H, d, J 14.5, 13-HH), 1.47-1.26 (3H, m, 1-HH, 6-H, 7-HH), 1.13 (3H, 
s, 15-H3), 1.12 (1H, m, 8-HH), 1.10 (3H, d, J 7.0, 16-H3), 1.03 (3H, d, J 6.5, 17-H3), 1.01 (3H, s, 18-H3). δC 
(101 MHz, CDCl3) 215.2 (C-11), 151.3 (C-4), 140.9 (C-19), 126.4 (C-3), 116.8 (C-20), 68.1 (C-14), 54.1 
(C-12), 53.7 (C-9), 45.7 (C-5), 45.6 (C-13), 45.0 (C-10), 43.4 (C-6), 39.5 (C-8), 33.2 (C-1), 30.5 (C-2), 28.3 
(C-7), 25.8 (C-18), 18.5 (C-16), 18.2 (C-15), 14.2 (C-17). HRMS (ESI) calc. for C20H31O2 [M+H]+ 303.2319. 
Found 303.2308. M.p. 82-84 °C (from CHCl3). []D
23 = −112.5 (c 0.24, CHCl3). IR (νmax/cm-1) (neat): 3501 
(alcohol O–H), 2926 (alkane C–H), 1695 (ketone C=O). 
Oxetane 217 
δH (400 MHz, CDCl3) 5.65 (1H, dd, J 17.5, 10.5, 19-H), 5.02 (1H, dd, J 10.5, 20-HH), 4.97 (1H, dd, J 17.5, 
20-HH), 3.85 (1H, dd, J 9.5, 8.0, 14-H), 3.33 (1H, q, J 7.0, 10-H), 2.64 (1H, dd, J 14.5, 9.5, 13-HH), 2.03 
(1H, m, 1-HH), 1.92-1.65 (6H, m, 3-HH, 6-H, 7-H2, 8-HH, 13-HH), 1.50-1.32 (4H, m, 2-H2, 3-HH, 8-HH), 
1.26 (3H, s, 18-H3), 1.17 (1H, m, 1-HH), 1.15 (3H, s, 15-H3), 1.13 (3H, d, J 6.5, 16-H3), 0.98 (3H, d, J 7.0, 
17-H3). δC (101 MHz, CDCl3) 210.9 (C-11), 142.3 (C-19), 113.7 (C-20), 97.4 (C-4), 82.9 (C-14), 66.6 (C-9), 
63.3 (C-5), 54.6 (C-12), 44.6 (C-6), 44.1 (C-10), 39.2 (C-1), 39.1 (C-13), 36.1 (C-7), 35.8 (C-8), 33.3 (C-3), 
25.5 (C-15), 23.2 (C-2), 21.7 (C-18), 14.1 (C-16), 13.3 (C-17). HRMS (ESI) calc. for C20H31O2 [M+H]+ 
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303.2319. Found 303.2336. []D
23 = −174.0 (c 1.00, CHCl3). IR (νmax/cm-1) (neat): 2935 (alkane C–H), 
1712 (ketone C=O). 
Demethylation of 4-epi-mutilin 149 
 
4-Epi-mutilin 149 (200 mg, 0.598 mmol) and triethylsilane (0.11 mL, 0.717 mmol) were dissolved in 
DCM (5 mL). Triflic anhydride (0.12 mL, 0.717 mmol) was added, followed by pyridine (97 µL, 
1.20 mmol). The reaction mixture was stirred at room temperature for 16 hours before quenching 
with water (10 mL). The solution was extracted with DCM (3 × 10 mL) and the combined organic layers 
were dried over MgSO4, filtered, and concentrated in vacuo. The crude material was purified by 
column chromatography (15% EtOAc in petrol) to give diol 218 (190 mg, 99%) as a white solid. 
δH (400 MHz, CDCl3) 5.61 (1H, dd, J 17.5, 10.5, 19-H), 5.07 (1H, d, J 17.5, 20-HH), 5.05 (1H, d, J 10.5, 
20-HH), 4.32 (1H, dd, J 6.5, 4.0, 3-H), 4.13 (1H, dd, J 10.5, 5.5, 14-H), 3.13 (1H, q, J 6.5, 10-H), 2.65 (1H, 
dd, J 14.5, 5.5, 13-HH), 2.39-2.26 (2H, m, 1-HH, 2-HH), 1.98 (1H, ddd, J 13.0, 4.5, 2.5, 8-HH), 1.89 (1H, 
m, 6-H), 1.89 (1H, dd, J 14.5, 10.5, 13-HH), 1.80-1.57 (3H, m, 2-HH, 7-H2), 1.65 (1H, d, J 4.0, 4-H), 1.27 
(3H, s, 18-H3), 1.25 (1H, m, 8-HH), 1.20 (3H, d, J 7.5, 16-H3), 1.19 (3H, s, 15-H3), 1.13 (1H, dt, J 9.5, 2.0, 
1-HH), 1.03 (3H, d, J 6.5, 17-H3). δC (101 MHz, CDCl3) 212.9 (C-11), 143.1 (C-19), 114.2 (C-20), 83.5 
(C-14), 80.5 (C-3), 69.1 (C-4), 53.8 (C-12), 49.6 (C-9), 48.1 (C-5), 40.8 (C-10), 38.2 (C-6), 37.7 (C-13), 36.8 
(C-8), 36.7 (C-1), 32.5 (C-15), 32.3 (C-7), 27.7 (C-2), 22.9 (C-18), 18.0 (C-17), 16.2 (C-16). HRMS (ESI) 
calc. for C20H30O2Na [M+Na−H2O]+ 325.2138. Found 325.2146. M.p. 88-90 °C (from CHCl3). []D
23  = 
−164.0 (c 1.00, CHCl3). IR (νmax/cm-1) (neat): 3779 (alcohol O–H), 2909 (alkane C–H), 1701 (ketone C=O). 
Synthesis of alkene 216 
 
4-Epi-mutilin 149 (100 mg, 0.299 mmol) was dissolved in DCM (2.5 mL) and a solution of boron 
tribromide in DCM (1 M, 0.36 mL, 0.360 mmol) was added slowly. After one hour at room temperature 
the reaction was quenched with water (2.5 mL) and extracted with DCM (3 × 2.5 mL). The combined 
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organic layers were dried over MgSO4, filtered, and concentrated in vacuo. The crude material was 
purified by column chromatography (0-10% EtOAc in petrol) to give alkene 216 (52 mg, 58%) as a white 
solid. 
Characterisation as given previously. 
Synthesis of ester 220 and diester 221 
 
Mutilin 129 (150 mg, 0.468 mmol) was dissolved in EtOAc (10 mL) and cooled to −45 °C. 
1-(trifluoroacetyl)imidazole 219 (0.32 mL, 2.81 mmol) was added and the reaction stirred for 30 
minutes before quenching with HCl (1 M, 5 mL). The reaction mixture was allowed to warm to room 
temperature and the layers were separated. The aqueous phase was washed with EtOAc (2 × 10 mL) 
and CHCl3 (10 mL). The combined organic layers were dried over MgSO4, filtered, and concentrated in 
vacuo. The crude material was purified by column chromatography (10% EtOAc in petrol) to give esters 
220 (160 mg, 82%) and 221 (31 mg, 13%) as white solids. 
Ester 220 
δH (400 MHz, CDCl3) 6.07 (1H, dd, J 18.0, 11.0, 19-H), 5.48 (1H, dd, J 18.0, 1.0, 20-HH), 5.33 (1H, dd, J 
11.0, 1.0, 20-HH), 4.97 (1H, d, J 7.0, 11-H), 4.30 (1H, t, J 6.5, 14-H), 2.39 (1H, pent, J 7.0, 10-H), 2.32 
(1H, dd, J 19.5, 10.5, 2-HH), 2.18 (1H, dt, J 19.5, 9.5, 2-HH), 2.07 (1H, s, 4-H), 1.97 (1H, dd, J 16.0, 7.5, 
13-HH), 1.85-1.65 (3H, m, 1-HH, 6-H, 8-HH), 1.75 (1H, d, J 16.0, 13-HH), 1.53-1.37 (3H, m, 1-HH, 7-H2), 
1.39 (3H, s, 15-H3), 1.34 (1H, d, J 5.5, OH), 1.15 (1H, td, 14.0, 5.0, 8-HH), 1.02 (3H, s, 18-H3), 0.97 (3H, 
d, J 7.0, 16-H3), 0.83 (3H, d, J 7.0, 17-H3). δC (101 MHz, CDCl3) 216.9 (C-3), 157.0 (q, J 42.0, CCF3), 138.4 
(C-19), 116.8 (C-20), 114.9 (q, J 286.0, CCF3), 82.4 (C-11), 66.9 (C-14), 59.3 (C-4), 45.1 (C-9), 44.6 (C-12), 
44.0 (C-13), 42.4 (C-5), 36.8 (C-6 and C-10) 34.5 (C-2), 30.3 (C-8), 28.7 (C-18), 27.3 (C-7), 25.3 (C-1), 
18.3 (C-16), 13.5 (C-15), 11.6 (C-17). δF (376 MHz, CDCl3) −74.7 (CF3). M.p. 173-175 °C (from CHCl3) [Lit. 
170-171 °C].282 []D
23 = +54.0 (c 1.00, CHCl3) [Lit. +46 (c 0.30, CHCl3)].242 






δH (400 MHz, CDCl3) 6.25 (1H, dd, J 17.5, 11.0, 19-H), 5.77 (1H, d, J 8.5, 14-H), 5.37 (1H, d, J 11.0, 
20-HH), 5.23 (1H, d, J 17.5, 20-HH), 5.00 (1H, d, J 7.0, 11-H), 2.54 (1H, pent, J 7.0, 10-H), 2.36 (1H, dd, 
J 20.0, 11.5, 2-HH), 2.30-2.16 (2H, m, 2-HH, 13-HH), 2.15 (1H, s, 4-H), 1.88-1.66 (3H, m, 1-HH, 6-H, 
8-HH), 1.55-1.38 (4H, m, 1-HH, 7-H2, 13-HH), 1.51 (3H, s, 15-H3), 1.18 (1H, td, 14.0, 4.5, 8-HH), 1.09 
(3H, s, 18-H3), 0.87 (3H, d, J 7.0, 17-H3), 0.71 (3H, d, J 7.0, 16-H3). δC (101 MHz, CDCl3) 215.5 (C-3), 157.0 
(q, J 42.0, CCF3), 156.3 (q, J 42.5, CCF3), 137.4 (C-19), 118.2 (C-20), 114.9 (q, J 286.0, CCF3), 114.6 (q, J 
286.0, CCF3), 81.6 (C-11), 73.6 (C-14), 58.3 (C-4), 45.2 (C-9), 44.5 (C-13), 43.2 (C-12), 42.3 (C-5), 36.5 
(C-6), 36.3 (C-10), 34.4 (C-2), 30.1 (C-8), 27.3 (C-18), 26.9 (C-7), 25.2 (C-1), 16.3 (C-16), 14.7 (C-15), 11.6 
(C-17). δF (376 MHz, CDCl3) −74.7 (CF3), −75.7 (CF3). HRMS (ESI) calc. for C24H30O5Na [M+Na]+ 535.1890. 
Found 535.1885. M.p. 126-128 °C (from CHCl3). []D
23 = +35.0 (c 1.00, CHCl3). IR (νmax/cm-1) (neat): 2939 
(alkane C–H), 1778 (ester C=O), 1739 (ketone C=O). 
Synthesis of trifuoroacetylglycolic acid 224 
 
Glycolic acid 222 (2.00 g, 26.2 mmol) was dissolved in DCM (20 mL) and cooled to 0 °C. Trifluoroacetic 
anhydride 223 (3.70 mL, 26.2 mmol) in DCM (30 mL) was added slowly via a dropping funnel. Once 
addition was complete the reaction was allowed to warm to room temperature and stirred for two 
days. The reaction mixture was concentrated in vacuo to give trifuoroacetylglycolic acid 224 (4.18 g, 
92%) as a colourless oil without further need for purification. 
δH (400 MHz, CDCl3) 8.90 (1H, s, COOH), 4.91 (2H, s, 2-H2). δC (101 MHz, CDCl3) 171.2 (C-1), 157.1 (q, J 
44.0, C-4), 114.4 (q, J 285.0, C-5), 62.1 (C-2). δF (376 MHz, CDCl3) −74.7 (CF3). 
Spectroscopic data in accord with the literature data.243 




Carboxylic acid 224 (134 mg, 0.793 mmol) was added to a solution of alcohol 220 (100 mg, 0.240 
mmol), EDCI.HCl (152 mg, 0.793 mmol), and DMAP (97 mg, 0.794 mmol) in DCM (15 mL). The reaction 
was stirred for 30 minutes at room temperature before quenching with MeOH (5 mL). Triethylamine 
(5 mL) was added and the solution stirred for 2 days at room temperature. The reaction was quenched 
with a saturated aqueous solution of NH4Cl (5 mL) and extracted with CHCl3 (3 × 5 mL). The combined 
organic layers were dried over MgSO4, filtered, and concentrated in vacuo. The crude material was 
purified by column chromatography (20% EtOAc in petrol) to give pleuromutilin 125 (81 mg, 95%) as 
a white solid. 
δH (400 MHz, CDCl3) 6.50 (1H, dd, J 17.5, 11.0, 19-H), 5.84 (1H, d, J 8.5, 14-H), 5.37 (1H, dd, J 11.0, 1.5, 
20-HH), 5.22 (1H, dd, J 17.5, 1.5, 20-HH), 4.08 (1H, dd, J 17.0, 5.5, 22-HH), 4.01 (1H, dd, J 17.0, 5.5, 
22-HH), 3.37 (1H, dd, J 10.5, 6.5, 11-H), 2.40-2.30 (2H, m, 10-H, OH), 2.30-2.15 (2H, m, 2-H2), 2.11 (1H, 
dd, J 16.0, 8.5, 13-HH), 2.10 (1H, d, J 3.0, 4-H), 1.78 (1H, dq, J 14.0, 3.0, 8-HH), 1.72-1.45 (5H, m, 1-H2, 
6-H, 7-HH, OH), 1.44 (3H, s, 15-H3), 1.38 (1H, m, 7-HH), 1.32 (1H, d, J 16.0, 13-HH), 1.18 (3H, s, 18-H3), 
1.13 (1H, m, 8-HH), 0.90 (3H, d, J 7.0, 17-H3), 0.71 (3H, d, J 7.0, 16-H3). δC (101 MHz, CDCl3) 217.0 (C-3), 
172.3 (C-21), 139.0 (C-19), 117.5 (C-20), 74.7 (C-11), 69.9 (C-14), 61.5 (C-22), 58.2 (C-4), 45.6 (C-9), 
44.9 (C-13), 44.2 (C-12), 42.0 (C-5), 36.8 (C-6), 36.2 (C-10), 34.6 (C-2), 30.5 (C-8), 27.0 (C-7), 26.5 (C-18), 
25.0 (C-1), 16.8 (C-16), 14.9 (C-15), 11.7 (C-17). M.p. 166-168 °C (from petrol/EtOAc). [Lit. 165-166 
°C].197 []D
21 = +29.0 (c 1.00, CHCl3) [Lit. +33 (c 0.2, CHCl3)].242 
Spectroscopic data in accord with the literature data.242 
Acetylation of 4-epi-mutilin 149 
 
4-Epi-mutilin 149 (250 mg, 0.747 mmol) was dissolved in pyridine (2 mL). Acetic anhydride (1.06 mL, 
11.2 mmol) and DMAP (23 mg, 0.187 mmol) were added and the solution was heated to 100 °C for six 
hours. The reaction was quenched with HCl (1 M, 5 mL) and extracted with EtOAc (3 × 5 mL). The 
combined organic layers were dried over MgSO4, filtered, and concentrated in vacuo. The crude 
material was purified by column chromatography (10% EtOAc in petrol) to give ester 226 (258 mg, 
92%) as a white solid. 
δH (400 MHz, CDCl3) 6.66 (1H, dd, J 17.5, 11.0, 19-H), 5.74 (1H, d, J 10.0, 14-H), 5.29 (1H, d, J 11.0, 
20-HH), 5.01 (1H, d, J 17.5, 20-HH), 3.46 (1H, ddd, J 11.5, 8.0, 5.5, 3-H), 3.22 (3H, s, OCH3), 2.93 (1H, q, 
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J 6.5, 10-H), 2.44 (1H, dd, J 15.5, 10.0, 13-HH), 2.19 (1H, ddd, J 13.5, 10.0, 3.0, 1-HH), 2.03 (3H, s, C-22), 
2.03-1.93 (2H, m, 2-HH, 8-HH), 1.70 (1H, d, 11.5, 4-H), 1.55 (1H, m, 7-HH), 1.53 (1H, d, J 15.5, 13-HH), 
1.43 (1H, dq, J 15.0, 4.0, 7-HH), 1.31 (1H, m, 6-H), 1.27-1.11 (2H, m, 1-HH, 2-HH), 1.24 (3H, s, 15-H3), 
1.18 (3H, s, 18-H3), 1.06 (1H, td, J 13.5, 4.0, 8-HH), 0.99 (3H, d, J 6.5, 17-H3), 0.81 (3H, d, J 7.0, 16-H3). 
δC (101 MHz, CDCl3) 215.5 (C-11), 170.4 (C-21), 140.5 (C-19), 118.3 (C-20), 83.3 (C-3), 71.7 (C-14), 64.3 
(C-4), 57.0 (OCH3), 54.0 (C-12), 47.7 (C-9), 45.5 (C-6), 45.0 (C-10), 44.7 (C-13), 43.2 (C-5), 40.5 (C-8), 
30.9 (C-1), 29.6 (C-2), 28.8 (C-7), 25.6 (C-18), 22.0 (C-22), 20.5 (C-15), 16.5 (C-16), 15.8 (C-17). HRMS 
(ESI) calc. for C23H36O4Na [M+Na]+ 399.2506. Found 399.2523. M.p. 80-82 °C (from CHCl3). []D
23  = 
−124.0 (c 1.00, CHCl3). IR (νmax/cm-1) (neat): 2928 (alkane C–H), 1728 (ester C=O), 1698 (ketone C=O). 
Synthesis of 14-O-acetyl mutilin 132 
 
Lucas’ reagent was prepared by slowly dissolving ZnCl2 in 12 M HCl until saturated. 0.8 mL were then 
added dropwise to a solution of ester 226 (100 mg, 0.266 mmol) in 1,4-dioxane (2 mL). After three 
hours the reaction was quenched via the slow addition of a saturated aqueous solution of NaHCO3 
(10 mL) and extracted with EtOAc (3 × 10 mL). The combined organic layers were dried over MgSO4, 
filtered, and concentrated in vacuo. The crude material was purified by column chromatography (20% 
EtOAc in petrol) to give 14-O-acetyl mutilin 132 (53 mg, 55%) as a white solid. 
δH (500 MHz, CDCl3) 6.53 (1H, dd, J 17.5, 11.0, 19-H), 5.72 (1H, d, J 8.5, 14-H), 5.35 (1H, dd, J 11.0, 1.5, 
20-HH), 5.20 (1H, dd, J 17.5, 1.5, 20-HH), 3.36 (1H, d, J 6.5, 11-H), 2.37 (1H, app. pent, J 7.0, 10-H), 
2.30-2.15 (2H, m, 2-H2), 2.10 (1H, d, J 2.0, 4-H), 2.06 (1H, dd, J 16.5, 9.0, 13-HH), 1.97 (3H, s, 22-H3), 
1.77 (1H, dq, J 14.5, 3.0, 8-HH), 1.70-1.61 (2H, m, 1-HH, 6-H), 1.56 (1H, qd, J 13.5, 3.5, 7-HH), 1.45 (3H, 
s, 15-H3), 1.36 (1H, dq, J 14.5, 3.5, 7-HH), 1.31 (1H, d, J 16.0, 13-HH), 1.17 (3H, s, 18-H3), 1.13 (1H, td, J 
14.0, 4.0, 8-HH), 0.88 (3H, d, J 7.0, 17-H3), 0.73 (3H, d, J 7.0, 16-H3). δC (126 MHz, CDCl3) 217.4 (C-3), 
170.1 (C-21), 139.4 (C-19), 117.2 (C-20), 74.8 (C-11), 68.1 (C-14), 58.4 (C-4), 45.6 (C-9), 45.2 (C-13), 
44.1 (C-12), 41.9 (C-5), 36.9 (C-6), 36.2 (C-10), 34.7 (C-2), 30.6 (C-8), 27.0 (C-7), 26.4 (C-18), 25.0 (C-1), 
22.1 (C-22), 16.7 (C-16), 15.1 (C-15), 11.7 (C-17). HRMS (ESI) calc. for C22H34O4Na [M+Na]+ 385.2349. 
Found 385.2340. M.p. 176-178 °C (from CHCl3). []D
21 = +42.0 (c 1.00, CHCl3). IR (νmax/cm-1) (neat): 3496 
(alcohol O–H), 2921 (alkane C–H), 1730 (ester C=O), 1702 (ketone C=O). 
Spectroscopic data in accord with the literature data.283 
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3.3.3. Biotransformation Studies 
Incubation of mutilin 129 
 
A solution of mutilin 129 (100 mg, 0.312 mmol) in CMP broth (100 mL) was incubated with an 
Aspergillus oryzae transformant containing ATF and P450 genes. After 10 days at 28 °C the A. oryzae 
mycelia were homogenised using a blender. EtOAc (300 mL) was added, the mixture was stirred 
vigorously for one hour, then filtered to the remove the cells. Water (300 mL) was added to the filtrate 
and the layers were separated. The aqueous layer was extracted with EtOAc (2 × 500 mL) and the 
combined organic layers were dried over MgSO4, filtered, and concentrated in vacuo. The crude 
material was purified by column chromatography (10-100% EtOAc in petrol) to give 14-O-acetyl 
mutilin 132 (62 mg, 55%) and pleuromutilin 125 (23 mg, 19%) as white solids. Mutilin 129 was also 
recovered (4 mg, 4%). 
14-O-Acetyl mutilin 132 and pleuromutilin 125 
Characterisation as given previously. 
Incubation of triol 131 
 
A solution of triol 131 (20 mg, 62.0 µmol) in CMP broth (100 mL) was incubated with an Aspergillus 
oryzae transformant containing ATF and P450 genes. After 10 days at 28 °C the A. oryzae mycelia were 
homogenised using a blender. EtOAc (400 mL) was added, the mixture was stirred vigorously for one 
hour, then filtered to the remove the cells. Water (400 mL) was added to the filtrate and the layers 
were separated. The aqueous layer was extracted with EtOAc (2 × 500 mL) and the combined organic 
layers were dried over MgSO4, filtered, and concentrated in vacuo. The crude material was purified by 
column chromatography (10-20% EtOAc in petrol) to give ester 227 (6 mg, 27%) as a colourless oil. 
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δH (400 MHz, CDCl3) 6.57 (1H, dd, J 17.5, 11.0, 19-H), 5.57 (1H, d, J 9.5, 14-H), 5.33 (1H, dd, J 11.0, 1.5, 
20-HH), 5.17 (1H, dd, J 17.5, 1.5, 20-HH), 4.56 (1H, t, J 5.5, 3-H), 3.17 (1H, d, J 6.0, 11-H), 2.21 (1H, m, 
6-H), 2.19 (1H, app. pent, J 7.0, 10-H), 2.06 (1H, dd, J 15.5, 9.5, 13-HH), 1.97 (3H, s, 22-H3), 1.95 (1H, 
m, 2-HH), 1.85 (1H, td, J 14.0, 4.5, 8-HH), 1.72 (1H, dq, J 14.5, 3.0, 8-HH), 1.69-1.59 (2H, m, 1-HH, 2-HH), 
1.52 (1H, d, J 3.0, 4-H), 1.50-1.40 (2H, m, 1-HH, 7-HH), 1.38 (1H, m, 7-HH), 1.24 (1H, d, J 15.5, 13-HH), 
1.23 (3H, s, 15-H3), 1.15 (3H, s, 18-H3), 0.81 (3H, d, J 7.0, 17-H3), 0.72 (3H, d, J 7.0, 16-H3). δC (101 MHz, 
CDCl3) 170.2 (C-21), 139.9 (C-19), 116.7 (C-20), 77.5 (C-3), 75.1 (C-11), 70.0 (C-14), 51.1 (C-4), 46.1 
(C-9), 45.6 (C-13), 45.0 (C-12), 41.2 (C-5), 36.8 (C-6), 35.7 (C-10), 34.4 (C-2), 32.9 (C-8), 31.9 (C-1), 27.8 
(C-7), 26.3 (C-18), 22.1 (C-22), 17.8 (C-15), 17.0 (C-16), 12.3 (C-17). HRMS (ESI) calc. for C22H36O4Na 
[M+Na]+ 387.2506. Found 387.2523. IR (νmax/cm-1) (neat): 3455 (alcohol O–H), 2926 (alkane C–H), 1732 
(ester C=O). 
Incubation of alkene 141 
 
A solution of alkene 141 (50 mg, 0.157 mmol) in CMP broth (500 mL) was incubated with an Aspergillus 
oryzae transformant containing ATF and P450 genes. After 10 days at 28 °C the A. oryzae mycelia were 
homogenised using a blender. EtOAc (300 mL) was added, the mixture was stirred vigorously for one 
hour, then filtered to the remove the cells. Water (300 mL) was added to the filtrate and the layers 
were separated. The aqueous layer was extracted with EtOAc (2 × 500 mL) and the combined organic 
layers were dried over MgSO4, filtered, and concentrated in vacuo. The crude material was purified by 
column chromatography (10-100% EtOAc in petrol) and the product containing fractions pooled and 
concentrated. Further purification was performed via HPLC (70-95% MeCN in water with 0.05% formic 
acid) to give ester 228 (23.6 mg, 42%) as a colourless oil. Diol 141 was also recovered (4.8 mg, 10%). 
δH (400 MHz, CDCl3) 6.50 (1H, dd, J 17.5, 11.0, 19-H), 5.61 (1H, d, J 8.5, 14-H), 5.30 (1H, dd, J 11.0, 1.5, 
20-HH), 5.14 (1H, dd, J 17.5, 1.5, 20-HH), 3.02 (1H, br. s, 11-H), 2.41-2.22 (2H, m, 2-H2), 2.25 (1H, pent, 
J 6.5, 10-H), 2.01-1.93 (2H, m, 8-HH, 13-HH), 1.96 (3H, s, 22-H3), 1.91 (3H, s, 2’-H3), 1.87 (1H, ddd, J 
14.5, 10.5, 5.0, 1-HH), 1.55 (1H, m, 7-HH), 1.43-1.32 (2H, m, 6-H, 7-HH), 1.38 (1H, s, 15-H3), 1.30-1.16 
(4H, m, 1-HH, 8-HH, 13-HH, OH), 1.05 (3H, s, 18-H3), 0.79 (3H, d, J 7.0, 16-H3), 0.78 (3H, d, J 7.0, 17-H3). 
δC (101 MHz, CDCl3) 170.1 (C-21), 140.6 (C-4), 139.6 (C-19), 134.8 (C-3), 116.6 (C-20), 75.6 (C-11), 69.8 
(C-14), 57.3 (C-9), 47.3 (C-5), 46.5 (C-13), 44.5 (C-12), 43.8 (C-6), 41.2 (C-2), 38.4 (C-8), 36.6 (C-10), 30.0 
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(C-1), 28.3 (C-7), 26.3 (C-18), 22.0 (C-22), 21.0 (C-15), 17.8 (C-2’), 16.7 (C-16), 11.5 (C-17). HRMS (ESI) 
calc. for C23H36O3Na [M+Na]+ 383.2557. Found 383.2553. 
Incubation of triol 151 
 
A solution of triol 151 (19 mg, 56.5 µmol) in CMP broth (100 mL) was incubated with an Aspergillus 
oryzae transformant containing ATF and P450 genes. After 10 days at 28 °C the A. oryzae mycelia were 
homogenised using a blender. EtOAc (400 mL) was added, the mixture was stirred vigorously for one 
hour, then filtered to the remove the cells. Water (400 mL) was added to the filtrate and the layers 
were separated. The aqueous layer was extracted with EtOAc (2 × 500 mL) and the combined organic 
layers were dried over MgSO4, filtered, and concentrated in vacuo. The crude material was purified by 
column chromatography (10-20% EtOAc in petrol) to give ester 229 (6 mg, 28%) as a white solid. 
δH (400 MHz, CDCl3) 6.56 (1H, dd, J 17.5, 11.0, 19-H), 5.65 (1H, d, J 9.0, 14-H), 5.32 (1H, dd, J 11.0, 1.5, 
20-HH), 5.16 (1H, dd, J 17.5, 1.5, 20-HH), 3.21 (1H, d, J 6.5, 11-H), 2.29 (1H, m, 6-H), 2.22 (1H, app. 
pent, J 7.0, 10-H), 2.10 (1H, dd, J 16.0, 9.0, 13-HH), 1.96 (3H, s, 22-H3), 1.96-1.83 (2H, m, 2-H2), 
1.73-1.57 (3H, m, 8-H2, OH), 1.54 (1H, m, 7-HH), 1.49 (3H, s, 2’-H3), 1.46 (1H, d, J 3.0, 4-H), 1.42 (1H, 
m, 7-HH), 1.28 (3H, s, 15-H3), 1.24 (1H, d, J 16.0, 13-HH), 1.16 (3H, s, 18-H3), 0.78 (3H, d, J 7.0, 17-H3), 
0.71 (3H, d, J 7.0, 16-H3). δC (101 MHz, CDCl3) 170.2 (C-21), 139.9 (C-19), 116.7 (C-20), 83.2 (C-3), 74.6 
(C-11), 69.8 (C-14), 53.2 (C-4), 48.8 (C-9), 45.8 (C-13), 44.6 (C-12), 43.9 (C-2), 42.8 (C-5), 35.8 and 35.6 
(C-6 and C-10), 35.2 (C-2’), 29.6 (C-1), 29.5 (C-8), 27.3 (C-7), 26.3 (C-18), 22.2 (C-22), 17.0 (C-16), 16.2 
(C-15), 12.5 (C-17). HRMS (ESI) calc. for C23H38O4Na [M+Na]+ 401.2662. Found 401.2674. IR (νmax/cm-1) 
(neat): 3430 (alcohol O–H), 2924 (alkane C–H), 1702 (ester C=O). 
Incubation of (2S)-hydroxy mutilin 169  
 
A solution of α-hydroxy ketone 169 (40 mg, 0.119 mmol) in CMP broth (400 mL) was incubated with 
an Aspergillus oryzae transformant containing ATF and P450 genes. After 10 days at 28 °C the A. oryzae 
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mycelia were homogenised using a blender. EtOAc (300 mL) was added, the mixture was stirred 
vigorously for one hour, then filtered to the remove the cells. Water (300 mL) was added to the filtrate 
and the layers were separated. The aqueous layer was extracted with EtOAc (2 × 500 mL) and the 
combined organic layers were dried over MgSO4, filtered, and concentrated in vacuo. The crude 
material was purified by column chromatography (10-100% EtOAc in petrol) and the product 
containing fractions pooled and concentrated. Further purification was performed via HPLC (30-95% 
MeCN in water with 0.05% formic acid) to give ester 230 (1.5 mg, 3%) as a colourless oil. 
δH (400 MHz, CDCl3) 6.50 (1H, dd, J 17.5, 11.0, 19-H), 5.71 (1H, d, J 8.5, 14-H), 5.35 (1H, dd, J 11.0, 1.5, 
20-HH), 5.20 (1H, dd, J 17.5, 1.5, 20-HH), 4.00 (1H, t, J 8.5, 7.5, 2-H), 3.31 (1H, br. s, 11-H), 2.47 (1H, 
br. s, OH), 2.32 (1H, pent, J 7.0, 10-H), 2.23 (1H, d, J 3.0, 4-H), 2.12-2.02 (2H, m, 1-HH, 13-HH), 1.98 
(3H, s, 22-H3), 1.93 (1H, dq, J 14.5, 3.0, 8-HH), 1.60 (1H, m, 7-HH), 1.47 (3H, s, 15-H3), 1.46-1.39 (2H, 
m, 1-HH, 6-H), 1.34 (1H, m, 7-HH), 1.33 (1H, d, J 16.0, 13-HH), 1.17 (3H, s, 18-H3), 1.02 (1H, td, J 14.0, 
4.5, 8-HH), 0.91 (3H, d, J 7.0, 17-H3), 0.75 (3H, d, J 7.0, 16-H3). δC (101 MHz, CDCl3) 218.3 (C-3), 170.0 
(C-21), 139.3 (C-19), 117.3 (C-20), 74.4 (C-11), 72.5 (C-2), 67.9 (C-14), 56.7 (C-4), 45.3 (C-13), 44.3 
(C-12), 42.4 (C-5), 42.2 (C-9), 38.3 (C-6), 36.3 (C-10), 34.7 (C-1), 32.8 (C-8), 26.8 (C-7), 26.5 (C-18), 22.1 
(C-22), 16.6 (C-16), 15.4 (C-15), 12.1 (C-17). HRMS (ESI) calc. for C22H34O5Na [M+Na]+ 401.2298. Found 
401.2309. 
Incubation of 2,2-dimethyl mutilin 179 
 
A solution of ketone 179 (30 mg, 86.1 µmol) in CMP broth (300 mL) was incubated with an Aspergillus 
oryzae transformant containing ATF and P450 genes. After 10 days at 28 °C the A. oryzae mycelia were 
homogenised using a blender. EtOAc (300 mL) was added, the mixture was stirred vigorously for one 
hour, then filtered to the remove the cells. Water (300 mL) was added to the filtrate and the layers 
were separated. The aqueous layer was extracted with EtOAc (2 × 500 mL) and the combined organic 
layers were dried over MgSO4, filtered, and concentrated in vacuo. The crude material was purified by 
column chromatography (10-100% EtOAc in petrol) and the product containing fractions pooled and 
concentrated. Further purification was performed via HPLC (50-95% MeCN in water with 0.05% formic 
acid) to give ester 231 (9.3 mg, 28%) and α-hydroxy ester 233 (3.7 mg, 11%) as colourless oils. Diol 179 




δH (400 MHz, CDCl3) 6.54 (1H, dd, J 17.5, 11.0, 19-H), 5.68 (1H, d, J 8.5, 14-H), 5.35 (1H, dd, J 11.0, 1.5, 
20-HH), 5.21 (1H, dd, J 17.5, 1.5, 20-HH), 3.32 (1H, d, J 6.5, 11-H), 2.45 (1H, d, J 3.0, 4-H), 2.31 (1H, app. 
pent, J 7.0, 10-H), 2.06 (1H, dd, J 16.0, 8.5, 13-HH), 1.97 (3H, s, 22-H3), 1.84-1.70 (2H, m, 6-H, 8-HH), 
1.64 (1H, d, J 13.5, 1-HH), 1.50 (1H, qd, J 14.0, 3.5, 7-HH), 1.42 (3H, s, 15-H3), 1.37-1.25 (3H, m, 1-HH, 
7-HH, 13-HH), 1.18 (3H, s, 18-H3), 1.13 (3H, s, 3’-H3 or 3’’-H3), 1.08 (3H, s, 3’-H3 or 3’’-H3), 1.06 (1H, td, 
J 14.0, 4.5, 8-HH), 0.83 (3H, d, J 7.0, 17-H3), 0.73 (3H, d, J 7.0, 16-H3). δC (101 MHz, CDCl3) 220.5 (C-3), 
170.1 (C-21), 139.4 (C-19), 117.2 (C-20), 75.4 (C-11), 68.3 (C-14), 55.1 (C-4), 45.1 (C-13), 44.2 (C-12), 
42.8 (C-9), 42.0 (C-1), 41.9 (C-2), 41.1 (C-5), 36.1 (C-6), 35.7 (C-10), 32.6 (C-8), 30.6 (C-3’ or C-3’’), 27.1 
(C-3’ or C-3’’, and C-7), 26.4 (C-18), 22.1 (C-22), 16.7 (C-16), 14.9 (C-15), 11.3 (C-17). HRMS (ESI) calc. 
for C24H39O4Na [M+H]+ 391.2843. Found 391.2840. 
α-Hydroxy ester 233 
δH (400 MHz, CDCl3) 6.51 (1H, dd, J 17.5, 11.0, 19-H), 5.81 (1H, d, J 8.5, 14-H), 5.37 (1H, d, J 11.0, 
20-HH), 5.23 (1H, d, J 17.5, 20-HH), 4.08 (1H, d, J 17.0, 22-HH), 4.01 (1H, d, J 17.0, 22-HH), 3.37 (1H, d, 
J 4.5, 11-H), 2.45 (1H, d, J 1.5, 4-H), 2.28 (1H, qd, J 7.0, 4.5, 10-H), 2.10 (1H, dd, J 16.0, 9.0, 13-HH), 1.81 
(1H, m, 6-H), 1.77 (1H, dq, J 14.5, 3.5, 8-HH), 1.65 (1H, d, J 13.5, 1-HH), 1.49 (1H, m, 7-HH), 1.41 (3H, s, 
15-H3), 1.39-1.27 (3H, m, 1-HH, 7-HH, 13-HH), 1.19 (3H, s, 18-H3), 1.14 (3H, s, 3’-H3 or 3’’-H3), 1.09 (3H, 
s, 3’-H3 or 3’’-H3), 1.08 (1H, td, J 14.0, 4.0, 8-HH), 0.85 (3H, d, J 7.0, 17-H3), 0.70 (3H, d, J 7.0, 16-H3). δC 
(101 MHz, CDCl3) 220.1 (C-3), 172.3 (C-21), 139.0 (C-19), 117.6 (C-20), 75.4 (C-11), 70.2 (C-14), 61.5 
(C-22), 54.9 (C-4), 44.8 (C-13), 44.3 (C-12), 42.8 (C-9), 42.0 (C-2), 41.9 (C-1), 41.3 (C-5), 35.9 (C-6), 35.8 
(C-10), 32.5 (C-8), 30.6 (C-3’ or C-3’’), 27.1 (C-3’ or C-3’’, and C-7), 26.5 (C-18), 16.8 (C-16), 14.8 (C-15), 
11.3 (C-17). HRMS (ESI) calc. for C24H38O5Na [M+Na]+ 429.2611. Found 429.2602. 
Incubation of enone 190210 
 
A solution of enone 190 (30 mg, 94.2 µmol) in CMP broth (300 mL) was incubated with an Aspergillus 
oryzae transformant containing ATF and P450 genes. After 10 days at 28 °C the A. oryzae mycelia were 
homogenised using a blender. EtOAc (300 mL) was added, the mixture was stirred vigorously for one 
hour, then filtered to the remove the cells. Water (300 mL) was added to the filtrate and the layers 
were separated. The aqueous layer was extracted with EtOAc (2 × 500 mL) and the combined organic 
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layers were dried over MgSO4, filtered, and concentrated in vacuo. The crude material was purified by 
column chromatography (10-100% EtOAc in petrol) to give ester 232 (18 mg, 51%) and α-hydroxy ester 
234 (8 mg, 23%) as white solids. 
Ester 232 
δH (500 MHz, CDCl3) 7.73 (1H, d, J 6.0, 1-H), 6.51 (1H, dd, J 17.0, 11.0, 19-H), 6.04 (1H, d, J 6.0, 2-H), 
5.69 (1H, d, J 9.0, 14-H), 5.37 (1H, dd, J 11.0, 1.5, 20-HH), 5.20 (1H, dd, J 17.0, 1.5, 20-HH), 3.01 (1H, 
dd, J 11.0, 7.0, 11-H), 2.31 (1H, pent, J 7.0, 10-H), 2.27-2.22 (2H, m, 4-H, 8-HH), 2.16 (1H, dd, J 16.0, 
9.0, 13-HH), 1.99 (3H, s, 22-H3), 1.69-1.58 (2H, m, 6-H, 7-HH), 1.55 (3H, s, 15-H3), 1.47 (1H, d, J 11.0, 
OH), 1.37-1.30 (2H, m, 7-HH, 13-HH), 1.14 (3H, s, 18-H3), 1.07 (3H, d, J 7.0, 17-H3), 0.97 (1H, m, 8-HH), 
0.80 (3H, d, J 7.0, 16-H3). δC (126 MHz, CDCl3) 207.6 (C-3), 170.1 (C-21), 165.4 (C-1), 139.2 (C-19), 133.0 
(C-2), 117.4 (C-20), 76.0 (C-11), 68.1 (C-14), 58.9 (C-4), 51.4 (C-9), 45.6 (C-13), 44.8 (C-12), 42.3 (C-5), 
39.0 (C-8), 38.4 (C-6), 35.6 (C-10), 27.1 (C-7), 26.2 (C-18), 22.0 (C-22), 16.3 (C-16), 14.7 (C-15), 12.4 
(C-17). HRMS (ESI) calc. for C22H32O4Na [M+Na]+ 388.2198. Found 388.2193. 
Purification and characterisation performed by Edith Rodríguez. 
α-Hydroxy ester 234 
δH (500 MHz, CDCl3) 7.74 (1H, d, J 6.0, 1-H), 6.49 (1H, dd, J 17.0, 11.0, 19-H), 6.05 (1H, d, J 6.0, 2-H), 
5.82 (1H, d, J 9.0, 14-H), 5.39 (1H, dd, J 11.0, 1.5, 20-HH), 5.22 (1H, dd, J 11.0, 1.5, 20-HH), 4.10 (1H, d, 
J 17.0, 22-HH), 4.04 (1H, d, J 17.0, 22-HH), 3.03 (1H, dd, J 11.0, 7.0, 11-H), 2.37-2.15 (4H, m, 10-H, 4-H, 
8-HH, 13-HH), 1.71-1.32 (4H, m, 6-H, 7-H2, 13-HH), 1.25 (3H, s, 15-H3), 1.16 (3H, s, 18-H3), 1.09 (3H, d, 
J 7.0, 17-H3), 0.98 (1H, m, 8-HH), 0.78 (3H, d, J 7.0, 16-H3). δC (126 MHz, CDCl3) 207.3 (C-3), 172.4 (C-21), 
165.2 (C-1), 138.8 (C-19), 133.0 (C-2), 117.8 (C-20), 75.9 (C-11), 69.9 (C-14), 61.5 (C-22), 58.7 (C-4), 
51.3 (C-9), 45.4 (C-13), 44.9 (C-12), 42.4 (C-5), 38.9 (C-8), 38.2 (C-6), 35.7 (C-10), 27.1 (C-7), 26.3 (C-18), 
16.4 (C-16), 14.6 (C-15), 12.4 (C-17). HRMS (ESI) calc. for C22H32O5Na [M+Na]+ 399.2161. Found 
399.2142. 
Purification and characterisation performed by Edith Rodríguez. 
3.3.4. Antimicrobial Bioassays210 
Bacillus subtilis was used to test the antibiotic activity of compounds through disk diffusion assays. 
50 mL of TSB (30 g/L tryptic soy broth premix) was inoculated with Bacillus subtilis then grown 
overnight at 30 °C. 1 mL of the culture was then used to inoculate 100 mL of TSA (30 g/L tryptic soy 
broth premix, 5 g/L agar) and was spread over the surface of the medium and incubated at 30 °C for 
a further six days. Sterile distilled water was used to harvest the culture, spores were activated (70 °C 
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for 30 minutes), then titrated and diluted to a concentration of 1 × 10-9 spores /mL. The spores were 
then aliquoted and stored at 4 °C until needed. 5 μL of B. subtilis spores and 37.5 μL of 4% TTC 
(2,3,5-triphenyl-2H-tetrazolium chloride) were poured onto the plate. A sterile round piece of filter 
paper was placed in the centre of the plate, and the required amount of substrate was pipetted over 
it. Plates were incubated at 30 °C for 48 hours, after which colony growth and inhibition zones were 
measured. Each strain was tested in triplicate and the standard deviation was calculated. 
These studies were performed by our collaborators in the Bailey group (Biological Sciences, Bristol). 
 
  
Compound Amount (µg) Average Inhibition Zone (mm) Standard Deviation 
125 100 12.8 0.8 
 25 6.2 1.3 
 5 3.7 0.3 
 1 0.0 0.0 
132 100 10.3 0.3 
 25 5.8 0.6 
 5 2.7 0.6 
 1 0.0 0.0 
234 100 15.7 1.8 
 25 8.0 2.2 
 5 2.5 0.9 
 1 0.0 0.0 
232 100 12.7 0.6 
 25 8.2 0.6 
 5 3.0 0.0 
 1 0.0 0.0 
190 100 8.0 0.0 
 25 2.0 0.0 
 5 0.0 0.0 
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